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1.1 Lipoproteins, Lipoprotein receptors, and lipid metabolism 
1.1.1 Lipoproteins   
Lipoproteins are macromolecular complexes of lipids and proteins that are essential for the 
transport of cholesterol, triglycerides (TG), and fat-soluble vitamins in the blood. 
Lipoproteins are composed of a hydrophobic lipid core containing triglycerides (TG) and 
cholesteryl esters (CE) surrounded by an amphipatic monolayer of phospholipids (PL), free 
cholesterol (FC), and specific proteins (Figure 1). Proteins associated with lipoproteins, 
called apolipoproteins, are required for the assembly, structure, and the function of 
lipoproteins. Apolipoproteins activate enzymes important in lipid metabolism and act as 
ligands for cell surface receptors (Table 1). Based on the relative densities of the 
lipoproteins upon density-gradient ultracentrifugation, five major classes of lipoproteins 
can be distinguished, including chylomicrons (CM), very-low-density lipoproteins 
(VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and 
high-density lipoproteins (HDL) 4. CM and VLDL are the major carriers of TG in the 
blood, while plasma cholesterol is mainly transported as CE in LDL and HDL. As shown 
in Table 2, each lipoprotein class comprises a family of particles that vary slightly in 
density, size, electrophoretic mobility, and protein composition. Generally, HDL can be 
classified into lipid-poor discoidal nascent pre-β HDL and lipid-rich spherical mature α-
HDL, based on their difference in electrophoretic mobility 5. Preβ-HDL contains mainly 
apoAI and phospholipids with small amounts of cholesterol. Preβ-HDL has been resolved 
into preβ1, preβ2, and preβ3 HDL particles according to increasing size by two-dimensional 
gel electrophoresis 5. α-HDL encompasses two main density classes, namely large 
cholesteryl ester (CE) -rich HDL2 (d: 1.063-1.125g/mL) and small CE-poor HDL3 (d: 
1.125-1.21 g/mL). They can be further subdivided by increasing size into HDL3c, 3b, 3a and 
HDL2a, 2b 5. The heterogeneity in lipoprotein size and composition induces changes in 










Figure 1. Molecular 
compositions of lipoprotein.  
See text for explanation. 









ApoAI Intestine, liver CM, HDL Structure protein for HDL Activation of LCAT 6 
ApoAII Liver CM, HDL Structure protein for HDL Enhancement of HL activity 7 
ApoAIV Intestine CM, HDL TG-rich lipoprotein/HDL metabolism Facilitation of CETP activity 8 
ApoAV Liver CM, VLDL Promotion of LPL-mediated TG lipolysis 9 
ApoB48 Intestine, Liver* CM Structure protein for CM 7 
ApoB100 Liver VLDL, IDL, LDL, Lp(a) 
Structure protein for VLDL, IDL, LDL, Lp(a) 
Ligand for binding to LDL receptor 10 
ApoCI Liver CM, VLDL, HDL Activation of LCAT 
11, inhibition of CETP 12, HL 
13, and SR-BI 14, inhibition of remnant uptake 13 
ApoCII Liver CM, VLDL, HDL Cofactor for LPL 15 
ApoCIII Liver CM, VLDL, HDL Inhibition of LPL 
16, inhibition of remnant uptake 
17 
ApoD Spleen, brain, testes, adrenals HDL 
Transport of multiple ligands, including 
arachidonic acid, progesterone, and 
phosphorylated MAPK 18, 19 
ApoE Liver CM remnants, IDL, HDL Ligand for binding to LDL receptor and LRP1 
20 
ApoH Liver CM, VLDL, LDL, HDL Antigen target for antiphospholipid antibody 
21 
ApoJ Liver HDL Binding and transport of Aβ 22 
ApoL Liver HDL Unknown 23 
ApoM Liver HDL Formation of preβ HDL 24 
Apo(a) Liver Lp(a) Unknown 25 
Abbreviations: CM, chylomicron; VLDL, very-low-density lipoprotein; IDL, intermediate-density 
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; LCAT, lectin-cholesterol 
acyltransferase; HL, hepatic lipase; CETP, cholesterol ester transfer protein; SR-BI, scavenger receptor BI; 
LPL, lipoprotein lipase; MAPK, mitogen-activated protein kinase; LRP, LDL receptor-related protein; Aβ, 
amyloid beta. *: only for mice and rat, not for human 
 
Table 2. Physical properties and composition of human plasma lipoproteins 4. 
 
 CM VLDL IDL LDL HDL 
Density (g/mL) <0.95 0.95-1.006 1.006-1.019 1.019-1.063 1.063-1.210 
Diameter (nm) 75-1200 30-80 25-35 18-25 5-12 
Mw (x 106 Da) 400 10-80 5-10 2.3 0.17-0.36 
Mobility* origin Pre-β Pre-β/β β Pre-β/α 
 
Lipid composition (weight%) 
TG 80-95 55-80 20-50 5-15 5-10 
Total cholesterol 2-7 5-15 20-40 40-50 15-25 
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1.1.2 Lipoprotein receptors  
Lipoprotein receptors play a crucial role in lipid metabolism. The main lipoprotein 
receptors include the LDL receptor (LDLr), LDLr-related protein 1 (LRP1), VLDL 
receptor (VLDLr), and several types of scavenger receptors. With respect to the scope of 
this thesis, the roles of the LDL receptor, LRP1, and scavenger receptor class B type I (SR-
BI) in lipoprotein metabolism will be discussed in more detail in the following paragraphs. 
 
1.1.2.1 Low-density lipoprotein receptor  
The LDL receptor is a membrane-spanning glycoprotein containing five functional 
domains: the ligand-binding domain, the epidermal growth factor (EGF) repeats domain, 
the O-linked polysaccharide domain, the transmembrane domain, and the cytoplasmic 
domain 26, 27 (Figure 2). The LDL receptor is expressed in most mammalian cells, 
including lymphocytes and macrophages 28, 29. The highest expression level is found in the 




Regulation of the LDL receptor expression 
The expression of the LDL receptor gene is under complex regulation at both 
transcriptional and posttranscriptional levels via a variety of signaling pathways. 
Cholesterol and cholesterol derivatives, and nonsterol mediators, like cytokines, growth 
factors, and some hormones, are able to regulate LDL receptor expression 32, 33. The sterol 
regulatory element-binding protein (SREBP) pathway is crucial for the transcriptional 
regulation of LDL receptor gene expression by cholesterol and its derivatives 34. In 
mammalian cells, there are three types of SREBP, namely SREBP-1a, SREBP-1c, and 
SREBP-2. Among them, SREBP-2 is the major activator of the LDL receptor gene 35. 
SREBPs are synthesized as inactive precursors in the endoplasmic reticulum (ER) 36. The 
SREBP precursor needs the escort of another ER membrane protein named SREBP 
cleavage-activating protein (SCAP) to get to the Golgi apparatus for cleavage 37. The 
cleavage of the SREBP precursor results in the release of nuclear SREBP, which enters the 
nucleus and activates transcription. When cholesterol or its derivatives are abundant in 
Figure 2 Structure of LDL receptor 
and LRP1. See text for explanation. 




cells, cholesterol can bind to SCAP and inhibit the dissociation of SCAP from a pair of ER 
membrane proteins named insulin-induced genes (Insig) 1 and 2, thereby trapping 
SREBP/SCAP in the ER and suppressing the SREBP-mediated transcription of the LDL 
receptor 38-42. On the contrary, when cells lack sterols, SCAP does not interact with the 
Insig proteins and the SREBP/SCAP complex is free to reach the Golgi apparatus for the 
generation of nSREBP. Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase, upregulate the expression of the LDL receptor via the SREBP 
pathway secondary to shutting down cholesterol biosynthesis 43. Furthermore, activation of 
extracellular signal-regulated kinase (ERK) is also crucial for the expression of LDL 
receptor. ERK activation induces the transcription of the LDL receptor through nSREBP 44 
and/or transcriptional factor Egr1 and c/EBPβ 45. A number of cytokines, such as tumor 
factor (TNF) α, interleukin (IL)-1, IL-6, and oncostatin M (OM) are able to activate the 
transcription of the LDL receptor gene in hepatocytes via activation of ERK 46. 
Interestingly, inflammation disrupts the cholesterol-sensitive feedback regulation of LDL 
receptor and cause statin resistance 47. 
Mechanisms for post-translational modulation of LDL receptor expression include 
proprotein convertase subtilisin/kexin type 9 (PCSK9) 48 and the E3 ubiquitin ligase Idol 
49. PCSK9 is a secreted protein predominantly expressed in the liver, small intestine, and 
kidney 50. In plasma, PCSK9 directly binds to the EGF-A extracellular domain of the LDL 
receptor in the liver 51, 52. This binding and the subsequent internalization of the PCSK9-
LDL receptor complex lead to the intracellular degradation of LDL receptor in lysosomes. 
In humans, gain-of-function mutations in PCSK9 result in autosomal hypercholesterolemia 
53. On the contrary, loss-of-function mutations within PCSK9 are associated with a 
reduction in plasma LDL cholesterol levels 54, 55. Interestingly, PCSK9 is also a target gene 
of SREBPs 56. In line, statins induce the expression of PCSK9. However, activation of 
janus kinase1 (JAK1), JAK2, and the downstream ERK suppresses the expression of 
PCSK9 57. In contrast, Idol triggers ubiquitination of the LDL receptor on conserved 
residues in its intracellular tail, leading to degradation of the receptor 49. Consistent with 
this mechanism, overexpression of Idol effectively inhibits LDL uptake by downregulation 
of the LDL receptor protein levels in vitro and in vivo. Conversely, knockdown of Idol 
results in an increase in LDL receptor expression and LDL uptake. Of note, Idol is a 
transcriptional target of liver X receptors (LXR) but not regulated by SREBPs. 
 
LDL receptor function in lipid metabolism and cellular cholesterol homeostasis 
LDL receptors on the cell surface bind and take up apoB- and/or apoE-containing 
lipoproteins (especially LDL). Seven cysteine-rich repeats (R1-R7) (Figure 2), the so-
called LDL receptor class A (LA) repeats at the amino-terminal end of the receptor are 
responsible for binding to apoB and apoE in lipoproteins 26. Whereas binding of apoB-100 
in LDL depends on the presence of R3-R7, only R5 appears essential for interaction with 
apoE in VLDL 58, 59. After endocytosis, the LDL receptor uncouples from its ligand and 
returns to the cell surface for recycling, while the LDL particle undergoes further 
metabolism 60.  
In the liver the LDL receptor is crucial for clearance of LDL from the circulation. 
In humans, the hepatic LDL receptor accounts for more than 70% of the total LDL 
clearance from plasma 61. Thus, LDL receptor gene mutations often result in highly 
increased LDL-cholesterol levels in the circulation, a disease called familial 
hypercholesterolemia (FH) 62. The binding of apoB-100 to the LDL receptor is required for 




and W4369Y, have been unequivocally linked to defective LDL receptor binding and 
hypercholesterolemia 63. In addition, endocytosis is also required for the clearance of LDL 
64. ARH1, an adaptor protein is required for internalization. Mutations in ARH1 lead to a 
rare autosomal recessive form of hypercholesterolemia (ARH) 65. Importantly, retroviral 
expression of normal human ARH1 rescues LDL receptor internalization in cells from 
patients with ARH 66. 
Uptake of LDL via the LDL receptor is an important pathway in supplying peripheral cells 
with cholesterol, which is required for the buildup and maintenance of membranes and the 
synthesis of biomolecules such as bile salts, vitamin D and the steroid hormones. However, 
excessive intracellular cholesterol accumulation inhibits the synthesis of the LDL receptor. 
This leads to the limited contribution of the macrophage LDL receptor to foam cell 
formation and atherogenesis 67, 68. 
 
1.1.2.2 Low-density lipoprotein receptor-related protein 1                
LRP1 is the largest receptor of the LDL receptor family. The modular structures within 
LRP1 include cysteine-rich ligand-binding domain, EGF repeats, β-propeller domains, a 
transmembrane domain, and a cytoplasmic domain 69 (Figure 2). Although LRP1 is 
structurally related to the LDL receptor, the function of LRP1 is more complex than the 
LDL receptor. LRP1 interacts with a number of functional diverse ligands, including apoE-
enriched lipoproteins, lipoprotein lipase (LPL), α2-macroglobulin-protease complexes 70. 
Also LRP1 can engage a variety of adaptor molecules in endocytosis, phagocytosis, and 
cell signaling via its cytoplasmic domain 71. LRP1 is expressed in various mammalian cell 
types, most highly in hepatocytes, neurons and fibroblasts 69, 72. Studies using mice in 
which LRP1 is selectively disrupted in neurons 73, hepatocytes 74, adipocytes 75, vascular 
smooth muscle cells 76, and macrophages 77, 78 have revealed tissue-specific functions of 
LRP1 and their roles in the pathogenesis of Alzheimer’s disease, hypercholesterolemia, 
atherosclerosis, and inflammation.  
 
Regulation of LRP1 expression 
Biosynthesis and maturation of LRP1 involves interaction with receptor-associated protein 
(RAP) and proteolytic processing into two receptor subunits. RAP is a molecular 
chaperone that is required for the proper folding and export of receptors from ER to the 
Golgi apparatus. Interaction with RAP also prevents premature association of LRP1 with 
ligands, ER retention, and subsequent degradation 79, 80. RAP deficiency thus results in 
intracellular accumulation and degradation of most of the synthesized LRP1 molecules 80. 
In the post-Golgi secretary compartment, furin, a proprotein-converting enzyme cleaves a 
600 kDa precursor protein into two subunits, namely a 515 kDa N-terminal subunit and an 
85 kDa C-terminal subunit 81, 82. Interestingly, studies using furin deficient cells indicate 
that the proteolytic processing of the LRP1 precursor is not required for transport of the 
receptor to the cell surface but may increase its endocytic activity 81.  
So far, the understanding of the regulation of LRP1 is still limited. Studies on the 
sequence and structure of the promoter region of LRP1 isolated from blood leukocytes 
indicate that it has no sterol regulatory element 83. However, at the transcriptional level, 
SREBPs do downregulate the expression of LRP1 in smooth muscle cells and macrophages 
after incubation with normal LDL or aggregated LDL 84-87. LRP1 is thus distinct from the 
LDL receptor in response to cholesterol loading. Also the proinflammatory cytokine 




RAW 264.7, a macrophage cell line 88. In contrast, transforming growth factor-β1 (TGFβ1) 
has no effect on LRP1 expression. However, pretreatment of TGFβ1 does rescue the LRP1 
expression that is suppressed by IFNγ  88. In addition, insulin affects the expression of 
LRP1 largely at post-translational level. It stimulates recycling of LRP1 in 3T3-L1 
adipocytes from an endosomal pool to the plasma membrane in a PI3K-dependent manner 
89, 90. However, in J774 macrophages, insulin induces a significant reduction in the LRP1 
protein content by activation of the proteasomal system 91. 
 
LRP1 Function in lipid metabolism and cellular cholesterol homeostasis 
When LRP1 was originally identified, its structural similarity to the LDL receptor and its 
expression in the liver suggested a role in lipoprotein metabolism. LRP1 binds apoE-rich 
βVLDL 92, 93 and chylomicron remnants 94 in vitro. However, no accumulation of remnant 
lipoproteins is evident in the circulation of wild-type mice with selective disruption of 
hepatic LRP1 74. Interestingly, liver-specific inactivation of LRP1 in LDL receptor 
knockout mice does lead to the accumulation of remnant lipoproteins in the circulation 74. 
The function of LRP1 in hepatic remnant metabolism is thus in concert with the LDL 
receptor. In addition, as LRP1 binds apoE, lipoprotein lipase (LPL), and hepatic lipase 
(HL), which facilitate the uptake of CE of HDL by the liver 95-97, LRP1 is also implicated 
in HDL metabolism.  
In addition, it participates in the uptake of matrix-retained LDL and aggregated 
LDL by macrophages 98 and smooth muscle cells 99, 100. Importantly, LRP1 also promotes 
the translocation of 12/15 lipoxygenase (LO) from the cytosol to the plasma membrane 101 
and thereby facilitates LDL oxidation 102 in J774A.1 macrophages. Overproduction of 
oxidized LDL can subsequently lead to macrophage foam cell formation 103. In adipocytes 
and neurons, the expression of LRP1 regulates cellular cholesterol levels primarily via 
uptake of apoE-containing lipoproteins 104, 105. In addition, the deletion of LRP1 is 
associated with downregulation of the ABC transporter A1 (ABCA1) expression, which 
might subsequently affect intracellular cholesterol trafficking and cellular cholesterol 
efflux 106.   
 
1.1.2.3 Scavenger receptor BI 
Scavenger receptors, first described by Brown and Goldstein 107, 108, are membrane 
glycoproteins that are involved in the cellular uptake of a broad range of polyanionic 
ligands including modified lipoproteins, collagen, apoptotic cells, and bacterial 
components. Scavenger receptors thus play important roles in foam cell formation, 
atherosclerosis, adhesion, and inflammation 109, 110. Table 3 summarizes the different types 
of scavenger receptors identified and their respective ligands.  
The scavenger receptor class B type I (SR-BI), a member of the CD36 superfamily, 
is a 82 kDa cell surface glycoprotein comprising two transmembrane and two cytoplasmic 
domains as well as a large extracellular loop with several N-glycosylation sites 111 (Figure 
3). SR-BI is expressed in various mammalian tissues and cells, including brain, kidney, 
intestine, heart, placenta, macrophages, endothelial cells, smooth muscle cells, and various 
epithelial cells 112. The highest expression of SR-BI, however, is in organs with critical 
roles in cholesterol metabolism (liver) and steroidogenesis (adrenal, ovary, testis) 113. It is 






Table 3: Major ligands of scavenger receptors 109, 122, 123  
Scavenger receptor Lipid and lipoprotein ligands Other ligands 
FC FA LDL HDL oxLDL acLDL agLDL 
A SR-A I/II     + + + AP, LPS, bacteria 
MARCO     + +  LPS, LTA, bacteria 
B CD36  +  + + +  
collagen, erythrocytes, 
AP, bacteria 
SR-BI + + + + + +  AP, hepatitic C virus 
C dSR-C1      +   
D Macrosialin     + +   
CD68     + +  AP 
E LOX-1     +    
F SREC     + + + calreticulin, avillin 
N* 
SR-PSOX     +   bacteria 
CD163        hemoglobin, bacteria 
CL-P1        bacteria 
FEEL-1      +  AGE-modified proteins, bacteria 
FEEL-2      +  AGE-modified proteins, bacteria 
SCARA5        bacteria 
Abbreviation: FC: free cholesterol, FA: fatty acid, oxLDL: oxidized LDL, acLDL: acetylated LDL, agLDL: 
aggregated LDL, LPS: lipopolysaccharide, LTA: lipoteichoic acid, AP: apoptotic cells, AGE: advanced 
glycation end-products. 





Regulation of SR-BI expression 
The transcription of SR-BI can be regulated by SREBPs 114, 115, steroidogenic factor-1 (SF-
1) 114, 116, liver receptor homolog 1 (LRH-1) 117, and the peroxisome proliferator-activated 
receptor-α (PPAR-α) 118-120. The stability of SR-BI proteins is modulated by Ras/mitogen-
activated protein kinase (MAPK) 121. Interestingly, SR-BI is regulated differently in liver 
Figure 3. Structure of SR-BI. See text for 





and in steroidogenic tissues. Overexpression of SREBP1a downregulates the transcription 
of hepatic SR-BI but induces its expression in ovaries 114, 115. Moreover, fibrates, PPAR-α 
agonists, reduce SR-BI in liver while they upregulate SR-BI in macrophages and have no 
effect on SR-BI in adrenals 118-120. Of note, the expression of SR-BI is also regulated 
differently in different types of cells at post-translational level. In hepatocytes as well as 
epithelial cells of the intestine, an adaptor protein, PDZK1 is essential for the expression of 
SR-BI on the cell surface as PDZK1 KO mice showed a ~95% and ~50% reduction in the 
protein levels of SR-BI in the liver and the small intestine, respectively 124. Also 
atherogenic diet-induced downregulation of SR-BI protein expression in the liver and 
intestine is associated with a reduction of PDZK1 115. Interestingly, in PDZK1 KO mice, 
the expression of SR-BI in adrenals and macrophages is unchanged 124. Moreover, small 
PDZK1-associated protein (SAAP) decreases PDZK1 in a liver-specific fashion, thereby 
resulting in downregulation of hepatic SR-BI, but again has no effect on the levels of SR-
BI in the adrenals or peritoneal macrophages 125. All these findings indicate that SR-BI is 
regulated in a cell type specific fashion.  
 
SR-BI Functions in lipid metabolism and cellular cholesterol metabolism  
Evidence for the physiological importance of SR-BI in HDL metabolism was obtained 
from studies in genetically engineered mice. Hepatic overexpression of SR-BI increased 
the selective uptake of HDL-CE by liver 126, 127, resulting in the virtual absence of plasma 
HDL-C 128, 129. On the contrary, impaired hepatic uptake of HDL-CE in mice with 
attenuated expression of SR-BI expression or complete SR-BI deficiency led to the 
accumulation of abnormally large HDL particles and increased plasma HDL-C levels 130-
132. In humans, a clear association between mutations in the coding and promoter regions 
of human SR-BI and increased plasma HDL-C has been shown in several populations 133-
135. Recent genome-wide association studies (GWAS) also demonstrated that single 
nucleotide polymorphism (SNPs) in and near SR-BI are significantly associated with 
plasma levels of HDL-C in humans 136. However, only very recently conclusive evidence 
was provided by Vergeer et al on the importance of SR-BI in controlling HDL cholesterol 
levels in humans. They identified a family in which heterozygous carriers of a unique 
mutation (P297S) in the extracellular domain of SR-BI showed a 37% elevation in plasma 
HDL-C levels. Importantly, hepatocytes that expressed the P297S mutant SR-BI displayed 
a reduced capacity to take up HDL-CE, thereby explaining the observed increase in HDL-
C in the circulation in carriers of the mutant SR-BI 137. By comparing the uptake of HDL-
CE with holo-particle uptake in SR-BI knockout (KO) mice and wild-type (WT) mice, SR-
BI is identified as the sole molecule responsible for the selective uptake of CEs from HDL 
in mice 138, 139. The extracellular domain of SR-BI and the proper orientation of apoAI 
molecules on the HDL particles are crucial for efficient lipid uptake via SR-BI 140-145. The 
selective uptake of HDL-CE is considered as a two-step process: the first step is the 
binding of the lipoprotein to the extracellular domain of SR-BI, followed by internalization 
of its CEs without net internalization and degradation of the lipoprotein itself 146. 
Moreover, HDL binding and CE uptake are independent processes 140, 147. High affinity 
HDL binding to SR-BI is not sufficient for efficient HDL-CE selective uptake 148, 149. 
Interestingly, SR-BI reconstituted into liposomes is still capable to avidly bind lipoproteins 
and selectively take up CEs, indicating that specific cellular structures and compartments 
are not required for SR-BI-mediated HDL-CEs uptake 150. In addition, several recent 
studies have indicated that a so-called retro-endocytosis pathway involving holo-particle 
uptake of HDL followed by re-secretion of CE-poor HDL could also contribute to the 




are delivered into an extra-lysosomal metabolically active membrane pool and 
subsequently hydrolyzed by neutral cholesteryl ester hydrolase 153-155, which is different 
from LDL-CEs which are hydrolyzed in the lysosomes by acidic cholesteryl ester 
hydrolase after endocytosis via LDL receptor 156, 157.  
SR-BI has also been implicated in the metabolism of apoB-containing lipoproteins, 
including LDL and VLDL. Wiersma et al demonstrated that the expression level of hepatic 
SR-BI is correlated with the production rate of VLDL by affecting the hepatic cholesterol 
content and the activity of microsomal triglyceride transfer protein (MTP) 158. Moreover, 
in-vitro studies clearly demonstrated that SR-BI binds apoB lipoproteins and facilitates the 
subsequent uptake of cholesterol from these lipoproteins 159-163. In vivo, SR-BI attenuation 
or deficiency led to increased VLDL and LDL cholesterol levels in WT 162, LDL receptor 
KO 164, and apoE KO mice 132, while mice overexpressing SR-BI displayed reduced levels 
of apoB-containing lipoproteins 126, 129, 165. In addition, SR-BI is also involved in 
chylomicron metabolism as evidenced by higher postprandial TG levels in the plasma of 
SR-BI KO mice and reduced association of chylomicron-like emulsion particles to freshly 
isolated hepatocytes lacking SR-BI 166. Béaslas et al recently demonstrated that 
postprandial micelles supplied to Caco2/TC7 enterocytes induced the clustering of SR-BI 
at the apical brush border membrane and movement from non-raft to raft domains 167. 
Importantly, competition, inhibition, or knockdown of SR-BI impairs the trafficking of 
apoB from apical towards secretory domains, indicating the involvement of SR-BI in the 
secretion of intestinal TG-rich lipoproteins 167. Moreover, overexpression of intestinal SR-
BI results in accelerated lipid absorption 168. Several studies on common polymorphisms of 
CLA-1, the human homologue of SR-BI, also suggested its role in the metabolism of apoB 
lipoproteins 133, 169-171 and postprandial lipoproteins in humans 172.  
The role of SR-BI in cellular cholesterol homeostasis is complex. Apart from 
selective uptake of CEs from HDL, like CD36, SR-BI binds modified lipoproteins and 
mediates their uptake by macrophages 173, 174[. Also SR-BI stimulates the bi-directional 
flux of free cholesterol (FC) between cells and mature HDL down the concentration 
gradient 175. In addition, SR-BI is also expressed in the late endo/lysosomes and might be 
involved in the intracellular cholesterol trafficking as SR-BI deficiency is associated with 
accumulation of lysosomal cholesterol in hepatocytes 176. 
The SR-BI mediated cholesterol efflux pathway has been shown to be crucial for 
prevention of macrophage foam cell formation, especially in the absence of ABCA1 177, 178. 
The mechanisms underlying SR-BI mediated bi-directional flux of cholesterol are largely 
unclear. Although not proven, it is often assumed that SR-BI accelerates aqueous diffusion 
of FC between cells and mature HDL. Binding to SR-BI will tether potential cholesterol 
acceptors in close proximity to the plasma membrane, thereby facilitating aqueous 
diffusion 179. The extracellular domain of SR-BI is crucial for mediating the bi-directional 
flux of FC 180. However, high-affinity binding alone is not sufficient to stimulate FC flux 
181. Interestingly, SR-BI also facilitates FC efflux by increasing the fraction of membrane 
cholesterol available for efflux 182. Cholesterol in this faction of the membrane is not 
available for lipid-free/poor apoAI, although apoAI can bind to SR-BI. One study, using 
mutated forms of SR-BI, suggests that low efficiency export of FC to HDL is related to low 
cholesterol availability in the plasma membrane rather than impaired binding of acceptors 
to the mutated forms of SR-BI 180. In addition, SR-BI mediated HDL retro-endocytosis, i.e. 
the uptake of whole HDL particles followed by re-secretion of CE-poor HDL, has also 
been implicated in SR-BI mediated cholesterol efflux 183, 184. This process appears 





1.1.3 Lipid metabolism 
The plasma lipid levels depend on the integrated balance of the exogenous and endogenous 
pathways of lipid metabolism. 
 
1.1.3.1 Exogenous lipid transport 
The exogenous pathway of lipid metabolism permits efficient transport of dietary lipids 
(Figure 4). Dietary TG and CE are hydrolyzed by the pancreatic lipase and cholesteryl 
esterase and absorbed by the epithelium in the proximal small intestine. Subsequently, TG, 
FC, PL, and apoB48, apoAI, apoAII, and apoAIV are packaged to form CMs. Nascent 
CMs are secreted into the intestinal lymph and delivered via the thoracic duct directly to 
the systemic circulation. Meanwhile, CMs loose apoAI and partly apoAIV and acquire 
apoCI, apoCII, apoCIII, and apoE. Upon entering the blood circulation, the TGs in the core 
of CMs are hydrolyzed by lipoprotein lipase (LPL) 185 and released fatty acids are taken up 
by peripheral tissues such as adipose tissue (for storage as TG), skeletal muscle and heart 
(as energy source), and the liver (as storage or generation of lipoproteins). As TGs are 
hydrolyzed and FC, PL and apoAI and apoC’s on the surface of CMs are in part transferred 
to HDL, CMs progressively shrink in size and turn into CM remnants. CM remnants are 
rapidly removed from the circulation by the liver via an apoE-specific recognition site on 
hepatocytes 186, including the LDL receptor, LRP1, heparan sulphate proteoglycans 
(HSPG), and as recently demonstrated SR-BI 166. 
 
 
Figure 4. Exogenous lipid transport. See text for explanation. CMs, chylomicrons; FA, fatty acid; 
TG, triglycerides; LPL, lipoprotein lipase. 
 
1.1.3.2 Endogenous lipid transport  
The endogenous pathway of lipoprotein metabolism refers to the hepatic secretion of TG-
rich VLDL and their metabolism (Figure 3). The TGs and cholesterol of VLDL are derived 
from either de novo synthesis or lipoprotein uptake. Nascent VLDL contains a single copy 
of apoB-100 as well as newly synthesized apoE and apoC’s. The packaging of nascent 




VLDL acquires multiple copies of apoE and apoC’s from HDL. The TGs of VLDL 
undergo lipolysis by LPL and PLs are transferred to HDL by phospholipid transfer protein 
(PLTP), leading to the formation of VLDL remnants or IDLs. The liver removes 
approximately 40-60% of the IDLs by receptor-mediated endocytosis via apoE. The 
remaining IDLs further loose TG, PL, apoE, and apoCs as a result of the action of hepatic 
lipase (HL), leading to the formation of LDL. The formed LDL particle contains apoB-100 
as the sole apolipoprotein, which is recognized by the LDL receptor for the clearance from 
the circulation. Cholesterol in LDL is the important source for the maintenance of 
membranes in cells and the production of steroids in steroidogenic tissues. In addition, 
LDL can be retained in the intima of arteries, where it can be modified and subsequently 
taken up by macrophages via scavenger receptors. 
 
 
Figure 5. Endogenous lipid transport. See text for explanation. VLDL, very-low-density 
lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; FA, fatty acid; 
TG, triglycerides; LPL, lipoprotein lipase; HL, hepatic lipase. 
 
1.1.3.3 Reverse cholesterol transport 
All nucleated cells synthesize cholesterol. However, only hepatocytes and enterocytes can 
efficiently excrete cholesterol from the body into feces. In the classical view, reverse 
cholesterol transport (RCT) is a process that describes the HDL-mediated transport of 
excess cholesterol from peripheral tissues to the liver for biliary secretion as bile acids or 
biliary cholesterol 187 (Figure 4). For a long time, this removal via hepatobiliary secretion 
was considered as the sole route in the RCT process. Of note, a novel non-biliary RCT 









Figure 6. Reverse cholesterol transport. See text for explanation. HDL, high-density lipoprotein; 
apoAI, apolipoprotein AI; ABCA1, ABC-transporter A1; ABCG1, ABC-transporter G1; SR-BI, 
scavenger receptor class B type 1; FC, free cholesterol; TG, triglycerides; LCAT, lecithin: 
cholesterol acyltransferase; CETP, cholesterol ester transfer protein; PLTP, phospholipid transfer 
protein; VLDL, very-low-density lipoprotein; LDL, low-density lipoprotein; HL, hepatic lipase; 
EL, endothelial lipase; ABCG5/8, ABC-transporter G5 and G8; ABCB11, ABC-transporter B11, 
TICE, transintestinal cholesterol efflux. 
 
HDL metabolism and reverse cholesterol transport  
HDL is a universal plasma acceptor for cholesterol efflux from both peripheral tissues and 
the liver by passive diffusion or cholesterol transporters, such as ABC-transporter A1 
(ABCA1), ABC-transporter G1 (ABCG1), and SR-BI 189, 190. As an important mediator in 
RCT, HDL metabolism is more complex than that of other major lipoprotein fractions, in 
that the individual lipid and apolipoprotein components of HDL are mostly acquired after 
secretion of the nascent particle, frequently exchanged with or transferred to other 
lipoproteins, actively remodeled within the plasma compartment, and cleared at least in 
part independent from one another 191. ApoAI, the main apolipoprotein of HDL, is 
synthesized by liver and intestine. Lipidation of apoAI with PL and FC via ABCA1 in the 
liver and intestine leads to the generation of pre-β HDL particles 192-195. Pre-β HDL is 
present as minor components in plasma. However, it is believed to play a role as initial 
acceptor of FC from cells 196. Lipidation of pre-β HDL constrains the conformation of 




into CE in pre-β HDL by lecithin-cholesterol acyltransferase (LCAT) generates spherical 
mature α-HDL 198.  
HDL particles undergo extensive remodeling within the plasma compartment by a 
variety of lipid transfer proteins and lipases. LCAT mediated FC esterification, and PLTP 
mediated particle fusion and surface remnant transfer convert HDL3 into HDL2 199-201, in 
which lipid-free or -poor apoAI is liberated 202. Conversely, HDL2 are converted into 
HDL3 and in turn lipid-free or -poor apoAI by cholesteryl ester transfer protein (CETP) 
mediated CE and triglycerides (TG) exchange with apoB containing lipoproteins 203. Also 
hepatic lipase (HL) and endothelial lipase (EL) mediated hydrolysis of PL and TG 204, 205 
and SR-BI mediated selective uptake of CE into liver and steroidogenic organs 2, 206 are 
involved in the conversion of HDL2 to HDL3. It has been shown that apoAI conformation 
and HDL particle size influence the interaction of the HDL particle with SR-BI 143, 207. The 
remodeling of HDL thus plays the critical role in determining the ultimate metabolic fate 
of HDL. 
HDL cholesterol is transported to the liver by both a direct and an indirect pathway. 
HDL cholesterol can be taken up by liver via SR-BI-mediated selective cholesterol uptake 
112. Also, apoE-enriched HDL can be taken up as a whole particle by the liver 208. In 
addition, CE of HDL can be transferred to apoB-containing lipoproteins in exchange for 
TG by CETP and then taken up by the liver through their lipoprotein receptors, such as 
LDL receptor and LRP1 203. Upon delivery of HDL cholesterol to the liver, the CEs are 
hydrolyzed for either lipoprotein assembly or sterol secretion into the bile via ABCG5/8 
(half-transporters that work together as heterodimers) and ABCB11 (BSEP)-mediated 
pathways 209, 210. 
 
Transintestinal cholesterol efflux and reverse cholesterol transport 
Several mouse models with diminished hepatobiliary cholesterol secretion show normal 
fecal sterol loss 211-216, indicating a non-biliary RCT route in addition to classical pathway 
through biliary secretion. Increasing evidence shows that the proximal part of the small 
intestine is able to secrete cholesterol actively, a pathway named TICE 188. Of note, in 
mice, TICE is sensitive to pharmacological manipulation. Activation of the liver X 
receptor (LXR) 214 and the peroxisome proliferator activated receptor δ (PPAR-δ) 217 
promotes TICE. Strikingly, TICE accounts for up to 70% of fecal neutral sterol excretion 
in mice 188. However, the understanding of the process of TICE is still limited. The origin 
of intestinally secreted cholesterol and the components involved in TICE remain to be 
elucidated. Moreover, the importance of TICE in humans still needs to be determined. 
 
1.1.4 Dyslipidemia as a major risk factor for atherosclerosis  
Dyslipidemia is a broad term that refers to a number of lipid disorders. The majority of the 
disorders (80%) are related to diet and lifestyle, although familial disorders (20%) are 
important as well. The basic categories of dyslipidemias include: elevated LDL-C, low 
HDL-C, excess lipoprotein(a), hypertriacylglycerolemia, atherogenic dyslipidemia, and 
mixed lipid disorders (Table 4) 218. A clear direct relationship exists between dyslipidemia 
and cardiovascular risk 103. Normalization of dyslipidemia is thus important for prevention 








Table 4. Primary hyperlipidemia caused by known single gene mutation.  
Genetic disorder Mutated gene 
Elevated 
Lipoproteins Clinical complications 
LPL deficiency LPL CM Xanthomas, hepatosplenomegaly, pancreatitis 219 
Familiar apoCII 
deficiency apoCII CM 
Xanthomas, hepatosplenomegaly, 
pancreatitis 15 
ApoAV deficiency apoAV CM, VLDL Xanthomas, hepatosplenomegaly, pancreatitis 220 




VLDL remnant Xanthomas, CHD, PVD 
20 
Familiar 
hypercholesterolemia LDLr LDL Xanthomas, CHD 
222 
Familiar defective apoB-
100 apoB100 LDL Xanthomas, CHD 
63 
Autosomal dominant 
hypercholesterolemia PCSK9 LDL Xanthomas, CHD 
222 
Autosomal recessive 
hypercholesterolemia ARH LDL Xanthomas, CHD 
223 
Sitosterolemia ABCG5/8 LDL Xanthomas, CHD 224 
Abbreviations: LPL, lipoprotein lipase; CM, chylomicron; VLDL, very-low-density lipoprotein; HL, hepatic 
lipase; CHD, coronary heart disease; PVD, peripheral vascular disease; ARH, autosomal recessive 
hypercholesterolemia; ABCG5/8, ABC-transporter G5/8 
 
1.2 Atherosclerosis  
Atherosclerosis is a progressive disease characterized by the accumulation of lipids and 
fibrous elements in large arteries. As the primary cause of myocardial infarction and 
cerebral stroke, atherosclerosis is the underlying cause of about 50% of all deaths in 
westernized societies. Epidemiological studies have revealed several important 
environmental (i.e. diet, smoking, and exercise) and genetic risk factors (e.g. dyslipidemia, 
hypertension, systemic inflammation, diabetes, and obesity) associated with atherosclerosis 
103. 
 
1.2.1 Pathogenesis of atherosclerosis 
Atherosclerosis is now appreciated to represent a chronic inflammatory reaction of the 
vascular wall in response to dyslipidemia and endothelial distress involving the 
inflammatory recruitment of leukocytes and the activation of resident vascular cells 225. 
Pathological studies have revealed a defined series of changes in the vessel during 
atherogenesis and suggested possible pathways of disease initiation and progression 
(Figure 7).  
Several hypotheses have been proposed on the initiation of atherosclerosis. 
According to the generally accepted “response-to-injury” hypothesis, atherogenesis is 
initiated by injury to the endothelial lining of the arterial wall and the underlying smooth 
muscle cells 226. Various risk factors such as hypertension and oxidized lipids, induce 
changes in the permeability of the arterial wall, expression of adhesion molecules, and the 
production of cytokines and chemokines, thereby leading to the migration of inflammatory 
cells including monocytes, T and B lymphocytes, neutrophils and mast cells from the 
circulation into the intima of the arterial wall. The “response-to-retention” hypothesis is 
based on the finding that lipoproteins can pass through endothelium by endothelial cell 




of the arterial wall 227. Oxidation of the lipoproteins in the subendothelial matrix results in 
dysfunction of the endothelium and subsequent recruitment of inflammatory cells.  
 
 
Figure 7. Development of atherosclerosis. See text for explanation. A. Initiation of 
atherosclerosis due to endothelial dysfunction. B. Lesion progression.  C. Lesion rupture and 
thrombosis. Adapted from Libby et al. 228 
 
Bifurcations and branches of the arteries are the most vulnerable sites for 
atherosclerosis 229. This might be due to hypoxia 230 and increased hemodynamic forces 231 
at these locations, which could induce endothelium dysfunction and create a 
proinflammatory environment with low-grade recruitment and accumulation of monocytes 
into the intima. Upon induction of hypercholesterolemia, these resident intimal monocyte-
derived cells initiate atherosclerosis by rapidly engulfing lipid and becoming the first foam 
cells in the nascent lesion 231 (Figure 7A).  
Macrophage foam cell formation is the hallmark of the early atherosclerotic lesion 
called the fatty streak 232, 233 (Figure 7A). LDL must be extensively modified before it can 
be taken up rapidly by macrophages to form foam cells. This modification presumably 
involves reactive oxygen species produced by ECs and macrophages, and several enzymes 
including myeloperoxidase (MPO) 234, sphingomyelinase 235, 236, and a secretory 
phospholipase 237, 238. Two scavenger receptors, SR-A and CD36 are of primary 
importance for the uptake of modified LDL by macrophages as mice lacking either 
receptor show a modest reduction in atherosclerotic lesions 239, 240. Also macrophages can 
release their cholesterol via various efflux pathways (described in detail in Chapter 4). 
Since macrophages cannot limit the uptake of cholesterol, functional cholesterol efflux 
pathways are crucial for prevention of foam cell formation and atherosclerosis. In line, 
impaired macrophage cholesterol efflux pathways, including facilitated transport via 
ABCA1, ABCG1, and SR-BI, promote the development of atherosclerosis 178, 241-243. 
As the early atherosclerotic lesions progress, additional inflammatory cells are 
recruited with the further accumulation of extracellular lipids. The inflammatory response 
in the lesions induces the transformation of smooth muscle cells (SMCs) from the 
quiescent “contractile” phenotype state to the active “synthetic” state. Vascular SMCs 
thereafter can proliferate and migrate from the media into the intima. SMCs can take up 
lipids, thereby contributing to foam cell accumulation. Also, they start to cover the core of 
the lesions constituted of extracellular lipids, foam cells, T cells and a poorly developed 
matrix of connective tissue 103. Further progression of the lesion results in the formation of 
the advanced lesion characterized by a fibrous cap and a cell-free lipid core 244 (Figure 7B). 
The fibrous cap is formed by migrated SMCs and their secreted extracellular matrix such 
as collagen. A uniformly thick fibrous cap provides stability to the atherosclerotic lesion. 
On the contrary, thinning of the fibrous cap due to the apoptosis of SMCs or increased 




the lesion. A complicated lesion is formed when the fissured atherosclerotic lesion induces 
secondary hemorrhage and thrombosis (Figure 7C), which may lead to occlusion of the 
artery and become clinically symptomatic as a myocardial infarction or cerebral stroke 245, 
246.  
 
1.2.2 Cells in atherosclerotic lesions  
A variety of cells have been found in human atherosclerotic lesions, including 
monocytes/macrophages/dendritic cells, T and B lymphocytes, smooth muscle cells, 
neutrophils, and mast cells. Studies in mice have revealed their respective roles in the 
pathogenesis of atherosclerosis. 
 
1.2.2.1 Monocytes, macrophages, and dendritic cells 
Monocytes are widely regarded as key cellular protagonists of atherosclerosis as in the 
absence of macrophages, severe hypercholesterolemia is not sufficient to drive the 
pathologic process 246, 247. Monocytes can differentiate into macrophages and dendritic 
cells and become foam cells after excessive accumulation of lipids in the intima, thereby 
initiating atherosclerosis. Monocyte accumulation in atherosclerotic lesions is progressive 
and correlates to the lesion size 248. The deficiency of monocyte chemoattrant protein-1 
(MCP-1) 249 or its receptor CC-chemokine receptor 2 (CCR2) 250 provides dramatic 
protection from monocyte recruitment and atherosclerotic lesion formation. However, 
when the fibrous cap is formed, further recruitment of monocytes is inhibited 247, 251. 
Subsets of monocytes with distinct patterns of surface markers and behaviors during 
inflammation have recently been characterized and shown to have complementary roles 
during progression of atherosclerosis 252, 253. In the mouse, one subset of monocytes with 
high expression of Ly6C (Ly6Chigh) promotes inflammation while the other subset with 
low expression of Ly6C (Ly6Clow) attenuates inflammation and promotes angiogenesis and 
granulation tissue formation in models of tissue injury 254. Ly6Chigh monocytes expand in 
hypercholesterolemic conditions, infiltrate into the intima via CCR2, CCR5 and C-X(3)-C 
motif chemokine receptor 1 (CX3CR1), and selectively give rise to macrophages in 
atheroma 252, 253. In contrast, Ly6Clow monocytes enter the atherosclerotic lesion less 
frequently and employ CX3CR1 and CCR5 to accumulate in the lesion and differentiate 
into cells expressing the dendritic cell-associated marker CD11c 253. Interestingly, the 
expression of MCP-1 in atherosclerotic lesions rises quickly after the initiation of lesion 
formation, while CX3CL3 only appears later and in more advanced lesions 255, 256, 
indicating that the two monocyte subsets may recruit sequentially during lesion 
development.  
Different environmental signals, including microbial products and cytokines 
activate macrophages diversely, leading to macrophage heterogeneity. Gordon and Taylor 
summarized evidence for the existence of two macrophage phenotypes, widely known as 
classically activated (M1) and alternatively activated (M2) macrophages 257. LPS or IFN-γ 
activated M1 macrophages have enhanced capacity in phagocytosis and produce 
proinflammatory mediators such as TNF-α and IL-6 257. Incubation of M-CSF-
differentiated macrophages with IL-4 or IL-13 induces the polarization of macrophages 
into M2 with increased expression of anti-inflammatory cytokines such as IL-10 and TGF-
β 258. Moreover, inducible nitric oxide synthase (iNOS) is upregulated during classical M1 
activation while arginase-1 that competes with iNOS for substrate is induced during 
alternative M2 activation. The balance of M1-M2 may thus greatly affect lesion 




oxide. Interestingly, oxidized LDL increases the expression of markers of both classical 
activation (MMP-1 and iNOS) and alternative activation (arginase-I) 259, 260. In line, foam 
cells isolated from atherosclerotic lesions express MMP-1 and reduced arginase-I, a feature 
of classical activation, and increased MMP-12, a feature of alternative activation 261. Of 
note, the phenotype of macrophages is plastic and reversible 262. However, whether 
modulation of M1-M2 can become a therapeutic target requires further investigation.  
Dendritic cells (DCs), as the most potent professional antigen-presenting cells 
(APC), are essential for the priming of adaptive immune responses and involved in 
maintaining immune tolerance to self antigens 263. DCs originate from bone marrow 
progenitors, penetrate peripheral tissues from the circulation, and give rise to immature 
DCs. In the peripheral tissues, DCs monitor the microenvironment and, when the cells 
encounter ‘danger’ signals, DCs undergo differentiation and maturation 264. The 
identification of DCs in the arterial walls of animal models 265, 266 facilitated the 
investigation of the impact of DCs in atherosclerosis. The significance of DCs in 
atherogenesis is evident in mice overexpressing hBcl-2 267. Expansion of the DC 
population in these animals alleviates atherosclerosis. However, this reduction of lesion 
size is correlated with decreased levels of plasma cholesterol. Conversely, depletion of 
DCs results in increased plasma cholesterol levels and accelerated atherosclerosis, 
indicating that DCs may act on lipid metabolism and thereby inhibit lesion development 
267. More importantly, vaccination using mature DCs pulsed with oxidized LDL induced 
oxidized-specific T cells with a lowered T-helper 1 (Th1) response, increases the levels of 
ox-LDL-specific antibodies and reduces lesion development in LDLr KO mice 268. 
Likewise, the development of atherosclerosis in human apoB-100 transgenic LDLr KO 
mice is attenuated by treatment with apoB-100 loaded tolerogenic dendritic cells 269. 
However, treatment with DCs pulsed with malondialdehyde modified LDL in apoE KO 
mice aggravates atherosclerosis 270. Therefore, the potential of DC-based therapy in 
atherosclerosis needs further investigation. 
 
1.2.2.2 Lymphocytes 
The antigen-specific adaptive immune system is involved in the development of 
atherosclerosis 271. Deficiency in both B and T cells inhibits the development of the early 
lesions rather than advanced lesions 272. Different B and T cell subsets can be distinguished 
with different effects on atherosclerosis. 
 
B lymphocytes 
B lymphocytes, essential players in humoral immunity, are mainly present in the 
adventitia rather than in the lesion 273, 274. The atheroprotective role of B lymphocytes 
was evidenced by the finding that B cell deficiency results in increased atherosclerotic 
lesion development in LDLr KO mice 275, while adoptive transfer of splenic B cells 
protects against atherosclerosis in apoE KO mice 276. In mice, several B cell subsets, 
including B1, B2, and B10 have been described 277. B1 cells, preferentially localized in 
the peritoneal cavity, have been recognized as producers of antibodies that mainly are 
immunoglobulins (Ig)M. IgM protects against atherosclerosis via clearance of apoptotic 
cells and oxidized LDL 278. Deficiency of IL-5, a cytokine that promotes the expansion of 
B1 cells, leads to reduced levels of IgM and concomitantly increased atherosclerosis. 
Therefore, B1 cells are atheroprotective. In contrast, B2 cells are conventional B cells and 
constitute the major B cell population in spleen and lymph nodes. They produce low 




atherogenic 279, 280. Depletion of B2 cells using a CD20-specific monoclonal antibody 
ameliorates, while adoptive transfer of B2 cells aggravates atherosclerosis. The 
atherogenic effect of B2 cells may be mediated by promoting T cells to secrete IFNγ and 
reduce IL-17 production 279, 281. Recently, a third subset called B10 cells have been 
identified as IL-10 producing B cells 282. Since IL-10 is anti-inflammatory and 
atheroprotective 283, 284, B10 cells might protect against atherosclerosis. 
 
T lymphocytes 
CD4+ T helper cells 
T cells in atherosclerotic lesions are mostly CD4+ T cells 285. Adoptive transfer of CD4+ T 
helper cells into severe combined immune deficient (scid) apoE KO mice revealed their 
pro-atherogenic role 286. The majority of the pathogenic CD4+ T cells in atherosclerosis are 
Th1 cells. Atherosclerosis-prone mice that are deficient in T-bet, a Th1-associated 
transcription factor, show attenuated atherosclerosis 287. Th1 cells secrete IFNγ as a 
signature cytokine which promotes atherosclerosis 288, 289. IL-12 is important in Th1 cell 
differentiation and IL-18 synergizes with IL-12 to induce IFNγ production 290. IL-12 or IL-
18 deletion results in a significant reduction in atherosclerotic lesion development 291, 292, 
while exogenous administration of IL-12 or IL-18 clearly accelerates lesion progression 234, 
293, 294. In contrast, Th2 cells are proposed to antagonize the pro-atherogenic Th1 effects 
and thereby confer atheroprotection. In mouse models that are relatively resistant to 
atherosclerosis, a Th2-bias has been shown to protect against early fatty streak 
development 295. IL-33, a powerful inducer of Th2 responses, results in less atherosclerosis 
in apoE KO mice 296. Th2 cells secrete IL-4, IL-5, and IL-10 and provide help for antibody 
production by B cells. IL-4 drives Th2 cell differentiation and downregulates IFNγ. 
Strikingly, IL-4 deficiency in bone marrow-derived cells results in attenuation of 
atherosclerosis in the aortic arch and the thoracic aorta 297. IL-5 drives production of IgM 
by B1 cells and inhibits atherogenesis 287. The protective effect of IL-10 in atherosclerosis 
is evidenced by the finding that IL-10 deficiency leads to increased lesion development 298-
300. Thus, the Th1/2 balance greatly influences atherosclerotic lesion development.  
Th17 cells represent a newly identified subset of CD4+ T helper cells producing 
IL-17. The role of Th17 cells and IL-17 in atherosclerosis is emerging. In atherosclerotic 
arterial walls, Th17 cells are present in both the adventitia and the lesion 301. Blockade of 
IL-17 by using a neutralizing antibody or the adenovirous producing IL-17A receptor 
results in reduced atherosclerosis while exogenous treatment of recombinant IL-17 or IL-
17A promotes the formation of atherosclerotic lesions 301-303. However, Taleb et al recently 
revealed that IL-17 might be atheroprotective as mice lacking a preponderance of Th17 
cells due to deficiency of SOCS3, a suppressor of signaling from IL-17 and several other 
cytokines, show less atherosclerotic lesion development 281. The function of IL-17 thus 
remains controversial and awaits more direct studies to further address the issue. 
 
CD8+ T cells 
In addition to CD4+ T cells, also CD8+ T cells are present in atherosclerotic lesions 285. 
However, the exact role of CD8+ T cells in atherosclerosis is still unknown. Activation 
and infiltration of CD8+ T cells seems to correlate with larger lesions in apoE KO mice 
treated with an agonist to the tumor necrosis factor-like surface protein CD137 304 and 






Regulatory T cells 
Regulatory T (Treg) cells are identified as a group of T cells that can suppress immune 
responses. In-vitro studies showed that naturally occurring Tregs, characterized by the 
expression of CD4, high levels of CD25 and the transcriptional factor Foxp3, steer 
macrophage differentiation towards M2 and inhibit macrophage foam cell formation by 
cell-to-cell contact and cytokine IL-10 and TGF-β 306. Evidence for the atheroprotective 
effects of Treg cells has been provided using mice with fewer Treg cells due to the 
deficiency of CD80-86 or CD28. Leukocyte deficiency in CD80-86 or CD28 results in 
more atherosclerosis 307. Interestingly, in apoE KO mice, the number and suppressive 
property of naturally occurring Tregs are decreased. Importantly, adoptive transfer of 
Tregs from WT into apoE KO mice inhibits lesion development 308. Moreover, induction 
of Tregs by oral administration of oxLDL or HSP60 results in less atherosclerosis 309, 310. 
Likewise, in vivo expansion of Tregs using a complex of IL-2 and anti-IL-2 mAb 
(monoclonal antibody), reduced atherosclerotic lesion formation in LDLr KO mice 311. 
On the contrary, vaccination against Foxp3, a transcriptional factor instrumental in 
mediating the suppressive functions of natural Treg cells, aggravates atherosclerosis 312. 
The cytokines secreted by Treg cells, such as TGF-β and IL-10, also have profound 
atheroprotective effects 313. Of note, oxidized LDL attenuates the suppressive function of 
Tregs 308. Therefore, therapeutic strategies aiming to induce Tregs may be more effective 
in the presence of anti-oxidants. 
 
1.2.2.3 Smooth muscle cells  
It is generally accepted that transition of SMCs from a contractile state to a proliferative 
and migratory state contributes to the growth of the atherosclerotic lesion. The first 
evidence is provided by one study on SMC-specific deletion of LRP1 in LDLr KO mice 76. 
Aggravation of atherosclerosis was shown to be correlated with increased expression of 
platelet-derived growth factor (PDGF) receptor-β on SMC and enhanced proliferation and 
migration of SMC due to the deletion of LRP1 76. Conversely, inhibition of SMC 
proliferation and migration due to the deficiency of β-arrestins, multifunctional adaptor 
proteins, reduces atherosclerosis in LDLr KO mice 314. SMCs are also responsible for the 
formation of the fibrotic cap that can stabilize and prevent the lesion from rupture 315. 
Using transgenic mice with selective induction of SMC apoptosis, Clark et al demonstrated 
the crucial role of SMC apoptosis for lesion vulnerability 316. Interestingly, histological 
studies of autopsy specimens of human coronary arteries ranging from infants to adults 
provide evidence that regions prone to the development of atherosclerosis contain 
abundant SMCs in the intima while regions that are more resistant to atherosclerosis 
contain few 317-319, indicating the potential role of SMCs in the lesion development. The 
underlying mechanisms might involve: 1) Atherogenic stimuli such as oxidized LDL 
stimulate SMCs to secrete larger and more highly sulfated proteoglycans, thereby altering 
the composition of extracellular matrix (ECM) and in turn increasing lipoprotein retention 
320. 2) Atherogenic stimuli such as hypercholesterolemia and proinflammatory cytokines 
increase the expression of receptors involved in cholesterol uptake, including LDL 
receptor, VLDL receptor, and scavenger receptors, thereby promoting SMCs 
transformation into foam cells 321, 322. 3) SMCs in the lesion express a variety of adhesion 
molecules including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1), and fractalkine, thereby leading to the retention of monocytes and 
macrophages inside the lesion 323-326. 4) Interaction of macrophages and lymphocytes with 
SMCs via ICAM-1 and VCAM-1 protects these cells against apoptosis, thus contributing 




transforming growth factor-β (TGF−β), interferon γ (IFNγ), and monocyte chemoattractant 
protein (MCP-1), all of which contribute to the initiation and propagation of the 
inflammatory response to lipid 328. 
 
1.2.2.4 Neutrophils 
In contrast to lymphocytes and monocytes/macrophages, neutrophils are not detected in 
high numbers in atherosclerotic lesions. Since neutrophils are primarily found at sites of 
lesion rupture and erosion or in thrombi 329, neutrophils were believed to be important only 
in the late-stage of atherosclerosis. However, neutrophils are present in atherosclerotic 
lesions of all stages and the surrounding adventitia in apoE KO and LDLr KO mice 330, 331. 
The low frequency of neutrophils found in the atherosclerotic lesions might be due to their 
short life span and rapid apoptosis upon activation 332. The functional importance of 
neutrophils for the initiation and development of atherosclerotic lesions was recently 
demonstrated by Zernecke et al 330 and Drechsier et al 333. Hypercholesterolemia enhances 
granulopoiesis and mobilization from bone marrow, thereby leading to neutrophilia 333. 
The degree of neutrophilia is correlated to the extent of early atherosclerotic lesions. 
Importantly, depletion of neutrophils in the circulation significantly inhibits early lesion 
development 330, 333. However, the development of advanced lesions was not affected by 
neutropenia 333, suggesting an important role of neutrophils in the initiation of 
atherosclerosis. 
Neutrophils can affect atherosclerosis through its granule proteins such as 
myeloperoxidase (MPO), elastase, and cathepsin G. First, deposition of neutrophil granule 
proteins on the endothelium may induce endothelial dysfunction, thereby triggering the 
retention of lipoproteins and the recruitment of leukocytes 334-338. Second, neutrophil 
granule proteins may also activate macrophages to produce and release proinflammatory 
cytokines such as TNFα and IFNγ to promote lesion development 339, 340. Third, neutrophil 
granule proteins induce apoptosis of endothelial cells, thereby contributing to the 
vulnerability and rupture of the lesion 341, 342. In addition, oxygen radicals produced by 
neutrophils via MPO, lipoxygenases, and NADPH oxidase also affect atherosclerosis by 
inducing lipid oxidation, endothelial dysfunction, and apoptosis of endothelial cells 343.  
 
1.2.2.5 Mast cells 
Activated mast cells are found in human atherosclerotic lesions and have a wide range of 
functions in the pathogenesis of atherosclerosis 263, 344. The recent studies by Sun et al. 345 
and Bot et al. 346-348 highlight the importance of mast cells in atherosclerosis. In 
atherosclerotic lesions, mast cells can be activated by oxidized LDL-IgG immune 
complexes 349 and neuropeptide substance P 347. Proinflammatory cytokines including IFNγ 
and IL-6 345 and chymase 348 secreted by activated mast cells promote lesion development 
and vulnerability. Moreover, mast cells can secrete several chemokines, including IL-8 and 
MCP-1, leading to the recruitment of other leukocytes 349. In addition, mast cells may play 
roles in lipid metabolism 350 and macrophage foam cell formation 351, 352, thereby 
influencing the susceptibility to atherosclerosis. 
 
1.3 ABCA1 and atherosclerosis: cholesterol homeostasis, reverse cholesterol 
transport, and inflammation  
ABCA1 is a plasma membrane protein which functions as a major regulator of cellular 
cholesterol and phospholipid homeostasis 353, 354. ABCA1 mediates cholesterol and 




ABCA1 cause Tangier’s disease characterized by low plasma HDL, macrophage 
accumulation and deposition of CEs, and premature atherosclerosis 356-358. Animal studies 
demonstrate that hepatic and intestinal ABCA1 are crucial for the biogenesis of HDL 194, 
195, 359, while macrophage ABCA1 promotes cholesterol efflux and thereby protects against 
foam cell formation 241, 360, 361. The atheroprotective effects of ABCA1 are primarily 
attributed to its role in promotion of reverse cholesterol transport from macrophages via 
HDL to the liver 362-364.  
In addition, effects of ABCA1 on the immune-inflammation response 365 might also 
influence the development of atherosclerosis. Leukocyte ABCA1 deficiency promotes 
macrophage infiltration into different tissues 241, 360, probably due to the increased 
chemotactic response of macrophages 366. Moreover, ABCA1 deficient macrophages show 
enhanced proinflammatory response to lipopolysaccharide (LPS) 367-369. Interestingly, 
ABCA1 is absent in the inflammatory monocyte subsets that are more apt to the 
proinflammatory effects induced by LPS/IFN-γ 370. The potent anti-inflammatory 
properties of ABCA1 can be directly attributed to its cholesterol export activity. ABCA1 
deficiency increases FC and lipid rafts in the membrane of macrophages and subsequently 
induces trafficking of MyD88-dependent Toll-like receptors to lipid rafts. Of note, Tang et 
al recently provide evidence that macrophage ABCA1 also functions as a direct anti-
inflammatory receptor, which is independent of its lipid transport function 371. The 
interaction between apoAI and ABCA1 in macrophage activates Janus kinase 2 
(JAK2)/STAT3 pathway and suppresses LPS-induced inflammation. In addition, ABCA1 
deficiency is associated with increased immune complex accumulation in the kidney, a 
phenotype of systemic lupus erythematosus (SLE) 372. Deranged apoptosis is implicated in 
the pathogenesis of SLE 373. Therefore, the SLE phenotype in ABCA1 KO mice might be 
related to a role of ABCA1 in prevention of apoptosis and clearance of apoptotic cells. 
First, due to its lipid transport function, ABCA1 protects against FC loading, ER stress, 
and oxidized lipid-mediated apoptosis 374. Second, ABCA1 is important for the efficient 
exposure of phosphatidylserine on apoptotic cells, which is necessary to guarantee 
recognition by phagocytes 375. Last, ABCA1 interacts with syntaxin 13 and flotillin-1 in 
Lubrol WX-insoluble raft microdomains in macrophages which participate in the 
formation of phagosomes 376. Therefore, the role of ABCA1 in apoptosis and clearance of 
apoptotic cells might also contribute to its immunosuppressive function. 
It is conceivable that ABCA1 is atheroprotective based on its role in the prevention 
of foam cell formation and inflammation. However, manipulation of ABCA1 expression in 
mouse models has yielded conflicting results. Mice lacking ABCA1 globally do not show 
increased susceptibility to atherosclerosis in LDLr KO and apoE KO mice 360. 
Overexpression of ABCA1 in both liver and macrophages even results in more 
atherosclerotic lesion formation in apoE KO 377 and LDLr KO 378 mice, although plasma 
HDL-C levels and biliary cholesterol secretion are upregulated 379. These might be due to 
the fact that manipulation of ABCA1 expression affects not only HDL-C levels but also 
cholesterol levels in apoB-containing lipoproteins. Bone marrow transplantation studies 
showed that leukocyte ABCA1 is atheroprotective as deletion of ABCA1 in bone marrow-
derived hematopoietic cells resulted in increased atherosclerosis 178, 241, 243, 360, 380 while 
overexpression of leukocyte ABCA1 reduced atherosclerosis 381. However, Brunham et al 
found that specific knockdown of macrophage ABCA1 in LDLr KO mice did not modulate 
the initiation and development of atherosclerosis 382. Interestingly, this study also 
demonstrated that liver-specific inactivation of ABCA1 leads to reduced HDL-C levels and 
accelerated atherosclerosis while overexpression of ABCA1 in the liver alleviates the 




anti-atherogenic role. In addition, modest overexpression of human ABCA1 on endothelial 
cells (EC) also protects the atherosclerotic lesion development in wild-type mice 383. 
Strikingly, EC-specific overexpression of human ABCA1 did not influence the 
atherosclerotic lesion development in ABCA1 KO or apoE KO mice, suggesting that the 
protective effect of ABCA1 on endothelium is conditional. The effects of ABCA1 on other 
cell types, such as T cells, B cells, and mast cells, on the development of atherosclerosis 
remain to be elucidated. 
 
1.4 SR-BI and atherosclerosis: beyond HDL metabolism  
Experiments using transgenic and KO mice have established that SR-BI protects against 
atherosclerosis. Disruption of SR-BI in wild-type as well as LDLr KO mice increases 
atherosclerosis 384, 385. Tissue-specific inactivation of SR-BI has dissected the discrete role 
of SR-BI in different cell types on atherosclerosis susceptibility. Liver-specific knockdown 
of SR-BI results in the accumulation of abnormally large HDL particles and accelerated 
atherosclerosis 384. Increased oxidative stress in SR-BI KO mice suggests that the 
abnormally large HDL particles are dysfunctional, which may also potentially promote 
atherogenesis 386. Normalization of HDL levels by CETP cannot reverse the oxidative 
stress and reduce atherosclerosis in SR-BI KO mice 387. Transgene or adenovirus-mediated 
hepatic overexpression of SR-BI markedly reduced atherosclerosis 165, 388, 389. The 
atheroprotective effect of hepatic SR-BI is thus largely attributed its role in HDL-mediated 
RCT. Of note, hepatic SR-BI is also involved in the clearance of VLDL 162 and CM 166, 
which might affect atherosclerotic lesion development.  
Extrahepatic SR-BI is also protective against atherosclerosis, as evidenced by the 
finding that knockout of hepatic SR-BI results in less lesion formation as compared to 
total-body SR-BI deficiency 384. Bone marrow transplantation studies indicate that 
macrophage SR-BI plays a unique dual role in the pathogenesis of atherosclerosis, 
depending on the stage of lesion development 390. The development of early fatty streak 
lesions is facilitated by macrophage SR-BI 177, while SR-BI on macrophages reduces the 
development of advanced atherosclerotic lesions 177, 385. This unique dual role is likely a 
direct effect of the multi-functional and multi-ligand qualities of SR-BI, which binds a 
wide array of native and modified lipoproteins and mediates the bi-directional flux of 
cholesterol between HDL and cells 390. Moreover, SR-BI is also expressed on ECs. 
Overexpression of SR-BI on ECs leads to decreased en face aortic lesion area in wild-type 
mice 391. Several lines of evidence have indicated that SR-BI on ECs is important for the 
atheroprotective effects of HDL. Endothelial SR-BI transports HDL through the 
endothelium by transcytosis to get access to the cells in the intima 392. Importantly, during 
the transcytosis, the size of HDL is reduced, but the protein moiety remained intact, which 
might increase the capacity of HDL as a cholesterol acceptor. Moreover, HDL prevents 
against apoptosis of EC 393, promotes EC migration to maintain the integrity of the 
endothelium 394, and induces the activation of endothelial nitric oxide synthase (eNOS) via 
SR-BI 395, 396.  
The atheroprotective effects of SR-BI might also be attributed to its role in 
inflammation. SR-BI-mediated cholesterol uptake by the adrenal is essential for optimal 
glucocorticoid production 397. Also SR-BI can bind to and internalize LPS 398. Therefore, 
enhanced immune response to LPS in SR-BI KO mice is largely the consequence of 
defective glucocorticoid production and hepatic LPS clearance 399. Importantly, 
overexpression of SR-BI reduces septic death 400. Interestingly, SR-BI on macrophage also 




inflammatory response to LPS 400. In addition, interaction of HDL with SR-BI on EC can 
inhibit expression of adhesion molecules VCAM-1 and ICAM-1 401, which may prevent 
the activation and infiltration of inflammatory cells. 
 
1.5 Macrophage reverse cholesterol transport: potential therapeutic target for 
atherosclerosis  
Reverse cholesterol transport is important for the removal of excessive cholesterol from 
peripheral tissues. Macrophage-derived foam cells, as major cellular components of early 
and advanced lesions, contribute to the initiation, development, and rupture of 
atherosclerotic lesions. Macrophage RCT, removal of cholesterol from macrophage foam 
cells in the atherosclerotic lesions, is thus crucial for the treatment of atherosclerosis. 
However, the mass of cholesterol derived from macrophage foam cells is only a tiny 
fraction of the overall flux of cholesterol from peripheral tissues. Mass-based methods 
cannot be used to trace such a small amount of cholesterol derived from macrophage foam 
cells. For this reason, the group of Dr. Rader developed a method to trace cholesterol 
efflux and reverse cholesterol transport specifically from macrophage foam cells to the 
feces 402. Macrophages are labeled with [3H]cholesterol in the presence of acetylated LDL 
and injected into the peritoneal cavity of mice. The tracer can be detected in the plasma, 
liver, bile, and feces. Although this assay has limitations, this method helps us to increase 
the understanding of the molecular regulation of RCT. More importantly, the rate of 
macrophage RCT predicts atherosclerosis better than the level of HDL-C in mice 403. 
Specific cellular cholesterol transporters including ABCA1, ABCG1, and SR-BI 362-364, 404 
and the quantity and quality of HDL-based acceptors 362, 405 greatly influence macrophage 
RCT in vivo. Therapeutic targeting of macrophage reverse cholesterol transport may 
potentially prevent progression or even induce regression of atherosclerosis. 
Overexpression of hepatic apoAI increases HDL levels and enhances macrophage RCT 406. 
LXR agonists increase cholesterol efflux by induction of ABCA1 and ABCG1 and 
promotes biliary cholesterol secretion by upregulation of ABCG5 and ABCG8, thereby 
facilitating macrophage RCT 407. Furthermore, induction of HDL by overexpression of 
hepatic apoAI 408, 409 and activation of LXR 410 is required for regression of atherosclerotic 
lesions. In addition, PPAR-α agonists could promote macrophage RCT and reduce 
atherosclerosis 411. Therefore, determination of the role of RCT, especially macrophage-
specific RCT in atherosclerosis are of essential importance for the treatment of 
atherosclerosis. 
  
1.6 Outline of the thesis  
ABCA1 and SR-BI are important mediators in RCT. To study the putative synergistic role 
of ABCA1 and SR-BI in RCT, ABCA1/SR-BI double knockout (dKO) mice were 
generated. In Chapter 2, the phenotype of dKO mice with respect to plasma lipid levels, 
HDL metabolism, blood cell counts, macrophage RCT, and tissue cholesterol homeostasis 
was characterized. Due to the lack of atherogenic lipids in the circulation, enhanced 
macrophage foam cell formation but no atherosclerosis was observed in ABCA1/SR-BI 
dKO mice. DKO mice were thus challenged with high fat/high cholesterol diet containing 
0.05% cholate to determine the effects of combined deficiency of ABCA1 and SR-BI on 
atherosclerosis in Chapter 3.  
Macrophage cannot limit the lipid uptake and depend on the cholesterol efflux 
mechanisms to prevent their transformation into foam cell formation. Several cholesterol 
efflux pathways have been identified including aqueous diffusion, SR-BI mediated efflux, 




cell formation in the atherosclerotic lesion is reviewed in Chapter 4. In Chapter 5, bone 
marrow cells from ABCA1/SR-BI dKO mice and respective control mice were 
transplanted into female LDLr KO mice to specifically investigate the effects of combined 
deficiency of ABCA1 and SR-BI in bone marrow-derived cells on atherosclerosis. 
Deletion of the macrophage LDL receptor impairs sterol-induced upregulation of ABCA1 
expression 412. To investigate the interaction of the LDL receptor and ABCA1 on 
leukocytes and the consequences for atherosclerotic lesion development in vivo, bone 
marrow transplantation experiments were performed using LDLr/ABCA1 dKO mice as 
donors in Chapter 6. In Chapter 7, bone marrow from ABCA1 KO mice was transplanted 
into LDLr/apoAI dKO mice to investigate whether leukocyte ABCA1 is atheroprotective 
in the absence of circulating apoAI. 
Different strategies, including dietary lipid lowering, overexpression of 
macrophage ABCA1, and infusion of synthetic cholesterol-free phosphatidylcholine (PC) 
particles, were used to induce cholesterol efflux from macrophages in established 
atherosclerotic lesions. The effect of dietary lipid lowering on the remodeling of 
established atherosclerotic lesions in LDLr KO mice was studied in Chapter 8. In 
Chapter 9, the dynamics of macrophage infiltration into the established lesions and the 
effect of macrophage ABCA1 overexpression were studied in LDLr KO mice. The 
beneficial effects of reconstituted HDL (composed of human apoAI and PC) infusion on 
atherosclerosis might be attributed to both its capacities to induce cholesterol efflux from 
macrophage foam cells and its anti-inflammatory actions. The effects of induction of 
macrophage cholesterol efflux by solely infusion of PC particle on established 
atherosclerotic lesions were investigated in Chapter 10. 
Finally, all the results obtained in this thesis and future perspectives are 
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High-density lipoprotein (HDL) mediated reverse cholesterol transport (RCT) is regarded 
to be crucial for prevention of foam cell formation and atherosclerosis. ABC-transporter 
A1 (ABCA1) and scavenger receptor BI (SR-BI) are involved in the biogenesis of HDL 
and the selective delivery of HDL cholesterol to the liver, respectively. In the present 
study, we phenotypically characterized mice lacking these two proteins essential for HDL 
metabolism. ABCA1xSR-BI double knockout (dKO) mice showed severe 
hypocholesterolemia mainly due to HDL loss, despite a 90% reduction of HDL cholesterol 
uptake by liver. VLDL production was increased in dKO mice. However, non-HDL 
cholesterol levels were reduced, probably due to enhanced clearance via LRP1. 
Hepatobiliary cholesterol transport and fecal sterol excretion were not impaired in dKO 
mice. In contrast, the macrophage RCT in dKO mice was markedly impaired as compared 
to WT mice, associated with the accumulation of macrophage foam cells in the lung and 
Peyer’s patches. Strikingly, no atherosclerotic lesion formation was observed in dKO mice. 
In conclusion, both ABCA1 and SR-BI are essential for maintaining a properly functioning 
HDL-mediated macrophage RCT, while the potential anti-atherosclerotic functions of 











Plasma HDL cholesterol levels are inversely correlated with the risk of atherosclerotic 
vascular disease [1]. HDL-mediated reverse cholesterol transport (RCT), a process in 
which excess peripheral cholesterol is removed and delivered to the liver for biliary 
secretion, has been regarded crucial for prevention of foam cell formation and 
atherosclerosis [2]. Two important genes recognized in RCT are the ATP-binding cassette 
transporter A1 (ABCA1) and the scavenger receptor class B type I (SR-BI) [2]. ABCA1 
promotes the efflux of cholesterol and phospholipid to lipid-poor apolipoprotein AI 
(ApoAI), leading to HDL particle maturation, the first step in RCT [2].  In contrast, SR-BI 
facilitates the bi-directional flux of cholesterol between cells and mature HDL down a 
concentration gradient. Importantly, SR-BI is essential for the selective uptake of 
cholesteryl esters (CEs) from HDL by the liver for biliary secretion, the last step in RCT 
[2].  
Recent genome-wide association studies (GWAS) have identified ABCA1 as a 
major gene influencing HDL levels in humans [3]. Targeted deletion of ABCA1 in the 
liver [4] and intestine [5] of mice has revealed the crucial roles of hepatic and intestinal 
ABCA1 for HDL biogenesis. In agreement, induction of hepatic and intestinal ABCA1 
expression increases plasma HDL cholesterol (HDL-C) levels [4,6]. In contrast, 
macrophage ABCA1 minimally contributes to plasma HDL cholesterol [7]. Patients with 
functional mutations in ABCA1 have Tangier disease (TD), characterized by a marked 
reduction in plasma HDL-C and increased macrophage foam cell formation in several 
tissues [8]. Likewise, ABCA1 knockout (KO) mice display the similar pathophysiologic 
phenotype as TD patients [9]. Cells from patients with TD and ABCA1 KO mice are 
defective in the efflux of cholesterol and phospholipid to apoAI and partially to HDL [8]. 
Also, macrophage RCT is impaired in ABCA1 KO mice, mainly due to HDL deficiency 
[10-11].  
In several population studies, a clear association between mutations in the coding 
and promoter regions of human SR-BI and increased plasma HDL-C has been shown 
[12,13]. Recent GWAS studies also demonstrated that single nucleotide polymorphism 
(SNPs) in and near SR-BI are significantly associated with plasma levels of HDL-C in 
humans [14]. However, only very recently conclusive evidence was provided on the 
importance of SR-BI for controlling HDL-C levels in humans. Vergeer et al identified a 
family in which heterozygous carriers of a unique mutation (P297S) in the extracellular 
domain of SR-BI showed 37% elevated HDL cholesterol levels [15]. Importantly, 
hepatocytes that expressed the P297S mutant SR-BI displayed a reduced capacity to take 
up CEs from HDL, thereby leading to the elevation in plasma HDL-C [15]. Also, SR-BI 
KO mice display increased HDL-C, due to impaired delivery of HDL-CEs to liver [16]. 
Interestingly, despite the high levels of HDL-C, SR-BI deficient mice have impaired 
macrophage RCT [17]. Conversely, overexpression of hepatic SR-BI decreases HDL-C 
and promotes macrophage RCT [17].  
Given that ABCA1 and SR-BI are involved in the different steps of RCT, it is 
conceivable that ABCA1 and SR-BI might act synergistically in the process of RCT. To 
study the RCT process under conditions in which both of these key mediators are absent, 
ABCA1/SR-BI double knockout (dKO) mice were generated. In this study, we describe the 
characterization of ABCA1/SR-BI dKO mice with respect to plasma lipids, HDL 
metabolism, blood cell counts, bile secretion, macrophage RCT, tissue cholesterol 
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Materials and Methods: 
For detailed methodology, please see the data supplement, available online at 
http://www.sciencedirect.com. Briefly, ABCA1/SR-BI dKO mice were generated by 
intercrossing double heterozygous offsprings obtained from crossbreeding of ABCA1 KO 
mice with SR-BI KO mice. Plasma cholesterol levels, the lipoprotein distribution, blood 
cell counts, and hepatic expression of lipoprotein receptors, including SR-BI, LDL receptor 
(LDLr), and LDLr related protein 1 (LRP1) were determined. Moreover, VLDL 
production, serum decay and liver uptake of [3H]-cholesteryl ether-labeled HDL, 
hepatobiliary and fecal cholesterol secretion, and macrophage RCT were analyzed. In 
addition, tissue macrophage cholesterol homeostasis and atherosclerosis susceptibility 
were examined by Oil-red-O staining and immunohistochemical staining against Moma-2. 
 
Results  
Hypocholesterolemia and HDL loss in ABCA1/SR-BI dKO mice 
To analyze the potential synergistic role of ABCA1 and SR-BI in the RCT process, we 
generated ABCA1/SR-BI dKO mice. The absence of ABCA1 and SR-BI in the dKO mice 
was verified at DNA level by performing PCR on genomic DNA (Supplementary Figure 
1). From the crosses of ABCA1/SR-BI double heterozygous mice, 7.2%, 6.5%, and 6.2% 
of the offspring were ABCA1 KO, SR-BI KO, and dKO mice, which are close to the 
expected Mendelian inheritance rate of 6.25%. Homozygous dKO males are fertile while 
dKO females, similar to SR-BI KO females [18,19], are infertile, which could be reversed 
by administering the cholesterol-lowering drug probucol. However, as described for 
ABCA1 KO mice [20], also under these conditions a lower frequency of pregnancy and 
extensive neonatal death of pups born from dKO mothers was observed. No significant 
differences in body weight between wild-type (WT), ABCA1 KO, SR-BI KO, and dKO 
mice were observed at the age of 12 weeks (22.7±0.9 g, 20.3±0.3 g, 22.0±0.6 g, 21.3±0.3 
g, respectively). Furthermore, dKO mice born from ABCA1 × SR-BI double heterozygous 
breedings did not appear to have a reduced life expectancy as they can reach ages of >1 
year. 
 
Figure 1. Hypocholesterolemia 
and HDL loss in ABCA1/SR-
BI double knockout mice. 
Total plasma cholesterol levels 
(A), lipoprotein distribution of 
total cholesterol (B), HDL 
cholesterol levels (C), and non-
HDL cholesterol levels (D) of 
WT, ABCA1 KO, SR-BI KO 
and ABCA1/SR-BI double KO 
mice (mixed male and female) at 
the age of 12-16 weeks old on 
chow. Bar graphs represent the 
means±SEM (n=8). Two 
hundred microliters of pooled 
mouse plasma from the different 
genotypes were fractioned by 
FPLC. Statistically significant 
difference *p<0.05, ***p<0.001 





In line with previous studies [8-9,18,19], SR-BI KO mice showed increased plasma 
free (5.5-fold, p<0.001) and total cholesterol (2.0-fold, p<0.001) levels as compared to WT 
animals and accumulated abnormally large HDL particles. ABCA1 KO mice on the 
contrary were severely hypocholesterolemic and had a near complete absence of HDL 
(Figure 1A-1C and Supplementary Table 4). Mice with a combined deficiency of ABCA1 
and SR-BI resembled single ABCA1 KO mice with a dramatic >80% and >99% decrease 
in the plasma TC and HDL-C levels, respectively (Figure 1A-1C). Of note, ABCA1 
deficiency dramatically reduced the plasma free cholesterol levels (22-fold, p<0.001) in the 
SR-BI KO background (Supplementary Table 4). SR-BI deficiency also led to an increase 
in plasma levels of phospholipids (1.2-fold, p<0.001) and triglycerides (1.2-fold, p<0.05). 
In contrast, both ABCA1 KO and dKO mice showed comparably reduced plasma levels of 
phosholipids (3.0-fold, p<0.001 vs WT) and triglycerides (1.7-fold, p<0.001 vs WT) 
(Supplementary Table 4).  
 
Figure 2. Reduced serum decay and liver uptake of [3H]CEt-HDL in ABCA1/SR-BI double knockout 
mice. Serum decay and liver uptake  was determined in 12-16 week old female animals on chow diet. (A) 
The clearance of [3H]CEt-HDL from the circulation in WT (×), ABCA1 KO (∆), SR-BI KO (∇) and 
ABCA1/SR-BI double KO (○) mice at 0, 1, 2, 4, and 24 hours after intravenous injection of 200 μg [3H]CEt-
HDL. (B) The amount of [3H]CEt-HDL in the circulation and the liver at 4 hours after injection. (C) The 
amount of [3H]CEt-HDL in the circulation and the liver at 24 hours after injection. Bar graphs represent the 
means±SEM (n=3/group). Statistically significant difference **p<0.01, ***p<0.001 vs WT mice; ###p<0.001 vs 
ABCA1 KO mice; $$$ p<0.001 vs SR-BI KO mice. 
Serum decay and hepatic uptake of HDL-CE in dKO mice were studied next. Upon 
injection of [3H]CEt-HDL into WT mice, 60.3±1.3% of the injected label was removed 
from the blood during the first 4 h (Figure 2A and 2B). Consistent with previous findings 
[21], serum clearance was severely delayed upon deletion of SR-BI. At 4 h after injection 
only 35.4±1.9% (p<0.001) was removed from the circulation in SR-BI KO mice. Notably, 
in ABCA1 KO mice, 87.6±1.4% (p<0.001) of the injected label was removed from the 
 
ABCA1xSR-BI double knockout mice 
 59
circulation at 4 h after injection. Combined disruption of ABCA1 and SR-BI led to a 
significantly delayed serum clearance of [3H]CEt-HDL (48.6±1.1% removed at 4h, 
p<0.001 vs WT mice; p<0.001 vs ABCA1 KO mice). Importantly, these findings in the 
dKO mice for the first time show that SR-BI deficiency dramatically decreases HDL-CEt 
clearance in the absence of a circulation pool of HDL. At this time point, in WT mice, 
26.5±1.5% of the injected dose (ID) was recovered in the liver while ABCA1 KO mice 
showed a 1.7-fold (46.0±3.1%, p<0.001) increase in uptake by the liver (Figure 2B). In 
contrast, only 3.5±0.6% (p<0.001 vs WT) and 3.2±0.3% (p<0.001 vs ABCA1 KO) of the 
ID accumulated in the liver of SR-BI KO and dKO mice, indicating that SR-BI is 
responsible for the majority (around 80-90%) of the removal of CEt from HDL in the 
circulation by liver. Moreover, the distribution of radioactivity over extrahepatic tissues 
was also analyzed at 4 hours after injection (Supplementary Table 3). It was found that the 
majority of the extrahepatic label was present in bone (6-9%), skin (4-9%), and the muscle 
(1-3%). The total recovery of label was between 79 to 82%. In line with previous study 
[21], SR-BI deficiency also led to an ~88% (p<0.001 vs WT) reduction of [3H]CEt uptake 
by adrenal. Similarly, the adrenal upake of [3H]CEt in dKO mice was also dramatically 
decreased 85% (p<0.001) and 97% (p<0.001) as compared to WT and ABCA1 KO mice, 
respectively (Supplementary Table 3). Interestingly, ABCA1 deficiency led to 6-fold 
(p<0.001 vs WT) more adrenal uptake of [3H]CEt. Also a 3-fold (p<0.01) increase in skin 
uptake of [3H]CEt was observed in ABCA1 KO mice as compared to WT mice. However, 
the absolute uptake by adrenal and skin in ABCA1 KO mice was only 3.5% and 2.6% of 
ID. Thus, increased clearance of [3H]CEt-HDL from the circulation in ABCA1 KO mice as 
compared to WT animals was mainly due to enhanced uptake by the liver. After 24 h, 
above 90% of injected [3H]CEt-HDL was removed from the circulation in WT, ABCA1 
KO, and dKO mice whereas 30.0±0.8% (p<0.001) of the injected label remained in the 
circulation of SR-BI KO mice (Figure 2A and 2C). At this time point, 46.0±2.3% and 
50.1±3.4% of ID were recovered in the liver of WT and ABCA1 KO mice. In contrast, 
only 10.2±0.3% (p<0.001 vs WT) and 5.9±0.2% (p<0.001 vs ABCA1 KO) of the ID had 
accumulated in livers of SR-BI KO and dKO mice, respectively (Figure 2C). 
 
In line with previous findings [22], deletion of SR-BI also resulted in a 1.3-fold 
(p<0.05) increase in non-HDL-C levels (Figure 1D). Interestingly, non-HDL-C levels were 
reduced 4.2-fold (p<0.001) and 5.1-fold (p<0.001) in ABCA1 KO and dKO animals, 
respectively as compared to WT mice (Figure 1D). However, ABCA1 deficiency did lead 
to a 1.5-fold (P<0.001) and 1.8-fold (P<0.01) higher VLDL production rate against both 
the WT and SR-BI KO background, respectively (Figure 3A). The observed reduction in 
non-HDL-C in ABCA1 KO and dKO mice was thus not the result of an impaired hepatic 
VLDL secretion. Next, we analyzed the hepatic expression of ABCA1, SR-BI, LDLr, and 
Figure 3. Increased VLDL production in 
ABCA1/SR-BI double knockout mice.  VLDL 
production rate was determined in 12-16 week old 
female animals on chow diet. VLDL production 
was determined by calculating the accumulation 
rate (g/h/kg body weight) of triglycerides in the 
plasma after blocking VLDL clearance by Triton 
WR-1339. Data are expressed as mean±SEM 
(n=5/group). Statistically significant difference 
**p<0.01, ***p<0.001 vs WT mice; $$$p<0.001 vs 




LRP1 at both the mRNA and the protein level. As anticipated, deletion of ABCA1 and/or 
SR-BI resulted in undetectable mRNA and protein expression of the respective proteins in 
the liver (Figure 4). ABCA1 deficiency did not affect the expression of hepatic SR-BI. 
Thus, the observed increased accumulation of [3H]CEt-HDL in the liver of ABCA1 KO 
mice might be due to the lack of an endogenous HDL pool, which could compete with 
[3H]CEt-HDL in binding with hepatic SR-BI. The mRNA levels of LDLr and LRP1 were 
increased 2.5-fold (p<0.01) and 2.0-fold (p<0.01), respectively in the liver of dKO mice as 
compared to WT and single KOs (Figure 4A). However, only the protein levels of hepatic 
LRP1 were significantly upregulated 1.7-fold (p<0.05) in the dKOs (Figure 4B). 
Strikingly, the protein levels of the LDLr in livers of the dKO mice were dramatically 
reduced (4-fold, p<0.05) (Figure 4B). Since dKO mice showed 3-fold (p<0.01) higher 
hepatic expression of PCSK9 protein as compared to WT mice and single KOs 
(Supplementary Figure 2A), the reduced LDLr protein levels in the liver might be due to 
enhanced degradation of the LDLr via PCSK9 [23] (Supplementary Figure 2A). In 
addition, the expression of P2Y13, an important player in HDL metabolism [24], was also 
analyzed by Western blot. As shown in Supplementary Figure 2B, single ABCA1 and SR-
BI deficiency did not affect the expression of P2Y13 in the liver. In contrast, dKO mice 
showed slightly increased hepatic levels of P2Y13 (1.5-fold, p<0.05 vs WT mice and 
single KOs).  
 
Figure 4. Expression levels of ABCA1, SR-BI, LDLr, and LRP1 in livers of ABCA1/SR-BI dKO mice. 
Livers were harvested from 16-week old chow-fed WT, ABCA1 KO, SR-BI KO, and dKO mice and total 
RNA and protein were isolated for real-time PCR analysis (A, n=6) and western blotting analysis (B, n=3), 
respectively as described in Materials and Methods. The expression levels in livers of WT animals were 
normalized to 1. Data are expressed as mean±SEM. Statistically significant difference *p<0.05, **p<0.01, 
***p<0.001 vs WT mice; #p<0.05, ##p<0.01, ###p<0.001 vs ABCA1 KO mice; $p<0.05, $$p<0.01, $$$p<0.001 vs 
SR-BI KO mice. 
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Normalized red blood cell and reticulocyte counts in ABCA1/SR-BI dKO mice 
Circulating white and red blood cells were next analyzed. No significant differences in 
white blood cells, including lymphocytes, monocytes, and granulocytes were observed 
among the different strains of animals (Supplementary Table 5). In line with previous 
study [25, 26], SR-BI KO mice showed a slightly reduced red blood cell (RBC) count 
(10.0±0.1 x109/mL vs 11.1±0.2 x109/mL in WT mice, p<0.01) with an increased 
reticulocyte count (215±15‰ vs 34±1‰ in WT mice, p<0.0001) (Supplementary Table 5). 
No significant differences in the RBC (11.5±0.2 x109/mL) and reticulocyte (36±2‰) count 
were found in ABCA1 KO mice as compared to WT mice. Notably, ABCA1 deficiency 
normalized the RBC and reticulocyte counts in SR-BI KO mice (dKO mice: RBC, 
10.8±0.3 x109/mL, p<0.05; reticulocyte, 38±5‰, p<0.001 vs SR-BI KO). This is most 
likely the consequence of the large reduction in FC levels in the dKO mice [25,26]. 
 
Unaltered hepatic lipid content and biliary and fecal sterol secretion in ABCA1/SR-
BI dKO mice 
Hepatic total cholesterol, phospholipids, and triglycerides levels were not changed in dKO 
mice as compared to WT and single KOs (Supplementary Table 6). In line with one 
previous study [27], ABCA1 deficiency did not influence biliary cholesterol secretion. 
Also, the biliary secretion rate of cholesterol was not impaired in dKO mice, although a 
slight but not significant decrease in biliary cholesterol secretion was observed in SR-BI 
KO mice. The expression of ABCG5 and ABCG8, important cholesterol transporters on 
hepatic canalicular membrane [28], was unaffected in SR-BI KO and dKO mice 
(Supplementary Figure 2C and 2D). Moreover, biliary secretion of phospholipid and bile 
salts were lower in dKO mice, but the differences were not statistically significant, which 
might be due to the high variation among the animals (Supplementary Table 6). 
Furthermore, dKO mice produced similar amount of feces (1.26±0.35 g/day) as compared 
to WT mice (1.13±0.08 g/day). Lipid analysis of fecal samples showed that combined 
deficiency of ABCA1 and SR-BI did not affect fecal cholesterol (2.34±0.04 vs 2.43±0.09 
mmol/kg) and bile salt content (12.75±2.28 vs 10.30±0.65 mmol/kg) as compared to WT 
mice. Thus, despite the absence of HDL, ABCA1 deficiency did not alter the hepatic lipid 
content and biliary and fecal sterol secretion in either the WT or the SR-BI KO 
background.  
 
Impaired macrophage RCT in ABCA1/SR-BI dKO mice 
Next, we investigated the effect of combined deficiency of ABCA1 and SR-BI on 
macrophage-specific RCT. First, bone marrow-derived macrophages from WT, ABCA1 
KO, SR-BI KO, and dKO mice were loaded with [3H]-cholesterol and acetylated LDL 
(acLDL). The lipid-laden macrophages were subsequently injected intraperitoneally into 
WT mice, and the transport of labeled cholesterol to blood, liver, and feces was measured 
at 24 h after the injection. Consistent with previous findings [11], ABCA1 deficiency on 
macrophages did result in a ~20% reduction (p<0.05) in the amount of tracer excreted into 
feces. However, given that the expression of macrophage SR-BI was undetectable after 
cholesterol loading, we could not pick up the effect of macrophage SR-BI deficiency on 
RCT in this experimental setting (Supplementary Figure 3). Thus, we next quantified the 
release of [3H]-cholesterol from acLDL-loaded WT macrophages to the plasma and their 
transport to the liver and ultimately the feces in WT, ABCA1 KO, SR-BI KO and dKO 
mice. In line with previous findings [10,11,17], at 24 hours after injection, the absence of 




plasma (13.5-fold, p<0.001), liver (1.5-fold, p<0.05), and feces (1.3-fold, p<0.05) (Figure 
5). SR-BI KO mice with impaired hepatic uptake of HDL-CE had significantly increased 
3H-cholesterol (1.7-fold, p<0.001) in the plasma but reduced 3H-cholesterol in the liver 
(1.4-fold, p<0.05) and feces (1.3-fold, p<0.05) (Figure 5). Combined deficiency of ABCA1 
and SR-BI also led to a significant reduction of 3H-cholesterol in the plasma (13.3-fold, 
p<0.001), liver (1.7-fold, p<0.05), and feces (1.4-fold, p<0.05). However, no added effect 
of ABCA1 and SR-BI on the reverse transport of cholesterol from WT macrophages was 
observed. 
 
Figure 5. Impaired macrophage-specific reverse cholesterol transport in ABCA1/SR-BI double 
knockout mice. Peritoneal macrophages from WT mice were prepared and labeled with [3H]-cholesterol and 
acetylated LDL (5 μCi/mL, 100 μg/mL) for 48 hours. After equilibration, [3H]-cholesterol labeled 
macrophage foam cells were harvested and injected into male WT, ABCA1 KO, SR-BI KO and ABCA1/SR-
BI double knockout mice at the age of 12-16 weeks old on chow. Blood (A), liver (B), and feces (C) were 
collected at 24 hours after injection and the tracer levels in various samples were measured. Data are 
expressed as percentage of the [3H]-cholesterol tracer relative to total dpm tracer injected ±SEM (n=6). 
*p<0.05, **p<0.01, ***p<0.001 vs WT mice; ###p<0.001 vs SR-BI KO mice. 
 
Tissue cholesterol homeostasis in ABCA1/SR-BI dKO mice 
To assess the morphological changes associated with combined ABCA1 and SR-BI 
deficiency, a necropsy of the mice at the age of 16 weeks old on chow diet was performed. 
No significant differences were observed in liver weight between WT, ABCA1 KO, SR-BI 
KO, and dKO mice (50.0±1.8 mg/g, 55.3±2.1 mg/g, 56.0±3.0 mg/g, 52.5±3.3 mg/g body 
weight, respectively). In line with previous findings [8,25,26], ABCA1 KO mice and SR-
BI KO mice showed a 1.3-fold (4.4±0.2 mg/g, p<0.05) and a 3.3-fold (11.0±0.5 mg/g, 
p<0.001) increase in spleen weight, respectively as compared to WT mice (3.3±0.2 mg/g 
body weight). Interestingly, the spleen weight of dKO mice was increased 1.9-fold to 
6.3±0.7 mg/g body weight (p<0.001 vs WT), which was significantly lower than the spleen 
weight of SR-BI KO mice (1.7-fold, p<0.001) and higher than the spleen weight of 
ABCA1 KO mice (1.4-fold, p<0.01). The splenomegaly observed in SR-BI KO mice was 
associated with enhanced erythropoiesis in the spleen and the accumulation of 
reticulocytes in the blood, due to the abnormally high plasma FC levels [25,26]. ABCA1 
deficiency did lower plasma FC levels and normalized the counts of reticulocytes in the 
circulation of SR-BI KO mice (Supplementary Table 4 and 5). The splenomegaly observed 
in the dKO mice thus can not be the result of enhanced erythropoiesis. 
To further determine the effect of combined deficiency of ABCA1 and SR-BI on 
tissue cholesterol homeostasis, cryostat sections of liver, spleen, lung, thymus, and Peyer’s 
patches in mice at the age of 16 weeks old on chow were stained for neutral lipids with 
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Oil-red-O. Interestingly, no visible lipid accumulation was found in liver, spleen, and 
thymus in WT, single ABCA1 KO, single SR-BI KO, and dKO mice at the age of 16 
weeks (data not shown). Thus, the splenomegaly observed in single and double KOs was 
also not due to lipid accumulation. Consistent with previous findings [9], neutral lipid 
accumulation was observed in the lung of the single ABCA1 KOs. Also, Peyer’s patches of 
 
Figure 6. Enhanced macrophage foam cell formation but no atherosclerosis in ABCA1/SR-BI double 
knockout mice. (A and B) A necropsy was performed on mice at the age of 16 weeks on chow diet. Cryostat 
sections of lung and Peyer’s patches were stained with Oil-red-O and a rat monoclonal antibody against 
Moma-2 to visualize lipid accumulation and macrophages, respectively by light microscopy. (C) 
Atherosclerosis was analyzed at the aortic root of mice at the age of 1 year old on chow diet. Representative 
photomicrographs from sections of the aortic root after Oil-red-O lipid staining.  
 
ABCA1 KOs showed red staining with Oil-red-O, consistent with lipid accumulation. 
Strikingly, dKO mice displayed more extreme macrophage foam cell formation in the lung 
and Peyer’s patches as evidenced by colocalization of Oil-red-O with Moma-2 macrophage 
staining (Figure 6A). Lipid quantification indicated that accumulated neutral lipid in the 
lung is cholesterol ester (dKO: 204.2±31.04 μg/mg protein vs WT: 1.8±1.2 μg/mg protein, 
p<0.001). Furthermore, atherosclerosis was analyzed at the aortic root of seperate mice at 
the age of 1 year old on chow diet. As shown in Figure 6B, no atherosclerotic lesions were 
evident in the WT, ABCA1 KO, and SR-BI KO mice. Despite enhanced macrophage foam 
cell formation in the lung and Peyer’s patches, also dKO mice did not develop any 
atherosclerotic lesions, even at the age of 1 year. This is most likely due to the fact that the 
dKO mice lack the high plasma levels of atherogenic lipoproteins needed to trigger arterial 
wall accumulation of macrophages. 
 
Discussion 
In the current study, we for the first time phenotypically characterized ABCA1/SR-BI dKO 




using these unique dKO mice lacking both transporters essential for HDL metabolism. 
ABCA1/SR-BI dKO mice resembled single ABCA1 KO mice in HDL loss and 
hypocholesterolemia. Although the transport of cholesterol from WT macrophages to feces 
was impaired in dKO mice, combined deficiency of ABCA1 and SR-BI did not result in an 
additive effect as compared to the rate of cholesterol transport to feces in single ABCA1 
KO and SR-BI KO mice. Interestingly, enhanced macrophage foam cell formation was 
evident in the lung and Peyer’s patches of dKO mice, clearly illustrating the importance of 
both ABCA1 and SR-BI for macrophage cholesterol homeostasis in these organs. 
However, no atherosclerotic lesion development was observed in these dKOs, even at the 
age of 1 year, probably due to the low levels of non-HDL-C. 
SR-BI mediated hepatic uptake of HDL cholesterol is nearly completely blocked in 
SR-BI KO and dKO mice, similar as in SR-BI KO mice. However, with respect to the lipid 
levels in the plasma and the lipoprotein distribution of cholesterol, our dKO mice 
resembled single ABCA1 KO mice. The HDL loss in the dKO mice is thus due to impaired 
HDL production, similarly as previously described for single ABCA1 KO mice [29]. 
Although ABCA1 deficiency did not affect the hepatic expression of SR-BI, ABCA1 KO 
mice did take up 2 times more [3H]-CEt from HDL by liver as compared to WT mice. This 
clearly indicates that endogenous HDL could compete with [3H]-CEt-HDL for uptake by 
the liver, thereby inhibiting the clearance of [3H]-CEt-HDL in wild-type mice. 
Importantly, the absence of the endogenous HDL pool in ABCA1 KO and dKO mice 
allowed us to study the role of SR-BI in HDL catabolism in absence of competition with 
endogenous HDL in the circulation. We hereby thus for the first time provide direct 
compelling in vivo evidence that SR-BI is the determining factor for the selective uptake 
CE from HDL by liver in the absence of the endogenous HDL pool. 
Interestingly, dKO mice also resembled the single ABCA1 KOs in non-HDL-C 
levels, which were significantly lower than WT and SR-BI KO mice. VLDL production, 
however, was increased in dKO and single ABCA1 KO mice. Chung et al previously 
demonstrated that pre-β migrating nascent HDL generated by ABCA1 inhibits VLDL 
production through activation of phosphoinositide 3 (PI3)-kinase [30]. As a result, ABCA1 
deficiency leads to increased VLDL production in vivo secondary to reduced PI3-kinase 
signaling [31]. Moreover, SR-BI has been shown to promote VLDL production through 
induction of microsomal triglyceride transfer protein (MTP) activity [32], which might also 
be regulated via PI3-kinase signaling [33]. In the present study and previous studies [22], 
we could not show the effect of SR-BI deficiency on VLDL production. SR-BI KO mice, 
however, do display increased non-HDL cholesterol levels which can be attributed to a 
direct role of SR-BI in the clearance of VLDL [22]. In the absence of competition with 
endogenous HDL, VLDL clearance via SR-BI thus might also contribute to the lower 
levels of non-HDL-C in ABCA1 KO mice. In contrast, the decreased non-HDL-C levels in 
the circulation of dKO mice are probably the consequence of compensatory upregulation 
of LRP1-mediated clearance pathway in the liver.  
In agreement with a previous study showing that biliary cholesterol secretion is not 
affected by the absence of HDL [27], our single ABCA1 KO and dKO mice did not 
display impaired biliary cholesterol secretion. The reduced biliary cholesterol secretion in 
SR-BI KO mice was observed in previous studies [34,35,36], which could not be 
confirmed in the current study. Differences in the background of mice [34,35] and 
treatment of mice, e.g. dietary challenge[35] and viral exposure [36], between the present 
study and previous studies might account for this different observation. The low levels of 
basal biliary cholesterol secretion in our single SR-BI KO and dKO mice indicate that SR-
BI might not be essential for the basal cholesterol secretion or that the other cholesterol 
secretion pathways such as ABCG5 and ABCG8 are redundant under this condition. 
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Although overexpression of SR-BI could increase biliary secretion in the absence of 
ABCG5 and ABCG8 [37], our results indicate that the contribution of SR-BI at the 
physiological level to the biliary cholesterol secretion still needs further investigation.  
Despite being a tiny pool for RCT, macrophage RCT is crucial for the prevention 
of macrophage foam cell formation and atherosclerosis [38]. Inactivation of ABCA1 
results in HDL deficiency, thereby impairing macrophage RCT [10-11]. Blocking the 
hepatic CE uptake from HDL by the deletion of SR-BI also impairs macrophage RCT [17]. 
In line, HDL deficiency in ABCA1/SR-BI dKO mice did lead to the reduced transport of 
the [3H]-cholesterol tracer from WT macrophages to feces. SR-BI deficiency, however, did 
not further impair macrophage RCT in the dKO mice as compared to single ABCA1 KO 
mice. Thus, in dKO mice, the effect of ABCA1 on generation of HDL rather than the 
delivery of HDL-C to the liver via SR-BI is the rate limiting factor for macrophage RCT. 
Notably, in ABCA1/SR-BI dKO mice, a substantial amount of the [3H]-cholesterol tracer 
could still be transferred from WT macrophages to the feces. [3H]-Cholesterol from the 
macrophages is detected in plasma not only in the HDL pool but also in the non-HDL pool 
[10-11]. Therefore, non-HDL lipoproteins might also participate in macrophage RCT. 
Augmentation of the clearance of non-HDL lipoproteins by liver might be thus important 
for promoting macrophage RCT, thereby protecting against foam cell formation and 
atherosclerosis. In line, macrophage-derived apoE promotes both the clearance of non-
HDL lipoproteins [39] and macrophage-specific reverse cholesterol transport in apoE KO 
mice [40]. Moreover, erythrocytes and albumin might also aid the transport of cholesterol 
through the circulation [41,42]. In addition, Van der Velde et al reported a novel reverse 
cholesterol transport pathway, namely transintestinal cholesterol transport (TICE) that 
directly transfers cholesterol from blood to the intestinal lumen via enterocytes. TICE can 
contribute for up to 70% of the daily total body neutral sterol secretion in mice [43]. 
Interestingly, TICE is not mediated through HDL particles because ABCA1 KO and our 
dKO mice show unaltered TICE (Vrins CLJ, unpublished data). How important TICE is 
for macrophage RCT, however, remains to be determined. 
ABCA1/SR-BI dKO mice display enhanced macrophage foam cell formation in the 
lung and Peyer’s patches. Macrophages cannot limit the uptake of cholesterol and thus 
depend on cholesterol efflux mechanisms to prevent foam cell formation. ABCA1, 
ABCG1, and SR-BI are important players in cholesterol efflux from macrophages [44]. 
ABCA1 and ABCG1 actively transfer cholesterol to lipid-free/poor apoAI and mature 
HDL, respectively while SR-BI induces cholesterol efflux to a phospholipid-containing 
acceptor like mature HDL down a concentration gradient. HDL deficiency and reduced 
macrophage RCT in single ABCA1 KO and dKO mice thus contribute to the macrophage 
foam cell formation observed in the lung and the Peyer’s patches. Interestingly, However, 
since more extreme foam cell formation was observed in dKO mice as compared to 
ABCA1 KO mice, probably also absence of ABCA1 and SR-BI in the macrophages will 
have contribution to the observed foam cell formation. Wang et al recently demonstrated 
that macrophage SR-BI does not promote macrophage RCT [45]. In the present study, we 
also failed to pick up the effect of macrophage SR-BI on macrophage RCT. However, 
cholesterol loading in vitro does downregulate the expression of SR-BI on WT 
macrophages [46]. Importantly, in previous bone marrow transplantation studies, we have 
shown that combined deficiency of macrophage ABCA1 and SR-BI did lead to massive 
foam cell formation in the peritoneal cavity and spleen of LDLr KO mice transplanted with 
dKO bone marrow and challenged with a Western-type diet [47]. Thus, the combined role 
of ABCA1 and SR-BI in cholesterol efflux could account for the enhanced formation of 
macrophage foam cells in the lung and Peyer’s patches of the dKO mice in vivo. 




in the peritoneal cavity as well as other macrophage-rich tissues, including liver, spleen, 
lung, Peyer’s patches and thymus [48]. Thus, despite the similarity in acceptor specificity 
of SR-BI and ABCG1, their relative in vivo importance could be affected by the biological 
environment of the macrophage and possibly the availability of substrates [47]. 
Interestingly, both ABCA1/ABCG1 dKO mice and ABCA1/SR-BI dKO mice show 
enhanced foam cell formation under hypocholesterolemia. The source of lipids for the 
observed foam cell formation is still elusive. Recent findings indicate that Toll-like 
receptor activation induces macrophage foam cell formation by promoting the lipid droplet 
formation in the absence of extracellular lipids [49]. Whether this mechanism contributes 
to the foam cell formation in our dKO mice warrants further investigation in future. Of 
note, like ABCA1/ABCG1 dKO mice [48], ABCA1/SR-BI dKO mice did not develop 
atherosclerotic lesions, further indicating the importance of high levels of atherogenic 
lipoproteins for the development of atherosclerosis.  
In summary, by characterizing our unique ABCA1/SR-BI dKO mice, we have 
provided more insight into the important roles of ABCA1 and SR-BI in lipid metabolism 
and macrophage foam cell formation in vivo. Our data indicate that both ABCA1-mediated 
HDL generation and HDL-CE delivery to the liver via SR-BI are essential for macrophage 
RCT.  Macrophage foam cells can be formed under hypocholesterolemia, while the 
presence of high levels of atherogenic lipoproteins is essential for the induction of 
atherosclerotic lesion formation. 
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Supplementary methods and data 
Materials and Methods 
Animals 
Both ABCA1 knockout (ABCA1 KO) and SR-BI knockout (SR-BI KO) mice, kindly provided by 
Dr. G. Chimini [1] and Dr. M. Krieger [2], respectively, were back-crossed onto a C57Bl/6 
background for at least 8 generations. Double heterozygous offsprings generated by cross-breeding 
were subsequently intercrossed to obtain the ABCA1/SR-BI double knockout (dKO) mice. The 
genotypes were analyzed using the primers shown in supplementary table 1. Mice were maintained 
on sterilized regular chow, containing 4.3% fat and no added cholesterol (RM3; Special Diet 
Services, Witham, UK). Animal experiments were performed at the Gorlaeus Laboratories of the 
Leiden/Amsterdam Center for Drug Research in accordance with the National Laws. All 
experimental protocols were approved by Ethics Committee for Animal Experiments of Leiden 
University. 
 
Plasma and hepatic lipid analyses 
After an overnight fasting-period, 200 μL of blood was drawn from the mice by tail bleeding. 
Hepatic lipids were extracted according to the method of Bligh & Dyer [3] and dissolved in 2% 
Triton X-100. Triglycerides (TG) and Phospholipids (PL) in serum and liver were determined using 
a standard enzymatic colorimetric assay (TG: Roche Diagnostics, Mannheim, Germany; PL: 
Spinreact, Girona, Spain). The concentrations of cholesterol in serum and liver were determined by 
incubation with 0.025 U/mL cholesterol oxidase (Sigma), 0.065 U/mL peroxidise, and 15 μg/mL 
cholesteryl esterase (Roche Diagnostics, Mannheim, Germany) in reaction buffer (1.0 KPi buffer, 
pH=7.7 containing 0.01 M phenol, 1 mM 4-amino-antipyrine, 1% polyoxyethylene-9-laurylether, 
and 7.5% methanol). Absorbance was read at 490 nm. The hepatic lipids levels were normalized to 
their protein concentrations determined using the BCATM protein assay (Pierce Biotechnology, 
Rockford, USA). HDL cholesterol was measured after precipitation with phosphotungstic acid and 
magnesium ions (Boehringer GmbH). The distribution of cholesterol over the different lipoproteins 
in serum was determined by fractionation of 30 μL of serum of the individual mice using a 
Superpose 6 column (3.2 x 300 mm, Smart system; Pharmacia, Uppsala, Sweden).  
 
Blood cell count 
Blood was drawn from the tail vein of mice on chow diet at the age of 12-16 weeks old. White and 
Red blood cells were quantified using an automated Sysmex XT-2000iV Veterinary Hematology 




Analysis of gene expression by real-time quantitative PCR 
Total RNA was extracted from liver of male animals at the age of 16 weeks old on chow by the 
acid guanidium thiocyanate-phenol chloroform extraction method according to Chomczynski et al 
[4]. cDNA was synthesized from 1 μg of total RNA using RevertAidTM M-MuLV Reverse 
Transcriptase according to manufacturer’s instructions. mRNA levels were quantitatively 
determined on an ABI Prism® 7700 Sequence Detection System (Applied Biosystems, Foster City, 
CA) using SYBR-green technology. PCR primers (Supplementary Table 2) were designed using 
Primer Express 1.5 Software with the manufacturer’s default settings (Applied Biosystems). 
mRNA expression levels are indicated relative to the average of the housekeeping genes 
hypoxanthine phosphoribosyltransferase (HPRT), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), ribosomal protein 36B4, and β-actin. 
 
Western blot Analysis 
Livers from 16-week old chow-fed male animals were homogenized with T-PER tissue protein 
extraction reagent with added protease inhibitors (Pierce Biotechnology, Rockford, USA). Cell 
debris was removed by centrifugation at 12,000 rpm for 10 min, and the protein content was 
determined by the Bio-Rad protein assay (Pierce Biotechnology). Aliquots of 50 μg of protein were 
separated by 7.5% SDS-PAGE electrophoresis and transferred onto nitrocellulose membranes 
(Schleicher and Schnell, Dassel, Germany). Immunolabelling was performed using either the rabbit 
polyclonal antibody α-SR-BI (ab3; Abcam, Cambridge, UK), rabbit polyclonal α-LDL receptor-
related protein type 1 (α-LRP-1) (H-80; Santa Cruz Biotechnology, CA), rabbit polyclonal α-LDL 
receptor (EP1553Y) and α-P2Y13 (Novus Biologicals, Cambridge, UK), rabbit polyclonal α-
PCSK9 (ab31762, Abcam, Cambridge, UK), rabbit polyclonal α-ABCG5 and α-ABCG8 (H-300, 
Santa Cruz Biotechnology), mouse monoclonal antibody α-β-actin (C4; Santa Cruz 
Biotechnology), or mouse monoclonal α-ABCA1 (AC-10, kindly provided by Dr M. R. Hayden 
(Vancouver, Canada)) as primary antibodies and horseradish peroxidase-conjugated goat-anti-
rabbit and goat-anti-mouse IgG (Jackson ImmunoResearch), respectively, as secondary antibodies. 
Finally, immunolabeling was detected using SuperSignal West Pico Chemiluminescent Substrate 
(Pierce Biotechnology).  
 
Hepatic HDL cholesterol uptake assay 
Human HDL was isolated from blood of healthy subjects by differential ultracentrifugation as 
described by Redgrave (1975). HDL (1.063 g/mL<d<1.21 g/mL) was labeled with [3H]-Cholesteryl 
oleoyl ether (CEt) via exchange from donor particles as reported previously [5]. Unilamellar 
liposome donor particles were formed by sonication of egg yolk phosphatidylcholine supplemented 
with 50 μCi of [3H-CEt]. A dose of 200 μg apolipoprotein (± 1.2 × 106 dpm) of [3H]CEt-HDL 
(total volume of 100 μL) was injected into the tail vein of the indicated types of female mice at the 
age of 12-16 weeks old on chow. At 3 min after injection, a blood sample was drawn to verify the 
injected dose. At 1h, 2h, 4h, and 24h after injection, blood samples were drawn to measure serum 
decay. For analysis of liver association, the liver was excised at 24 h after tracer injection, weighed, 
solubilized, and counted for [3H] radioactivity in a Packard liquid scintillation unit. A correction 
was made for the radioactivity in the blood present in the liver at the time of sampling as 
determined by injection of screened [125I]BSA (84.7 μL/g wet weight). Recovery of radioactivity in 
tissues is around 80% in all different strains of mice (Supplementary Table 3). 
 
In-vivo VLDL production 
Female animals at the age of 12-16 weeks old on chow were injected intravenously with 500 mg of 
Triton WR-1339 (Sigma) per kg body weight as a 15 g/dL solution in 0.9% NaCl after an overnight 
fast. Previous studies have shown that plasma VLDL clearance is virtually completely inhibited 
under these conditions [6]. Blood samples (50 μL) were taken at 0, 1, 2, and 3h after Triton WR-
1339 injection. Plasma triglycerides were analyzed enzymatically as described above and were 
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related to the body mass of the animals. The hepatic VLDL production was calculated from the 
slope of the curve and expressed as g/h/kg body weight. 
 
Bile sampling and biliary Lipid Content determination 
Bile was collected from 12-16 weeks old chow-fed male mice by cannulation of the gallbladder 
under hypnorm (fentanyl/fluanisone; 1 mg/kg) and diazepam (10 mg/kg) anaesthesia, using a 
humidified incubator to maintain body temperature. Bile was collected at 15 min intervals, and 
production was determined gravimetrically. All collected bile samples were examined for bile salt 
and lipid content as described previously [7-8]. 
 
Fecal sterol secretion 
The male animals at 12-16 weeks old on chow were placed individually in a metabolic cage with 
food and water available ad libitum. Feces were collected for 24 hours. Fecal samples were 
lyophilized, weighed and homogenized. Neutral sterols and bile salts were analyzed by gas liquid 
chromatographic procedures [8]. 
 
In-vivo macrophage-specific reverse cholesterol transport assay  
Thioglycollate-elicited peritoneal macrophages (PMs) from wildtype mice were loaded with 5 
μCi/mL [1α,2α(n)-3H]-cholesterol (Amersham Biosciences Europe GmbH, Germany) and 100 
μg/mL of acetylated LDL (acLDL) in DMEM/0.2% BSA for 48 hours, while bone marrow-derived 
macrophages (BMMs) from different genotypic mice were loaded with 50 μg/mL [3H]-cholesterol-
labeled acLDL (5 μCi/mL) in fresh differentiation media containing 4 μg/mL 22-hydroxy-
cholesterol and 1 μmol/L 9-cis retinoic acid for 48 hours. These cells were washed, equilibrated 
and harvested by treatment with accutase (PAA) for 15 min at 37oC. Radioactivity incorporated in 
the macrophages was determined by lipid extraction and liquid scintillation counting (Beckman). 
To determine the effect of combined deletion of macrophage ABCA1 and SR-BI on RCT, 5x106 
3H-cholesterol labeled-BMMs in 0.5 mL PBS were injected intraperitoneallly into wildtype male 
mice on chow at the age of 12-16 weeks old. Next, the different genotypic male mice on chow at 
the age of 12-16 weeks old were injected intraperitoneallly with 2×106 3H-cholesterol labeled-PMs 
in 0.5 mL PBS to determine the effect of combined hepatic ABCA1 and SR-BI deficiency on RCT. 
Blood was collected at 24 hours after injection via the vena cava and plasma was used for liquid 
scintillation counting (Beckman). Livers were removed, weighed, solubilized, and counted in a 
scintillation vial. Feces were collected, dried at 50oC, weighed and rehydrated in 10 mL miliQ 
water overnight. Fecal samples were then homogenized and radioactivity was determined by liquid 
scintillation counting (Beckman). The amount of 3H-tracer in plasma, liver, and feces was 
expressed as a percent of the injected dose. 
 
Histological and tissue lipid analysis 
Histological analyses were performed on 10-μm cryosections of lung, liver, spleen, thymus, and 
Peyer’s patches from 16-week old chow-fed animals. Lipid accumulation was determined by oil 
red O staining, combined with hematoxylin to visualize nuclei. Macrophages were visualized by 
immunolabeling against Moma-2 (Research diagnostics). Novared was used as the substrate. The 
red color is the positive staining, visible with regular light microscropy. Atherosclerotic lesion 
development was quantified in the aortic root of dKO mice of 1 year old animals on chow as 
described before [9]. 
Statistical Analysis 
Values are expressed as mean±SEM. A one way ANOVA and the Student Newman Keuls posttest 
were used to compare means after confirming normal distribution by the method Kolmogorov and 









Supplementary Figure 1. Verification of the ABCA1/SR-BI dKO mice. PCR analysis of genomic DNA to 






Supplementary Figure 2 Hepatic protein levels of PCSK9 (A), P2Y13 (B), ABCG5 (C), and ABCG8 (D) 
in ABCA1/SR-BI dKO mice. Livers were harvested from 16-week old chow-fed WT, ABCA1 KO, SR-BI 
KO, and dKO male mice and total protein was isolated for Western blot analysis as described in Materials 
and Methods. The expression levels in livers of WT animals were normalized to 1. Data are expressed as 
mean±SEM (n=3). Statistically significant difference *p<0.05 and **p<0.01 vs WT mice; #p<0.05 and 
##p<0.01 vs ABCA1 KO mice; $p<0.05 and $$p<0.01 vs SR-BI KO mice. 
 
 




Supplementary Figure 3 Effect of combined deletion of macrophage ABCA1 and SR-BI on reverse 
cholesterol transport. (A) Macrophages from WT and SR-BI KO mice were labeled with 50 μg/mL [3H]-
cholesterol-labeled acLDL before intraperitoneal injection into male WT mice on chow at the age of 12-16 
weeks old. (B) Macrophages from WT, ABCA1 KO, and ABCA1/SR-BI dKO mice were labeled with 50 
μg/mL [3H]-cholesterol-labeled acLDL in the presence of 4 μg/mL 22-hydroxy-cholesterol and 1 μmol/L 9-
cis retinoic acid before intraperitoneal injection into male wildtype mice on chow at the age of 12-16 weeks 
old. Quantification of macrophage-specific RCT was determined at 24 hours after injection. Data are 
expressed as mean±SEM (n=4-6/group). Statistically significant difference *p<0.05. Macrophage SR-BI 
deficiency did not affect macrophage-specific RCT, while macrophage ABCA1 deletion led to reduced 
macrophage-specific RCT. Combined deletion of ABCA1 and SR-BI led to a similar reduction of 
macrophage-specific RCT as single ABCA1 deficiency.  
 
Supplementary Table 1: Primers for detection of both wild type and the disrupted 
ABCA1 and SR-BI gene  
 
































Supplementary Table 2: Hepatic mRNA expression levels measured by quantitative real-





Forward Primer Reverse Primer Amplicon Size  
ABCA1 NM013454 GGTTTGGAGATGGTTATACAATAGTTGT 
TTCCCGGAAACGCAAGT
C 96 
SR-BI NM016741 GGCTGCTGTTTGCTGCG GCTGCTTGATGAGGGAGGG 63 
LDLR Z19521 CTGTGGGCTCCATAGGCTATCT 
GCGGTCCAGGGTCATCT
TC 68 
LRP1 NM008512 TGGGTCTCCCGAAATCTGTT ACCACCGCATTCTTGAAGGA 95 
HPRT J00423 TTGCTCGAGATGTCATGAAGGA 
AGCAGGTCAGCAAAGAA
CTTATAGC 91 
GAPDH NM008084 TCCATGACAACTTTGGCATTG 
TCACGCCACAGCTTTCC
A 103 
36B4 NM007475 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 85 




Supplementary Table 3. Recovery of radioactivity in tissues in ABCA1/SR-BI dKO mice 
Organ WT ABCA1 KO SR-BI KO dKO 
Serum 39.7±1.30 12.4±1.4 64.6±1.9 51.4±1.1 
Liver 26.5±1.5 46.0±3.1 3.5±0.6 3.1±0.3 
Spleen 0.22±0.02 0.85±0.26 nd nd 
Pancreas nd 0.02±0.01 nd 0.01±0.01 
Kidney nd 0.03±0.02 nd nd 
Adrenal 0.59±0.06 3.48±0.11a 0.07±0.01b 0.09±0.01b 
Stomach 0.15±0.09 0.29±0.10 0.35±0.14 0.42±0.19 
Small intestine nd 1.15±0.30 nd 0.09±0.09 
Large intestine 0.04±0.02 0.69±0.11 nd nd 
Bladder 0.02±0.01 0.03±0.01 nd 0.06±0.01 
thymus  0.02±0.01 0.06±0.01 nd 0.06±0.01 
Lung nd 0.25±0.02 nd nd 
Heart 0.13±0.03 0.13±0.01 0.28±0.03 0.29±0.03 
fat 0.40±0.07 0.48±0.08 0.29±0.05 1.09±0.06 
muscle 0.84±0.32 2.55±0.32c 1.03±0.20 3.41±0.21d 
Bone 5.49±0.68 6.39±1.08 5.70±0.52 8.57±0.27 
skin 4.42±0.39 3.96±0.67 6.40±0.25 8.78±0.19 
Recovery 78.6% 78.7% 82.3% 77.4% 
HDL labeled with [3H]CEt was injected into the tail vein of female different genotypic mice at the age of 12-
16 weeks old. At 4h after injection, the animals were sacrificed, serum was collected and tissues were 
removed. Tissues were assayed for [3H] counts and a correction was made for the contribution of serum to 
the measured organ associated radioactivity (See Materials and methods). Values are presented as mean ± 
SEM of 3 female animals at the age of 12-16 weeks old in each group. n.d.: not detectable. Significant 
difference ap<0.001 vs WT, SR-BI KO, and dKO; bp<0.001 vs WT and ABCA1 KO; cp<0.01 and dp<0.001 
vs WT and SR-BI KO mice. 
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Supplementary Table 4. Plasma lipid levels of ABCA1/SR-BI dKO mice 
Genotype WT ABCA1 KO SR-BI KO dKO 
Free cholesterol (mg/dL) 14.7±0.9 3.6±0.3a 80.5±2.0a,c 3.6±0.2a,d 
Total cholesterol (mg/dL) 61.6±2.1 8.3±0.7a 123.7±5.7a,c 10.5±1.3a,d 
Phospholipids (mg/dL) 136.9±3.5 46.3±4.8a 157.5±2.4a,c 47.5±2.0a,d 
Triglycerides (mg/dL) 51.9±3.6 32.9±3.8a 63.7±4.0b,c 30.8±2.8a,d 
Plasma was collected from mice (mixed male and female) at the age of 12-16 weeks old on chow after 
overnight fasting for lipid analysis. Values are presented as mean ± SEM for 8-13 animals in each group. 




Supplementary Table 5. Blood cell count of ABCA1/SR-BI dKO mice 
Genotype WT ABCA1 KO SR-BI KO dKO 
White blood cells (x106/mL) 12.6±1.0 11.7±0.6 11.2±0.4 10.9±0.7 
Lymphocytes (x106/mL) 10.6±0.8 10.4±0.8 9.4±0.3 9.5±0.7 
Monocytes (x106/mL) 0.45±0.10 0.32±0.04 0.37±0.05 0.35±0.03 
Granulocytes (x106/mL) 1.54±0.25 1.03±0.12 1.17±0.11 0.91±0.12 
Red blood cells (x109/mL) 11.0±0.2 11.5±0.2 10.0±0.1a,c,d 10.8±0.3 
Reticulocytes (x109/mL) 0.51±0.02 0.49±0.03 2.12±0.10b,c,e 0.50±0.05 
Reticulocytes (‰) 45.8±2.5 42.2±2.4 214.9±15.3b,c,e 46.3±4.6 
Blood were drawn from the tail vein of mice (mixed male and female) at the age of 12-16 weeks old on chow 
without fasting for cell counting by Sysmex hematology analyzer. Values are presented as mean ± SEM for 
6-8 animals in each group. Statistically significant difference ap<0.01 and bp<0.001 vs WT; cp<0.001 vs 











Supplementary Table 6. Hepatic lipid content and biliary lipid and bile salt secretion in 
ABCA1/SR-BI dKO mice 
Genotype WT ABCA1 KO SR-BI KO dKO 
Hepatic total cholesterol (mg/g) 51.2±3.2 52.8±2.1 56.8±6.1 54.4±2.5 
Hepatic Phospholipids (mg/g) 69.5±3.3 77.9±1.9 81.4±8.9 69.8±5.1 
Hepatic triglycerides (mg/g) 64.3±5.6 51.7±2.1 68.7±7.5 67.3±10.5 
Biliary cholesterol secretion 
(nmol/min/100 g BW) 0.92±0.15 0.93±0.38 0.79±0.04 0.86±0.18 
Biliary phospholipid secretion 
(nmol/min/100 g BW) 26.5±3.7 21.4±6.9 24.6±1.5 17.0±3.3 
Biliary bile salt secretion 
(nmol/min/100 g BW) 177.8±35.7 119.9±48.6 179.1±14.2 109.7±19.0
Values are presented as mean ± SEM for 5-6 male animals at the age of 12-16 weeks old on chow diet in 
each group. BW, body weight. No significant differences were found among different genotypic mice in 
hepatic lipid content and biliary lipid and bile salt secretion. 
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Objective: The aim of this study is to investigate the effect of combined deletion of 
ABCA1 and SR-BI, important facilitators of reverse cholesterol transport, on 
atherosclerosis.  
Methods and Results: ABCA1xSR-BI double knockout (dKO) mice and respective 
controls were challenged with an atherogenic diet (ATD) for 10 weeks to induce 
atherosclerosis. Upon challenge with ATD, dKO mice showed substantially lower 
cholesterol levels, mainly due to the absence of HDL. The levels of non-HDL cholesterol 
in dKO mice were similar to WT mice, higher than ABCA1 KO mice, but much lower than 
SR-BI KO mice. However, dKO mice accumulated more extreme foam cells in the 
peritoneal cavity. Also, combined deletion of ABCA1 and SR-BI led to enhanced Ly6Chigh 
monocytosis in the circulation. Strikingly, despite more susceptible to atherosclerosis than 
WT animals, dKO mice, similar to ABCA1 KO mice, developed smaller lesions than SR-
BI KO mice. This was associated with reduced recruitment of monocytes, probably due to 
lower levels of the adhesion molecule ICAM-1 in the arterial wall and the monocyte 
chemoattractant MCP-1 in plasma. 
Conclusion: ABCA1 and SR-BI are essential for prevention of macrophage foam cell 
formation and leukocytosis. ABCA1 deficiency, however, attenuates atherosclerosis in SR-
BI KO mice, probably by lowering the circulating levels of atherogenic lipoproteins and 











Reverse cholesterol transport (RCT) is important for macrophages to get rid of excess 
cholesterol, thereby inhibiting foam cell formation and atherosclerosis. Macrophage 
cholesterol efflux pathways, the first step of RCT, include passive diffusion, and 
transporter-mediated efflux via ABC-transporter A1 (ABCA1), ABC-transporter G1 
(ABCG1), and scavenger receptor class B type I (SR-BI) [1]. ABCA1 and ABCG1 
actively transport cholesterol to lipid-free apolipoprotein AI (apoAI) and HDL, 
respectively, while SR-BI promotes cholesterol efflux to HDL down the gradient [1]. 
Recently, we showed that macrophage ABCA1 and SR-BI synergistically protect against 
macrophage foam cell formation and atherosclerotic lesion development in LDL receptor 
knockout (LDLr KO) mice upon challenge with Western-type diet (WTD) [2]. In addition 
to macrophages, also hepatocytes of the liver express ABCA1 and SR-BI, where they play 
a role in the generation of HDL and clearance of HDL cholesterol by selective uptake of 
cholesteryl ester (CE), respectively. Total-body ABCA1 x SR-BI double knockout (dKO) 
mice showed enhanced foam cell formation in the lung and Peyer’s patches [3]. However, 
no atherosclerotic lesion development was evident in these dKO mice even when fed WTD 
for 20 weeks (Zhao Y et al. unpublished data). This might be due to the lack of circulating 
atherogenic lipoproteins. To investigate the putative synergistic effect of ABCA1 and SR-
BI on atherosclerosis, we fed dKO mice a high fat/high cholesterol atherogenic diet (ATD) 
for 10 weeks. Interestingly, our data demonstrate that ABCA1 deficiency induces 
macrophage foam cell formation and leukocytosis but inhibits atherosclerotic lesion 
development in SR-BI KO mice. 
 
 
Materials and Methods: 
Animals 
Both ABCA1 KO mice, a kind gift of Dr. G. Chimini [4], and SR-BI KO mice obtained 
from Dr. M. Krieger [5] were back-crossed onto a C57Bl/6 background for at least 8 
generations.  Subsequently the mice were cross-bred to generate double heterozygous 
offspring, which were further intercrossed to obtain the ABCA1/SR-BI double knockout 
(dKO) mice, and single ABCA1 KO, SR-BI KO, and wild-type (WT) littermates. All mice 
were maintained on sterilized regular chow containing 4.3% (w/w) fat and no added 
cholesterol (RM3, Special Diet Services). At 12-16 weeks of age, female animals were fed 
a semisynthetic atherogenic diet (ATD), containing 15% (w/w) fat, 1% (w/w) cholesterol, 
and 0.5% (w/w) cholate (Diet N, Abdiets) for 10 weeks. Animal experiments were 
performed at the Gorlaeus Laboratories of the Leiden/Amsterdam Center for Drug 
Research in accordance with the National Laws. All experimental protocols were approved 
by Ethics Committee for Animal Experiments of Leiden University. 
 
Lipid Analyses 
After an overnight fasting-period, 100 μL of blood was drawn from the mice by tail 
bleeding. The concentrations of cholesterol in serum were determined as described before 
[2]. The distribution of cholesterol over the different lipoproteins in serum was determined 
by fractionation of 200 μL of pooled serum using a Superose 6 column (3.2 x 300 mm, 
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Serum Atherogenicity Assay 
RAW 264.7 (mouse leukaemic monocyte/macrophage cell line) cells were incubated with 
3% mouse serum from each group of mice at 37oC for 24 hours. Cells were then stained 
with Oil-red-O for detection of lipid accumulation and counterstained with hematoxylin.  
   
Blood and Peritoneal Leukocyte Analysis 
Upon sacrifice the blood was collected by retro-orbital puncture under anesthesia. The 
peritoneal cavity of the mice was lavaged with 10 mL cold PBS to collect peritoneal 
leukocytes. Total white blood cells, neutrophil, lymphocyte, and monocyte counts in the 
blood and macrophage foam cells in the peritoneal cavity were analyzed using an 
automated Sysmex XT-2000iV Veterinary Heamatology analyzer (Sysmex Corporation). 
Corresponding samples were cytospun for manual confirmation and stained with Oil-red-O 
for detection of lipid accumulation, and counterstained with hematoxylin. 
 
Flow cytometry 
Cell surface immunolabelling was performed according to the manufacturer’s instructions 
(eBioscience & BD Biosciences). At sacrifice, blood, spleen, and mediastinal lymph nodes 
near the heart (HLN) were isolated. Single cell suspensions were obtained by squeezing the 
organs through a 70 μm cell strainer. Red blood cells were removed from blood and 
splenocytes using erythrocyte lysis buffer. Subsequently, cells were stained for the surface 
markers CD11b, CD8, CD44, CD62L (eBiosciences), CD4, Ly6G, and Ly6C (BD 
Biosciences) for 30 min at 4oC in labeling buffer (1% mouse serum in PBS). Flow 
cytometric analysis was performed with FacsCalibur and then analyzed with CellQuest 
software (Becton Dickinson, San Jose), correcting for nonspecific staining with isotype 
antibody controls. 
 
Histological Analysis of the Aortic Root 
On sacrifice the arterial tree was perfused in situ with PBS and the heart was excised and 
stored in 3.7% neutral-buffered formalin (Formal-fixx; Shandon Scientific) until use. 
Atherosclerotic lesion development was quantified in the aortic root from Oil-red-
O/hematoxylin-stained cryostat sections using the Leica image analysis system, consisting 
of a Leica DMRE microscope coupled to a video camera and Leica Qwin Imaging 
software (Leica Ltd). Mean lesion area (in μm2) was calculated from 10 Oil-red-
O/hematoxylin-stained sections, starting at the appearance of tricuspid valves. Sections 
were immunolabeled against MOMA-2 (monoclonal rat IgG2b, dilution 1:50, Research 
diagnostics), Ly6G (monoclonal rat IgG2b, dilution 1:100, eBioscience), and CD3 
(polyclonal Rabbit IgG, dilution 1:150, Neomarkers) for detection of macrophages, 
neutrophils, and T cells. ICAM-1 expression was visualized using purified anti-mouse 




Values are expressed as mean±SEM. One way ANOVA and the Student Newman Keuls 
posttest were used to compare means after confirming normal distribution by the method 
Kolmogorov and Smirnov using Graphpad Instat Software (San Diego, USA). A p value of 








Plasma cholesterol levels in ABCA1/SR-BI dKO mice upon challenge with ATD 
On a chow diet containing 4.3% fat and no added cholesterol, as reported previously [3], 
inactivation of SR-BI increased plasma total cholesterol (TC) (137±3 mg/dL vs 59±2 
mg/dL in WT mice, p<0.001) due to the impaired hepatic uptake of HDL-cholesterol 
(HDL-C). Hypocholesterolemia was evident in both ABCA1 KO (9±1 mg/dL, p<0.001) 
and ABCA1/SR-BI dKO (12±1 mg/dL, p<0.001) mice as a result of impaired HDL 
production. To induce atherosclerotic lesion formation, WT, ABCA1 KO, SR-BI KO and 
dKO mice were fed ATD containing 15% fat, 1% cholesterol, and 0.5% cholate for 10 
weeks. Upon sacrifice, plasma cholesterol levels were determined. Upon challenge with 
ATD, plasma TC levels were increased 2.9-fold and 4.7-fold, respectively in WT mice 
(172±6 mg/dL) and SR-BI KO mice (640±62 mg/dL) (Figure 1A). In SR-BI KO mice, 
around 60% of TC in the plasma is free cholesterol (374±38 mg/dL, p<0.001 vs WT mice). 
Figure 1. Effect of combined ABCA1 
and SR-BI deficiency on plasma 
cholesterol levels under an atherogenic 
diet. Plasma free and total cholesterol 
levels (A), lipoprotein distribution of 
total cholesterol (B), HDL cholesterol 
levels and non-HDL cholesterol levels 
(C) of WT (open bar/open square), 
ABCA1 KO (light gray bar/close 
square), SR-BI KO mice (dark gray 
bar/close circle), and ABCA1/SR-BI 
dKO mice (dark bar/open circle) at 10 
weeks on an atherogenic diet. Bar graphs 
represent the means±SEM (n=9-15). 
Two hundred microliters of pooled 
mouse plasma from the different 
genotypes were fractioned by FPLC. 
Statistically significant difference 
*p<0.05, **p<0.01, and ***p<0.001 vs WT 
mice; ###p<0.001 vs ABCA1 KO mice; 
$$$p<0.001 vs SR-BI KO mice. 
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Moreover, in agreement with previous findings [12, 13] , the largely elevated TC in SR-BI 
KO mice on ATD was mainly due to increased cholesterol levels in both large HDL and 
VLDL (Figure 1B). As compared to WT mice, SR-BI KO mice displayed 5.6-fold 
(p<0.001) and 2.9-fold (p<0.001) higher cholesterol levels in HDL-C and non-HDL-C, 
respectively (Figure 1C). When fed ATD, ABCA1 KO mice showed a 3.0-fold increase in 
plasma total cholesterol levels (27±4 mg/dL), which were, however, 6.4-fold (p<0.01) 
lower than the levels in WT mice. As shown in Figure 1B and 1C, absence of HDL-C and 
lower levels of non-HDL-C (3.2-fold, p<0.01 vs WT mice) accounted for the lower levels 
of plasma total cholesterol observed in ABCA1 KO mice. DKO mice fed ATD showed a 
5.9-fold elevation in plasma TC levels (71±12 mg/dL). TC levels in dKO mice, however, 
also remained substantially lower than the levels in WT mice (2.4-fold, p<0.05) and SR-BI 
KO mice (9.0-fold, p<0.001). Given the absence of HDL-C, plasma cholesterol in dKO 
mice accumulated in the non-HDL fraction (Figure 1B). Interestingly, dKO mice showed 
similar levels of non-HDL-C as WT mice, which, notably, were 2.5-fold (p<0.05) higher 
than the levels in ABCA1 KO mice but 4.0-fold (p<0.001) lower than the levels in SR-BI 




ABCA1 deficiency reduced the atherogenicity of serum in the SR-BI KO mice 
Macrophage foam cell formation by uptake of atherogenic lipoproteins is the hallmark of 
atherosclerosis [6]. The serum atherogenicity was tested by determination of foam cell 
formation after incubation of RAW cells with 3% serum of the different types of mice. As 
compared to serum from WT mice, serum from SR-BI KO mice induced extreme foam cell 
formation (2.9-fold, p<0.001) (Figure 2A and 2B), while ABCA1 deficiency dramatically 
reduced the serum atherogenicity against both WT (13-fold, p<0.001) and SR-BI KO (10-
Figure 2. Effect of combined ABCA1 and SR-BI 
deficiency on the serum atherogenicity under an 
atherogenic diet. (A) Photomicrographs of oil-red-
O-stained RAW cells at 24 after incubation with 
3% serum from separate mice. (B) Bar graph 
showing the quantification of the foam cell 
formation. Values are mean±SEM. Statistically 
significant difference **p<0.01 and ***p<0.001 vs 




fold, p<0.001) background. The atherogenicity of the serum in the different groups of 
animals is thus SR-BI>WT>dKO>ABCA1 KO and corresponds to the TC levels in serum. 
 
Combined ABCA1 and SR-BI disruption enhances macrophage foam cell formation 
in the peritoneal cavity upon challenge with ATD  
Next, in vivo foam cell formation was examined in the peritoneal cavity. The percentage of 
foam cells was increased 3-fold (p<0.05 vs WT) in the peritoneum of ABCA1 KO mice 
(Figure 3A). Despite more atherogenic lipids in serum, almost no foam cells were observed 
in peritoneal cavity of SR-BI KO mice. Strikingly, in dKO mice, lipid-laden peritoneal 
cells were even more numerous (6-fold, p<0.001) as compared to single ABCA1 KO mice 
(Figure 3A), which were also evident in Oil-red-O stained cytospins of the peritoneal cells 
(Figure 3B). These data indicate that not only serum lipids, but also the combined action of 
ABCA1 and SR-BI in macrophages determines the susceptibility to macrophage foam cell 
formation. 
 
Figure 3. Effect of combined ABCA1 and SR-BI deficiency on macrophage foam cell formation in 
the peritoneal cavity under an atherogenic diet. (A) Macrophage foam cell formation in the 
peritoneal cavity of WT (open bar), ABCA1 KO (light gray bar), SR-BI KO (dark gray bar), and 
ABCA1/SR-BI dKO (dark bar) mice at 10 weeks on an atherogenic diet was quantified as percentage of 
total leukocytes in the peritoneal cavity. (B) Photomicrographs of Oil-red-O-stained cytospins of 
peritoneal cells. Values are mean±SEM. Statistically significant difference *p<0.05 and ***p<0.001 vs 
WT mice; #p<0.05 and ###p<0.001 vs ABCA1 KO mice; $$$p<0.001 vs SR-BI KO mice. 
 
Combined ABCA1 and SR-BI disruption increased leukocytosis upon challenge with 
ATD 
Leukocytosis, particularly monocytosis [7] and neutrophilia [8] has been implicated in the 
development of atherosclerosis. Therefore, circulating leukocytes were analyzed using a 
hematology analyzer and flow cytometry. As compared to WT mice, SR-BI KO mice 
displayed a trend towards a larger amount of white blood cells (5.9±0.8 x106/mL vs 
3.8±0.7 x106/mL, p=0.09) in the circulation (Figure 4A), mainly due to the elevation of 
circulating lymphocytes (1.8-fold, p<0.05) (Figure 4B). ABCA1 deficiency resulted in an 
increase in total white blood cell counts on both the WT (2.6-fold, p<0.001) and SR-BI KO 
(2.9-fold, p<0.001) background (Figure 4A). Not only lymphocyte counts, but also 
neutrophil and monocyte counts were elevated in ABCA1 KO mice (lymphocytes: 2.6-
fold, p<0.001; neutrophils: 3.8-fold, p<0.05; monocytes: 9.0-fold, p<0.05) and dKO mice 
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(lymphocytes: 2.1-fold, p<0.01; neutrophils: 5.6-fold, p<0.01; monocytes: 30.7-fold, 
p<0.01) (Figure 4B, 4C, and 4D). Of note, dKO mice displayed even higher levels of 
circulating monocytes (3.5-fold, p<0.01) compared to single ABCA1 KO mice. This was 
associated with a ~2-fold increase in the percentage of Ly6Chigh monocytes (Figure 2E). 
Thus, on ATD, combined deletion of ABCA1 and SR-BI resulted in enhanced Ly6Chigh 
monocytosis. 
 
Figure 4. Effect of combined ABCA1 and SR-BI deficiency on circulating leukocyte counts under 
an atherogenic diet. Circulating total white blood cells (A), lymphocytes (B), neutrophils (C), and 
monocytes (D) in WT (open bar), ABCA1 KO (light gray bar), SR-BI KO (dark gray bar), and 
ABCA1/SR-BI dKO (dark bar) mice at 10 weeks on an atherogenic diet were analyzed using a 
hematology analyzer. Monocyte (CD11b+ly6G-) subsets expressing different levels of Ly6C were 
quantified using flow cytometry. Values represent the mean±SEM. Statistically significant difference 
*p<0.05, **p<0.01, and ***p<0.001 vs WT mice; #p<0.05, ##p<0.01, and ###p<0.001 vs ABCA1 KO mice; 
$$p<0.01 and $$$p<0.001 vs SR-BI KO mice. 
 
Next, the peritoneal leukocyte counts were analyzed. The total amount of 
leukocytes was not changed in the peritoneal cavity of ABCA1 KO or SR-BI KO mice 
(Supplementary Figure 1A). Interestingly, leukocyte counts were increased ~2-fold in the 
peritoneal cavity of dKO mice. This was mainly due to elevation of the amount of 
neutrophils (>=5-fold, p<0.001) and monocytes/macrophages (~2-fold, p<0.01) 
(Supplementary Figure 1C and 1D). In line with the observed increased Ly6Chigh 
monocytosis, the percentage of Ly6Chigh monocyte-derived macrophages in the peritoneal 








Figure 5. Effect of combined ABCA1 and SR-BI deficiency on the development of atherosclerotic 
lesions. (A) Photomicrographs showing a scatter dot plot of atherosclerotic lesion quantification (left 
panel) and representative Oil-red-O stained sections (right panel, original magnification 40x). Each 
symbol represents the mean lesion area in a single mouse. The horizontal line represents the mean of the 
group. Bar graphs showing the amount of neutrophils (B), T cells (C), and macrophages (D) in the 
lesion visualized by immunohistochemical staining with antibodies against Ly6G, CD3, and Moma-2, 
respectively. Statistically significant difference *P<0.05, **P<0.01, and ***P<0.001 vs WT mice; 
#P<0.05 and ###P<0.001 vs ABCA1 KO mice; $P<0.05 and $$$P<0.001 vs SR-BI KO mice. 
 
ABCA1 deficiency attenuated atherosclerotic lesion development in SR-BI KO mice 
Atherosclerotic lesion development was quantified at the aortic root of mice challenged 
with ATD for 10 weeks. The lesion size of ABCA1 KO mice and SR-BI KO mice was 
increased 4.4-fold (p<0.05) and 27-fold (p<0.01), respectively as compared to the lesion 
size of WT mice (Figure 5A). Strikingly, despite enhanced foam cell formation and 
leukocytosis, dKO mice, similar to ABCA1 KO mice, displayed only 4.7-fold larger 
lesions than WT mice. Of note, the lesion size of dKO mice was 5.7-fold smaller (p<0.05) 
than SR-BI KO mice (Figure 5A). As the main component of lesions, the amount of 
macrophages was increased 3.5-fold (p<0.05) and 18-fold (p<0.001), respectively in 
lesions of ABCA1 KO and SR-BI KO mice as compared to WT mice (Figure 5B). Despite 
enhanced Ly6Chigh monocytosis, dKO mice displayed only 4.3-fold more macrophages in 
lesions as compared to WT mice. Of note, the amount of macrophages in lesions of dKO 
mice was 4.3-fold (p<0.001) lower than in lesions of SR-BI KO mice (Figure 5B). The 
reduced lesion formation in dKOs compared to SR-BI KOs might thus be attributed to 
reduced recruitment of monocytes from circulation.   
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Next, neutrophils and T cells in lesions and adventitias were quantified. The 
amount of neutrophils was increased ~5-fold (p<0.001) in lesions of single ABCA1 KOs 
and SR-BI KOs as compared to WT mice (Figure 5C). Interestingly, combined deletion of 
ABCA1 and SR-BI deficiency led to an additional ~1.4-fold (p<0.05) induction of 
neutrophil infiltration into the lesion (Figure 5C). Furthermore, ABCA1 deficiency also 
resulted in increased infiltration of T cells (~3-fold, p<0.05) into lesions on both the WT 
and SR-BI KO background (Figure 5C). Interestingly, SR-BI KO mice showed a trend to 
an increased amount of T cells (2-fold, p=0.10) in lesions as compared to ABCA1 KO and 
dKO mice. However, neutrophils and T cells in the adventitia underlying lesions were 
comparably increased ~4-fold (p<0.01 vs WT) and ~3-fold (p<0.01 vs WT), respectively in 
all single and double KOs (Supplementary Figure 2A and 2B). 
 
 
ABCA1 deficiency attenuates the induction of ICAM-1 in the vascular wall and 
reduced the plasma MCP-1 levels of SR-BI KO mice 
Adherence of leukocytes, especially monocytes to the endothelial layer is required before 
migration into the intima, thereby promoting atherogenesis [9]. The expression of the 
Figure 6. Effect of combined ABCA1 and 
SR-BI deficiency on the expression of 
ICAM-1 in the vascular wall under an 
atherogenic diet. (A) ICAM-1 in the arterial 
wall at the aortic root of  the WT (open bar), 
ABCA1 KO (light gray bar), SR-BI KO 
(dark gray bar), and ABCA1/SR-BI dKO 
(dark bar) mice was detected by 
immunohistochemistry using a monoclonal 
rat anti-mouse ICAM-1 antibodies. (B) 
Representative photomicrographs showing 
the expression of ICAM-1 in the arterial wall 
at the aortic root of separate mice. Values are 
mean±SEM. Statistically significant 
difference *p<0.05and ***p<0.001 vs WT 
mice; ###p<0.001 vs ABCA1 KO mice; 




adhesion molecule, ICAM-1 on the vascular wall was thus determined. ICAM-1 
expression was upregulated 2.0-fold (p<0.05) and 4.3-fold (p<0.001), respectively in the 
endothelial layer overlying lesions of ABCA1 KO and SR-BI KO mice as compared to WT 
mice (Figure 6A and 6B). Also, dKO mice showed a 2.3-fold (p<0.05 vs WT mice) 
increase in expression of ICAM-1 in the endothelium overlying lesions. In line with the 
observed effects on lesion size and macrophage content of lesions, the expression of 
ICAM-1 in the endothelium of lesions of dKO mice was 1.8-fold (p<0.001) lower than of 
lesions of SR-BI KO mice (Figure 6A and 6B).  
In addition, the plasma levels of MCP-1, a potent chemoattractant for monocyte 
migration were also determined. MCP-1 levels were increased 1.6-fold (p<0.05) in plasma 
of both ABCA1 KO and dKO mice. Again, consistent with the lesion size and the amount 
of macrophage in lesions, dKO mice showed 1.5-fold lower levels of MCP-1 as compared 
to single SR-BI KO mice. 
 
Discussion 
In the current study, we investigated the effects of combined deletion of ABCA1 and SR-
BI, important transporters in HDL metabolism, on atherogenesis. Disruption of ABCA1 in 
SR-BI KO mice led to increased foam cell formation in the peritoneal cavity despite lower 
levels of pro-atherogenic lipids upon challenge with ATD. Also, Ly6Chigh monocytosis was 
enhanced by ABCA1 deficiency in SR-BI KO mice. Despite these apparent pro-
atherogenic conditions, ABCA1 deficiency attenuated atherosclerotic lesion development 
in SR-BI KO animals, probably by lowering the circulating levels of atherogenic 
lipoproteins and reducing the recruitment of monocytes from the circulation into the 
arterial wall. 
HDL-mediated reverse cholesterol transport is hypothesized to be crucial for 
prevention of atherosclerotic lesion development. Indeed, impairment of HDL production 
via ABCA1, disruption of SR-BI-mediated delivery of HDL-C to the liver, or both was 
associated with increased atherosclerosis. Impaired delivery of HDL-C to the liver in 
single SR-BI KO mice, however, led a more dramatic increase in atherosclerosis 
susceptibility as compared to virtual absence of HDL in the circulation due to ABCA1 
deficiency on both WT and SR-BI KO background. Combined deletion of ABCA1 and 
SR-BI on the other hand led to the highest level of foam cell formation in the peritoneal 
cavity.  Enhanced foam cell formation in the peritoneal cavity thus not necessarily 
correlates with the development of atherosclerotic lesions, especially under 
hypocholesterolemic conditions.  
Previously, we showed that in vivo RCT was impaired to a similar degree upon 
injection of WT macrophages into ABCA1 KO mice, SR-BI KO mice, and dKO mice [3]. 
This seems to be in contrast to a recent study by Yamamoto et al showing that suppression 
of hepatic ABCA1 activity by probucol promotes in vivo RCT in SR-BI KO mice [10]. Of 
note, in contrast to ABCA1/SR-BI dKO mice, SR-BI KO animals treated with probucol 
still transported a substantial amount of their cholesterol in HDL which might be required 
for the enhancement of RCT by probucol. Importantly, the similar impairment of RCT in 
ABCA1 KO, SR-BI KO, and dKO mice cannot explain the observed differences in 
macrophage foam cell in vivo formation nor atherosclerosis susceptibility. Macrophage 
foam cell formation is determined by the balance between cholesterol influx and efflux. 
Furthermore, animal studies have shown that a concentration of 250 mg/dL total 
cholesterol in serum is required for the induction of atherosclerosis [11]. Consistent with 
previous studies [12], single SR-BI KO mice also displayed a dramatic elevation of plasma 
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cholesterol levels upon challenge with ATD due to the accumulation of large HDL as well 
as VLDL. This is because SR-BI also plays an important physiological role in the 
clearance of VLDL [13]. Due to the increased content of pro-atherogenic lipoproteins, 
plasma of SR-BI KO mice had a high capacity to induce foam cell formation upon 
incubation with RAW cells, which also corresponded to the increased susceptibility to 
atherosclerotic lesion development of these animals. Furthermore, HDL that accumulates 
in SR-BI KO mice has reduced anti-oxidant properties, as evidenced by increased 
oxidative stress in these animals [14]. Oxidative modification of HDL by myeloperoxidase 
(MPO) induces the expression of adhesion molecules on aortic endothelial cells [15]. In 
agreement, SR-BI KO mice showed increased expression of ICAM-1 in the endothelial 
layer overlying atherosclerotic lesions. 
Single ABCA1 KO and ABCA1/SR-BI dKOs, when fed ATD, displayed a total 
cholesterol concentration of only ~25 mg/dL and ~70 mg/dL. This is because disruption of 
ABCA1 in SR-BI KO mice not only diminished HDL but also greatly reduced the amount 
of cholesterol transported by VLDL. ABCA1 deficiency increases VLDL production in 
mice on chow [3]. However, the absence of apoE-rich HDL, which accumulates in plasma 
of SR-BI KO mice, might result in less competition with VLDL for uptake via the LDLr 
and LDLr-related protein 1 (LRP1) in dKO mice. Of note, the non-HDL cholesterol levels 
of dKO mice were higher than single ABCA1 KO mice, stressing the importance of SR-BI 
for the clearance of VLDL. However, plasma of ABCA1 KO and ABCA1/SR-BI dKO 
mice had a similarly low capacity to induce foam cell formation upon incubation with 
RAW cells, which was substantially lower than the capacity of plasma from single SR-BI 
KO mice. Furthermore, ICAM-1 expression in the endothelial layer overlying the 
atherosclerotic lesions of single ABCA1 KO and ABCA1/SR-BI dKO mice was reduced as 
compared to single SR-BI KO mice. It is interesting to speculate that this might be the 
result of the absence of dysfunctional HDL particles and the reduction of pro-atherogenic 
lipoproteins due to inactivation of ABCA1 in SR-BI KO mice. Nevertheless, ABCA1 KO 
and dKO mice did develop moderate atherosclerotic lesions when challenged with ATD 
for 10 weeks. The atherosclerosis susceptibility of single ABCA1 KO and dKO mice is 
thus likely the consequence of other pro-atherogenic factors than lipids in the plasma.  
Epidemiological observations showed that leukocytosis, especially monocytosis 
and neutrophilia, is strongly associated with the progression of atherosclerosis [16]. 
Hypercholesterolemia induces leukocytosis, in particular neutrophilia and monocytosis [7, 
8]. Of note, even under hypocholesterolemia increased amounts of neutrophils and 
monocytes were evident in single ABCA1 KO and ABCA1/SR-BI dKO mice on ATD. 
Yvan-Charvet et al recently showed that HDL is essential to suppress the proliferation of 
hematopoietic stem cells (HSC) [17]. The observed increase in circulating neutrophils and 
monocytes might thus be due to lack of suppression by HDL [17]. HDL-mediated 
cholesterol efflux mechanisms are crucial for inhibiting the proliferation of HSC [17]. The 
large HDL that accumulates in SR-BI KO mice has enhanced cholesterol efflux capacity 
[18]. In line, no induction of monocytosis and neutrophilia was observed in SR-BI KO 
mice despite hypercholesterolemia. Moreover, the cholesterol efflux transporters ABCA1 
and ABCG1 are important for cholesterol homeostasis of HSC [17]. Currently, it is 
unknown if SR-BI is expressed on HSC and might be involved in HSC cholesterol 
homeostasis. DKO mice on ATD showed increased monocytosis as compared with single 
ABCA1 KO mice. This suggests that SR-BI might indeed be involved in maintaining HSC 
cholesterol homeostasis. 
Circulating monocytes, the precursors of macrophages, are a heterogenous 




Ly6Chigh monocytosis is promoted by hypercholesterolemia [7]. Enhanced Ly6Chigh 
monocytosis in dKO mice as compared to single ABCA1 KO mice might thus also be 
attributed to elevated levels of non-HDL cholesterol. Ly6Chigh monocytes selectively 
populate sites of experimentally induced inflammation, while their Ly6Clow counterparts 
can enter lymphoid and nonlymphoid tissues under homeostatic conditions [19]. In line, 
the major population of monocytes/macrophages in the peritoneal cavity of WT, single 
ABCA1 KO, and SR-BI KO mice was Ly6Clow. Increased accumulation of Ly6Chigh 
monocytes/macrophages in the peritoneal cavity of dKO mice might be attributed to 
enhanced Ly6Chigh monocytosis in the circulation. In addition, macrophage foam cells in 
the peritoneal cavity of the dKO mice, as a source of pro-inflammatory factors, might 
preferentially attract Ly6Chigh monocytes from circulation.  
Drechsler et al. has elegantly shown that hypercholesterolemia-induced 
neutrophilia and subsequent infiltration of neutrophils promotes the development of early 
atherosclerotic lesions in apoE KO mice [8]. Upon activation, these neutrophils can secrete 
oxygen which induces endothelial dysfunction and initiates lesion development [20]. 
Despite lack of atherogenic lipoproteins, single ABCA1 KO and dKO mice showed a 
dramatic increase of neutrophils in lesions. Accelerated lesion development of single 
ABCA1 KOs and dKOs might thus be a consequence of the observed neutrophilia in these 
animals and enhanced recruitment of neutrophils into the arterial wall. In contrast to the 
neutrophilia, Ly6Chigh monocytosis, particularly in the dKO mice, did not lead to a further 
enhancement of atherosclerosis. Recruitment of monocytes into atherosclerotic lesions 
involves several adhesion molecules, including ICAM-1 and VCAM-1, and chemokines 
[9]. As indicated above, ICAM-1 expression in the endothelial layer overlying the 
atherosclerotic lesions of single ABCA1 KO and ABCA1/SR-BI dKO mice was reduced as 
compared to single SR-BI KO mice. Furthermore, the attenuated atherosclerosis in dKO 
mice (as compared to single SR-BI KO mice) was associated with lower levels of MCP-1, 
an important chemoattractant for monocytes. Deletion of monocyte chemoattractant MCP-
1 or ICAM-1 inhibits the development of atherosclerotic lesions [21, 22], indicating that 
these are essential factors for recruitment of monocytes into the subendothelial space of the 
arterial wall. The reduced levels of MCP-1 in the blood and lower level of ICAM-1 
expression in the endothelium might thus explain why the enhanced Ly6Chigh monocytosis 
in the dKO mice did not lead to larger lesions as compared with ABCA1 KO mice with 
less extreme monocytosis.  
In summary, by using our unique ABCA1/SR-BI dKO mice, we have provided 
more insights into roles of facilitators of reverse cholesterol transport in atherogenesis in 
vivo. Our data indicate that ABCA1-mediated HDL generation and HDL-C delivery to the 
liver via SR-BI are essential for prevention of atherosclerosis. Despite more foam cell 
formation and leukocytosis, ABCA1 deficiency inhibits the recruitment of monocytes from 
the circulation and attenuated atherosclerotic lesion development in SR-BI KO mice. This 
is probably due to the reduction of proatherogenic lipoproteins, including VLDL and 
dysfunctional HDL by inactivation of ABCA1. Therefore, lowering cholesterol levels of 
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Supplementary Figure 1. Effect of combined ABCA1 and SR-BI deficiency on peritoneal leukocytes 
under an atherogenic diet. Total white blood cells (A), lymphocytes (B), neutrophils (C), and monocytes 
(D) in the peritoneal cavity of WT (open bar), ABCA1 KO (light gray bar), SR-BI KO (dark gray bar), and 
ABCA1/SR-BI dKO (dark bar) mice at 10 weeks on an atherogenic diet were analyzed using a hematology 
analyzer. Monocyte (CD11b+ly6G-) subsets expressing different levels of Ly6C were quantified using flow 
cytometery. Values represent the mean±SEM. Statistically significant difference **p<0.01 and ***p<0.001 vs 
WT mice; ##p<0.01, and ###p<0.001 vs ABCA1 KO mice; $$p<0.01 and $$$p<0.001 vs SR-BI KO mice. 
 
 




Supplementary Figure 2. Effect of combined ABCA1 and SR-BI deficiency on the recruitment of 
neutrophils and T cells into the adventitia underlying atherosclerotic lesions under an atherogenic diet. 
Bar graphs showing the amount of neutrophils (A) and T cells (B) in the adventitia visualized by 
immunohistochemical staining with antibodies against Ly6G and CD3, respectively. Statistically significant 
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Purpose of this review 
Cholesterol efflux mechanisms are essential for macrophage cholesterol homeostasis. 
HDL, an important cholesterol efflux acceptor, comprises a class of heterogeneous 
particles that induce cholesterol efflux via distinct pathways. This review focuses on the 
understanding of the different cholesterol efflux pathways and physiological acceptors 
involved, and their regulation in atherosclerotic lesions.  
 
Recent findings 
The synergistic interactions of ATP-binding cassette A1 (ABCA1) and G1 (ABCG1) as 
well as ABCA1 and scavenger receptor class B type I (SR-BI) are essential for cellular 
cholesterol efflux and the prevention of macrophage foam cell formation. However, the 
importance of aqueous diffusion should also not be underestimated. Significant progress 
has been made in understanding the mechanisms underlying ABCA1-mediated cholesterol 
efflux and regulation of its expression and trafficking. Conditions locally in the 
atherosclerotic lesion, e.g. lipids, cytokines, oxidative stress, and hypoxia, as well as 
systemic factors, including inflammation and diabetes, critically influence the expression 
of cholesterol transporters on macrophage foam cells. Furthermore, HDL modification and 
remodeling in atherosclerosis, inflammation, and diabetes impairs its function as an 
acceptor for cellular cholesterol.  
 
Summary 
Recent advances in the understanding of the regulation of cholesterol transporters and their 
acceptors in atherosclerotic lesions indicate that HDL-based therapies should aim to 














Cholesterol efflux pathways are pivotal for prevention of macrophage foam cell formation 
as macrophages cannot limit the uptake of excessive cholesterol. The efficiency of 
cholesterol efflux from macrophage foam cells in atherosclerotic lesions is determined by 
the quantity and quality of the extracellular acceptors, the activity of cholesterol 
transporters, and the availability of cholesterol for efflux. Significant progress has been 
made in the understanding of the mechanisms involved in cellular cholesterol efflux from 
macrophage foam cells in atherosclerotic lesions. In this review we will focus on the 
current view of the various cellular cholesterol efflux pathways and the physiological 
acceptors involved, and discuss their relative contributions to the prevention of 
macrophage foam cell formation in atherosclerotic lesions. 
 
Macrophage cholesterol efflux pathways and their physiological 
acceptors  
 
An important cholesterol efflux acceptor and facilitator of reverse cholesterol transport 
(RCT) from macrophage foam cells in the arterial wall to liver is high-density lipoprotein 
(HDL) [1]. Transport of HDL across the endothelium is essential for removal of the excess 
cholesterol from macrophage foam cells in atherosclerotic lesions. Two studies from the 
group of Von Eckardstein recently showed that transcytosis of apoAI through the 
endothelial layer occurs via ABC-transporter A1 (ABCA1), while ABC-transporter G1 
(ABCG1) and scavenger receptor class B type I (SR-BI) mediate the transcytosis of HDL 
[2,3•]. 
HDL comprises a heterogeneous class of particles with a density (d) higher than 
1.063 g/mL. HDL heterogeneity has recently been carefully reviewed by Rothblat and 
Phillips [4]. Generally, HDL can be classified into lipid-poor discoidal nascent pre-β 
HDL and lipid-rich spherical mature α-HDL, based on their difference in electrophoretic 
mobility [5,6]. Mature α-HDL functions as an acceptor for free cholesterol (FC) that 
dissociates from the cell membrane by aqueous diffusion [7,8].  Aqueous diffusion is a 
passive process driven by the FC gradient between cells and acceptors. It is thus thought 
that aqueous diffusion is inefficient. In contrast, scavenger receptor class B type I (SR-BI) 
and ATP-binding cassette G1 (ABCG1) facilitate FC efflux to mature α-HDL [9,10]. 
Furthermore, pre-β HDL induces phospholipid (PL) and FC efflux via ATP-binding 
cassette A1 (ABCA1) [11]. 
 
SR-BI facilitates passive transport of cholesterol to mature α-HDL  
SR-BI is a multi-functional cell surface receptor [12,13]. One of its functions is to 
stimulate the bi-directional flux of FC between cells and α-HDL down the concentration 
gradient [10]. Interestingly, SR-BI is also found in the late endo/lysosomes and SR-BI 
deficiency is associated with accumulation of lysosomal cholesterol [14]. Thus, SR-BI may 
be involved in intracellular cholesterol trafficking from late endo/lysosomes.  
Although not proven, it is often assumed that SR-BI accelerates aqueous diffusion 
of FC between cells and α-HDL. Binding to SR-BI will tether α-HDL in close proximity 
to the plasma membrane, thereby probably facilitating aqueous diffusion [15]. However, 
high-affinity binding alone is not sufficient to stimulate FC flux [16]. Moreover, SR-BI 
increases the fraction of membrane cholesterol available for efflux to α-HDL but not lipid-  
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free apoAI, although apoAI can bind to SR-BI [16,17]. Thus, the efficiency of SR-BI-
mediated cholesterol efflux is related to its ability to enrich the membrane with cholesterol 
for efflux rather than to its binding to α-HDL[18]. In addition, SR-BI mediated HDL retro-
endocytosis, i.e. the uptake of HDL whole particles followed by re-secretion of CE-poor 
HDL, has been implicated in SR-BI mediated cholesterol efflux [19,20]. This process 
appears independent of cholesterol transport out of the lysosome [20]. Currently, however, 
the importance for mass cholesterol efflux and prevention of macrophage foam cell 
formation is unclear.   
 
Regulation of SR-BI expression in macrophages 
SR-BI is undetectable in human monoytes, but its expression increases upon differentiation 
into macrophages [21,22]. Furthermore, the expression of SR-BI in macrophages is under 
control of peroxisome proliferator-activated receptor (PPAR) α and γ [23]. In liver, SR-BI 
stability and expression are posttranscriptionally regulated by PDZK1, a multi-PDZ 
domain containing adaptor protein [24]. Interestingly, targeted deletion of PDZK1 in mice 
reduced SR-BI expression in liver by 95%, but did not affect SR-BI expression in 
macrophages [25], indicating that macrophages have different posttranscriptional 
regulatory mechanisms.  
 
Regulation of SR-BI expression in atherosclerosis 
SR-BI is expressed in macrophages of atherosclerotic lesions [21,23,26] and regulated by 
lesional factors such as lipid, oxidative stress, and hypoxia (Figure 1). Cholesterol loading 
of macrophages reduces the mRNA levels of SR-BI through mechanisms independent of 
liver-X-receptor (LXR) and sterol regulatory element binding proteins (SREBPs) [22]. 
Interestingly, induction of atherosclerotic lesion regression by transplantation of plaque-
containing arterial segments from apoE knockout (KO) mice into WT animals is associated 
with increased SR-BI expression in macrophages of atherosclerotic lesions [27]. Moreover, 
there is evidence that oxidative stress dampens the expression of SR-BI. Depletion of 
paraoxonase 1 (PON1), a major HDL-associated anti-oxidant enzyme, reduces mRNA and 
protein levels of SR-BI in peritoneal macrophages [28•]. SR-BI transcription is also 
suppressed by 7-ketocholesterol (7-KC), a major oxysterol in atherosclerotic lesions [29]. 
In addition, exposure of macrophages to hypoxic conditions decreased SR-BI transcription 
[26].  
 
ABCG1 actively transports sterols to mature α-HDL 
ABCG1 is an ABC half-transporter that actively transports sterols, including FC and 7-KC 
to α-HDL [9,30,31]. In non-cholesterol loaded macrophages, ABCG1 locates 
intracellularly [32]. Cholesterol loading or activation of LXR leads to the trafficking of 
ABCG1 from intracellular organelles, principally the Golgi, to the plasma membrane [32]. 
This ABCG1 redistribution is associated with increased cholesterol efflux to HDL.  
Several lines of evidence have suggested that aqueous diffusion is involved in 
ABCG1-mediated cholesterol efflux. First, binding of HDL to ABCG1 is not required for 
induction of cholesterol efflux [30,33••]. Second, induction of ABCG1-mediated 
cholesterol efflux is linked to its capacity to enrich the membrane cholesterol pool for 
removal [34]. Cholesterol in ABCG1 generated lipid domains can only be removed by 




HDL [33••], which is in line with the fact that PL has a lower aqueous solubility as 
compared to FC. Some studies have suggested that ABCG1-mediated cholesterol efflux is  
 
 
Figure1. Regulation of cholesterol efflux from macrophage foam cells to α-HDL in atherosclerotic 
lesions. (1) Two pathways for the infiltration of α-HDL into subendothelial space can be distinguished: 
paracellular transfer and ABCG1- and SR-BI-mediated transcytosis. Subsequently, α-HDL can induce efflux 
of free cholesterol (FC) from macrophages by aqueous diffusion (2) as well as via ABCG1 (3) and SR-BI (4). 
(5) In atherosclerotic lesions, MPO (myeloperoxidase)- and MDA (malondialdehyde)-mediated oxidation as 
well as AGEs (advanced glycation end products)-mediated glycation of HDL decrease its acceptor capacities 
to remove cholesterol by all these pathways. (6) Cholesterol traffics among different organelles. (7) FC can 
be esterified into cholesteryl ester (CE) by acyl-CoA:cholesterol acyltransferase (ACAT) while neutral 
cholesterol ester hydrolase (NCEH) hydrolyzes CE into FC. (8) Steroidogenic acute regulatory protein 
(StAR) transfers FC into mitochondrion where (9) FC is converted into 27-hydroxycholesterol (27-HOC) by 
sterol 27-hydroxylase (Cyp27). (10) 7-ketocholesterol (7-KC) is generated from FC and becomes the main 
sterol in atherosclerotic lesions. ABCG1 also exports 7-KC to HDL (3). The expression of ABCG1 and SR-
BI in macrophages in lesions is regulated by different factors, thereby influencing their capacity to facilitate 
FC efflux. (11) ABCG1 transcription is induced by 27-HOC-mediated activation of liver-X-receptor (LXR) 
and recruitment of G protein suppressor 2 (GPS2). LXR heterodimerises with the retinoid-X-receptor (RXR) 
and induces transcription. (12) 7-KC-3-sulfate derived from 7-KC in lesions is an antagonist of LXR. (13) 
Activation of Toll-like receptor (TLR) can inhibit the expression of LXR through interferon regulatory factor 
(IRF) and indirectly decrease the ABCG1 expression. (14) In addition, the expression of ABCG1 can be 
downregulated by C-reactive peptide (CRP), glucose and oxidative stress. (15) After translation, ABCG1 is 
transported to the plasma membrane. (16) Fatty acids LA (linoleate acid) and AA (arachidonic acid) as well 
as 12SHETE (12S-hydroxyeicosatetranoic acid) and AGEs promote ABCG1 degradation, while insulin 
might increase the protein levels of ABCG1 by inhibition its degradation. (17) SR-BI transcription is under 
control of peroxisome proliferator-activated receptor alpha and gamma (PPARα and PPARγ). (18) Glucose 
might upregulate SR-BI expression through PPAR. (19) The transcription of SR-BI can be decreased by 
AGEs, hypoxia, and oxidative stress. 
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sphingomyelin-dependent [35,36]. Reduced cellular sphingomyelin levels due to a 
mutation of the ceramide transfer protein (CERT) are associated with a reduction of 
cholesterol efflux via ABCG1 [36]. Conversely, overexpression of CERT enhances 
ABCG1-mediated cholesterol efflux [36]. Different from SR-BI, ABCG1-mediated 
cholesterol transport is uni-directional from cells to HDL [33••]. 
 
Regulation of ABCG1 expression in macrophages 
ABCG1 expression is highly regulated by LXR [37,38].  27-hydroxycholesterol (27-HOC), 
an endogenous LXR ligand in macrophages, increases the expression of ABCG1 [39]. 
Activation of LXR by GW3965, an LXR agonist, triggers the recruitment of G protein 
suppressor 2 (GPS2), LXR, and the coactivator complex to the promoter for induction of 
ABCG1 transcription in THP-1 cells [40••]. Furthermore, knockdown of GPS2 by siRNA 
specifically decreases GW3965 induced ABCG1 expression. In addition, superoxide 
anions in macrophages, induced by C-reactive peptide (CRP), decrease the expression of 
ABCG1 in THP-1 cells, which can be abolished by the anti-oxidant selenon-L-methionine 
[45]. 
 
Regulation of ABCG1 expression in atherosclerotic lesions 
In atherosclerotic lesions, ABCG1 co-localizes with macrophage foam cells [41]. Sterols, 
fatty acids (FAs), and oxidative stress regulate ABCG1 expression in macrophages (Figure 
1). Cholesterol loading increases the accumulation of oxysterols, which activate LXR and 
induce the transcription of ABCG1 [37,39]. In contrast, the unsaturated FAs (uFAs) 
linoleic and arachidonic acid that accumulated in lesions promote the degradation of 
ABCG1 [42].  
Oxidative stress in atherosclerotic lesions is also a negative regulator for ABCG1 
expression. 12/15-lipoxygenase, highly expressed in macrophages of early atherosclerotic 
lesions [43], destabilizes ABCG1 through generation of an uFA metabolite named 12S-
hydroxyeicosatetranoic acid (12SHETE) [42,44•]. 12SHETE promotes the serine 
phosphorylation of ABCG1 through p38- and JNK2-dependent pathways, thereby 
increasing proteasome-mediated ABCG1 degradation [44•].  
Interestingly, ABCG1 is undetectable in macrophages from patients with diabetes, 
leading to a 30% decrease in cholesterol efflux to HDL [46]. High glucose levels in these 
patients reduce the mRNA and protein levels of ABCG1 in macrophages [47]. Importantly, 
insulin treatment increases the protein but not mRNA levels of ABCG1 [47].  
 
ABCA1 mediated phospholipid and cholesterol efflux to lipid-free/poor 
apoAI  
 
ABCA1 is an ABC full transporter that facilitates the efflux of PL and FC to lipid-
free/poor apolipoproteins [11,48,49]. ABCA1 localizes to the plasma membrane and 
intracellular compartments, including the Golgi apparatus and endo/lysosomes [50]. 
Deletion of the C-terminal VFVNFA and PDZ motifs of ABCA1 inhibits the exit of 
ABCA1 from the endoplasmic reticulum (ER) [51], while palmitoylation of the cysteines 
of ABCA1 promotes its trafficking to the plasma membrane [52••]. Interestingly, in 
macrophages, SPTLC1, a subunit of the serine palmitoyltransferase enzyme, can bind to 
ABCA1 and trap it in the ER [51]. In addition, Rab8, a Rab GTPase was recently 
suggested to regulate ABCA1 trafficking to the plasma membrane in macrophages from 




organelles containing β1 integrin and transferrin, while overexpression of Rab8 increases 
ABCA1 levels at the cellular membrane and reduces cholesterol deposition in foam cells 
[53••].  
Several different models for ABCA1-mediated cholesterol efflux have been 
suggested. According to the simplest model, ABCA1 acts as an apoAI receptor that 
induces the transfer of PL and FC upon binding [54,55]. ABCA1 expression, however, 
changes the cellular membrane lipid microenvironment [56-58]. Furthermore, the ATPase 
activity of ABCA1 is necessary for apoAI binding to the cell surface [59]. Therefore, 
another view is that apoAI interacts with specialized lipid domains in the plasma 
membrane formed by ABCA1 and subsequently induces lipid removal. In addition, a 
hybrid model has been proposed [60-62]. ApoAI first interacts with ABCA1 to activate 
janus kinase 2 (JAK2), which in turn increases binding of apoAI to ABCA1. This latter 
binding facilitates the interaction of apoAI to the lipid domains generated by ABCA1, 
thereby promoting apoAI lipidation. By using various ABCA1 mutants, Vaughan et al. 
recently further revealed the interdependency between JAK2 activation, apoAI binding and 
lipid export via ABCA1 [63•].  
ApoAI binding to ABCA1 can lead to internalization of the ABCA1/apoAI 
complex [64]. It has been proposed that apoAI enters the cell and is re-secreted as a 
lipidated particle during ABCA1-mediated cholesterol efflux from macrophages [64,65]. 
However, other groups showed that apoAI lipidation occurs on the cell surface and that 
apoAI is degraded in the lysosome after internalization [66,67]. Recently, Lu et al. 
provided evidence that binding of apoAI to ABCA1 prevents ABCA1 degradation after 
internalization and promotes rapid recycling of ABCA1 to the cell surface in non-
cholesterol loaded THP-1 cells [68]. Under this condition, blockade of clathrin-mediated 
ABCA1 endocytosis by cytochalasin D increased ABCA1 expression on the cell surface 
and subsequently enhanced apoAI lipidation, indicating that endocytic recycling of 
ABCA1/apoAI is not required for lipid efflux to apoAI. In contrast, blockade of clathrin-
mediated endocytosis by monodansyl cadaverine leads to increased ABCA1 expression on 
the cell surface of acetylated LDL (acLDL) loaded THP-1 cells, but reduces cholesterol 
efflux to apoAI, indicating that intracellular trafficking of ABCA1/apoAI is important for 
cholesterol efflux under conditions that macrophages have accumulated excess cholesterol 
[69••].   
In human serum, pre-β1 HDL generated by ABCA1 is characterized as a 67 kDa 
subspecies of HDL, containing two apoAI molecules with several molecules of PL and FC 
[70]. Similar to lipid-free apoAI, preβ1 HDL can interact with ABCA1 for further 
cholesterol efflux. Although pre-β1 HDL only comprises around 5% of the amount of 
apoAI in the circulation, it is suggested that the levels and function of pre-β1 HDL are 
important for prevention of atherosclerosis. Llera-Moya et al. recently demonstrated that 
the concentration of pre-β1 HDL in serum of healthy individuals significantly correlates to 
the serum efflux capacity via ABCA1, and is negatively associated with the carotid intima 
thickness [71••].  
 
Regulation of ABCA1 in macrophages 
ABCA1 is preferentially expressed on ly6Clow tissue macrophages [72•]. The transcription 
of ABCA1 is upregulated through 27-HOC-induced activation of LXR [39,73]. In line, 
increasing 27-HOC by enhancement of cholesterol delivery to mitochondrial sterol 27-
hydroxylase (Cyp27) by steroidogenic acute regulatory protein (StAR) increases the 
expression of ABCA1 [74•]. LXR has two isoforms, namely LXRα and LXRβ. While 
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LXRα is primarily involved in the transcriptional regulation of ABCA1, LXRβ regulates 
ABCA1 protein expression posttranslationally [75••]. In absence of cholesterol loading, 
LXRβ binds to the C-terminus of ABCA1 and stabilizes it on the cellular membrane. 
Interestingly, this stabilization is associated with reduced ABCA1-mediated cholesterol 
efflux, thereby preventing excessive elimination of cholesterol. Upon cholesterol loading, 
increased oxysterols bind to LXRβ, leading to dissociation of LXRβ from ABCA1 and a 
rapid restoration of ABCA1 activity in cholesterol efflux. This interaction between 
ABCA1 and LXRβ thus provides a novel regulatory mechanism for cells to quickly 
respond to cholesterol loading. 
ApoAI stabilizes ABCA1 by inhibition of thiol protease-mediated and calpain-
mediated proteolysis [76-78]. Phosphorylation of a PEST sequence, rich in proline, 
glutamic acid, serine, and threonine at the cytoplasmic region of ABCA1 directs calpain-
mediated degradation [77]. Iwamoto et al. recently demonstrated that calmodulin directly 
binds to a motif of ABCA1 near the PEST sequence in a Ca2+ dependent manner and 
protects ABCA1 from calpain-mediated degradation [79•]. Since binding of apoAI to 
ABCA1 quickly induces Ca2+ influx [80], it is conceivable that Ca2+/calmodulin 
contributes to the apoAI-increased ABCA1 stability. In addition, activation of Ras 
homolog family member A (RhoA) is involved in the apoAI-induced ABCA1 stabilization 
[81•]. The binding of apoAI to ABCA1 transiently activates RhoA, whereas inhibition of 
RhoA activation by pharmaceutical inhibitors or expression of a negative RhoA mutant 
block the ability of apoAI to stabilize ABCA1. 
 
Regulation of ABCA1 in atherosclerotic lesions 
In atherosclerotic lesions, ABCA1 co-localizes with macrophage foam cells [82,83]. 
Below important factors, known to regulate the expression of ABCA1 in atherosclerotic 
lesions and thus are expected to influence the net transfer of cholesterol out of lesions, are 
described (Figure 2). 
 
Sterols and fatty acid  
ABCA1 expression in atherosclerotic tissue correlates with LXRα mRNA levels [83]. 7-
KC, a highly toxic oxysterol found in atherosclerotic lesions [84], induces ABCA1 
transcription by activation of LXR [85]. In agreement, overexpression of LXRα in 
macrophages increases ABCA1-mediated cholesterol efflux to apoAI and prevents the 
development of atherosclerosis [86]. In advanced atherosclerotic lesions, accumulation of 
FC in macrophages decreases the expression of ABCA1 protein by proteasome-mediated 
degradation [87]. Moreover, uFA linoleic acid decreases the transcription of ABCA1 [47]. 
Like ABCG1, ABCA1 is destabilized by unsaturated fatty acids (uFAs) that accumulate in 
atherosclerotic lesions [88-90]. In line, deletion of macrophage fatty acid synthase 
increases cellular cholesterol efflux to apoAI [91•]. 
 
Inflammation  
Atherosclerotic lesions are inflammatory sites containing various cytokines [92,93]. The 
balance between pro- and anti-inflammatory cytokines in atherosclerotic lesions is an 
important determinant for macrophage foam cell formation by regulation of ABCA1 
expression. The pro-inflammatory cytokines IFNγ  and TNFα downregulate ABCA1 
transcription in macrophage foam cells [94,95]. Interestingly, the anti-inflammatory 




ABCA1, respectively [95,96].  In agreement, overexpression of macrophage IL-10 reduces 
CE accumulation in atherosclerotic lesions and inhibits atherogenesis [97].  
 
 
Figure 2. Regulation of cholesterol efflux from macrophage foam cells to lipid-free/poor 
apolipoproteins in atherosclerotic lesions. (1) Macrophages do not produce apoAI. Therefore, transport of 
apoAI across endothelium is pre-requisite for apoAI-mediated removal of cholesterol from macrophage foam 
cells in lesions. ABCA1 on endothelial cells is involved in transcytosis of apoAI. (2) ApoAI and 
macrophage-derived apoE induce ABCA1-mediated PL and FC efflux to form preβ HDL, which can further 
remove phospholipid (PL) and FC via ABCA1. (3) MPO inhibits the dissociation of apoAI from α-HDL. (4) 
Phospholipid and cholesteryl ester transfer protein (PLTP and CETP) can generate preβ HDL from α-HDL. 
(5) MPO- and MDA-mediated oxidation as well as AGEs-mediated glycation of lipid-free/poor apoAI impair 
its function as cholesterol acceptor. The expression of ABCA1 can be regulated by several factors locally in 
the atherosclerotic lesion. (6) LXR activation by the oxysterols 27-HOC and 7-KC induce the transcription of 
ABCA1. (7) In atherosclerotic lesions, 7-KC can be converted into 7-KC-3-sulfate, which decrease the 
transcription of ABCA1 by inhibiting the activation of LXR. (8) In hypoxic regions of lesions, hypoxia-
inducible factor 1 (HIF1) induces the expression of ABCA1. (9) Activation of TLR during inflammation 
decreases the gene expression of LXR through IRF, thereby indirectly decreasing the expression of ABCA1. 
Inflammation can also downregulate the expression of ABCA1 through (10) the proinflammatory cytokines 
IFNγ and TNFα as well as (11) a key innate immunity signaling kinase (IRAK-1). IRAK-1 reduces the levels 
of nuclear factor of activated T-cells (NFAT) as well as retinoid acid receptor (RAR), thereby 
downregulating the expression of ABCA1. The trafficking of ABCA1 to the plasma membrane is important 
for its function. (12) SPTLC1 (a subunit of the serine palmitoyltransferase enzyme) binds ABCA1 and 
inhibits the exit of ABCA1 from the endoplasmic reticulum (ER), while (13) Rab8 participates in the 
trafficking of ABCA1 from recycling organelles to the plasma membrane. (14) Binding of apoAI to ABCA1 
inhibits ABCA1 degradation and facilitates the recycling of ABCA1 back to the plasma membrane. 
Furthermore, (15) FC, FA (fatty acid), and AGEs promote the protein degradation of ABCA1. (16) Insulin 
increases the protein levels of ABCA1 probably by increasing the protein stability of ABCA1. 
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Viral and bacterial pathogens have long been suspected to be modulators of 
atherosclerosis. Microbial ligands activate toll-like receptor (TLR) signaling, which blocks 
LXR activation by interferon regulatory factors, thereby decreasing the expression of 
ABCA1 and increasing lipid accumulation in macrophages [98,99]. Conversely, LXR 
activation reduces TLR-mediated macrophage foam cell formation [99,100]. Importantly, 
Maitra et al. recently provided a novel connection between innate immunity signaling and 
the regulation of ABCA1 expression in macrophages [101•]. This study identified binding 
sites for retinoic acid receptor (RAR) and nuclear factor of activated T-cells (NFAT) in the 
promoter of ABCA1, and revealed that IRAK-1, a key innate immunity signaling kinase, 
suppressed ABCA1 transcription by downregulation of RARα and NFATc2.  
In addition, CRP, an acute phase (AP) protein of inflammation, inhibits ABCA1 
expression and cholesterol efflux in macrophage foam cells by activation of extracellular 
signal regulated kinase 1 and 2 (ERK1/2) [45]. In line, Zhou et al. demonstrated that 
inhibition of ERK1/2 increases the mRNA and protein levels of ABCA1 in macrophages 
independent of LXR [102•]. Interestingly, inhibition of ERK1/2 and activation of LXR 
synergistically induce ABCA1 expression and macrophage cholesterol efflux [102•]. Thus, 
combined targeting of ERK1/2 and LXR might be a potent therapeutic strategy for 
inhibition of atherosclerosis.  
 
Oxidative stress 
Induction of oxidative stress by iron/ascorbate or CRP in THP-1 cells decreases the mRNA 
and protein expression of ABCA1 [45,103]. Importantly, anti-oxidant treatment can rescue 




Hypoxia-inducible factor 1 (HIF1), activated under hypoxic conditions [104,105], is a 
heterodimer composed of HIF1α and HIF1β [106]. Importantly, in macrophages isolated 
from human atherosclerotic lesions, ABCA1 expression showed a strong correlation with 
HIF1β expression [107••], indicating that HIF1β is a major regulator of macrophage 
ABCA1 transcription in atherosclerotic lesions. However, hypoxia also promotes the 
secretion of inflammatory mediators, fatty acid biosynthesis, ATP depletion and lipid 
droplet formation [108]. Thus, hypoxia is associated with increased macrophage foam cell 
formation despite HIF1-mediated induction of macrophage ABCA1 transcription. 
 
Diabetes 
In diabetes, high levels of glucose decrease the mRNA and protein levels of ABCA1 in 
macrophages [47]. In line, macrophages in diabetic mice show a reduced expression of 
ABCA1 [109]. Moreover, glyoxal and glycoaldehyde acutely and severely destabilize the 
ABCA1 protein [110].  
Interestingly, ABCA1 expression on beta-cells of pancreatic islets influences insulin 
secretion and glucose homeostasis [111, 112•]. Like ABCG1, the protein levels of ABCA1 
are elevated by insulin treatment [47]. Macrophages have a functional insulin receptor 
signaling pathway, and downregulation of this pathway due to insulin resistance has been 
implicated in the progression of advanced atherosclerotic lesions [113]. Thus, macrophage 
insulin resistance might favor increased foam cell formation in atherosclerosis by 




The relative role of each pathway for net cholesterol efflux from 
macrophage foam cells in atherosclerotic lesions 
 
The relative contribution of aqueous diffusion and the ABCA1-, ABCG1-, and SR-BI-
mediated pathways for the net cholesterol efflux from macrophage foam cells to serum has 
been evaluated in vitro by using cholesterol-loaded macrophages isolated from ABCA1, 
ABCG1, and SR-BI KO mice [114,115]. The studies indicate that ABCA1, ABCG1 and 
SR-BI are responsible for approximately 35%, 21%, and 9%, respectively of the efflux 
capacity of the cells. Interestingly, a staggering 35% of the cholesterol is effluxed simply 
via aqueous diffusion. Moreover, data from in vivo RCT assays, in which in vitro 3H-
cholesterol/acLDL laden macrophages are injected into the peritoneal cavity of WT mice 
and the excretion of the 3H-label into the feces is followed, suggest a similar contribution 
of the different pathways [114,115]. However, it must be noted that the following 
limitations in the experimental setups of these studies might impede an accurate evaluation 
of the relative roles of the different cholesterol efflux pathways. 1) In vitro cell culture 
might change the expression of the transporters studied; 2) Most studies use acLDL, which 
is not an endogenous modified lipoprotein, to induce macrophage foam cell formation. In 
relation to this it is important to be aware that acLDL-laden macrophages exhibit a 
different phenotype from oxidized LDL-laden cells [116]; Moreover, acLDL loading 
increases the cellular cholesterol poor for efflux to apoAI via the ABCA pathway while 
cells loaded with native LDL preferentially efflux cholesterol to HDL [117]; 13) 
Nonlipidemic serum as acceptor used for in vitro cholesterol efflux studies and WT mice 
used as recipients for the macrophage foam cells in the in vivo RCT assays are not likely to 
accurately reflect the conditions in atherosclerotic lesions in vivo. 
The net cholesterol efflux from macrophage foam cells in atherosclerotic lesions is 
not simply a sum of the amount cholesterol removed via each individual pathway. 
Competitive and synergistic interactions of different efflux pathways can result in more or 
less net cholesterol efflux. Lipidation of apoAI via ABCA1 generates the substrates for 
ABCG1-mediated cholesterol efflux, suggesting that ABCA1 and ABCG1 work in 
sequence and in synergy to export cholesterol [118]. Combined deletion of ABCA1 and 
ABCG1 on macrophages results in a dramatic decrease in net cholesterol mass efflux to 
HDL in vitro and largely reduced macrophage RCT in vivo [115,119-121]. Accordingly, 
massive macrophage foam cell accumulation was observed in the peritoneal cavity as well 
as various organs such as spleen, lymph nodes, liver, Peyer’s patches, and lung in total 
body ABCA1/ABCG1 double KO (dKO) mice on chow [119]. In contrast, single ABCA1 
KO and ABCG1 KO mice only displayed a relatively small number of foam cells in the 
lung. In bone marrow transplanted LDLr KO mice on either chow or Western-type diet 
(WTD), single ABCA1 deficiency leads to a slight increase in the percentage of foam cells 
in the peritoneal cavity. Also a small number of foam cells were observed in the lung of 
ABCG1 KO transplanted animals. In contrast, combined deletion of ABCA1 and ABCG1 
leads to massive foam cell accumulation in various tissues and the peritoneal cavity 
[120,121] (Out R, unpublished data), further illustrating the importance of ABCA1 and 
ABCG1 in preventing macrophage foam cell formation. As ABCA1/ABCG1 dKO mice do 
express SR-BI, the ABCA1- and ABCG1-mediated pathways have been thought to account 
for the majority of the cholesterol effluxed from macrophage foam cells in vivo, while SR-
BI seems to be only a minor contributor. In line, SR-BI KO macrophages exhibit a small 
decrease in cholesterol efflux to HDL in vitro as compared to WT macrophages [114,122]. 
Also, SR-BI deficiency in macrophages does not influence in vivo RCT in WT mice [115]. 
SR-BI is a multifunctional receptor that can influence macrophage foam cell formation via 
different mechanisms. First, SR-BI facilitates cholesterol efflux from macrophages to α-
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HDL, which will limit foam cell formation. Second, SR-BI promotes the uptake of 
atherogenic ligands like βVLDL and oxidized LDL [12,13,122], thereby promoting 
macrophage foam cell formation. Third, SR-BI mediates selective uptake of CE from HDL 
will promote CE accumulation in macrophages [123], but also may generate CE-
depleted/PL-rich HDL particles that are efficient acceptors for cholesterol efflux. Thus, the 
net effect of SR-BI on macrophage foam cell formation in vivo is difficult to predict and 
may vary with conditions studied. Consistently, SR-BI on macrophages accelerates the 
development of small fatty streak lesions in LDLr KO mice [122], whereas the 
development of advanced atherosclerotic lesions in LDLr KO and apoE KO mice is 
inhibited by macrophage SR-BI [122,124,125]. In line, Yancey et al. showed dramatically 
increased FC and CE accumulation in peritoneal macrophages of apoE/SR-BI dKO mice as 
compared to those of apoE KO mice [126]. Interestingly, Cuchel et al. recently showed 
that FC mobilization in vivo in response to rHDL infusion is primarily mediated by SR-BI 
but not ABCA1 or ABCG1 [127••]. Moreover, Yvan-Charvet et al. demonstrated that 
overexpression of apoAI in heterozygous LDLr KO mice can protect against 
atherosclerosis in the absence of macrophage ABCG1 and ABCA1 [128••]. Thus, SR-BI 
might be more important for controlling cellular cholesterol homeostasis in vivo than was 
initially anticipated. In agreement, we found that combined deletion of macrophage 
ABCA1 and SR-BI resulted in massive foam cell formation in the peritoneal cavity and 
spleen of LDLr KO mice on WTD (Zhao Y, unpublished data). These data indicate that, at 
least under severe hypercholesterolemia, the synergistic action of ABCA1 and SR-BI-
mediated cholesterol efflux from macrophage foam cells, similarly as the combined 
function of ABCA1 and ABCG1, is important for preventing excessive macrophage foam 
cell formation in vivo.  
Importantly, a recent study demonstrated that in human cholesterol-loaded 
macrophages, ABCA1 and Cla-1, the human ortholog of SR-BI, rather than ABCG1 are 
key mediators in cholesterol efflux to HDL [129••], suggesting distinguished differences 
in the relative roles of the ABCG1 and SR-BI pathway in net cholesterol efflux from 
human and mouse macrophages.  
Aqueous diffusion might be underestimated [114,115]. Since mature α-HDL is an 
important acceptor for cholesterol released from macrophages via aqueous diffusion as 
well as for ABCG1 and SR-BI mediated cholesterol efflux, combined deletion of ABCG1 
and SR-BI will be essential for determination of the relative importance of aqueous 
diffusion for the prevention of macrophage foam cell formation in vivo. In addition, 
ABCG1/SR-BI dKO mice will be a useful tool for studying the interaction between 
macrophage ABCG1 and SR-BI and the subsequent effects on macrophage foam cell 
formation in vivo. 
 
HDL modification and remodeling in atherosclerosis 
Epidemiological studies have consistently shown that high levels of HDL cholesterol 
(HDL-C) are associated with reduced susceptibility to cardiovascular disease (CVD) 
[130,131]. However, increasing evidence indicates that HDL functionality rather than 
HDL-C level is a good predictor of cardiovascular risk [131]. HDL has multiple functions, 
including cholesterol efflux induction, anti-inflammation, anti-oxidation, anti-thrombosis, 
and enhancement of endothelial function [131,132]. Many of these functions are linked to 
various proteins associated with HDL particles [131,133•]. Changes in the protein and/or 
lipid composition of HDL might lead to the formation of a dysfunctional HDL particle that 
is no longer protective against atherosclerosis. Several pathological states, including 




remodel the HDL, leading to a compromised function as a cellular lipid acceptor (Figure 1 
& 2). 
MPO, a potent oxidizing enzyme secreted by macrophages and neutrophils in 
atherosclerotic lesions [141,142], is regarded as a good in vivo biomarker, associated with 
dysfunctional HDL. MPO binds to apoAI and uses hydrogen peroxide to generate 
chlorinated and nitrated apoAI [143,144] that shows a reduced ABCA1-binding capacity 
and an impaired ability to promote cholesterol efflux [145•]. Importantly, human 
atherosclerotic lesions are enriched in chlorinated and nitrated apoAI and patients with 
CVD have higher circulating levels of chlorinated and nitrated apoAI [143,144]. Also 
MPO-modified HDL is no longer capable of interacting with SR-BI [146•]. Recently, 
Cavigiolio et al. provided evidence that MPO-mediated crosslinking of apoAI retards the 
spontaneous dissociation of apoAI from HDL, thereby limiting the availability of lipid-free 
apoAI for efflux [147••]. Oxidation of methionine in apoAI by MPO also inhibits its 
ability to activate LCAT, a critical step in HDL metabolism and RCT [148]. In line, 
overexpression of MPO impairs in vivo reverse cholesterol transport [149]. In addition, 
MPO-modified HDL is proinflammatory as these particles can activate NF-kappaB 
(nuclear factor kappa-light-chain-enhancer of activated B) and increase the expression of 
adhesion molecules in aortic endothelial cells [146•]. 
Malondialdehyde (MDA) is a product of lipid peroxidation [150,151]. In human 
atherosclerotic lesions, MDA-apoAI adducts are elevated [152•]. This modification is 
suggested to hinder the interaction of apoAI with lipids and ABCA1, thereby reducing 
cholesterol efflux via ABCA1.  
In addition, in-vitro experiments have shown that lipid-free apoAI and pre-β−HDL 
are sensitive to proteolytic degradation by matrix metalloproteinases [153], cathepsins 
[154], and the mast cell-derived enzymes chymase and tryptase [155, 156], which are 
present in atherosclerotic lesions. Interestingly, in fatty streaks, mast cells are localized 
close to foam cells [157]. Thus, chymase and tryptase secreted by mast cells in the 
atherosclerotic lesions could promote macrophage foam cell formation by reducing the 
availability of extracellular acceptors for ABCA1-mediated cholesterol efflux. In line, 
systemic activation of mast cells by compound 48/80 results in an impaired capacity of 
serum and intraperitoneal fluid to promote cellular cholesterol efflux from macrophage 
foam cells in culture [158●]. 
 
Conclusion 
The relative importance of the different pathways for cholesterol efflux from macrophage 
foam cells in atherosclerotic lesions is attributed to the activity of SR-BI, ABCA1, and 
ABCG1, the interaction between these transporters, as well as the quantity and quality of 
their respective acceptors. Conditions locally inside the atherosclerotic lesions, including 
the presence of lipids, cytokines, hypoxia, and oxidative stress as well as systemic factors 
(e.g. diabetes and inflammation) modulate cholesterol efflux from macrophages by 
influencing the activity of the transporters involved and modification of their acceptors 
(Figure 1 & 2). Thus, improvement of HDL quality as well as quantity will be an important 
clinical goal for atherosclerosis treatment. Hereto, international consensus is required on 
standardized methodologies for HDL isolation and protocols for evaluation of HDL 
function. HDL proteome analysis may lead to a more comprehensive understanding of the 
differential functions of individual HDL subclasses. Importantly, increased understanding 
of the various cholesterol efflux pathways and HDL functionality will promote the 
development of new HDL-based therapies.  
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Abstract 
Rationale. Macrophages are incapable of limiting the uptake of lipids and therefore rely on 
cholesterol efflux mechanisms for maintaining cellular cholesterol homeostasis. Important 
mediators of macrophage cholesterol efflux are ABCA1, which mediates the efflux of 
cholesterol to lipid-poor apoAI, and SR-BI that promotes efflux to mature HDL.  
Objective. The aim of the current study was to increase the insight into the putative 
synergistic roles of ABCA1 and SR-BI in foam cell formation and atherosclerosis,  
Methods and Results. LDL receptor knockout (LDLr KO) mice were transplanted with 
bone marrow from ABCA1/SR-BI double knockout mice, the respective single knockouts, 
or wildtype littermates. Serum cholesterol levels were lower in ABCA1/SR-BI double 
knockout transplanted animals, as compared to the single knockout and wildtype 
transplanted animals on Western-type diet. Despite the lower serum cholesterol levels, 
massive foam cell formation was found in macrophages from spleen and the peritoneal 
cavity. Interestingly, ABCA1/SR-BI double knockout transplanted animals also showed a   
major increase in pro-inflammatory KC (murine IL-8) and IL-12p40 levels in the 
circulation. Furthermore, after 10 weeks Western-type diet feeding atherosclerotic lesion 
development in the aortic root was more extensive in the LDLr KO mice reconstituted with 
ABCA1/SR-BI double knockout bone marrow.  
Conclusions. This study shows that deletion of ABCA1 and SR-BI in bone marrow-
derived cells enhances in vivo macrophage foam cell formation and atherosclerotic lesion 
development in LDLr KO mice on Western diet, indicating that under high-dietary lipid 
conditions both macrophage ABCA1 and SR-BI contribute significantly to cholesterol 









The hallmark of atherosclerotic lesion development is the accumulation of macrophage 
foam cells (1). Transporters implicated in cholesterol efflux from macrophages include the 
ATP-binding cassette (ABC) transporters ABCA1 and ABCG1, and scavenger receptor BI 
(SR-BI) (2,3). ABCA1 is a full-size ABC-transporter that facilitates cholesterol efflux to 
lipid-poor apoAI (2,3). Total-body ABCA1 knockout mice and Tangier disease patients 
with dysfunctional ABCA1 display a virtual absence of HDL, showing the essential role 
for ABCA1 in HDL metabolism (3). Targeted inactivation of ABCA1 in bone marrow-
derived cells in mice leads to increased atherosclerotic lesion formation (4,5), whereas 
overexpression of ABCA1 inhibits the progression of atherosclerosis (6). Macrophages 
lacking ABCA1, however, still have substantial ability to efflux cholesterol to HDL despite 
impaired efflux to lipid-poor apoAI, suggesting that macrophages have additional 
pathways via which cellular cholesterol can be exported. In addition to ABCA1, 
macrophages also express the ABC half-transporter ABCG1. In contrast to ABCA1, 
ABCG1 facilitates cellular cholesterol efflux from macrophages to mature HDL, but not to 
lipid-free apolipoproteins (7,8). Furthermore, HDL levels are not affected in genetically-
engineered mice lacking ABCG1 (8). Disruption of ABCG1 specifically in macrophages 
has only a moderate effect on atherosclerotic lesion development (9-11). Combined 
deletion of ABCA1 and ABCG1 on macrophages, however, led to a major impairment of 
cholesterol mass efflux to apoAI and HDL and a dramatic accumulation of foam cells in 
tissues (12-14). Transplantation of ABCA1/ABCG1 double KO bone marrow into LDL 
receptor knockout (LDLr KO) mice led only to modest atherosclerosis when challenged 
with a Western-type diet which was associated with markedly decreased plasma 
cholesterol levels (12). In heterozygous LDLr KO mice fed a high cholesterol/cholate diet 
disruption of ABCA1 and ABCG1 in bone marrow-derived cells, however, did not affect 
serum cholesterol levels and consequently led to markedly increased atherosclerotic lesion 
development as compared to mice receiving single ABCA1 KO or ABCG1 KO bone 
marrow (14). These studies clearly illustrate the importance of studying the effects of 
combined deficiency of cholesterol transporters to establish the importance of a specific 
transporter for preventing foam cell formation and atherosclerotic lesion development in 
vivo. 
In addition to ABCA1 and ABCG1, also scavenger receptor class B type I (SR-BI) 
has been implicated in macrophage cholesterol efflux. SR-BI facilitates the transport of 
cholesterol from macrophages down a concentration gradient to mature HDL and mediates 
the selective uptake of cholesterol esters from HDL by the liver (2,3). Complete disruption 
of SR-BI function in mice is associated with the accumulation of abnormally large HDL 
particles in the circulation, reflecting impaired delivery of cholesteryl esters to the liver (3). 
Bone marrow-specific deletion of SR-BI did not affect serum HDL cholesterol levels and 
inhibited early atherosclerotic development (15), while the progression of advanced lesions 
was induced (15-17), indicating a unique dual role for macrophage SR-BI in the 
pathogenesis of atherosclerosis. Recent studies using macrophages from SR-BI knockout 
mice and inhibitors of SR-BI and ABCA1-mediated efflux showed that macrophage SR-BI 
does not promote cholesterol efflux from murine macrophages in culture (18). In addition, 
reverse transport of cholesterol from SR-BI KO macrophages to feces after transfer into 
wildtype C57BL/6 mice was not affected (19). Based on these studies the role of 
macrophage SR-BI for cellular cholesterol efflux was considered to be limited. However, 
studies from Yancey et al. demonstrated that macrophages with a combined deficiency of 
SR-BI and apoE display a reduced efflux capacity and accumulate free cholesterol in 
lysosomes (20). Moreover, recently Cuchel et al. showed that free cholesterol mobilization 
in vivo in response to reconstituted HDL infusion is primarily mediated by SR-BI and not 
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ABCA1 or ABCG1 (21). In addition, overexpression of apoAI in heterozygous LDLr KO 
mice can protect against atherosclerosis in the absence of macrophage ABCG1 and 
ABCA1 (22). Thus, SR-BI might be more important for controlling cellular cholesterol 
homeostasis in vivo than was initially anticipated. 
In the present study, we investigated the putative synergistic effects of combined 
disruption of ABCA1 and SR-BI in bone marrow-derived cells and thus macrophages on 
lipoprotein metabolism and atherosclerosis. Our results indicate that both ABCA1 and SR-
BI in macrophages have a significant protective role in foam cell formation and Western-
type diet induced atherosclerotic lesion development in vivo. 
 
Methods 
For detailed methodology, please see the data supplement. Briefly, bone marrow 
transplantations were performed with ABCA1/SR-BI double KO mice as donors and LDLr 
KO mice as recipients. Plasma lipids were determined by enzymatic colorimetric assays 
and cytokines in serum by using the mouse Bio-Plex suspension array (Bio-Rad, Sweden). 
For histological analysis cryostat sections were routinely stained with oil-red-O. Peritoneal 
leukocytes were analyzed with a hematology cell analyzer. Atherosclerotic lesion areas in 
oil-red-O stained cryostat sections of the aortic root and coronary arteries and en face 
lesions in the aortic arch and thoracic aorta were quantified using the Leica image analysis 
system. Macrophage-cholesterol efflux studies were performed using bone marrow-derived 
macrophages (BMDM) and thioglycollate-elicited macrophages. 
 
Results  
Reduced VLDL/LDL cholesterol levels by combined deletion of ABCA1 and SR-BI in 
bone marrow-derived cells 
To study the effects of combined macrophage ABCA1 and SR-BI deficiency on 
lipoprotein metabolism and atherosclerosis in vivo, LDLr KO recipient mice were 
transplanted with bone marrow from wildtype (WT), ABCA1 KO, SR-BI KO, or 
ABCA1/SR-BI double KO littermates. Deletion of ABCA1, SR-BI or both ABCA1 and 
SR-BI in bone marrow-derived cells did not affect total serum cholesterol concentrations at 
8 weeks after transplantation when fed a regular chow diet (Figure 1A). Furthermore, no 
significant effects were observed of single ABCA1 or combined ABCA1/SR-BI deletion 
on the cholesterol lipoprotein distribution profile on chow diet (Figure 1B). Single SR-BI 
deletion resulted in 1.7-fold (n=10, p<0.05) lower HDL cholesterol levels, while VLDL 
and LDL cholesterol levels showed a tendency to increased values, but this failed to reach 
statistical significance. At 8 weeks after bone marrow transplantation the diet was switched 
from regular chow diet to a Western-type diet (WTD), containing 15% (w/w) total fat and 
0.25% (w/w) cholesterol to induce atherosclerotic lesion development. After 10 weeks 
feeding WTD the effects on serum cholesterol levels and the lipoprotein-distribution 
profiles were analysed. The diet switch induced a large increase in serum cholesterol 
concentrations to 1856±111 mg/dL in the WT (n=12) and 1722±84 mg/dL in SR-BI KO 
(n=9) transplanted LDLr KO mice. In agreement with our previous studies (4,13), deletion 
of ABCA1 in bone marrow-derived cells resulted in lower serum cholesterol levels upon 
challenge with WTD (1429±78 mg/dL, n=8, p<0.01). Interestingly, more dramatically 
lower serum cholesterol levels were found in the ABCA1/SR-BI double KO transplanted 
animals upon challenge with WTD (812±84 mg/dL, n=11, p<0.001 as compared to WT 
transplanted animals) (Figure 1C). In the WT and SR-BI KO transplanted groups the 
increase in serum cholesterol was mainly due to increased VLDL and LDL levels (Figure 




VLDL and LDL levels was observed, although to a lower extent as compared to the mice 
transplanted with WT or SR-BI KO bone marrow. The increase in VLDL and LDL in the 
ABCA1/SR-BI double KO transplanted animals, however, was largely attenuated as 
compared to the other 3 groups (Figure 1D).  
 
 
Figure 1. Total serum cholesterol levels and lipoprotein cholesterol distribution profile in LDLr KO 
mice reconstituted with WT, ABCA1 KO, SR-BI KO and ABCA1/SR-BI double KO bone marrow at 8 
weeks after transplantation (chow) and at 18 weeks after transplantation (Western-type diet). 
Total serum cholesterol concentrations on chow (A) and on Western-type diet (C) of LDLr KO mice 
transplanted with WT (open bars), ABCA1 KO (grey bars), SR-BI KO (dark grey bars), and ABCA1/SR-BI 
double KO (black bars) bone marrow. Lipoprotein distribution of total cholesterol of WT (○), ABCA1 KO 
(▲), SR-BI KO (∆), and ABCA1/SR-BI double KO (●) reconstituted mice on chow (B) and Western-type 
diet (D). Values are means±SEM (n=8-12). Statistically significant difference **p<0.01, ***p<0.001. 
 
To investigate the effects of combined deletion of ABCA1 and SR-BI in bone 
marrow-derived cells on cholesterol homeostasis, food intake and cholesterol absorption 
by the animals was analysed at 16 weeks post-transplant after 8 weeks WTD feeding. Food 
intake was reduced by 15% (p<0.01) in ABCA1/SR-BI double KO transplanted animals 
(2.16±0.13 g/day, n=6) as compared to WT transplanted mice (2.55±0.28 g/day, n=6). 
Moreover, the intestinal cholesterol absorption was mildly reduced by 27% (p<0.05, n=4) 
in ABCA1/SR-BI double KO transplanted animals as compared to controls, while 
triglyceride absorption was reduced by 43% (p<0.05, n=4). In addition, we tested whether 
combined ABCA1 and SR-BI deletion in bone marrow-derived cells affected VLDL 
synthesis by in vivo inactivation of lipolysis using Triton WR1339. The VLDL production 
rate was significantly lower in mice lacking ABCA1 and SR-BI in bone marrow-derived 
cells (1,814 ± 228 µg/mL/h, n=3) as compared to control transplanted animals (3,337 ± 
570 µg/mL/h, n=3, p<0.01). In addition, a 1.8-fold reduction in hepatic HMGCoA 
reductase mRNA expression from 0.30±0.5 in WT to 0.17±0.2 in ABCA1/SR-BI double 
knockout transplanted animals (n=4, p<0.05) was observed. Hepatic lipase mRNA 
expression in the liver was not affected (data not shown). In summary, reduced food 
intake, impaired intestinal lipid absorption, and reduced VLDL production by the liver will 
have contributed to the observed reduction in serum cholesterol levels in de ABCA1/SR-BI 
double KO transplanted animals. 
 
Enhanced atherosclerotic lesion development in the aortic root upon combined 
deletion of ABCA1 and SR-BI in bone marrow-derived cells 
Atherosclerotic lesion development was analyzed in cryostat sections of the aortic 
root after 10 weeks WTD feeding (18 weeks post-transplant). As anticipated, deletion of 
ABCA1 and/or SR-BI in bone marrow-derived cells resulted in total erasure of the 
respective proteins in the lesions of the transplanted mice (Figure 2A). Selective disruption 
of either ABCA1 or SR-BI in bone marrow-derived cells induced a 1.4–fold (p<0.001) and 
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1.5–fold (p<0.001) increase in the mean atherosclerotic lesion size as compared to WT 
transplanted animals, respectively (Figure 2B). Thus, as previously demonstrated, both 
leukocyte ABCA1 (4,5) and SR-BI (16-18) have an important role in the protection against  
 
 
Figure 2. Atherosclerotic lesion development in the aortic root of LDLr KO mice reconstituted with 
WT, ABCA1 KO, SR-BI KO, and ABCA1/SR-BI double KO bone marrow. 
(A) Expression of ABCA1 and SR-BI was immunofluorescently detected (red) in the aortic roots of WT, 
ABCA1 KO, SR-BI KO, or ABCA1/SR-BI double KO transplanted LDLr KO mice at 18 weeks post 
transplantation including a 10-week Western-type diet-feeding period. Nuclei were stained with DAPI (blue). 
Original magnification 10x10. (B) Photomicrographs showing representative oil-red-O stained sections 
(original magnification 10x5) and mean atherosclerotic lesion size in the aortic roots of mice, transplanted 
with WT (n=20), ABCA1 (n=20), SR-BI KO (n=20), or ABCA1/SR-BI double knockout (n=21) bone 
marrow. Each symbol represents the mean lesion area in a single mouse. The horizontal line represents the 
mean of the group ( WT: 348±30*103 μm2; ABCA1 KO: 496±53*103 μm2; SR-BI KO 533±27*103 μm2; 
Double KO: 693±41*103 μm2). Statistically significant difference **p<0.01, ***p<0.001.  
 
atherosclerosis. Combined deletion of ABCA1 and SR-BI in bone marrow-derived cells 
resulted in a more dramatic 2.0-fold (p<0.001) increase in the mean atherosclerotic lesion 
area compared to WT (Figure 2B). In addition, the lesion size in the ABCA1/SR-BI double 
KO transplanted animals was also significantly larger as compared to mice transplanted 
with single ABCA1 KO or SR-BI KO bone marrow (1.4-fold and 1.3-fold, respectively, 
p<0.01). Morphometric analysis of the composition of the lesions showed that the 
macrophage content of the lesions of LDLr KO mice transplanted with ABCA1/SR-BI 
double KO bone marrow [31±4%, n=9] was significantly reduced as compared to WT, 
single ABCA1 KO, and single SR-BI KO transplanted animals (46±6% [n=11p<0.05], 
41±4% [n=8, p<0.01], and 49±5% [n=8, p<0.01], respectively). In addition, a significant 
increase in the necrotic core content of lesions of ABCA1/SR-BI double KO transplanted 




SR-BI KO transplanted animals (8±2% [n=10, p<0.01], 15±3% [n=8, p<0.05], and 10±2% 
[n=8, p<0.05], respectively). No effect was observed on the collagen content of the lesions. 
The decreased macrophage content and increased necrotic area in atherosclerotic lesions of 
the ABCA1/SR-BI double KO transplanted animals are consistent with the presence of 
more advanced lesions. 
In addition to the aortic root, lesion development was also determined in the aortic 
arch, thoracic aorta, and right coronary artery after 10 weeks WTD feeding 
(Supplementary Figure I). In WT and SR-BI KO transplanted mice 4.0±0.2% and 
4.6±1.0%, respectively of the aortic arch was covered with lesion. Single deletion of 
ABCA1 and combined deletion of ABCA1 and SR-BI in bone marrow-derived induced a 
similar 2.3-fold increase (p<0.01) in the vessel area covered by lesion. In the thoracic aorta 
only 1.4±0.2% of the vessel was covered with lesion in WT transplanted mice. Deletion of 
SR-BI in bone marrow-derived cells resulted in a 3.5-fold decrease (p<0.05) in the area 
covered by lesion. These findings are in agreement with our earlier published studies 
showing that SR-BI in bone marrow-derived cells induces early lesion development, does 
not affect intermediate lesions, and protects against the development of advanced lesions 
(15). Also in the thoracic aorta no additional induction of lesion development was observed 
upon combined deletion of ABCA1 and SR-BI as compared to single deletion of ABCA1 
(2.9±0.7% and 3.2±0.5%, respectively). The lesion size in the coronary artery was 
3.6±0.3x103 μm2 and 3.6±0.4x103 μm2 in mice transplanted with WT and SR-BI KO bone 
marrow, respectively after 10 weeks WTD feeding. Deletion of ABCA1 induced a 2.2-fold 
increase in coronary artery lesion size to 8.0±1.6x103 μm2 (p<0.05), while lesions in 
ABCA1/SR-BI dKO transplanted animals were 9.0±1.5x103 μm2 (p<0.05).  
 
Figure 3. Effect of combined deletion of ABCA1 and SR-BI in bone marrow-derived cells in LDLr KO 
mice on lipid accumulation in liver, lung, lymph node, small intestine, and Peyer’s patches. 
At 18 weeks post transplant, including 10 weeks Western-type diet feeding, indicated organs were isolated 
from LDLr KO mice transplanted with WT, ABCA1 KO, SR-BI KO, and ABCA1/SR-BI double KO bone 
marrow. Cryostat sections were stained with oil-red-O to visualize lipid accumulation. Original magnification 
5x10. 
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Massive foam cell formation in spleen and peritoneum by combined deletion of 
ABCA1 and SR-BI in bone marrow-derived cells 
To assess potential morphological changes associated with combined ABCA1 and 
SR-BI deficiency in bone marrow-derived cells outside the vasculature, a necropsy of the 
transplanted mice was performed. Due to the WTD feeding period, massive lipid 
accumulation was induced in livers of the transplanted animals (Figure 3). However, 
quantitative lipid analysis revealed no differences in lipid accumulation in the livers of the 
different groups of transplanted mice (data not shown). Microscopically no heavily lipid-
laden foam cells were evident in the liver. Furthermore, no foam cells were found in the 
lamina propria of the intestines, the largest reservoir of macrophages in the body, of either 
of the transplanted groups. The Peyer’s patches, lungs, and lymph nodes of the 
ABCA1/SR-BI double knockout transplanted mice showed slightly enhanced lipid 
accumulation (Figure 3). Most striking differences, however, were observed on spleen 
morphology. No significant effect of leukocyte SR-BI deficiency was observed on spleen 
weight (3.7±0.4 mg/g bodyweight [n=9] as compared to 3.8±0.3 mg/g [n=9] for WT 
transplanted mice, p>0.05). ABCA1 and combined deletion of ABCA1 and SR-BI, 
however, induced a 1.6-fold (6.0±0.9 mg/g, n=9, p<0.05) and a 4.5-fold (17.1±3.1 mg/g, 




spleen weight, respectively. Analysis of oil-red-O stained sections of the spleen indicated 
that WT and SR-BI knockout transplanted animals displayed only a few lipid-laden cells in 
the spleen (Figure 4A). Deletion of ABCA1 in bone marrow-derived cells resulted in 
slightly enhanced accumulation of lipid-laden cells. However, spleens of the mice 
Figure 4. Massive lipid accumulation in 
the red pulp of spleens of LDLr KO 
mice transplanted with ABCA1/SR-BI 
double KO bone marrow. 
At 18 weeks post transplant, including 10 
weeks Western-type diet feeding, spleens 
were isolated from LDLr KO mice 
transplanted with WT, ABCA1 KO, SR-BI 
KO, and ABCA1/SR-BI double KO bone 
marrow. (A) Cryostat sections were stained 
with oil-red-O to visualize lipid 
accumulation. Original magnification 
5x10. (B) Co-localization of oil-red-O 
(left) and the macrophage marker F4/80 
(right) in spleen sections of ABCA1/SR-BI 
double KO transplanted mice. Original 
magnification 20x10. (C) Quantification of 
free and cholesterol ester content of 
spleens of WT (open bars), ABCA1 KO 
(grey bars), SR-BI KO (dark grey bars), 
and ABCA1/SR-BI double KO (black 
bars) transplanted mice. Values are 





transplanted with ABCA1/SR-BI double KO bone marrow displayed massive lipid 
loading. The lipid loading was especially evident in the red pulp of the spleen, constituting 
the reticulo-endothelial system of the spleen, where it co-localized with macrophages 
(Figure 4B). Analyses of the lipid content of the spleens showed no significant effect of 
combined ABCA1 and SR-BI deletion in bone marrow on phospholipid, triglyceride, and 
free cholesterol concentrations. However, substantial effects were observed on cholesteryl 
ester accumulation. Single ABCA1 deletion induced a 3.7-fold (n=5, p<0.05) increase in 
the cholesteryl ester content of the spleen as compared to WT transplanted animals, while 
single SR-BI deficiency in bone marrow resulted in 3-fold (n=5) lower splenic cholesteryl 
ester levels, which failed to reach statistical significance (Figure 4C). Combined deletion 
of bone marrow ABCA1 and SR-BI, however, induced a dramatic 12.5-fold (n=5, p<0.05) 
increase in cholesteryl ester accumulation in spleens.  
 
 
Figure 5. Identification of heavily lipid-laden macrophage foam cells in peritoneal cavity of LDLr KO 
mice transplanted with ABCA1/SR-BI double KO bone marrow. 
At 18 weeks post transplant, including 10 weeks Western-type diet feeding, the peritoneal cavity of the LDLr 
KO mice transplanted with WT (open bar), ABCA1 KO (grey bar), SR-BI KO (dark grey bar), and 
ABCA1/SR-BI double KO (black bar) bone marrow was lavaged, and the collected peritoneal leukocytes 
were analyzed using an automated Veterinary Hematology analyzer. (A) Scattergrams of peritoneal 
leukocytes isolated from LDLr KO mice reconstituted with WT, ABCA1 KO, SR-BI KO, or ABCA1/SR-BI 
double KO bone marrow. Side scattered light (SSC), indicating the complexity of the cells, is plotted against 
side fluorescent light (SFL), determining the nucleic acid content of the cells. (B) Photomicrographs of 
cytospins of peritoneal cells of the corresponding animals after oil-red-O lipid staining. Original 
magnification 40x10. (C) Quantification of the number of macrophage foam cells as percentage of the total 
amount of isolated cells by gating of the cells in the upper right hand corner of panel A (left, n=8-12 per 
group) and quantification of the cholesterol ester content of the cells (right, n=4 per group). Note the massive 
lipid-accumulation in peritoneal leukocytes of LDLr KO mice transplanted with ABCA1/SR-BI double KO 
bone marrow. Values are means±SEM. Statistically significant difference **p<0.01, ***p<0.001, and ns for 
non-significant.  
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Interestingly, in addition to the observed increase in spleen size also more lipid-
laden macrophages were present in the peritoneum of mice reconstituted with ABCA1/SR-
BI double KO bone marrow (22±1.2%, n=11, p<0.001), compared to the WT reconstituted 
animals (2.5±0.5%, n=12) (Figure 5). In the peritoneum also increased numbers lipid-laden 
cells were observed in single ABCA1 KO transplanted animals (7.5±1.1%, n=8, p<0.01), 
but the effect was less severe as compared to combined deletion of ABCA1 and SR-BI. In 
addition, a tendency to reduced lipid-loading was observed in peritoneal macrophages from 
mice reconstituted with SR-BI KO bone marrow (0.2±0.04%, n=9, p>0.05), in line with 
the dual function of SR-BI in macrophage foam cell formation and atherosclerotic lesion 
development (15). Quantitative analysis of the lipid content of the peritoneal leukocytes 
confirmed that combined deletion of ABCA1 and SR-BI resulted in a highly significant 
(p<0.001) increase in cholesterol ester accumulation in peritoneal macrophages as 
compared to single deletion of ABCA1 (WT: 11±5 (n=4), SR-BI KO:10±7 (n=4), ABCA1 
KO:44±4 (n=4), ABCA1/SR-BI dKO:249±38 μg/mg (n=4)). 
 
Combined deletion of ABCA1 and SR-BI leads to reduced cholesterol efflux capacity 
from macrophages to both apoAI and HDL 
To get more insight in the mechanism behind the massive lipid accumulation in peritoneal 
leukocytes and macrophages of the spleen, in vitro cholesterol efflux experiments were 
performed (Figure 6A). As previously shown (15), macrophage SR-BI deficiency resulted 
in 24% (n=8, p<0.01) lower cholesterol efflux to HDL. Combined deletion of ABCA1 and 
SR-BI resulted in a similar 20% (n=8, p<0.05) decrease in cholesterol efflux to HDL. In 
addition, macrophages lacking both ABCA1 and SR-BI showed an almost complete 
absence of apoAI-induced cholesterol efflux, similar to ABCA1-deficient macrophages. To 
exclude that the observed effects on cholesterol efflux might be the consequence of down-
regulation of ABCG1, the expression of the major cholesterol transporters was analysed by 
Western blotting (Figure 6B). As expected, in cells from ABCA1 deficient mice ABCA1 
was absent, while cells from the SR-BI knockout mice lacked SR-BI expression. ABCG1 
expression was similarly upregulated in all 3 groups as compared to WT macrophages, 




Figure 6. Impaired cholesterol efflux from macrophages lacking ABCA1 and SR-BI. (A) Cellular 
cholesterol efflux to apoAI (10 µg/mL) and HDL (50 µg/mL) from in vivo 3H-cholesterol-labeled peritoneal 
macrophages. (B) Quantification of ABCA1, SR-BI, and ABCG1 protein expression in the peritoneal 
macrophages by Western blotting. Values are means±SEM (n=3-4). Statistically significant difference of 





Cholesterol efflux experiments were also performed using macrophages laden with 
acetylated LDL. Under these conditions, however, no additional effect of combined 
deletion of ABCA1 and SR-BI over single deletion of ABCA1 was observed on 
cholesterol mass and 3H-label efflux due to absence of SR-BI expression in all groups 
examined (Supplementary Figure II). 
 
Increased inflammation by combined deletion of ABCA1 and SR-BI in bone marrow-
derived cells 
Studies in patients with Tangier disease have suggested a dual function for ABCA1 
in both lipid metabolism and inflammation (23). Furthermore, we have shown that 
disruption of ABCA1 in bone marrow-derived cells results in an enhanced recruitment of 
leukocytes into peripheral tissues (4). In agreement with our earlier data, ABCA1-
deficiency in bone marrow-derived cells resulted in a 2-fold (p<0.01) increase in the 
number of resident leukocytes in the peritoneal cavity (6.17±0.96*106 cells [n=8] as 
compared to 3.15±0.33*106 cells [n=12] for WT transplanted animals, Figure 7). No effect 
of single SR-BI deficiency was observed on peritoneal leukocyte counts (2.69±0.21*106 
cells). Interestingly, combined deletion of ABCA1 and SR-BI in bone marrow-derived 
cells resulted in a more dramatic increase in peritoneal leukocyte accumulation 
(8.79±0.71*106 cells; n=11, p<0.001 as compared to WT and SR-BI KO transplanted 
animals and p<0.01 as compared to ABCA1 KO reconstituted mice). As indicated in 
Figure 7, the increased peritoneal leukocyte counts in the single ABCA1 KO reconstituted 
animals were the result of a 1.6-fold increase (n=8, p<0.05) in macrophage counts and a 
3.2-fold increase (n=8, p<0.01) in lymphocytes. In the ABCA1/SR-BI double KO 
transplanted animals a similar increase in macrophage counts was observed. The 
lymphocyte counts, however, were more dramatically increased (5.4-fold, n=11, p<0.001).  
 
Figure 7. Enhanced leukocyte accumulation in the peritoneal cavity of LDLr KO mice transplanted 
with ABCA1/SR-BI double KO bone marrow. 
At 18 weeks post transplant including 10 weeks Western-type diet feeding, the peritoneal cavity of the LDLr 
KO mice transplanted with WT (open bar), ABCA1 KO (grey bar), SR-BI KO (dark grey bar), and 
ABCA1/SR-BI double KO (black bar) bone marrow was lavaged, and the collected peritoneal leukocytes 
were analyzed using an automated Sysmex XT-2000iV Veterinary Hematology analyzer for total cell 
(TOTAL), macrophage (MACRO), lymphocyte (LYMPHO), and neutrophil (NEUTRO) counts. Values are 
means±SEM (n=8-12). Statistically significant difference *p<0.05, **p<0.01, ***p<0.001, and ns for non-
significant. 
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In addition, a striking accumulation of neutrophilic granulocytes was observed in the 
peritoneal cavity, accounting for 20% of the increase in the peritoneal leukocyte count in 
mice transplanted with ABCA1/SR-BI double KO bone marrow. Combined deletion of 
ABCA1 and SR-BI did not affect the peripheral WBC counts (5.6±0.6*109 cells/L, n=12 as 
compared to 5.8±0.8*109 cells/L, n=11 for WT transplanted animals), nor the percentile 
composition of the blood cells (data not shown). The increased neutrophil counts in the 
peritoneal cavity were thus primarily the result of increased recruitment of neutrophils. 
Since no thioglycollate or other additional trigger was used to elicit the recruitment of 
neutrophils, an endogenous trigger inside the peritoneal cavity most likely has caused the 
recruitment of the cells. It is interesting to speculate that this is the consequence of the 
extensive foam cell accumulation inside the peritoneal cavity. Next, live neutrophils inside 
the lesions were visualized using a naphthol AS-D chloroacetate esterase activity kit. 
Surprisingly, based on this esterase activity assay no significantly higher neutrophil counts 
were observed within the atherosclerotic lesions of ABCA1/SR-BI double KO transplanted 
mice (49±15 [n=8] versus 39±6 for WT transplanted mice [n=10], p=0.51) or in the 
adventitia surrounding the lesion (134±18 [n=8] versus 93±14 [n=10] for WT transplanted 
mice, p=0.08). In addition to the esterase activity assay, an immunohistochemical staining 
for the neutrophil specific marker Ly-6G was performed. Interestingly, using this staining 
we did find a highly significant increase in the Ly-6G positive area of lesions of 
ABCA1/SR-BI double KO (5.2±0.8% [n=5], p<0.0001) versus WT (0.2±0.04% [n=5]) 
transplanted animals. Ly-6G staining was primarily localized in acellular regions of the 
corners of the necrotic areas of the lesions, indicating the increased presence of residues of 
neutrophils that had infiltrated the lesion. 
 
 
Figure 8. Increased circulating cytokine levels in LDLr KO mice transplanted with ABCA1/SR-BI 
double KO bone marrow. 
Serum from the transplanted LDLr KO mice was collected at 18 weeks after transplantation including 10 
weeks Western-type diet feeding. A Bio-Plex suspension array was used to measure 8 different cytokines, 
including IL-1β, IL-5, IL-6, KC (murine IL-8), IL-10, IL-12, TNF-α, and RANTES. The concentrations of 
IL-5, KC (murine IL-8), IL-10, and IL-12 in WT (open bars), ABCA1 KO (grey bars), SR-BI KO (dark grey 
bars) and ABCA1/SR-BI double KO (black bars) transplanted mice are shown. No significant differences 
were observed in the concentrations of IL-1β, IL-6, TNF-α, or RANTES between the four groups of mice. 
Values are means±SEM (n=5-10). Statistically significant difference *p<0.05, **p<0.01, ***p<0.001, and ns 
for non-significant.  
An inflammatory response involves a complex set of events that, in addition to 




profiles. Therefore, also the serum cytokine levels were examined in the different groups 
of transplanted animals using a Bio-Plex suspension array. On chow diet, no effect on 
cytokine levels was observed (data not shown). After 4 weeks WTD feeding, however, a 
significant 1.8-fold increase (n=6, p<0.01) in the pro-inflammatory cytokine KC (murine 
ortholog of IL-8) was observed in mice reconstituted with ABCA1/SR-BI double KO bone 
marrow, while no significant effect was observed on the other cytokines tested (IL-1β, IL-
6, IL-5, IL-10, IL-12, TNF-α, or RANTES). After 10 weeks WTD feeding, an even more 
dramatic 17-fold (n=5, p<0.001) increase in KC levels was observed in the ABCA1/SR-BI 
double KO transplanted animals, while under these conditions also IL-12p40 levels were 
highly increased (11-fold, n=5, p<0.001).  (Figure 8). In addition, an increase in the anti-
inflammatory cytokines IL-5 and IL-10 was observed in the ABCA1/SR-BI double KO 
reconstituted animals. The levels of the anti-inflammatory cytokines, however, remained 
substantially lower as compared to the pro-inflammatory cytokines (7.2±3.7 and 10.0±3.7 
pg/ml for IL-5 and IL-10 as compared to 139±16 pg/ml and 858±192 pg/ml for KC and IL-
12p40, respectively). The effects on the cytokine levels thus increase with a prolonged 
duration of the WTD feeding period. 
 
No increased foam cell formation and atherosclerosis in the aortic root as a result of 
combined deletion of ABCA1 and SR-BI in bone marrow-derived cells in LDL 
receptor knockout mice on chow diet. 
To investigate if the WTD-induced increase in pro-inflammatory cytokines is required to 
induce massive foam cell formation and promote atherosclerotic lesion development in the 
aortic root upon combined disruption of ABCA1 and SR-BI in bone marrow-derived cells 
of LDLr KO mice, a bone marrow transplantation experiment was performed and 
atherosclerotic lesion development was analysed at 14 and 20 weeks after transplantation 
while maintaining the mice on regular chow diet. At 14 weeks, WT transplanted animals 
developed small foam cell-rich lesions with an average size of 85±8x103 μm2 (n=11). 
Consistent with our previously published pro-atherogenic role of SR-BI in small foam cell-
rich lesions, disruption of SR-BI in bone marrow-derived cells  in LDLr KO mice on chow 
diet resulted in slightly smaller atherosclerotic lesions (62±7x103 μm2, n=12, p<0.05). 
Deletion of ABCA1 led to a significant 1.5-fold increase in lesion size (127±18x103 μm2, 
n= 11, p<0.05). In contrast to the result obtained in mice fed WTD, no added effect of 
combined deletion of ABCA1 and SR-BI in bone marrow-derived cells was found in LDLr 
KO mice on chow (140±22x103 μm2, n=11) as compared to single deletion of ABCA1. 
Also at 20 weeks after transplantation no added effect of combined ABCA1 and SR-BI 
deletion was found on chow as compared to single deletion of ABCA1 (data not shown).  
Under chow conditions, also similarly increased foam cell accumulation was observed in 
the peritoneal cavity of ABCA1 KO and ABCA1/SR-BI dKO transplanted animals 
(1.1±0.11% [n=11] and 1.3±0.22% [n=10], respectively, as compared to 0.15±0.02% 
[p<0.001, n=11] and 0.25±0.07% [n=11, p<0.001] for WT and SR-BI knockout 
transplanted mice. Foam cell counts, however, were much less as compared to the levels in 
transplanted animals challenged with WTD. No effect on total peritoneal leukocyte counts 
was observed (data not shown) and neutrophil counts remained low (~5% in all groups). 
Furthermore, no lipid accumulation was observed in the spleens nor a change in spleen size 
was observed of ABCA1/SR-BI dKO transplanted animals. The WTD challenge is thus 
essential to induce the enhanced foam cell formation, atherosclerotic lesion development, 
and inflammation in LDLr KO mice upon combined deletion of ABCA1 and SR-BI in 
bone marrow-derived cells. 
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Discussion 
In the current study we show that specific disruption of both ABCA1 and SR-BI in 
bone marrow-derived cells of LDLr KO mice led to an added increase in atherosclerotic 
lesion development in the aortic root upon challenge with WTD, compared to single 
ABCA1 KO or SR-BI KO reconstituted LDLr KO mice, despite lower serum cholesterol 
levels. Massive lipid accumulation was found in peritoneal macrophages as well as 
macrophages in the red pulp of the spleens of LDLr KO animals reconstituted with 
ABCA1/SR-BI double KO bone marrow. Furthermore, in addition to the lipid parameters a 
significant increase in inflammation markers was noticed in the ABCA1/SR-BI double KO 
transplanted mice on WTD, which is expected to have contributed to the observed dramatic 
increase in lesion development. In line, no enhanced foam cell formation and 
atherosclerotic lesion development was observed upon combined deletion of ABCA1 and 
SR-BI as compared to single deletion of ABCA1 in bone marrow-derived cells in LDLr 
KO mice fed regular chow diet that did not show enhanced inflammatory markers. 
Important to note is that this might also be the consequence of the less advanced stage of 
lesion development in the animals on chow. Furthermore, the site examined for 
atherosclerosis determines the outcome, as no additional effect of combined deletion of 
ABCA1/SR-BI over single ABCA1 deletion was observed in less advanced lesions in the 
aortic arch, thoracic aorta, and coronary arteries of LDLr KO mice challenged with WTD. 
The massive lipid accumulation in peritoneal leukocytes and the red pulp of spleens 
upon combined deletion of ABCA1 and SR-BI in LDLr KO mice on WTD highlights the 
pivotal role of these transporters in cellular lipid homeostasis in vivo under high dietary 
lipid conditions. Furthermore, it is interesting to speculate that the presence of ABCG1 is 
not sufficient to compensate for the absence of these two cholesterol transporters under 
these conditions. ABCA1 stimulates the active transport of both cholesterol and 
phospholipids from the cell to lipid-poor apoAI, but only little to mature HDL (2). SR-BI 
and ABCG1 on the other hand require a phospholipid-containing acceptor, like mature 
HDL, to induce cholesterol efflux (2). In vitro studies showed that the transfer of lipids to 
apoAI mediated by ABCA1 activity is sufficient to generate an efficient acceptor for 
ABCG1-mediated cholesterol efflux (24,25). ABCA1 and ABCG1 thus function 
sequentially in the cholesterol efflux process in which ABCA1 first lipidates apoAI thereby 
forming a substrate for ABCG1 mediated efflux (2). The similarity in acceptor specificity 
between ABCG1 and SR-BI would suggest that SR-BI also cooperatively works with 
ABCA1 in cholesterol export. However, recent siRNA-mediated knockdown studies using 
the RAW macrophage cell line suggested that the interaction of lipid-free apoAI with 
ABCA1 generates a particle that interacts with ABCG1, but not with SR-BI (26). The 
observed massive in vivo lipid loading in peritoneal leukocytes and spleens as well as the 
increased atherosclerotic lesion development in the aortic root of ABCA1/SR-BI double 
knockout transplanted animals on WTD, however, indicate that combined deletion of 
ABCA1 and SR-BI in bone marrow-derived cells does have an added effect on foam cell 
formation in vivo. Cholesterol efflux studies showed that combined deletion of ABCA1 
and SR-BI leads to a complete ablation of apoAI-induced cholesterol efflux, similar as 
observed upon single deletion of ABCA1. However, in addition, a moderate reduction in 
HDL cholesterol efflux could be observed. It is tempting to speculate that the increased 
foam cell formation observed in vivo is the result of the combined impairment of both 
apoAI and HDL-mediated efflux. However, since the effects observed on cholesterol 
efflux in vitro, were relatively small it cannot be excluded that in addition to effects on 
cholesterol efflux also other mechanisms contribute to the increased foam cell formation 
observed in the ABCA1/SR-BI double knockout transplanted animals. Remarkably, 




combined deletion of ABCA1 and SR-BI in bone marrow-derived cells, despite the 
presence of ABCG1. On the other hand, in recent studies with ABCA1/ABCG1 double KO 
transplanted animals, we and others showed that combined deletion of ABCA1 and 
ABCG1 in bone marrow-derived cells also results in massive foam cell formation despite 
the presence of functional SR-BI (12-14). It can be anticipated that ABCG1 and SR-BI 
might have different roles in cholesterol homeostasis at different stages of macrophage 
foam cell formation. As previously shown, the role of macrophage SR-BI in atherosclerotic 
lesion development is dual: it accelerates early atherosclerotic development (15), while it 
slows down the progression of more advanced lesions (15-17). In agreement, in the current 
study the percentage of peritoneal macrophages with a single SR-BI deletion that are 
transformed into foam cells appear to be reduced. SR-BI is a multifunctional receptor 
capable of binding a wide array of native and modified lipoproteins as well as mediating 
the bidirectional flux of cholesterol. This leads to the unique function of macrophage SR-
BI that it can facilitate initial lesion formation by inducing the uptake of pro-atherogenic 
lipoproteins by macrophages (15) and inhibit more advanced lesion formation by 
promoting cholesterol efflux when foam cells are heavily loaded with cholesterol. 
Alternatively, SR-BI and ABCG1 might efflux cholesterol from different specific 
cellular compartments or functionally distinct cellular pools of cholesterol. Wang et al 
showed that LDL cholesterol is preferentially effluxed to HDL, whereas cholesterol from 
modified acetylated LDL (AcLDL) is primarily effluxed to lipid-poor apoAI in an 
ABCA1-dependent fashion (27). In agreement, SR-BI only mediated LDL-cholesterol 
efflux and not AcLDL-cholesterol efflux (28). It is currently, however, unknown if SR-BI 
and ABCG1 mediate efflux from distinct or similar cellular cholesterol pools. Upon 
combined deletion of ABCA1 and SR-BI massive foam cell formation was primarily 
observed in peritoneal leukocytes and macrophages of the red pulp in the spleen. 
Interestingly, combined deletion of ABCA1 and ABCG1 in bone marrow-derived cells of 
LDLr KO mice resulted not only in massive oil red O-positive lipid staining in peritoneal 
leukocytes and macrophages of the red pulp of the spleen, but also in other tissues rich in 
macrophages, including the liver, spleen, lymph nodes, lamina propria of the intestine, and 
Peyer’s patches (12). Importantly, in contrast to ABCA1/SR-BI double knockout 
transplanted LDLr KO mice, ABCA1/ABCG1 transplanted animals did display foam cell 
accumulation in macrophage-rich organs on chow diet, although less extreme than when 
challenged with WTD (unpublished observation from our group). Thus, although the 
similarity in acceptor specificity of SR-BI and ABCG1 suggests possible redundancy of 
these transporters on macrophages for cholesterol efflux to HDL, apparently also the 
biological environment of the macrophage and possibly the availability of substrates 
influence their in vivo importance. Generation of ABCG1/SR-BI double knockout mice, 
ABCA1/ABCG1/SR-BI triple knockouts, and ABCA1/SR-BI double knockout mice, 
overexpressing ABCG1 is expected to shed further light on the (in)dependent roles of these 
cholesterol transporters in macrophage foam cell formation and atherosclerosis. 
Atherosclerotic lesion development results from a combination of hyperlipidemia 
and an inflammatory response. In LDLr KO mice, reconstituted with ABCA1/SR-BI 
double knockout bone marrow, excessive atherosclerosis develops in the aortic root, 
despite largely reduced serum cholesterol levels. Interestingly, the pro-inflammatory 
cytokines KC (murine IL-8) and IL-12p40 were greatly elevated in LDLr KO mice 
transplanted with ABCA1/SR-BI double deficient bone marrow. Both IL-12 and IL-8 are 
important pro-atherogenic cytokines. Daily administration of IL-12 promotes 
atherosclerosis in young apoE KO mice (29), while targeted deletion of IL-12 and 
vaccination against IL-12 attenuates atherosclerotic lesion development in murine models 
of atherosclerosis (30,31). IL-8 is a powerful, independent predictor of cardiovascular 
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events (32). Furthermore, deletion of KC (murine IL-8) in LDLr KO mice attenuates 
atherosclerosis (33). Interestingly, IL-8 production is dose-dependently induced in human 
macrophage foam cells as a response to cholesterol loading with modified LDL, suggesting 
that the observed increase in KC (murine IL-8) levels are a direct effect of the massive 
foam cell formation in the ABCA1/SR-BI double KO transplanted animals (34,35). 
Excessive free cholesterol accumulation in macrophage foam cells induces cytokine 
secretion as a result of endoplasmic reticulum (ER) stress triggered by excess cholesterol 
in the ER (36). No effect of combined ABCA1/SR-BI deficiency was observed on free 
cholesterol loading. Therefore, it is unlikely that increased ER stress as a result of excess 
free cholesterol is the general cause for the increased cytokine production. Alternatively, 
KC (murine IL-8) secretion by macrophages could be induced as a result of increased 
accumulation of oxysterols, including 25-hydroxycholesterol, 7beta-hydroxycholesterol, 
and 7-ketocholesterol (37). KC (murine IL-8) triggers monocyte arrest on early 
atherosclerotic endothelium (38) and plays a central role in macrophage accumulation in 
established fatty streak lesions (39). Interestingly, IL-8 is also one of the most potent 
chemoattractants for neutrophils (40,41) and the increased levels of KC (murine IL-8) in 
the ABCA1/SR-BI double KO transplanted animals clearly parallel the increased 
accumulation of neutrophils in the peritoneal cavity. Neutrophils are short-lived phagocytic 
cells that serve as essential early cellular effectors of innate immunity and constitute the 
''first line of defense''. The sequestration of neutrophils into the peritoneal cavity is thus 
most likely a protective response induced by the accumulation of heavily lipid-laden 
peritoneal macrophages in absence of both SR-BI and ABCA1. Interestingly, neutrophil 
activation is increased in patients with significant coronary stenosis (42) and enhanced 
neutrophil infiltration is observed in culprit lesions in acute coronary syndromes (43), 
suggesting an important role for neutrophils in atherosclerosis. In agreement, neutrophil 
depletion reduces atherosclerotic lesion development in apoE knockout mice (44). 
Although a clear increase in neutrophil accumulation was observed in the peritoneal cavity 
in ABCA1/SR-BI double knockout transplanted mice, within the atherosclerotic lesions 
and in the adventitia surrounding the lesion no significant increase in the amount of 
neutrophils was observed based on esterase activity. Immunohistochemical staining for the 
neutrophil specific marker Ly-6G did show a significant increase in the Ly-6G positive 
area of lesions of ABCA1/SR-BI double knockout versus WT transplanted animals. Ly-6G 
positive staining was primarily localized in acellular regions of the corners of the necrotic 
areas of the lesions, suggesting the increased presence of residues of neutrophils that had 
infiltrated the lesion. Necrotic core formation during lesion development can in turn elicit 
an inflammatory response, which could further increase the recruitment of neutrophils. 
Analysis of the potential contribution of neutrophils locally in the arterial wall to the 
excessive atherosclerotic lesion development in mice with a combined deletion of ABCA1 
and SR-BI in bone marrow-derived cells forms an interesting future challenge. 
In addition, to the observed increase in the pro-inflammatory cytokines KC (murine 
IL-8) and IL-12p40, we also observed an increase in the anti-inflammatory cytokines IL-5 
and IL-10, probably as a feed-back reaction to control the inflammatory response. The 
absolute levels of the IL-5 and IL-10, however, remained substantially lower as compared 
to the KC (murine IL-8) and IL-12p40 levels, suggesting a pro-inflammatory balance. 
Interestingly, several lines of evidence suggest that pro- and anti-inflammatory cytokines 
can affect the amount of circulating lipids. Previously, we have shown that IL-10 
overexpression in LDLr KO mice results in a significant reduction in plasma cholesterol 
levels (45). Interestingly, the ABCA1/SR-BI double KO transplanted animals with the 
highest IL-10 concentrations also had the lowest serum cholesterol levels. Furthermore, 




the mechanism of the inflammation induced reduction in serum cholesterol levels is still 
largely unclear it might have contributed to the lower serum cholesterol levels observed in 
this study. A recent study by Lo et al. showed that disruption of the production of the 
potent pro-inflammatory cytokines LIGHT and lymphotoxin leading to reduced T cell 
numbers reduces serum cholesterol levels, which is associated with increased hepatic 
lipase levels (47). Combined disruption of ABCA1 and SR-BI in bone marrow-derived 
cells, however, did not affect T cell counts or hepatic lipase expression in the liver. In 
contrast, we showed that food intake, intestinal lipid absorption, and HMGCoA expression 
and VLDL production by the liver were reduced, all processes that are likely to have 
contributed to the observed reduction in serum cholesterol levels in de ABCA1/SR-BI 
double KO transplanted animals.  
In conclusion, despite lower serum cholesterol levels, combined deletion of 
ABCA1 and SR-BI in bone marrow-derived cells induces massive foam cell formation and 
promotes inflammation and atherosclerotic lesion development in LDLr KO mice 
challenged with a WTD, indicating that both macrophage ABCA1 and SR-BI contribute 
significantly to healthy cholesterol homeostasis in the macrophage in vivo and are essential 
for reducing the risk for atherosclerosis. 
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Supplementary methods and figures 
Detailed Methods  
Mice 
ABCA1 knockout (ABCA1 KO) mice were a kind gift of Dr. G. Chimini (14) and SR-BI knockout 
(SR-BI KO) mice were obtained from Dr. M. Krieger (21). The ABCA1 KO and SR-BI KO mice 
(both at least 8 generations backcrossed to the C57Bl/6 background) were cross-bred to generate 
double heterozygous offspring, which were subsequently intercrossed to obtain the ABCA1/SR-BI 
double knockout (double KO) mice, and single ABCA1 KO, SR-BI KO, and wildtype (WT) 
littermates. LDL receptor knock out (LDLr KO) mice were obtained from the Jackson Laboratory 
(Bar Habor, USA). All mice were housed in a light and temperature controlled environment. Food 
and water were supplied ad libitum. Mice were maintained on regular chow (RM3, Special Diet 
Services, Whitham, UK), or were fed a Western-type diet, containing 15% (w/w) total fat and 
0.25% (w/w) cholesterol (Diet W, Special Diet Services, Whitham, UK). Drinking water was 
supplied with antibiotics (83 mg/L ciprofloxacin and 67 mg/L polymyxin B sulphate) and 6.5 g/L 
sucrose. Animal experiments were performed at the Gorlaeus laboratories of the 
Leiden/Amsterdam Center for Drug Research in accordance with the National Laws. All 
experimental protocols were approved by the Ethics Committee for Animal Experiments of Leiden 
University. 
 
Bone Marrow Transplantation 
Female LDLr KO mice (n=20/group), age 11 weeks, were lethally irradiated with a single dose of 9 
Gy (0.19 Gy/min, 200 kV, 4 mA), 1 day before transplantation. Bone marrow was harvested by 
flushing the femurs and tibias from male ABCA1/SR-BI double KO mice, single ABCA1 KO 
littermates, single SR-BI KO littermates or non transgenic (WT) littermates. Irradiated recipients 
received 5 x 106 bone marrow cells by intravenous injection into the tail vein. 

Assessment of Chimerism 
The reconstitution of the transplanted bone marrow was determined using PCR on genomic DNA 
from bone marrow. The wildtype ABCA1 gene was detected using a forward primer (5'-
TgggAACTCCTgCTAAAAT-3’) and a reverse primer (5'-CCATgTggTgTgTAgACA-3') resulting 
in a 751 bp PCR-fragment. The mutant ABCA1 gene was detected using a forward primer (5'-
TTTCTCATAgggTTggTCA-3') and a reverse primer (5'-TgCAATCCATCTTgTTCAAT-3') 
resulting in a 540 bp PCR-fragment. The wildtype and mutant SR-BI gene were detected using a 
forward primer (5'-gATgggACATgggACACgAAgCCATTCT-3’) and a reverse primer (5'-
CTgTCTCCgTCTCCTTCAggTCCTgA-3') resulting in a 1000 bp PCR-fragment for the wildtype 




After an overnight fasting-period, 100 μl of blood was drawn from the mice (n=10/group) by tail 
bleeding. Triglycerides in serum were determined using a standard enzymatic colorimetric assay 
(Roche Diagnostics, Mannheim, Germany). The concentrations of cholesterol in serum were 
determined by incubation with 0.025 U/mL cholesterol oxidase (Sigma) and 0.065 U/mL 
peroxidase and 15 μg/mL cholesteryl esterase (Roche Diagnostics, Mannheim, Germany) in 
reaction buffer (1.0 KPi buffer, pH=7.7 containing 0.01 M phenol, 1 mM 4-amino-antipyrine, 1% 
polyoxyethylene-9-laurylether, and 7.5% methanol). Absorbance was read at 490 nm. The 
distribution of cholesterol over the different lipoproteins in serum was determined by fractionation 
of 30 μL serum of 2 individual mice using a Superose 6 column (3.2 x 300 mm, Smart-system; 
Pharmacia, Uppsala, Sweden). Cholesterol content of the effluent was determined as indicated. 
Splenic free cholesterol, cholesterol ester and triglyceride content were determined as described 




100. Phospholipid content of the spleens was determined using a standard enzymatic colorimetric 
assay (Wako chemicals GmbH, Neuss, Germany). 
 
Intestinal lipid absorption 
The intestinal absorption of cholesterol and triglycerides was determined by a dual isotope ratio 
method 16 weeks post-transplant after 8 weeks Western-type diet feeding. Briefly, mice were 
fasted overnight and lipoprotein lipase activity was inhibited by intravenous injection of 500 mg/kg 
Triton WR1339 as a 15 g/dL solution in 0.9% NaCl (Sigma) to inhibit the clearance of 
chylomicrons. Subsequently, mice were dosed intragastrically with a bolus of 200μl olive oil 
containing 1 g/L cholesterol, 2 μCi of [14C] cholesterol (Amersham) and 2 μCi of [3H] triolein 
(Amersham). Blood was collected at 1,2,3, and 4h after gavage and serum was isolated for 
scintillation counting to determine the 14C and 3H activity. The percentage of cholesterol and 
triglyceride absorption was expressed as percentage of administered dose absorbed.  

In vivo VLDL production 
VLDL production was measured 16 weeks post-transplant after 8 weeks Western-type diet feeding. 
Hereto, mice were injected intravenously with 500 mg of Triton WR-1339 (Sigma) per kg body 
weight as described above after an overnight fast to inhibit plasma VLDL clearance. Mice were 
fasted throughout the experiment. Blood samples were taken at 0, 1, 2, 3, and 4 hours after Triton 
WR1339 injection. Plasma triglycerides were analysed enzymatically and were related to the body 
mass of the animals. The hepatic VLDL production rate was calculated from the slope of the curve 
and expressed as g/h/kg body weight. 

Analysis of gene expression by Real-Time Quantitative PCR 
Total RNA was extracted from livers of transplanted animals at 18 weeks post-transplant after 10 
weeks Western-type diet feeding by the acid guanidium thiocyanate-phenol chloroform extraction 
method according to Chomczynski et al. (2). cDNA was synthesised from 0.5–1 μg of total RNA 
using RevertAid™ M-MuLV Reverse Transcriptase according to manufacturer’s instructions. 
mRNA levels were quantitatively determined on an ABI Prism® 7700 Sequence Detection system 
(Applied Biosystems, Foster City, CA) using SYBR-green technology. PCR primers were designed 
using Primer Express 1.5 Software with the manufacturer's default settings (Applied Biosystems). 
For detection of hepatic lipase 5’-CAGCCTGGGAGCGCAC-3’ and 5’-
CAATCTTGTTCTTCCCGTCCA-3’ were used as forward and reverse primers, respectively. 
mRNA expression levels are indicated relative to the average of the housekeeping genes 
hypoxanthine phosphoribosyltransferase (HPRT), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), ribosomal protein 36B4, and 18Sr-RNA. 
 
Histological Analysis of the Atherosclerosis 
To analyze the development of atherosclerosis at the aortic root, the transplanted LDLr KO mice 
(n=20/group) were sacrificed at 18 weeks after bone marrow transplantation (age 29 weeks). All 
mice were fed the Western-type diet for 10 weeks before sacrifice. The arterial tree was perfused in 
situ with PBS and the heart was excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; 
Shandon Scientific Ltd., UK) until use. The hearts were bisected just below the atria, and the base 
of the hearts plus aortic roots were taken for analysis. The hearts were then sectioned perpendicular 
to the axis of the aorta, starting within the heart and working in the direction of the aortic arch as 
described by Paigen et al. (3). Once the aortic root was identified by the appearance of aortic valve 
leaflets, alternate 10-μm sections were taken and mounted on gelatinized slides and stained with 
oil-red-O. The atherosclerotic lesion area in the sections was quantified by using a Leica image 
analysis system, consisting of a Leica DMRE microscope coupled to a camera and Leica QWin 
Imaging software (Leica Ltd., Cambridge, UK). Mean lesion area was calculated (in μm2) from 10 
sections, starting at the appearance of the tricuspid valves. Cryostat sections of the aortic root were 
stained immunofluorescently with primary antibodies specific for murine ABCA1 (Santa Cruz, 
Santa Cruz, USA) or SR-BI (Abcam, Cambridge, UK) to visualize the ABCA1 and/or SR-BI 
expression in the lesions. Photomicrographs of sections immunofluorescently labeled for ABCA1 
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or SR-BI were taken using a Bio-Rad Radiance 2100 MP confocal laser scanning system equipped 
with a Nikon Eclipse TE2000-U inverted fluorescence microscope. For morphological analysis, 
sections were stained with Masson’s Trichrome Accustain according to manufacturer's instructions 
(Sigma). Neutrophils were visualized using a naphthol AS-D chloroacetate esterase activity kit 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) according to manufacturer’s instructions. Where 
indicated atherosclerosis was also analysed in oil-red-O stained cross sections of the right coronary 
artery near the aortic root and en face in the aortic arch and thoracic aorta. All analyses were 
performed blinded. 

Peritoneal leukocyte analysis 
Upon sacrifice of the transplanted LDLr KO mice at 18 weeks after transplantation (including 10 
weeks Western-type diet), the peritoneal cavity of the mice was lavaged with 10 ml cold PBS to 
collect peritoneal leukocytes for quantification of neutrophil, lymphocyte, and macrophage counts 
using an automated Sysmex XT-2000iV Veterinary Hematology analyzer (Sysmex Corporation, 
Kobe, Japan). The XT-2000iV employs a fluorescent flow cytometry method using a fluorescent 
dye staining cellular DNA and RNA and a semiconductor laser to detect forward-, side-scattered, 
and fluorescent light. Corresponding samples were cytospun for manual confirmation and stained 
with oil-red-O for detection of lipid accumulation. 

Macrophage cholesterol efflux studies 
Macrophage cholesterol efflux studies were performed using bone marrow-derived macrophages 
(BMDM) and thioglycollate-elicited peritoneal macrophages (PM) isolated from WT, SR-BI KO, 
ABCA1 KO, and SR-BI/ABCA1 dKO mice fed chow diet. To label PM with 3H-cholesterol the in 
vivo method was used that was previously developed in our lab (4), allowing the study of 
cholesterol efflux with minimal culture times. Briefly, PM were elicited by intraperitoneal injection 
with 1 ml 3% Brewer’s thioglycollate medium (Difco, Detroit, USA). After five days, the elicited 
PM were labelled in vivo by intraperitoneal injection of 3H-cholesterol. The injection sample was 
prepared by dissolving 6.25 μCi of 3H-cholesterol in 6.25 μL ethanol and subsequent addition of 
500 μl PBS of 37oC. At 3.5 hours after injection, PM were harvested and seeded on 24-well plates 
at a density of 0.5 x 106 cells in 500 μL Dulbecco’s modified Eagle’s medium (DMEM)/0.2% free 
fatty acid free BSA. After 1 hour, nonadherent cells were removed by washing. The cholesterol 
mass of the cells was 60.4±3.0, 64.6±2.2, 60.3±2.7, and 60.3±1.7 μg/mg cell protein for WT, 
ABCA1 KO, SR-BI KO, and ABCA1/SR-BI double knockout macrophages, respectively.  
For culture of BMDM, bone marrow cells were isolated from both femurs and tibias, plated, and 
differentiated in DMEM supplemented with 10% fetal bovine serum, 2 mmol/L glutamine, 20% 
L929 cell-conditioned media (as a source of M-CSF), and penicillin-streptomycin for 6 days. 
Subsequently, cells were loaded with cholesterol for 48 hours with acetylated LDL (50 μg/mL) and 
0.5 μCi/mL 3H-cholesterol in DMEM/BSA. The loading medium was removed and the cells 
washed twice in PBS, then incubated overnight (16 hours) with DMEM/BSA, supplemented with 
22-hydroxycholesterol (10 μmol/L) and 9-cis retinoic acid (1 μmol/L).  
Cholesterol efflux from in vivo labeled PM and cholesterol-loaded BMDM was subsequently 
studied by incubation of the cells with DMEM/BSA alone, or supplemented with either 10 μg/ml 
apoAI (Calbiochem) or 10 or 50 μg/ml human HDL (isolated according to Redgrave et al. (5)). 
After a 24-hours efflux period, radioactivity in the cells and medium was determined by liquid 
scintillation counting. Efflux of 3H-cholesterol label is defined as (dpmmedium/ dpmcell 
+dpmmedium) x 100%. When indicated cell and media samples were also extracted and analyzed 
for free and esterified cholesterol mass by HLPC, as previously described (6). Cell proteins were 
measured using the BCA assay (Pierce). For mass analysis, HDL samples were separately analyzed 
to allow correction for HDL cholesterol present in relevant media samples. Mass cholesterol efflux 
is expressed as the percentage of total cell cholesterol present in the medium. Basal efflux to media 






Western blot analysis 
Macrophages (peritoneal and BMDM) were generated as described above and scraped in 50 mM 
Tris-HCL, 100 mM NaCl, and 0.5% Triton X-100 in the presence of protease inhibitors (Roche 
Molecular Biochemicals). The protein content was determined by the Bio-Rad protein assay. 
Aliquots of 20 μg (for BMDM) or 40 μg of protein (for peritoneal macrophages) were separated by 
6% SDS-PAGE electrophoresis and transferred onto nitrocellulose membranes. Immunolabelling 
was performed using polyclonal antibodies directed against SR-BI (Santa Cruz Biotechnology Inc) 
or ABCG1 (Novus) or a murine monoclonal antibody against　 ABCA1 (AC-10, kindly provided 
by Dr M. R. Hayden (Vancouver, Canada)). 
 
Cytokine serum levels 
At 8 (chow diet), 12 weeks (4 weeks Western-type diet), and 18 weeks (10 weeks Western-type 
diet) post-transplant blood was collected from the transplanted animals. Serum was separated by 
centrifugation and stored at -80°C until analysis. The mouse Bio-Plex suspension array (Bio-Rad 
Laboratories AB, Sundbyberg, Sweden) was used to measure 8 different cytokines: interleukin (IL) 
1β, IL-5, IL-6, KC (murine ortholog of IL-8), IL-10, IL-12, tumor necrosis factor (TNF)-α, and 
RANTES (regulated on activation and normally T cell expressed and secreted). The assay was 
performed according to the protocol of the manufacturer. In brief, serum samples were thawed on 
ice and centrifuged at 4500 rpm for 3 min at 4°C. After this initial step, serum was incubated with 
microbeads labeled with specific antibodies to one of the indicated cytokines for 30 min. Samples 
were washed after the incubation and were then incubated with the detection antibody cocktail. 
This step was followed by another wash step, and the beads were incubated with streptavidin-
phycoerythrin for 10 min, again washed, and the concentration of each cytokine was determined 
using the array reader. 
 
Statistical analysis 
Values are expressed as mean±SEM. A one way ANOVA and the Student Newman Keuls posttest 
were used to compare means after confirming normal distribution by the method Kolmogorov and 






Supplementary Figure I. Atherosclerotic lesion quantification in the right coronary artery (A), the 
aortic arch (B), and the thoracic aorta (C) of LDLr KO mice, transplanted with WT, ABCA1 KO, SR-
BI KO, or ABCA1/SR-BI double KO (dKO) bone marrow. Each symbol represents the mean lesion area 
in the coronary artery of single mouse, or the ratio of lesion area to surface area in the aortic arch and 
thoracic aorta of single mouse. The horizontal bar indicates the mean value for the group. Statistically 
significant difference *p<0.05, **p<0.01 and ***p<0.001. 
 





Supplementary Figure II. Cholesterol mass (A) and 3H-label (B) efflux from acetylated LDL-loaded 
macrophages to apoAI (10 μg/mL) and HDL (10 μg/mL). (C) Quantification of ABCA1, SR-BI, and 
ABCG1 protein by Western blotting. Values are means±SEM. Statistically significant difference *p<0.05 
and ***p<0.001. Note that no additional effect of combined deletion of ABCA1 and SR-BI over single 
deletion of ABCA1 was observed on cholesterol mass and 3H-label efflux due to absence of SR-BI 
expression under this condition where macrophages are loaded with acetylated LDL. 
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Objective: The present study aims to investigate whether LDL receptor (LDLr) deficiency 
influences the atheroprotective effects of leukocyte ABC-transporter A1 (ABCA1) in vivo. 
Methods and Results: LDLr-/- mice were transplanted with bone marrow from LDLr-/-
/ABCA1-/- mice, LDLr+/+/ABCA1-/- mice, and their respective controls. Plasma cholesterol 
levels were significantly reduced upon deletion of leukocyte ABCA1 after 8 weeks of 
Western-type diet feeding. Also, leukocyte ABCA1 deficiency led to increased 
monocytosis, recruitment of macrophages into peripheral tissues, and macrophage foam 
cell formation. None of these effects was influenced by the deletion of the leukocyte LDLr. 
Despite relatively low plasma cholesterol levels, animals transplanted with LDLr-/-
/ABCA1-/- and LDLr+/+/ABCA1-/- bone marrow developed 1.6-fold (p<0.01) and 1.4-fold 
(p<0.05) larger lesions, compared to their respective controls. Two-way ANOVA analysis 
also demonstrated that deletion of the leukocyte LDLr reduced lesion development 
(p<0.001). Interestingly, in LDLr-/-/ABCA1-/- transplanted mice, the reduced lesion size 
was associated with reduced lymphocytosis and recruitment of T cells into the adventitia of 
lesions. 
Conclusions: Leukocyte LDLr deficiency does not affect the atheroprotective effects of 
leukocyte ABCA1. Furthermore, in addition to promoting macrophage cholesterol efflux, 
leukocyte ABCA1 also protects against atherosclerosis through inhibiting lymphocytosis 











Macrophage foam cell formation is a hallmark of atherosclerosis. Since macrophages 
cannot limit lipid uptake, cholesterol efflux is crucial for prevention of macrophage foam 
cell formation and atherosclerosis. ABC-transporter A1 (ABCA1) facilitates cholesterol 
efflux to lipid-free or lipid-poor apoAI [1]. Patients with Tangier disease, due to loss-of-
function mutations in the ABCA1 gene, display macrophage foam cell accumulation in 
peripheral tissues and premature atherosclerosis [2]. Bone marrow transplantation (BMT) 
studies in LDL receptor knockout (LDLr-/-) mice indicate that leukocyte ABCA1 is 
atheroprotective. Leukocyte ABCA1 deficiency accelerates atherosclerosis [3], while 
overexpression of ABCA1 in leukocytes prevents the progression of atherosclerosis [4]. 
The atheroprotective effects of leukocyte ABCA1 have been primarily attributed to 
ABCA1 in macrophages. Mice that specifically lack ABCA1 in macrophages and 
neutrophils were generated in the group of Dr. Parks by crossing ABCA1 floxed mice with 
mice expressing Cre recombinase under the control of the macrophage/neutrophil-specific 
lysozyme M promoter [5]. Surprisingly, specific deletion of macrophage ABCA1 on LDLr-
/- background does not promote atherosclerosis [6]. BMT studies in LDLr-/- mice were 
performed using bone marrow from single ABCA1-/- mice and thus, in contrast to the 
LDLr-/- mice with specific knockdown of macrophage ABCA1, the leukocytes in the 
BMT animals do express the LDLr. Interestingly, a direct link between macrophage LDLr 
and ABCA1 expression has been suggested. Macrophages lacking the LDLr display 
reduced expression of ABCA1 [7]. In these macrophages, oxysterols cannot inactivate 
sterol regulatory element-binding protein 1 (SREBP1), which suppresses ABCA1 
expression via microRNA33 [8]. Thus, impaired induction of ABCA1 in macrophages 
lacking the LDLr in response to oxysterol loading might explain why no effect was 
observed of specific deletion of macrophage ABCA1 on atherosclerosis.  
To test if absence or presence of the LDLr determines the effects of leukocyte 
ABCA1 deficiency on atherosclerosis, bone marrow from LDLr-/-/ABCA1-/-, 
LDLr+/+/ABCA1-/-, and their respective controls was transplanted into LDLr-/- mice. After 
8 weeks recovery, the animals were fed Western-type diet (WTD) for an additional 8 
weeks before determination of atherosclerotic lesion formation. Our results clearly 
demonstrate that leukocyte ABCA1 deficiency led to an increased susceptibility to 
atherosclerotic lesion development both in the absence and presence of the LDLr. 
Importantly, the present study also for the first time provides evidence that suppression of 
lymphocytosis and T-cell recruitment into the adventitia of lesions contributes to the 
atheroprotective function of leukocyte ABCA1. 
 
Methods 
For detailed methodology, please see the data supplement, available online at 
http://atvb.ahajournals.org. Briefly, bone marrow transplantations were performed with 
LDLr-/-/ABCA1-/- , LDLr-/-/ABCA1-/-, and respective control mice as donors and LDLr-/- 
mice as recipients. Plasma lipids were determined by enzymatic colorimetric assays. 
Atherosclerotic lesion area and lesion composition in cryostat sections of the aortic root 
were quantified using the Leica image analysis system. Peritoneal leukocytes and white 
blood cells were analyzed with hematology cell analyzer. Macrophages (CD11b+Ly6G-) in 
the spleen were quantified using flow cytometry. Macrophages in the liver and T cells in 
atherosclerotic lesions were detected by immunolabelling with anti-F4/80 and anti-CD3 
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Results  
Leukocyte ABCA1 deficiency inhibited the WTD-induced increase in plasma 
cholesterol independently of LDL receptor expression  
To investigate the effects of combined deficiency of leukocyte ABCA1 and LDLr on foam 
cell formation and atherogenesis, bone marrow from LDLr-/-/ABCA1-/-, LDLr+/+/ABCA1-/-, 
LDLr-/-/ABCA1+/+, and LDLr+/+/ABCA1+/+ mice was transplanted into LDLr-/- mice, which 
represent an established model for the development of atherosclerosis. Successful 
reconstitution of the recipient mice with donor bone marrow was confirmed by analysis of 
LDLr and ABCA1 transcripts in genomic DNA from bone marrow of transplanted mice as 
described previously [3, 9] (data not shown). Deletion of ABCA1, LDLr, or both ABCA1 
and LDLr in bone marrow-derived cells did not affect plasma total cholesterol levels when 
fed regular chow diet (277±8, 263±7, 286±5, and 289±8 mg/dL for LDLr+/+/ABCA1+/+, 
LDLr+/+/ABCA1-/-, LDLr-/-/ABCA1+/+, and LDLr-/-/ABCA1-/- transplanted animals, 
respectively), as shown in Figure 1A. At 8 weeks after BMT, the animals were switched 
from regular chow diet to WTD to induce atherosclerotic lesion formation. After 8 weeks 
on WTD, the total plasma cholesterol levels in both LDLr+/+/ABCA1+/+ and LDLr-/-
/ABCA1+/+ transplanted mice increased approximately 4-fold (1108±72 mg/dL) and 3.6-
fold (1017±63 mg/dL) (Figure 1A), respectively. In line with previous studies [10, 11], 
deletion of ABCA1 in bone marrow cells resulted in lower plasma cholesterol levels upon 
challenge with WTD (568±14, p<0.001 vs LDLr+/+/ABCA1+/+ and LDLr-/-/ABCA1+/+ 
transplanted mice). Like LDLr+/+/ABCA1-/- transplanted animals, LDLr-/-/ABCA1-/- 
transplanted animals showed lower plasma cholesterol levels (611±16, p<0.001 vs 
LDLr+/+/ABCA1+/+ and LDLr-/-/ABCA1+/+ transplanted mice), indicating that the effect of 
leukocyte ABCA1 on plasma cholesterol levels is independent of LDLr expression (Figure 
1A). The lower levels of plasma cholesterol in the LDLr+/+/ABCA1-/- and LDLr-/-/ABCA1-
/- transplanted animals were mainly due to reduced VLDL and LDL levels (Figure 1B).  
 
 
Figure 1. Plasma cholesterol levels on chow and Western-type diet (A) and lipoprotein cholesterol 
distribution profile on Western-type diet (B) in LDLr-/- mice reconstituted with LDLr+/+/ABCA1+/+, 
LDLr+/+/ABCA1-/-, LDLr-/-/ABCA1+/+, and LDLr-/-/ABCA1-/- bone marrow. Values are mean±SEM. 








Leukocyte ABCA1 and LDLr deficiency independently affected atherosclerotic lesion 
development  
The development of atherosclerotic lesions was analyzed at the aortic root. After 8 weeks 
on WTD, atherosclerotic lesion size in the aortic root was 475±73×103 μm2 in 
LDLr+/+/ABCA1+/+ and 359±41×103 μm2 in LDLr-/-/ABCA1+/+ transplanted mice (Figure 
2A and 2B). In line with previous studies [3, 10, 11], despite the lower plasma cholesterol 
levels, selective disruption of ABCA1 in bone marrow-derived cells resulted in a 1.4-fold 
increase (681±33×103 μm2, p<0.05) in the mean atherosclerotic lesion size as compared to 
LDLr+/+/ABCA1+/+ transplanted mice. Notably, LDLr-/-/ABCA1-/- transplanted mice also 
developed 1.6-fold (563±41×103 μm2, p<0.01) larger atherosclerotic lesions as compared 
to LDLr-/-/ABCA1+/+ transplanted mice, indicating that leukocyte ABCA1 could protect 
against atherosclerosis even in the absence of LDLr expression (Figure 2A). Interestingly, 
two-way ANOVA analysis demonstrated not only the atheroprotective effect of leukocyte 
ABCA1 (p<0.001) but also a pro-atherogenic effect of LDLr expression on leukocytes 
(p<0.001). No interaction between the effect of leukocyte ABCA1 and LDLr deletion on 
atherosclerosis was observed (p=0.93) (Figure 2B). 
Quantitative morphological analysis of the atherosclerotic lesions showed that the 
macrophage content in the lesions was significantly reduced in LDLr+/+/ABCA1-/- 
(19.6±2.5%, p<0.001) and LDLr-/-/ABCA1-/- (14.6±3.3%, p<0.001) transplanted mice as 
compared to LDLr+/+/ABCA1+/+ (35.8±3.3%) and LDLr-/-/ABCA1+/+ (41.3±3.8%) 
transplanted mice, respectively (Figure 2C and 2D). As determined by Masson’s 
Trichrome staining, ABCA1 deficiency and combined deficiency of ABCA1 and LDLr in 
bone marrow-derived cells led to a 2.8-fold (9.5±1.4%, P<0.001) and 4.6-fold (11.8±1.0%, 
p<0.001) increase in collagen deposition in lesions as compared to LDLr+/+/ABCA1+/+ 
(3.4±0.7%) and LDLr-/-/ABCA1+/+ (2.6±0.4%) transplanted animals, respectively (Figure 
2C and 2D). Furthermore, an increased necrotic core content was also evident in lesions of 
LDLr+/+/ABCA1-/- (4.5-fold, P<0.01 vs LDLr+/+/ABCA1+/+) and LDLr-/-/ABCA1-/- (5.0-
fold, P<0.001 vs LDLr-/-/ABCA1+/+) transplanted animals (Figure 2D). Taken together, 
leukocyte ABCA1 deficiency led to more advanced lesion formation even in the absence 
of LDLr expression. 
 
Leukocyte ABCA1 deficiency impaired cellular cholesterol efflux in vitro and 
increased foam cell formation in vivo independently of LDLr expression  
Next, we determined the combined effect of leukocyte ABCA1 and LDLr deficiency on 
cellular cholesterol efflux using bone marrow-derived macrophages. As shown in Figure 3, 
LDLr deficiency did not influence cholesterol efflux from macrophages to apoAI, while 
ABCA1 deficiency, as expected, diminished macrophage cholesterol efflux to apoAI in 
both the absence and presence of the LDLr (>90% decrease, p<0.001). In contrast, 
macrophage cholesterol efflux to HDL was not affected by deletion of ABCA1, LDLr, or 
both (Figure 3). Moreover, cholesterol loading with LDL (Figure 3A) or oxidized LDL 
(Figure 3B) did not influence the effect of macrophage ABCA1 deficiency on cholesterol 
efflux. In line with the cholesterol efflux data, foam cells within the peritoneal cavity of 
both LDLr+/+/ABCA1-/- (11.9±1.0%, p<0.001) and LDLr-/-/ABCA1-/- (11.1±0.7%, 
p<0.001) transplanted mice were similarly increased as compared to LDLr+/+/ABCA1+/+ 
(1.1±0.3%) and LDLr-/-/ABCA1+/+ (1.5±0.4%) transplanted mice (Figure 4A). This was 
also evident from peritoneal cells stained for neutral lipids with oil-red-O (Figure 4B). 
These data indicate that the essential role of macrophage ABCA1 in prevention from foam 
cell formation is independent of LDLr expression. 
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Figure 2. Atherosclerosis in the aortic root of LDLr-/- mice reconstituted with LDLr+/+/ABCA1+/+, 
LDLr+/+/ABCA1-/-, LDLr-/-/ABCA1+/+, and LDLr-/-/ABCA1-/- bone marrow at 8 weeks on WTD. A, 
Photomicrographs showing representative oil-red-O-stained sections (50x). B, Mean atherosclerotic lesion 
size in the aortic root of mice. Each symbol (Left panel) represents the mean lesion area in a single mouse. 
The horizontal line represents the mean of the group. Statistically significant difference *P<0.05, **P<0.01, 
***P<0.001. Two-way ANOVA analysis (right panel) of the effect of ABCA1 and LDLr on mean 
atherosclerotic lesion size in the aortic root of mice. C, Photomicrographs showing the lesion compositions in 
the aortic root of mice. Sections of the aortic roots were stained with antibody against Moma-2 to visualize 
macrophages (100x). Morphological staining of atherosclerotic lesions in the aortic root with Masson’s 
Trichrome Accustain, which stains cytoplasma and muscle fiber red and collagen blue (100x). D, Bar graphs 
showing the quantification of macrophages, collagen, and necrotic core content of lesions in the aortic root of 
mice, transplanted with LDLr+/+/ABCA1+/+ (open bar), LDLr+/+/ABCA1-/- (gray bar), LDLr-/-/ABCA1+/+ 
(dark gray bar), and LDLr-/-/ABCA1-/- (black bar) bone marrow. Values represent the mean±SEM. 
Statistically significant difference **P<0.01 and ***P<0.001 vs LDLr+/+/ABCA1+/+ group; ##P<0.01 and 








Figure 3. Cholesterol efflux from 
LDL-loaded (A) and oxidized LDL-
loaded macrophages to apoAI and 
HDL. Bone marrow macrophages 
from LDLr+/+/ABCA1+/+ (open bar), 
LDLr+/+/ABCA1-/- (gray bar), LDLr-/-
/ABCA1+/+ (dark gray bar), and LDLr-
/-/ABCA1-/- (black bar) transplanted 
mice were labeled for cholesterol 
efflux as described in the materials 
and methods. Basal efflux to media (in 
the absence of added acceptors) has 
been substracted from the data shown. 
Values are mean±SEM (n=3 
mice/group). Statistically significant 
difference **P<0.01, ***P<0.001 vs 
LDLr+/+/ABCA1+/+ group; ##P<0.01, 
###P<0.001 vs LDLr-/-/ABCA1+/+ 
group.
Figure 4. Macrophage foam cell 
formation in the peritoneal cavity of 
LDLr-/- mice reconstituted with 
LDLr+/+/ABCA1+/+ (open bar), 
LDLr+/+/ABCA1-/- (gray bar), LDLr-
/-/ABCA1+/+ (dark gray bar), and 
LDLr-/-/ABCA1-/- (black bar) bone 
marrow at 8 weeks on WTD.  
A, Quantification of macrophage foam 
cells as percentage of the total amount 
of macrophages. Values are 
mean±SEM. Statistically significant 
difference ***P<0.001 vs 
LDLr+/+/ABCA1+/+ group; ###P<0.001 
vs LDLr-/-/ABCA1+/+ group. B, 
Photomicrographs of oil-red-O-stained 
cytospins of peritoneal cells.  
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The deletion of leukocyte LDLr reduced lymphocytosis and inhibited the recruitment 
of T cells into the adventitia underlying the lesions of animals transplanted with 
ABCA1 KO bone marrow. 
Deletion of ABCA1 in bone marrow-derived cells has been shown to enhance leukocytosis 
[3]. In line, also in the current study, the concentration of monocytes in the blood was 
 
increased ~2-fold in LDLr+/+/ABCA1-/- (0.50±0.10×106/mL, p<0.05) as compared to 
LDLr+/+/ABCA1+/+ (0.23±0.03×106/mL) transplanted mice. A similar increase was 
observed in LDLr-/-/ABCA1-/- (0.44±0.07×106/mL, p<0.05) transplanted mice as compared 
to LDLr-/-/ABCA1+/+ (0.22±0.04×106/mL) (Figure 5A). Moreover, in line with our 
previous study [3], leukocyte ABCA1 deficiency also resulted in increased numbers of 
macrophages in the peritoneal cavity (1.7-fold, p<0.001 vs WT), the spleen (1.5-fold, 
Figure 5. Leukocytosis and 
recruitment of leukocytes into 
peripheral tissues in the LDLr-/-  
mice reconstituted with 
LDLr+/+/ABCA1+/+ (open bar), 
LDLr+/+/ABCA1-/- (gray bar), 
LDLr-/-/ABCA1+/+ (dark gray 
bar), and LDLr-/-/ABCA1-/- 
(black bar) bone marrow at 8 
weeks on WTD. 
    Monocytes/macrophages, 
granulocytes, and Lymphocytes, in 
the blood (A, E, G) and peritoneal 
cavity (B, F, H) were analyzed 
using a hematology analyzer. 
Macrophages in the spleen (C) 
were quantified using flow 
cytometry as CD11b+Ly6G- cells. 
In the liver (D), the macrophage 
content was determined by 
immunohistochemistry by using 
F4/80, a specific marker for mature 
tissue macrophages. Values 
represent the mean±SEM. 
Statistically significant difference 
*P<0.05, **P<0.01, and ***P<0.001 
vs LDLr+/+/ABCA1+/+ group; 
#P<0.05, ##P<0.01, and ###P<0.01 vs 
LDLr-/-/ABCA1+/+ group; $P<0.05, 





p<0.05 vs WT), and the liver (1.7-fold, p<0.001 vs LDLr+/+/ABCA1+/+) (Figure 5B, C, and 
D). In contrast, leukocyte LDLr deficiency did not affect the recruitment of macrophages 
into the organs studied. Also, LDLr-/-/ABCA1-/- transplanted animals showed increased 
macrophage recruitment in the peritoneal cavity (1.7-fold, p<0.001), the spleen (1.8-fold, 
p<0.05), and liver (1.6-fold, p<0.001) as compared to LDLr-/-/ABCA1+/+ transplanted 
animals (Figure 5B, C, and D). Taken together, the effects of leukocyte ABCA1 on 
monocytosis and recruitment of macrophages into peripheral tissues are independent of 
leukocyte LDLr expression. 
As shown in Figure 5E, single deletion of either leukocyte ABCA1 or leukocyte 
LDLr did not significantly affect circulating granulocytes, as compared to 
LDLr+/+/ABCA1+/+ transplanted animals. However, as compared to LDLr+/+/ABCA1-/- 
transplanted mice, both LDLr-/-/ABCA1-/- and LDLr-/-/ABCA1+/+ transplanted animals 
displayed a similar 1.7-fold reduction (p<0.05) in the circulating levels of granulocytes. 
Strikingly, despite the lower amount of circulating granulocytes, combined deletion of 
leukocyte LDLr and ABCA1 resulted in enhanced recruitment of granulocytes into the 
peritoneal cavity (3.8-fold, p<0.05 vs LDLr-/-/ABCA1+/+), similar to the effect of single 
ABCA1 deficiency (3.0-fold, p<0.05 vs LDLr+/+/ABCA1+/+) (Figure 5F).  
 
In addition to increased monocytosis, leukocyte ABCA1 also led to increased 
lymphocytosis as evidenced by increased levels of circulating lymphocytes (1.8-fold, 
p<0.05 vs WT) (Figure 5G). Although deletion of the leukocyte LDLr alone did not 
significantly affect lymphocyte counts in the circulation, combined deletion of leukocyte 
Figure 6. Recruitment of T cells into 
the lesions (A) and adventitia (B) of 
the LDLr-/- mice reconstituted with 
LDLr+/+/ABCA1+/+ (open bar), 
LDLr+/+/ABCA1-/- (gray bar), LDLr-
/-/ABCA1+/+ (dark gray bar), and 
LDLr-/-/ABCA1-/- (black bar) bone 
marrow at 8 weeks on WTD.  
Values are mean±SEM. Statistically 
significant difference ***P<0.001 vs 
LDLr+/+/ABCA1+/+ group; #P<0.05 vs 
LDLr-/-/ABCA1+/+ group; $$P<0.01 vs 
LDLr+/+/ABCA1-/- group. Two-way 
ANOVA analysis (C) of the effect of 
ABCA1 and LDLr on the recruitment 
of T cells into the adventitia 
underlying atherosclerotic lesions in 
the aortic root of mice. 
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LDLr and ABCA1 resulted in a 1.6-fold reduction (p<0.01) as compared to single 
leukocyte ABCA1 deficiency. In the peritoneal cavity lymphocyte counts were increased 
in LDLr+/+/ABCA1-/- (2.9-fold, p<0.001 vs LDLr+/+/ABCA1+/+) transplanted mice and 
LDLr-/-/ABCA1-/- (2.0-fold, p<0.05 vs LDLr-/-/ABCA1+/+) transplanted animals. Of note, 
the counts in the peritoneal cavity of LDLr-/-/ABCA1-/- transplanted animals were 1.6-fold 
lower (p<0.001) as compared to LDLr+/+/ABCA1-/- transplanted animals (Figure 5H). 
Single deletion of the leukocyte LDLr did not affect the already low amount of peritoneal 
lymphocytes as compared to LDLr+/+/ABCA1+/+ transplanted mice.  
T lymphocytes are important players in the progression of atherosclerotic lesions 
[12]. We next analyzed the number of T cells in the lesions and underlying adventitias. As 
shown in Figure 6A, the number of T cells was limited inside the lesions, and no 
significant difference in the number of T cells was observed in the lesions of the different 
groups. In contrast, more T cells were visible in the underlying adventitia (Figure 6B). 
Leukocyte ABCA1 deficiency resulted in a 1.7-fold increase (p<0.001 vs 
LDLr+/+/ABCA1+/+) in the recruitment of T cells into the adventitia. Also, LDLr-/-/ABCA1-
/- transplanted animals showed 1.5-fold (p<0.05) more T cells in the adventitia as compared 
to LDLr-/-/ABCA1+/+ transplanted animals. Deletion of the leukocyte LDLr resulted in 1.2-
fold lower amount of T cells in the adventitia, which however failed to reach the statistical 
significance. Combined deletion of leukocyte LDLr and ABCA1 did lead to a significant 
reduction in recruitment of T cells into the adventitia (1.3-fold, p<0.01) as compared to 
single leukocyte ABCA1 deficiency. Of note, two-way ANOVA analysis demonstrated 
that leukocyte ABCA1 deficiency (p<0.001) increased, while leukocyte LDLr deficiency 
decreased (p<0.05) the recruitment of T cells into the adventitia of the atherosclerotic 
lesions. No interaction of leukocyte ABCA1 and LDLr on recruitment of T cells into the 
adventitia was observed (p=0.16) (Figure 6C). Interestingly, pearson correlation analyses 
demonstrated that the size of lesions was highly correlated with the number of T cells 
(r=0.72, p<0.0001) in the adventitia. 
 
Discussion 
Using bone marrow transplantation, we investigated the combined effects of leukocyte 
ABCA1 and LDLr deficiency on foam cell formation and atherosclerosis. In line with 
previous studies [3, 10, 11], transplantation of ABCA1-/-/ LDLr+/+ bone marrow into LDLr-
/- mice led to increased foam cell formation and atherosclerosis. Importantly, ABCA1-/-
/LDLr-/- transplanted animals also showed more foam cell formation and increased lesion 
development as compared to ABCA1+/+/LDLr-/- transplanted animals, clearly 
demonstrating that LDLr deficiency did not affect the atheroprotective function of 
leukocyte ABCA1. Interestingly, ABCA1-/-/LDLr-/- transplanted animals showed reduced 
lymphocytosis and less atherosclerotic lesion formation as compared to ABCA1-/-/LDLr+/+ 
transplanted animals, indicating a pro-atherogenic role of LDLr on leukocytes.  
Zhou et al demonstrated that deletion of the LDLr in peritoneal macrophages 
impairs sterol-induced ABCA1 expression and ABCA1-mediated cholesterol efflux [7]. 
However, in our studies, cholesterol efflux from bone marrow-derived macrophages 
lacking the LDLr to either apoAI or HDL was not affected. Importantly, in line with our 
cholesterol efflux studies, absence of the LDLr in bone marrow-derived cells also did not 
enhance foam cell formation upon WTD challenge in vivo. Interestingly, deletion of the 
LDLr in bone marrow-derived cells did lead to a small but significant reduction in 
atherosclerosis susceptibility in both the presence and absence of ABCA1. The 
transcription of the LDLr on macrophages is quickly downregulated after cholesterol 




macrophage LDLr to foam cell formation and atherosclerosis in LDLr-/- mice upon 
transplantation with LDLr+/+ bone marrow [9, 14]. In agreement, we found no effect of 
leukocyte LDLr deletion on macrophage foam cell formation in vivo. In contrast, the 
presence of the LDLr on lymphocytes is crucial for the proliferation of lymphocytes [15]. 
In the present study, the circulating lymphocyte count was reduced in ABCA1-/-/LDLr-/- 
transplanted animals as compared to ABCA1-/-/LDLr+/+  transplanted mice. Therefore, we 
speculate that the effect of leukocyte LDLr deficiency on atherosclerosis in the present 
study might be rather due to its effect on the proliferation of lymphocytes, which becomes 
evident under conditions where lymphocyte counts are highly elevated due to the absence 
of ABCA1. 
Hypercholesterolemia induces leukocytosis, in particular monocytosis [16] and 
neutrophilia [17], which promotes the development of atherosclerosis. The cholesterol 
efflux transporters ABCA1 and ABCG1 inhibit hypercholesterolemia-induced leukocytosis 
by suppressing bone marrow myeloid cell proliferation [18]. In line, increased leukocytosis 
and monocytosis was observed in ABCA1-/- transplanted LDLr-/- animals upon WTD 
challenge in previous [3] and present studies. Of note, the absence of LDLr did not 
influence the effects of leukocyte ABCA1 deficiency on monocytosis. In addition, in 
agreement with our previous study [3], also elevated circulating lymphocyte counts were 
observed in animals transplanted with ABCA1-/- bone marrow. Cholesterol accumulation 
in T lymphocytes is associated with increased proliferation [19]. Increased lymphocytosis 
in ABCA1-/- transplanted animals might thus be the consequence of the impaired 
cholesterol efflux from lymphocytes via ABCA1. Interestingly, blockade of cholesterol 
uptake via LDLr could reverse it, indicating the importance of the LDLr-mediated 
cholesterol uptake pathway for the induction of lymphocytosis. 
Extensive evidence suggests an atheroprotective role for macrophage ABCA1. 
First, bone marrow transplantation studies showed that deficiency of leukocyte ABCA1 
results in increased atherosclerotic lesion formation [3] while overexpression of leukocyte 
ABCA1 prevents the progression of atherosclerosis [4]. Second, ABCA1-mediated 
cholesterol efflux is crucial for the prevention of macrophage foam cell formation in vitro 
and in vivo [3, 10, 11]. Third, macrophage ABCA1 functions as an anti-inflammatory 
molecule [5, 20, 21]. Fourth, ABCA1 deficiency impairs the migration of macrophages 
[22], which might lead to the retention of macrophages in lesions. However, Brunham et al 
recently showed that macrophage-specific inactivation of ABCA1 on the LDLr KO 
background did not change the susceptibility to atherosclerosis [6]. The authors 
hypothesized that the failure to pick up the effect of macrophage ABCA1 on 
atherosclerosis might be due to the LDLr-/- background, as LDLr-/- macrophages were 
shown to have significantly less ABCA1 expression compared to wild-type macrophages 
[7]. In the present study, we excluded this possibility by clearly showing that absence of 
the LDLr did not affect the effects of leukocyte ABCA1 deficiency on macrophage foam 
cell formation in vivo nor atherosclerotic lesion development. Brunham et al also 
hypothesized that the enhanced lymphocytosis observed in ABCA1 KO transplanted 
animals might contribute to the increased lesion formation upon deletion of ABCA1 in 
bone marrow-derived cells of LDLr-/- mice. Interestingly, in the present study, we found 
that absence of the leukocyte LDLr did reduce the circulating lymphocyte counts and T 
cell recruitment into the adventitia of lesions in ABCA1-/- transplanted animals. 
Importantly, the number of T cells in the adventitia underlying lesions was highly 
associated with the lesion size. Our data thus indicate that enhanced lymphocytosis and T 
cell infiltration into the adventitia might contribute to the effects of leukocyte ABCA1 
deficiency on atherosclerosis. Generation of T cell-specific ABCA1-/- mice is needed in the 
future to elucidate the extent of the atheroprotective effects of ABCA1 on T cells. Of note, 
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despite that ABCA1-/-/LDLr-/- transplanted animals developed less lesions as compared to 
ABCA1-/-/LDLr+/+ transplanted animals, lesions of both types of animals contained more 
necrotic core material. Therefore, the effects of macrophage ABCA1 on the vulnerability 
of lesions also warrants further investigation. 
In conclusion, deletion of the leukocyte LDLr does not affect the atheroprotective 
effect of leukocyte ABCA1. Furthermore, in addition to promoting macrophage cholesterol 
efflux, leukocyte ABCA1 also protects against atherosclerosis probably through inhibiting 
lymphocytosis and recruitment of T cells into the adventitia of lesions. 
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LDLr-/- mice were obtained from the Jackson Laboratory (Bar Habor, USA). ABCA1-/- mice, a kind 
gift of Dr. G. Chimini [1] were backcrossed to the C57Bl/6 background for at least 8 generations. 
LDLr+/-/ABCA1+/- offsprings, which were generated from cross-breeding, were intercrossed to 
obtain the LDLr-/-/ABCA1-/- mice, LDLr+/+/ABCA1-/-, LDLr-/-/ABCA1+/+, and LDLr+/+/ABCA1+/+ 
littermates. All mice were housed in a light and temperature controlled environment. Food and 
water were supplied ad libitum. Mice were maintained on regular chow (RM3, Special Diet 
Services, Whitham, UK), or were fed a Western-type diet, containing 15% (w/w) total fat and 
0.25% (w/w) cholesterol (Diet W, Special Diet Services, Whitham, UK). Drinking water was 
supplied with antibiotics (83 mg/L ciprofloxacin and 67 mg/L polymyxin B sulphate) and 6.5 g/L 
sucrose. Animal experiments were performed at the Gorlaeus Laboratories of the 
Leiden/Amsterdam Center for Drug Research in accordance with the National Laws. All 
experimental protocols were approved by the Ethics Committee for Animal Experiments of Leiden 
University. 
 
Bone Marrow Transplantation 
Female LDLr-/- mice were lethally irradiated with a single dose of 9 Gy (0.19 Gy/min, 200 kV, 4 
mA) at the age of 12 weeks. Bone marrow was harvested by flushing the femurs and tibias from 
male LDLr-/-/ABCA1-/- mice, LDLr+/+/ABCA1-/-, LDLr-/-/ABCA1+/+, and LDLr+/+/ABCA1+/+ 
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littermates. Irradiated recipients received 5 x 106 bone marrow cells by intravenous injection into 
the tail vein at 1 day after irradiation. 
 
Plasma cholesterol analyses 
After an overnight fasting-period, 100 μL of blood was drawn from the mice by tail bleeding. The 
concentrations of cholesterol in serum were determined by incubation with 0.025 U/mL cholesterol 
oxidase (Sigma) and 0.065 U/mL peroxidase and 15 μg/mL cholesteryl esterase (Roche 
Diagnostics, Mannheim, Germany) in reaction buffer (1.0 KPi buffer, pH=7.7 containing 0.01 M 
phenol, 1 mM 4-amino-antipyrine, 1% polyoxyethylene-9-laurylether, and 7.5% methanol). 
Absorbance was read at 490 nm. The distribution of cholesterol over the different lipoproteins in 
serum was determined by fractionation of 30 μL serum of individual mice using a Superose 6 
column (3.2 x 300 mm, Smart-system; Pharmacia, Uppsala, Sweden). Cholesterol content of the 
effluent was determined as indicated. 
 
Histological Analysis of the Aortic Root 
To analyze the development of atherosclerosis at the aortic root, the transplanted LDLr-/-mice 
(n=13-16/group) were sacrificed at 16 weeks after bone marrow transplantation. All mice were fed 
the Western-type diet for 8 weeks before sacrifice. The arterial tree was perfused in situ with PBS 
and the heart was excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; Shandon 
Scientific Ltd., UK) until use. The hearts were bisected just below the atria, and the base of the 
hearts plus aortic roots were taken for analysis. The hearts were then sectioned perpendicular to the 
axis of the aorta, starting within the heart and working in the direction of the aortic arch as 
described by Paigen et al. [2]. Once the aortic root was identified by the appearance of aortic valve 
leaflets, alternate 10-µm sections were taken and mounted on gelatinized slides and stained with 
oil-red-O. The atherosclerotic lesion area in the sections was quantified by using a Leica image 
analysis system, consisting of a Leica DMRE microscope coupled to a camera and Leica QWin 
Imaging software (Leica Ltd., UK). Mean lesion area was calculated (in µm2) from 10 sections, 
starting at the appearance of the tricuspid valves. Macrophages and T cells were detected by 
incubation of consecutive sections with α-MOMA-2 (Research diagnostics, USA) and α-CD3 
(Neomarkers, USA), respectively. For morphological analysis, sections were stained with Masson’s 
Trichrome Accustain according to manufacturer's instructions (Sigma). All analyses were 
performed blinded.  
 
White blood cells and peritoneal leukocyte analysis 
Upon sacrifice of the transplanted LDLr-/- mice at 16 weeks after transplantation, the blood and 
peritoneal leukocytes were collected as before [3]. Lymphocyte, monocyte/macrophage, and 
granulocyte counts were quantified using an automated Sysmex XT-2000iV Veterinary 
Hematology analyzer (Sysmex Corporation, Kobe, Japan). The XT-2000iV employs a fluorescent 
flow cytometry method using a fluorescent dye staining cellular DNA and RNA and a 
semiconductor laser to detect forward-, side-scattered, and fluorescent light. Corresponding 
samples were cytospun for manual confirmation and stained with oil-red-O for detection of lipid 
accumulation.  
 
Macrophage cholesterol efflux studies 
Macrophage cholesterol efflux studies were performed using bone marrow-derived macrophages 
(BMDM). For culture of BMDM, bone marrow cells were isolated from both femurs and tibias, 
plated, and differentiated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum, 2 mmol/L glutamine, 20% L929 cell-conditioned media (as a source of M-
CSF), and penicillin-streptomycin for 6 days. BMDM were subsequently harvested and plated at 
0.5 x 106 cells/well in 24-well plates in medium without L cell-conditioned medium. The next day, 
the cells were washed and incubated with either 100 μg/mL LDL or 20 μg/mL oxidized LDL and 




cholesterol. Cholesterol efflux from BMDM was subsequently studied by incubation of the cells 
with DMEM/0.2% free fatty acid-free BSA alone, or supplemented with either 10 µg/mL apoAI 
(Calbiochem) or 50 µg/mL human HDL. After a 24-hours efflux period, radioactivity in the cells 
and medium was determined by liquid scintillation counting. Cholesterol efflux is defined as 
(dpmmedium/ dpmcell +dpmmedium) x 100%. 
 
Quantification of macrophages in the spleen and liver 
Splenocytes were isolated and stained with fluorochrome-conjugate combinations of the following 
monoclonal antibodies aganist CD11b and Ly6G from eBioscience at 4oC for 30 min in labeling 
buffer (1% mouse serum in PBS). Flow cytometry was performed with FacsCalibur and then 
analyzed with CellQuest software (Becton-Dickinson, San Jose), correcting for nonspecific staining 
with isotype antibody controls. 
Cryostat sections of the liver (6 μm) were collected and immunolabeled with rat anti-
mouse F4/80 (BMA Biomedicals) for detection of macrophages. The positive area in liver was 
quantified by using the Leica image analysis system. 
 
Statistical Analysis 
Statistical analysis was performed using ANOVA and the Student-Newman-Keuls post-
test (GraphPad InStat and Prism software). A Pearson r test was used to perform 
correlation analysis. A level of p<0.05 was considered significant. 
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Abstract 
Objective: ABC-transporter A1 (ABCA1) facilitates macrophage cholesterol efflux to 
lipid-free/poor apolipoprotein AI (ApoAI). The aim of the present study was to investigate 
the importance of ApoAI for macrophage ABCA1-mediated reverse cholesterol transport 
(RCT) and the atheroprotective effects of leukocyte ABCA1. 
Methods and Results: Deletion of ABCA1 on macrophages did not impair cellular 
cholesterol efflux to HDL and lipoprotein-depleted serum of ApoAI-/-/LDLr-/- mice nor 
radiolabeled cholesterol excretion into feces in ApoAI-/-/LDLr-/- mice. However, leukocyte 
ABCA1 deficiency in ApoAI-/-/LDLr-/- mice did promote atherosclerotic lesion 
development at both the aortic root and aortic arch. This coincided with enhanced 
neutrophilia and monocytosis in the circulation, increased plasma levels of pro-
inflammatory chemoattractants KC and MCP-1, and augmented neutrophil accumulation in 
lesions. 
Conclusion: ApoAI and macrophage ABCA1 are identified as functional partners in 
macrophage RCT. Nevertheless, leukocyte ABCA1 protects against atherosclerosis in 











Atherosclerosis is the principle cause of coronary artery disease and stroke. A growing 
body of evidence indicates that induction of the levels of high-density lipoprotein (HDL) 
inhibits the progression of atherosclerosis in mice and humans 1, 2. HDL protects against 
atherosclerosis through several mechanisms, such as preserving the endothelial integrity 
and its anti-inflammatory and anti-oxidative properties 3-6. However, the most important 
atheroprotective function of  HDL is facilitation of reverse cholesterol transport (RCT), a 
process in which excess cholesterol from peripheral tissues is transferred to the liver via 
HDL for bile acid synthesis and excretion into the feces 7. Macrophage-derived foam cells 
are major cellular components of early and advanced lesions which contribute to the 
initiation, development, and rupture of atherosclerotic lesions. Macrophages cannot limit 
the uptake of lipids. Removal of cholesterol from macrophage foam cells by RCT is thus 
crucial for inhibition of atherosclerosis 8. ABC-transporter A1 (ABCA1) is an important 
facilitator of macrophage cholesterol efflux to lipid-free/poor apolipoproteins, including 
apolipoprotein AI (ApoAI) 8. Bone marrow transplantation studies have demonstrated that 
leukocyte ABCA1 protects against atherosclerosis, probably by inhibiting macrophage 
foam cell formation 9. The importance of ApoAI for macrophage ABCA1-facilitated RCT 
and the atheroprotective effects of leukocyte ABCA1, however, are still unknown. 
The current study investigated the interrelationship between ApoAI and 
macrophage ABCA1 in RCT and the effects of hematopoietic ABCA1 deficiency on 
atherosclerosis in mice lacking ApoAI. Our results show that macrophage ABCA1 and 
ApoAI are functional partners in RCT. Interestingly, leukocyte ABCA1 protects against 




Homozygous low-density lipoprotein receptor (LDLr) knockout (-/-) mice were obtained 
from The Jackson Laboratory (Bar Harbor, Me, USA) as mating pairs and bred at the 
Gorlaeus Laboratory (Leiden, The Netherlands). ApoAI/LDLr double -/- (ApoAI-/-/LDLr-/-) 
mice were kindly provided by Amsterdam Molecular Therapeutics (AMT, Amsterdam, 
The Netherlands). ABCA1-/- mice were a kind gift of Dr. G. Chimini (Centre 
d’Immunologie de Marseille Luminy, France). The ABCA1-/- mice were at least 8 
generations backcrossed to the C57bl/6 wild-type background. Mice were housed in 
sterilized filter-top cages in a temperature-controlled room with a 12-h light/dark cycle and 
food and water were provided ad libitum. Mice were maintained on sterilized regular chow 
containing 4.3% (w/w) fat and no added cholesterol (RM3, Special Diet Services, Witham, 
UK) or fed Western-type diet (WTD) containing 15% (w/w) cacao butter and 0.25% (w/w) 
cholesterol (Diet W, Ab diets, Woerden, The Netherlands). Drinking water was supplied 
with antibiotics (83 mg/L ciprofloxacin and 67 mg/L polymyxin B sulfate) and 6.5 g/L 
sucrose. Animal experiments were performed at the Gorlaeus Laboratories of the 
Leiden/Amsterdam Center for Drug Research in accordance with the National Laws. All 
experimental protocols were approved by the Ethics Committee for Animal Experiments of 
Leiden University and carried out in compliance with the Dutch government guidelines. 
 
Lipoprotein isolation and characterization 
Non-HDL, HDL and lipoprotein-depleted serum (LPDS) were isolated from serum of 
ApoAI+/+/LDLr-/- and ApoAI-/-/LDLr-/- mice on WTD by sequential ultracentrifugation at 
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100,000 g for 24 h at densities <1.063, 1.063-1.21 and >1.21 g/mL, respectively 10. After 
dialysis to PBS/1mM EDTA, the volume of the isolated fractions was adjusted to the 
original amount of serum from which it was isolated. HDL total and free cholesterol were 
determined using enzymatic colorimetric assays (Roche Diagnostics, Mannheim, 
Germany), with 0.03 U/mL cholesterol oxidase (Sigma Diagnostics, St. Louis, MO, USA), 
0.065 U/mL peroxidase, and 15 μg/mL cholesteryl esterase (Seikagaku, Tokyo, Japan) in 
reaction buffer (1.0 KPi buffer, pH=7.7 containing 0.01 M phenol, 1 mM 4-amino-
antipyrine, 1% polyoxyethylene-9-laurylether, and 7.5% methanol). The concentrations of 
phospholipids and triglycerides in HDL were determined using enzymatic colorimetric 
assays (Spinreact S.A., Girona, Spain and Roche Diagnostics, Mannheim, Germany, 
respectively). Protein concentrations were determined by the BCA method (Pierce, 
Brebières, France). 
For analysis of the ApoAI and ApoE content of HDL and LPDS, 10 μL HDL or 
LPDS, isolated from ApoAI+/+/LDLr-/- and ApoAI-/-/LDLr-/- mice (corresponding to the 
amount of HDL in 10 µL serum) were mixed with 10 µL Laemli sample buffer (Bio-Rad, 
California, US) and incubated for 5 min at 100°C in the presence of β-mercaptoethanol 
(Sigma-Aldrich, St. Louis, MO, USA). Murine ApoAI and ApoE were separated by 10%-
SDS polyacrylamide electrophoresis and detected by Western blot analysis with specific 
antibodies. Antiserum to mouse ApoAI was produced by subcutaneous immunization of a 
rabbit with the purified protein as previously described 11, whereas for detection of ApoE a 
commercial goat polyclonal anti-ApoE antibody was used (Santa Cruz Biotechnology, 
Inc., Heidelberg, Germany). Mouse ApoAI and ApoE bands were evaluated with a 
Chemidoc 2000 densitometer and Quantity One software (Bio-Rad, California, USA) 10.  
 
Macrophage cholesterol efflux studies 
Bone marrow (BM) cells, isolated from ABCA1+/+ and ABCA1-/- mice, were cultured for 7 
days in complete RPMI medium supplemented with 20% fetal calf serum (FCS) and 30% 
L929 cell-conditioned medium, as the source of macrophage colony-stimulating factor (M-
CSF), to generate BM-derived macrophages (BMDM). 
Subsequently, cells were incubated with 2.5% endogenous non-HDL lipoproteins 
isolated from LDLr-/- and ApoAI-/-/LDLr-/- serum in the presence of 0.5 µCi/mL [1α,2α(n)-
3H]-cholesterol in DMEM/0.2% BSA (fatty acid free) for 24 hours at 37°C. Cholesterol 
efflux was studied by incubation of the cells with DMEM/0.2% BSA supplemented with 
either 2.5%  LPDS or 15 µg/mL HDL (protein concentration of HDL) isolated from the 
plasma of LDLr-/- and ApoAI-/-/LDLr-/- mice. Radioactivity in the medium and the cells 
was determined by scintillation counting (Beckman Coulter, Woerden, the Netherlands) 
after 24 hours of incubation. Cholesterol efflux was calculated as the amount of 
radioactivity in the medium compared to the total amount of radioactivity measured in the 
medium plus cells. 
 
In vivo macrophage-specific reverse cholesterol transport assay 
BMDM from WT and ABCA1-/- mice were generated as described above. Subsequently, 
macrophages were loaded with 5 µCi/mL [1α,2α(n)-3H]-cholesterol (Amersham 
Biosciences Europe GmbH, Germany) and 50 µg/mL of acetylated LDL (acLDL) in 
DMEM/0.2% BSA for 48 hours at 37oC. The cells were washed, equilibrated and 
harvested by treatment with 4 mM EDTA for 15 min at 37oC. Radioactivity incorporated 
in the macrophages was determined by liquid scintillation counting (Beckman). LDLr-/- 




3H-cholesterol labeled-macrophages in 0.5 mL PBS (cell viability was above 75% in all 
cases, measured by trypan blue exclusion). Similar amounts of radioactivity were injected 
for ABCA1+/+ and ABCA1-/- macrophages (with means of 13×106 vs 10×106 dpm/mouse, 
respectively). Blood was collected at 24 hours after injection and plasma was used for 
liquid scintillation counting (Beckman). Feces were collected, dried at 50oC, weighed and 
rehydrated in 10 mL milliQ water overnight. Fecal samples were then homogenized and 
radioactivity was determined by liquid scintillation counting. The amount of 3H-tracer in 
plasma and feces was expressed as a percent of the injected dose. 
 
Bone marrow transplantation 
To induce BM aplasia, male LDLr-/- and ApoAI-/-/LDLr-/- recipient mice of 10-12 weeks 
old were exposed to a single dose of 9 Gy (0.19 Gy/min, 200 kV, 4 mA) total body 
irradiation using an Andrex Smart 225 Röntgen source (YXLON International, Hamburg, 
Germany) with a 6-mm aluminum filter 1 day before the transplantation (n=17-20 per 
group). BM was isolated by flushing the femurs and tibias from the donor ABCA1+/+ and 
ABCA1-/- mice with phosphate-buffered saline (PBS). Single-cell suspensions were 
obtained by passing the cells through a 70-µm cell strainer (Falcon, The Netherlands). 
Irradiated recipients received 5x106 BM cells by intravenous injection into the tail vein. 
After that, the transplanted LDLr-/- and ApoAI-/-/LDLr-/- mice were maintained on regular 
chow diet for 8 weeks, to allow repopulation with donor-derived cells. To induce 
atherosclerosis, the transplanted mice were fed high fat WTD for an additional 6 weeks.  
 
Blood and lipoprotein analyses  
After an overnight fast, ~100 µL of blood was drawn from each mouse by tail bleeding. 
The concentrations of total cholesterol (TC) in serum were determined as described above. 
HDL cholesterol was measured after precipitation with phosphotungstic acid and 
magnesium ions (Roche Diagnostics GmbH, Mannheim, Germany). For this purpose, 
lipidemic plasmas were diluted 1:2 with saline prior to precipitation of ApoB-containing 
lipoproteins and, in all cases, the supernatant was clear. Non-HDL cholesterol was 
calculated as the difference between TC and HDL cholesterol 12. Precipath I (Roche 
Diagnostics, Mannheim, Germany) was used as an internal standard.  
 
Histological analysis of the aortic root and arch 
Upon sacrifice, hearts and descending aortas were excised and stored in 3.7% neutral-
buffered formalin (Formal-fixx; Shandon Scientific Ltd, UK) after in situ perfusion. Next, 
10-µm cross-sections were made of the aortic roots using a cryostate, while aortic arches 
were cut longitudinally. Mean atherosclerotic lesion area (in µm2) was calculated from 10 
oil-red-O/hematoxylin-stained sections of the aortic root, starting at the appearance of the 
tricuspid valves, and from 10 sections with maximal lesion area of the aortic arch. 
The collagen content of the lesions was visualized by a Masson’s Trichrome 
staining according to the manufacturer’s instructions (Sigma Diagnostics, St. Louis, MO, 
USA). Macrophages, T cells, and neutrophils in the atherosclerotic lesions were stained by 
immunohistochemistry with antibodies directed against the macrophage specific antigen 
MOMA2 (monoclonal rat IgG2b, Research Diagnostics Inc, NJ), CD3 (polyclonal rabbit 
IgG, Neomarkers, USA) and Ly6G (monoclonal rat IgG2b, eBioscience, Austria), 
respectively. The collagen, macrophage, and neutrophil positive area of the lesions were 
quantified and expressed as percentage of total lesion area (five sections from each mouse). 
All quantifications were performed blinded by using the Leica image analysis system, 
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consisting of a Leica DMRE microscope coupled to a video camera and Leica Qwin 
Imaging software (Leica Ltd., Cambridge, UK).  
 
Quantification of macrophage and neutrophil recruitment into liver and spleen  
At sacrifice, spleen and liver were isolated and single cell suspension were obtained by 
squeezing the organs through a 70-μm cell strainer (Falcon). Red blood cells were 
removed from the splenocyte suspension using erythrocyte lysis buffer (0.15 M NH4Cl, 10 
mM NaHCO3, 0.1 mM EDTA, pH 7.3). Leukocytes in spleen and liver were stained using 
antibodies directed against CD11b and Ly6G according to the manufacturer’s protocol 
(eBioscience). Neutrophils (CD11b+Ly6G+) and macrophages (CD11b+Ly6G-) were 
quantified by Flow cytometry (FACSCantoII, Beckton Dickinson, CA). Data were 
analyzed using FACSDiva software (Beckton Dickinson).   
 
White blood cell analysis 
Upon sacrifice of the transplanted mice at 14 weeks after transplantation, the blood was 
collected as before 13. Lymphocyte, monocyte, and neutrophil counts were quantified using 
an automated Sysmex XT-2000iV Veterinary Hematology analyzer (Sysmex Corporation, 
Kobe, Japan). The XT-2000iV employs a fluorescent flow cytometry method using a 
fluorescent dye staining cellular DNA and RNA and a semiconductor laser to detect 
forward-, side-scattered, and fluorescent light.   
 
Determination of plasma levels of MCP-1 and KC 
Commercial ELISA kits were used for determination of monocyte chemotactic protein-1 
(MCP-1) (eBioscences) and keratinocyte-derived chemokine (KC) (Invitrogen) according 
to manufacturer’s instructions. 
 
Data analyses 
Data are expressed as mean ± S.E.M. A one way ANOVA and the Student Newman Keuls 
posttest were used to compare means after confirming normal distribution by the method 
of Kolmogorov and Smirnov using Graphpad Instat Software (San Diego, USA). P value 




ApoAI was required for macrophage ABCA1-facilitated reverse cholesterol transport  
To determine the interrelationship between macrophage ABCA1 and ApoAI in RCT, the 
cholesterol efflux rate from ABCA1+/+ and ABCA1-/- BMDM to 2.5% endogenous LPDS 
and 15 μg/mL HDL, isolated from WTD-fed ApoAI+/+/LDLr-/- and ApoAI-/-/LDLr-/- mice, 
was analyzed (Figure 1A). Deletion of ABCA1 in macrophages led to a 1.7-fold (p<0.01) 
and 1.6-fold (p<0.001) reduction in cholesterol efflux to LPDS and HDL of 
ApoAI+/+/LDLr-/- mice, respectively. Also, absence of ApoAI impaired the cholesterol 
efflux capacity of LPDS (1.3-fold, p<0.05) and HDL (1.6-fold, p<0.001) from ABCA1+/+ 
macrophages. Interestingly, no further decrease in efflux was observed from ABCA1-/- 
macrophages to LPDS and HDL of ApoAI-/-/LDLr-/- mice (Figure 1A), indicating that 
ApoAI is essential for ABCA1-mediated cholesterol efflux from macrophages. As shown 
in Supplementary Figure 1A, HDL of ApoAI-/-/LDLr-/- mice contains more free cholesterol 




that of LDLr-/- mice. However, the main difference is that ApoE is the major apolipoprotein 
of HDL in ApoAI-/-/LDLr-/- mice instead of ApoAI in ApoAI+/+/LDLr-/- mice 
(Supplementary Figure 1B). The finding that macrophage ABCA1 deficiency did not affect 
cholesterol efflux to HDL of ApoAI-/-/LDLr-/- mice thus indicates that the ApoE-rich HDL 
from these animals does not serve as an acceptor for ABCA1-mediated efflux. Of note, 
ApoE was not detectable in LPDS of either ApoAI+/+/LDLr-/- or ApoAI-/-/LDLr-/- mice 
(data not shown).  
 
Figure 1. Macrophage ABCA1 deficiency does not impair macrophage RCT in absence of ApoAI.  
(A) Cholesterol efflux was studied by incubation of cholesterol labelled ABCA1+/+ (open bar) and 
ABCA1-/- (close bar) BMDM with DMEM/0.2% BSA alone or supplemented with either 2.5% LPDS or 
15 µg/mL HDL from either LDLr-/- or ApoAI-/-/LDLr-/- plasmas. (B) 3H-cholesterol return to the 
circulation and feces from ABCA1+/+ (open bar) or ABCA1-/- (close bar) macrophage foam cells loaded 
with acLDL was measured at 24 hours after injection into peritoneal cavity of either LDLr-/- or ApoAI-/-
/LDLr-/- mice. Values represent the mean ± SEM. Statistically significant difference *P<0.05 and 
***P<0.001.  
 
Next, the importance of circulating ApoAI for macrophage ABCA1-facilitated in 
vivo RCT was investigated. Hereto, ApoAI+/+/LDLr-/- and ApoAI-/-/LDLr-/- mice fed WTD 
were injected intraperitoneally with 3H-cholesterol labeled/acLDL loaded ABCA1+/+ or 
ABCA1-/- BMDM. Transport of labeled cholesterol from the macrophages to the 
circulation and feces was assessed after 24 hours (Figure 1B). In agreement with previous 
studies 14, transport of radiolabeled tracer into the circulation and the feces was reduced 
1.5-fold (p<0.05) and 2.6-fold (p<0.001) by macrophage ABCA1 deficiency in 
ApoAI+/+/LDLr-/- mice, respectively. Also, absence of circulating ApoAI led to a 1.8-fold 
(p<0.05) and 2.2-fold (p<0.001) decreased recovery of the tracer in plasma and feces, 
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respectively upon injection of ABCA1+/+ macrophages into ApoAI-/-/LDLr-/- mice. 
Interestingly, when ABCA1-/- macrophages were injected into ApoAI-/-/LDLr-/- mice, a 
similar reduction of tracer cholesterol was detected in both plasma (1.6-fold, p<0.05) and 
feces (3.0-fold, p<0.001). Thus, in agreement with the in vitro cholesterol efflux studies, 
deletion of macrophage ABCA1 did not further impair in vivo macrophage-specific RCT in 
absence of circulating ApoAI.  
 
Leukocyte ABCA1 deficiency reduced non-HDL cholesterol in absence of circulating 
ApoAI 
To investigate the importance of ApoAI for the atheroprotective effects of leukocyte 
ABCA1, ApoAI+/+/LDLr-/- or ApoAI-/-/LDLr-/- mice were transplanted with bone marrow 
from ABCA1+/+ and ABCA1-/- mice. During the first 8 weeks after bone marrow 
transplantation, animals were fed regular chow. As shown in Table 1, leukocyte ABCA1 
deficiency did not affect plasma cholesterol levels in ApoAI+/+/LDLr-/- or ApoAI-/-/LDLr-/- 
mice on chow. In line with previous observations 15, ApoAI-/-/LDLr-/- mice on chow did 
show reduced (~1.3-fold, p<0.01) total plasma cholesterol levels, mainly due to a virtual 
absence of HDL cholesterol (Table 1). To induce atherosclerotic lesion development, 
animals were fed WTD for an additional 6 weeks. As previously shown 13, 16, upon 
challenge with WTD, leukocyte ABCA1 deficiency resulted in lower total (1.2-fold, 
p<0.05) and non-HDL cholesterol (1.3-fold, p<0.05) levels in ApoAI+/+/LDLr-/- mice 
(Table 1). Also, ApoAI-/-/LDLr-/- mice reconstituted with ABCA1-/- bone marrow showed a 
1.7-fold (p<0.001) reduction in both total and non-HDL cholesterol levels as compared to 
ApoAI-/-/LDLr-/- mice transplanted with ABCA1+/+ bone marrow. The effect of leukocyte 
ABCA1 deficiency on plasma cholesterol levels is thus independent of the presence of 
ApoAI.  
 
Table 1. Plasma cholesterol levels in ApoAI+/+/LDLr-/- and ApoAI-/-/LDLr-/- mice transplanted with 
ABCA1+/+ or ABCA1-/- bone marrow after 8 weeks on chow diet and 6 weeks on WTD.  






ABCA1 BM+/+ →  ApoAI+/+/LDLr-/- 232.9 ± 8.6 148.2 ± 16.2 84.7 ± 15.9 
ABCA1 BM -/- →  ApoAI+/+/LDLr-/- 213.1 ± 3.8 115.2 ± 14.3 99.7 ± 14.5 
ABCA1 BM +/+ → ApoAI-/-/LDLr-/- 180.1 ± 7.5 ** 173.4 ± 9.2  6.0 ± 2.6 ***, ### 
ABCA1 BM -/- → ApoAI-/-/LDLr-/- 174.7 ± 15.7 ** 170.4 ± 16.1  4.2 ± 1.3 ***, ### 
WTD 
ABCA1 BM +/+ →  ApoAI+/+/LDLr-/- 587.5 ± 47.3  546.6 ± 46.8   40.8 ± 6.2  
ABCA1 BM -/- →  ApoAI+/+/LDLr-/- 471.6 ± 16.3 * 436.7 ± 17.7 *  34.9 ± 4.3  
ABCA1 BM +/+ → ApoAI-/-/LDLr-/- 652.5 ± 42.2 ## 647.1 ± 42.8 ###  5.3 ± 0.8 ***, ### 
ABCA1 BM -/- → ApoAI-/-/LDLr-/- 388.8 ± 32.5 **, ∂∂∂ 383.9 ± 32.7 **, ∂∂∂ 4.8 ± 1.4 ***, ### 
Values represent the mean ± SEM. Statistically significant difference *p<0.05, **p<0.01, ***p<0.001 vs 
ABCA1 BM +/+ → ApoAI+/+/LDLr-/-. #p<0.05, ##p<0.01, ###p<0.001 vs ABCA1 BM -/- → ApoAI+/+/LDLr-/-. 
∂p<0.05, ∂∂p<0.01, ∂∂∂p<0.001 vs ABCA1 BM +/+ → ApoAI-/-/LDLr-/-. 
 
Leukocyte ABCA1 deficiency enhances atherosclerotic lesion development and 
promotes the recruitment of neutrophils into lesions in absence of circulating ApoAI 
Atherosclerotic lesion development was evaluated at the aortic root and aortic arch of the 
transplanted animals after 6 weeks WTD feeding. At the aortic root, leukocyte ABCA1 





Figure 2. Enhanced atherosclerotic lesion development in the aortic root of ApoAI-/-/LDLr-/- mice 
reconstituted with ABCA1-/- bone marrow after 6 weeks on WTD. (A) Photomicrographs showing a 
scatter dot plot of atherosclerotic lesion quantification (left panel) and representative Oil-red-O stained 
sections (right panel, original magnification 40x). Each symbol represents the mean lesion area in a 
single mouse. The horizontal line represents the mean of the group. (B) Photomicrographs showing the 
lesion compositions in the aortic root of mice. Sections of the aortic roots were stained with antibody 
against Moma-2 to visualize macrophages (100x). Morphological staining of atherosclerotic lesions in 
the aortic root with Masson’s Trichrome Accustain, which stains cytoplasma and muscle fiber red and 
collagen blue (100x). Bar graphs showing the amount of collagen (C), macrophages (D), and 
neutrophils (E) in the lesion. Neutrophils were visualized by immunohistochemistry staining using 
antibody against Ly6G. Values represent the mean ± SEM of ≥11 (root) and 6 (arch) mice per group. 
Statistically significant difference *P<0.05, **P<0.01, and ***P<0.001.  
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(Figure 2A). Similarly, circulating ApoAI deficiency increased the lesion size 2.7-fold 
(p<0.05) in mice transplanted with ABCA+/+ bone marrow. Interestingly, deletion of 
leukocyte ABCA1 in ApoAI-/-/LDLr-/- mice aggravated atherosclerotic lesion development 
an additional 1.6-fold (P<0.05) (Figure 2A). This clearly indicates that leukocyte ABCA1 
protects against atherosclerosis even in absence of circulating ApoAI. Quantification of 
lesion composition showed that leukocyte ABCA1 deficiency was associated with more 
collagen (2.6-fold, p<0.05, in ApoAI+/+/LDLr-/- mice; 2.5-fold, p<0.001, in ApoAI-/-/LDLr-
/- mice) and less macrophages (1.5-fold, p<0.05, in ApoAI+/+/LDLr-/- mice; 1.9-fold, 
p<0.05, in ApoAI-/-/LDLr-/- mice) in lesions (Figure 2B, 2C and 2D). It must be noted that 
ApoAI-/-/LDLr-/- mice transplanted with ABCA1-/- bone marrow showed 1.7-fold (p<0.01) 
higher collagen and 1.6-fold (p=0.10) lower macrophage content of lesions as compared to 
ApoAI+/+/LDLr-/- mice transplanted with ABCA1-/- bone marrow (Figure 2B, 2C and 2D). 
Thus, in absence of circulating ApoAI, leukocyte ABCA1 deficiency led to the formation 
of more advanced lesions in the aortic root. 
In addition, other inflammatory cells, including T cells and neutrophils, were 
analysed in lesions at the aortic root. Only a limited amount of T cells was visible in 
lesions and there was no difference between the different groups of transplanted animals 
(data not shown). Neutrophils in lesions of ApoAI+/+/LDLr-/- mice transplanted with 
ABCA1-/- bone marrow, however, were increased 5.1-fold (p<0.01 vs ApoAI+/+/LDLr-/- 
mice transplanted with  ABCA1+/+ bone marrow) (Figure 2E). Also, a similar 4.1-fold 
(p<0.05) increase in neutrophils was evident as a result of circulating ApoAI deficiency in 
mice transplanted with ABCA1+/+ bone marrow. Strikingly, deletion of leukocyte ABCA1 
in ApoAI-/-/LDLr-/- mice promoted neutrophil recruitment into lesions an additional 2.2-
fold (p<0.001 vs ApoAI-/-/LDLr-/- mice transplanted with ABCA1+/+ bone marrow).  
 
Figure 3. Enhanced atherosclerotic lesion development in the aortic arch of ApoAI-/-/LDLr-/- mice 
reconstituted with ABCA1-/- bone marrow after 6 weeks on WTD. Bar graphs showing the mean 
lesion area (A) developed in the aortic arch, and relative amount of macrophages (B) and neutrophils 
(C) in lesions of aortic arch. Values represent the mean ± SEM. Statistically significant difference 
*P<0.05.  
 
In mouse models of atherosclerosis, the aortic root is the site most susceptible to 
lesion development. In line, much smaller lesions were observed in the aortic arch of the 
transplanted animals after 6 weeks WTD challenge. The mean lesion size at the aortic arch 




μm2, as compared to 86±9 x103 μm2 in the aortic root (Figure 3A). Strikingly, leukocyte 
ABCA1 deficiency in ApoAI+/+/LDLr-/- mice did not enhance lesion development at this 
site; neither did deficiency of circulating ApoAI in animals transplanted with ABCA1+/+ 
bone marrow. However, leukocyte ABCA1 deficiency in ApoAI-/-/LDLr-/- mice did lead to 
a 1.8-fold (p<0.05) increase in lesion size in the aortic arch, demonstrating again that 
leukocyte ABCA1 deficiency enhances atherosclerosis susceptibility in absence of ApoAI 
(Figure 3A). The enlarged lesions at the aortic arch of ApoAI-/-/LDLr-/- mice transplanted 
with ABCA1-/- bone marrow were fatty streak lesions, primarily composed of macrophages 
(Figure 3B). However, also in these early lesions, neutrophils were increased 4.8-fold 
(p<0.05) upon deletion of leukocyte ABCA1 in ApoAI-/-/LDLr-/- mice (Figure 3C). Taken 
together, leukocyte ABCA1 prevented the development of atherosclerotic lesions and 
inhibited recruitment of neutrophils into lesions in absence of circulating ApoAI. 
 
Figure 4. Increased leukocytosis in ApoAI-/-/LDLr-/- mice reconstituted with ABCA1-/- bone 
marrow after 6 weeks on WTD. Leukocytes (A), neutrophils (B), monocytes (C), and lymphocytes 
(D) in whole blood were analyzed using a Sysmex XT-2000iV Hematology Analyzer. Values represent 
the mean ± SEM. Statistically significant difference *P<0.05 and ***P<0.001. 
 
Leukocyte ABCA1 deficiency increases neutrophilia and monocytosis in absence of 
circulating ApoAI 
To investigate if the enhanced neutrophil infiltration observed in atherosclerotic lesions 
and peripheral tissues was the consequence of neutrophilia in the circulation, blood 
leukocyte counts were analyzed. As previously described 9, disruption of leukocyte 
ABCA1 in ApoAI+/+/LDLr-/- mice led to leukocytosis (1.6-fold, p<0.05), including 
neutrophilia (1.7-fold, p<0.05), monocytosis (1.9-fold, p<0.05), and lymphocytosis (Figure 
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4A-D). Leukocytosis was more severe in ApoAI-/-/LDLr-/- mice with functional ABCA1 
(2.2-fold increase, p<0.001). However, only a trend towards increased neutrophil counts 
(1.4-fold, p=0.0605) was observed in ApoAI-/-/LDLr-/- mice reconstituted with ABCA1+/+ 
bone marrow as compared to ApoAI+/+/LDLr-/- mice transplanted with ABCA1+/+ bone 
marrow (Figure 4B). Leukocytosis induced by absence of circulating ApoAI in animals 
transplanted with ABCA1+/+ bone marrow was mainly due to increased amounts of 
monocytes (2.7-fold, p<0.05) (Figure 4C) and lymphocytes (3.3-fold, p<0.05) (Figure 4D). 
Interestingly, despite no further induction of leukocytosis and lymphocytosis, leukocyte 
ABCA1 deficiency in ApoAI-/-/LDLr-/- mice led to higher neutrophil (2.7-fold, p<0.001) 
(Figure 4B) and, to a lesser extent, monocyte (1.8-fold, p<0.05) counts (Figure 4C). 
Leukocyte ABCA1 thus inhibits monocytosis and neutrophilia even in absence of 
circulating ApoAI.  
 
Figure 5. Enhanced recruitment of neutrophils and monocytes into the liver and spleen of ApoAI-
/-/LDLr-/- mice reconstituted with ABCA1-/- bone marrow after 6 weeks on WTD. Neutrophils and 
macrophages in the liver (A and C) and spleen (B and D) were quantified by flowcytometry as 
described in methods. Values represent the mean ± SEM. Statistically significant difference *P<0.05 
and ***P<0.001. 
 
Leukocyte ABCA1 deficiency promotes recruitment of neutrophils and monocytes 
into peripheral tissues in absence of circulating ApoAI 
To investigate whether the observed increase in neutrophilia and monocytosis could lead to 
enhanced recruitment of neutrophils and monocytes into peripheral tissues, the amount of 
macrophages in liver and spleen was evaluated next. Accumulation of neutrophils in liver 
and spleen was not influenced by either leukocyte ABCA1 deficiency in ApoAI+/+/LDLr-/- 
mice or absence of circulating apoAI in animals transplanted with ABCA1+/+ bone marrow 




deficiency in ApoAI-/-/LDLr-/- mice increased neutrophil accumulation in both the liver 
(~2.0-fold, p<0.05) and the spleen (~1.5-fold, p<0.05). As previously shown 14, the amount 
of macrophages was elevated in liver (2.6-fold, p<0.001) and spleen (1.3-fold, p<0.05) 
upon disruption of leukocyte ABCA1 in ApoAI+/+/LDLr-/- mice (Figure 5C and 5D). Also, 
leukocyte ABCA1 deficiency in ApoAI-/-/LDLr-/- mice induced macrophage recruitment 
into liver (2.2-fold, p<0.05) and spleen (1.2-fold, p<0.05) (Figure 5C and 5D). However, 
absence of circulating apoAI in mice transplanted with ABCA1+/+ bone marrow only led to 
a slight increase in macrophage accumulation in spleen (1.3-fold, p<0.05) but not liver.  
 
Leukocyte ABCA1 deficiency increases the plasma levels of MCP-1 and KC 
Pro-inflammatory chemokines MCP-1 and KC are known inducers of monocytosis and 
neutrophilia, respectively 17, 18. Therefore, the plasma levels of MCP-1 and KC were 
determined. The concentrations of MCP-1 and KC in plasma were increased ~3.0-fold 
(p<0.05) and ~2.5-fold (p<0.05), respectively by deletion of leukocyte ABCA1 in both 
ApoAI+/+/LDLr-/- and ApoAI-/-/LDLr-/- mice (Figure 7A and 6B). However, absence of 
circulating ApoAI in the transplanted animals did not affect the plasma levels of MCP-1 
and KC, indicating that the effects of leukocyte ABCA1 deficiency on plasma levels of 
MCP-1 and KC are independent of the presence of circulating ApoAI. 
 
Figure 6. Increased plasma levels of MCP-1 and KC in the ApoAI-/-/LDLr-/- mice reconstituted 
with ABCA1-/- bone marrow after 6 weeks on WTD.  MCP-1 (A) and KC (B) were determined by 




The present study for the first time assessed the importance of circulating ApoAI for 
macrophage ABCA1-facilitated RCT and the atheroprotective effects of leukocyte 
ABCA1. In-vitro cholesterol efflux and in-vivo macrophage RCT studies demonstrated the 
functional partnership of macrophage ABCA1 and ApoAI for these processes. 
Unexpectedly, our studies also established that leukocyte ABCA1 ameliorates 
atherosclerotic lesion development in absence of circulating ApoAI. These ApoAI-
independent atheroprotective effects of leukocyte ABCA1 were associated with 
suppression of monocytosis and neutrophilia in the circulation and reduction of plasma 
levels of MCP-1 and KC, important chemoattractants of these cell types. 
Functional macrophage RCT is regarded crucial for prevention of atherosclerosis 
19. Previously, the importance of ABCA1 for macrophage RCT has been unequivocally 
established both in vitro 20 and in vivo 14, 21. In agreement, in the current study we show 
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that macrophage ABCA1 deficiency inhibited cholesterol efflux to LPDS and HDL from 
ApoAI+/+/LDLr-/- mice and led to impaired macrophage RCT in vivo. Moreover, in line 
with a previous study 22, absence of ApoAI in LDLr-/- mice reduced RCT from 
macrophages with functional ABCA1 expression. This can likely be attributed to the 
virtual absence of HDL in these animals. In addition, we showed that the HDL that 
circulates in ApoAI-/-/LDLr-/- mice, which is rich in apoE, has a reduced cholesterol efflux 
capacity. ABCA1 mediates cholesterol efflux from macrophages not only to ApoAI, but 
also to other lipid-free/poor apolipoproteins, including ApoE 23. Deletion of macrophage 
ABCA1, however, did not reduce cholesterol efflux to HDL of ApoAI-/-/LDLr-/- mice. Also 
using LPDS from ApoAI-/-/LDLr-/- mice as a lipid acceptor, the primary source of lipid-free 
apolipoproteins, no effect of macrophage ABCA1 deficiency was found. Of note, no ApoE 
was found in the LPDS that was added as acceptor. Also, endogenous ApoE secreted by 
the macrophages was apparently not sufficient to induce ABCA1-mediated efflux under 
these conditions.  
The effects of leukocyte ABCA1 on atherosclerosis have been investigated using 
bone marrow transplantation studies. Selective inactivation of leukocyte ABCA1 
accelerates atherosclerosis 9, 24, while overexpression of leukocyte ABCA1 inhibits 
atherosclerotic lesion progression 25. ABCA1-faciliated macrophage cholesterol efflux and 
RCT were considered the primary contributors to the atheroprotective effects of leukocyte 
ABCA1. In the present study, we found that leukocyte ABCA1 deficiency induced 
atherosclerotic lesion development even in absence of circulating ApoAI, despite the fact 
that macrophage RCT in ApoAI-/-/LDLr-/- mice was not further impaired by deletion of 
macrophage ABCA1. Thus, the atheroprotective effects of leukocyte ABCA1 cannot be 
solely attributed to induction of macrophage cholesterol efflux and RCT, especially under 
conditions in which circulating ApoAI is absent. Atherosclerotic lesion development 
results from a combination of hypercholesterolemia and an inflammatory response. In 
addition to their roles in macrophage RCT, both ABCA1 and ApoAI also have anti-
inflammatory functions 22, 26. Importantly, in absence of circulating ApoAI, leukocyte 
ABCA1 deficiency induced neutrophilia and monocytosis in the circulation, enhanced the 
recruitment of neutrophils and monocytes into peripheral tissues, as well as increased the 
plasma levels of pro-inflammatory chemokines MCP-1 and KC. Furthermore, neutrophil 
accumulation in lesions of ApoAI-/-/LDLr-/- mice transplanted with ABCA1-/- bone marrow 
was largely increased. These ApoAI-independent anti-inflammatory properties of 
leukocyte ABCA1 could thus contribute to its atheroprotective effects.   
Hypercholesterolemia induces monocytosis 27 and neutrophilia 30, mainly due to 
increased proliferation of bone marrow cells 27, 30. In the current study, leukocytosis was 
evident in ApoAI-/-/LDLr-/- mice transplanted with ABCA1+/+ bone marrow. Moreover, 
consistent with our previous findings 9, deletion of leukocyte ABCA1 in ApoAI+/+/LDLr-/- 
mice was associated with elevated levels of leukocytes. Interestingly, in absence of 
circulating ApoAI, leukocyte ABCA1 deficiency further enhanced monocytosis and 
neutrophilia, indicating that the effects of ApoAI and leukocyte ABCA1 on these processes 
are, at least partly, independent. In agreement, Yvan-Charvet et al. recently demonstrated 
that overexpression of ApoAI suppresses the proliferation of hematopoietic stem cells 
(HSC) deficient of ABCA1 and ABCG1 29. In addition, important inducers of monocytosis 
17 and neutrophilia 18 include not only growth factors  GM-CSF (granulocyte-macrophage 
colony-stimulating factor) 30 and G-CSF 31 but also pro-inflammatory chemokines MCP-1 
and KC. Deletion of ABCA1 induces the secretion of  MCP-1 32 and KC [Zhao Y, 
unpublished data] by macrophages. In line, the plasma levels of MCP-1 and KC were 




mice. No effect was observed of ApoAI deficiency, indicating that leukocyte ABCA1 does 
not require ApoAI to maintain low levels of MPC-1 and KC secretion.  
Epidemiological observations showed that leukocytosis, especially monocytosis 
and neutrophilia, is strongly associated with the progression of atherosclerosis 33. 
Monocytes are widely regarded as key cellular protagonists of atherosclerosis 34, 35. 
Accumulation of monocytes in atherosclerotic lesions is progressive and correlates with 
lesion size 36. Deficiency of MCP-1, an important chemoattractant of monocytes, inhibits 
monocyte recruitment into lesions and hence reduces atherosclerotic lesion formation 37. 
The observed increase in plasma levels of MCP-1 upon deletion of leukocyte ABCA1 
might thus have aided the increase in lesion development in ApoAI+/+/LDLr-/- and ApoAI-/-
/LDLr-/- mice. Moreover, deletion of ABCA1 on macrophages increases their migratory 
capacity in response to chemotactic factors 32. In line, enhanced macrophage accumulation 
in the liver and spleen was evident in animals transplanted with ABCA1-/- bone marrow. 
Similar effects on MCP-1 and macrophage accumulation in tissues were observed in both 
ApoAI+/+/LDLr-/- and ApoAI-/-/LDLr-/- recipients, indicating that these are not the causative 
factors for the increased lesion development in the latter. The level of monocytosis, 
however, was higher in ApoAI-/-/LDLr-/- recipients, suggesting that increased monocyte 
pressure from the circulation might have contributed to the enhanced atherosclerotic lesion 
development in ApoAI-/-/LDLr-/- mice transplanted with ABCA1-/- bone marrow. Lately, 
several animal studies unveiled a prominent role of neutrophils in atherogenesis 28, 38-40, 41. 
Upon activation, neutrophils release mediators that have been implicated in the 
pathogenesis of coronary artery disease, such as oxygen radicals, cytokines and matrix 
metalloproteinases 30, 38-40. Drechsler et al demonstrated that neutrophils infiltrate early 
lesions of apoE-/- mice on a high fat diet (HFD; 21% fat), while numbers decline in more 
advanced lesions. Furthermore, depletion of neutrophils inhibited the development of early 
lesions after 4 weeks HFD feeding, but not of advanced lesions (>16 weeks HFD feeding) 
28. In the current study we found massive infiltration of neutrophils in advanced lesions of 
ApoAI-/-/LDLr-/- mice transplanted with ABCA1-/- bone marrow fed WTD for 6 weeks. It 
is thus likely that in this model neutrophil accumulation will also have contributed to the 
development of advanced lesions. In agreement we previously showed that LDLr-/- mice 
transplanted with ABCA1/SR-BI dKO bone marrow, when fed WTD for 10 weeks, 
displayed enhanced neutrophil accumulation in advanced lesions 13. KC is one of the most 
potent chemoattractant for neutrophils. Plasma KC levels were induced by deletion of 
leukocyte ABCA1. However, neutrophil accumulation in the liver, spleen, and lesions of 
aortic arch was only promoted by leukocyte ABCA1 deficiency in ApoAI-/-/LDLr-/- mice. 
Therefore, the induction of neutrophil infiltration in these animals might be the combined 
consequence of the severe neutrophilia in the circulation and the elevated KC levels in 
plasma. 
In conclusion, macrophage ABCA1 and ApoAI are functional partners in cellular 
cholesterol efflux and RCT. However, leukocyte ABCA1 remains atheroprotective in 
absence of circulating ApoAI. The ApoAI-independent atheroprotective effects of ABCA1 
might be attributed to its anti-inflammatory function in suppression of monocytosis and 
neutrophilia and reduction of the secretion of MCP-1 and KC. 
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Supplemental Figure 1. Characterization of HDL lipoprotein from LDLr-/- and ApoAI-/-/LDLr-/- 
mice. (A) Relative weight of free cholesterol, cholesteryl ester, phospholipids, triglycerides, and protein 
in HDL particles from both types of mice expressed as the percentage of total HDL mass. (B) Western 
blot analysis of HDL lipoproteins. Murine ApoAI and ApoE were determined after 10%-SDS 
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Lipid lowering reduces cardiovascular morbidity and mortality. However, the dynamic 
remodeling of established atherosclerotic lesions upon lipid lowering is poorly understood. 
Early and advanced lesions in the aortic root were induced by feeding LDL receptor 
knockout mice a high fat/high cholesterol Western-type diet for 5 and 9 weeks, 
respectively. Lipid lowering was achieved by switching mice to chow diet. In the first 
week after the diet switch, plasma total cholesterol (TC) levels dropped 70%, but both 
early and advanced lesions increased in size. Early lesions grew due to an increase in 
smooth muscle cells while advanced lesions showed an enlargement of the absolute 
macrophage area. From 1 to 3 weeks, plasma TC levels were completely normalized. This 
did not influence the size of early lesions. However, advanced lesions became smaller due 
to a reduction of the absolute macrophage area. From 3 to 6 weeks, both early and 
advanced lesions progressed further as a result of expansion of the absolute collagen and 
necrotic core area. In contrast, early lesions became proinflammatory as evidenced by the 
increased infiltration of neutrophils, increased oxidative stress, probably caused by the 
activation of mast cells in the adventitia. 
In conclusion, the severity of the atherosclerotic lesion affects its dynamic response to lipid 
lowering, indicating the importance of establishing stage-specific therapeutic protocols for 












Atherosclerosis, the leading cause of morbidity and mortality in the Westernized society, is 
a multifactorial complex disease with numerous etiologies that work synergistically to 
promote lesion development [1]. Among the many cardiovascular risk factors, 
hypercholesterolemia, especially due to elevated levels of very-low-density lipoprotein 
cholesterol (VLDL-C) and LDL-C, is sufficient to initiate and promote atherogenesis even 
in the absence of other known risk facors [2]. Clinical trials have shown that the extent of 
LDL-C lowering is negatively associated with the rate of atherosclerosis progression [3-5]. 
However, after normalization of hypercholesterolemia by lipid lowering therapy, a 
considerable proportion of patients still showed continued progression of atherosclerosis 
and the occurrence of clinical events, such as myocardial infarction [6-7]. In the 
ASTEROID trial, after intensive LDL-C lowering by rosuvastatin, approximately 35% of 
the patients still showed atherosclerotic lesion progression in the coronary artery [3,8]. 
Also the recent METEOR study showed that intensive LDL-C lowering by rosuvastatin 
only reduced rather than stopped the progression of carotid atherosclerosis in 
asymptomatic subjects with low risk of cardiovascular disease [9]. Thus, there is a clear 
need for a better insight into the mechanisms underlying the effects of plasma lipid 
lowering on atherogenesis.  
The progression of an atherosclerotic lesion is a dynamic process, involving the 
influx and efflux of lipids, cell migration and emigration, cell proliferation and death, and 
matrix synthesis and degradation [10]. Identification of lesion dynamics is expected to 
have important implications for the treatment of atherosclerosis, as it will allow 
establishment of the optimal timing for modulating specific cellular or acelluar 
components of the lesion to induce lesion stabilization or regression. In the current study, 
we for the first time addressed the effects of plasma lipid lowering on the dynamic 
remodeling of atherosclerotic lesions with different degrees of severity in LDL receptor 
knockout (LDLr KO) mice by applying a dietary switch from a high fat/high cholesterol 
Western-type diet (WTD) to regular chow diet. Evidence is provided that the complexity of 




LDL receptor knockout (LDLr KO) mice, obtained from the Jackson Laboratory (Bar Habor, USA) 
were bred at the Gorlaeus Laboratories and maintained on sterilized regular chow, containing 4.3% 
(w/w) fat and no added cholesterol (RM3; Special Diet Service, Witham, UK). Mice at the age of 12 
weeks received a Western-type diet containing 15% (w/w) total fat and 0.25% (w/w) cholesterol (Diet 
W, Special Diet Services, Whitham, UK) for 5 weeks (n= 32) and 9 weeks (n= 32) to induce the 
development of early and advanced atherosclerotic lesions, respectively. Subsequently, 8 animals were 
euthanized (control group). The remaining animals were divided into 3 groups (n=8/group) and fed a 
regular chow for 1 (W1 group), 3 (W3 group), and 6 (W6 group) weeks, respectively. Animal 
experiments were performed at the Gorlaeus Laboratories of the Leiden/Amsterdam Center for Drug 
Research in accordance with the National Laws. All experimental protocols were approved by the 
Ethics Committee for Animal Experiments of Leiden University. 
 
Lipids Analysis 
After an overnight fasting-period, blood was collected by retro-orbital puncture under anesthesia. 
Hepatic lipids were extracted according to the method of Bligh & Dyer [11] and dissolved in 2% Triton 
X-100. Triglycerides (TG) and Phospholipids (PL) in serum and liver were determined using a standard 
enzymatic colorimetric assay (TG: Roche Diagnostics, Mannheim, Germany; PL: Spinreact, Girona, 
Spain). The concentrations of cholesterol in serum and liver were determined by incubation with 0.025 
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U/mL cholesterol oxidase (Sigma) and 0.065 U/mL peroxidase and 15 μg/mL cholesteryl esterase 
(Roche Diagnostics, Mannheim, Germany) in reaction buffer (1.0 KPi buffer, pH=7.7 containing 0.01 
M phenol, 1 mM 4-amino-antipyrine, 1% polyoxyethylene-9-laurylether, and 7.5% methanol). 
Absorbance was read at 490 nm. The hepatic lipids levels were normalized to their protein 
concentrations determined using the BCATM protein assay (Pierce Biotechnology, Rockford, USA). The 
distribution of cholesterol over the different lipoproteins in serum was determined by fractionation of 30 
μL of serum of individual mice using a Superpose 6 column (3.2 x 300 mm, Smart system; Pharmacia, 
Uppsala, Sweden).  
 
Circulating leukocyte analysis 
Upon sacrifice, blood was collected by retro-orbital puncture under anesthesia. Total white blood cells, 
neutrophil, lymphocyte, and monocyte counts in the blood were analyzed using an automated Sysmex 
XT-2000iV Veterinary Hematology analyzer (Sysmex Corporation, Kobe, Japan).  
 
Histological Analysis of the Aortic Root 
On sacrifice the arterial tree was perfused in situ with phosphate buffer solution (PBS) and the heart was 
excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; Shandon Scientific Ltd., UK) until 
use. 10-μm sections were taken once the aortic root was identified by the appearance of aortic valve 
leaflets. The aortic arches were frozen and longitudinal 8-μm cryosections were taken. Atherosclerotic 
lesion development was quantified in the aortic root and aortic arch from oil red O/hematoxylin-stained 
cryostat sections using the Leica image analysis system, consisting of a Leica DMRE microscope 
coupled to a video camera and Leica Qwin Imaging software (Leica Ltd). Mean lesion area (in μm2) 
was calculated from 10 oil red O/hematoxylin-stained sections in the aortic root and 15 of the sections 
with maximal lesion area in the aortic arch. Sections were immunolabeled against MOMA-2 
(monoclonal rat IgG2b, dilution 1:50, Research diagnostics), α-smooth muscle actin (monoclonal 
mouse IgG2a, dilution 1:500, Sigma), CD3 (polyclonal Rabbit IgG, dilution 1:150, Neomarkers), and 
Ly6G (monoclonal rat IgG2b, dilution 1:100, eBiosciences) for detection of monocytes/macrophages, 
smooth muscle cells, T lymphocytes, and neutrophils, respectively. Collagen content of the lesions was 
visualized with aniline blue by using Masson’s Trichrome accustain according to the manufacturer’s 
instructions (Sigma). TUNEL staining of lesions was performed to visualize apoptotic cells using the in 
Situ Cell Death Detection kit (Roche Diagnostics). Mast cells were stained with naphthol AS-D 
chloroacetate esterase (Sigma). Histochemical stainings were subsequently quantified in 5 consecutive 
sections by computer-aided morphometric analysis using the Leica image analysis system. Furthermore, 
quantifications of necrotic core area were performed on oil red O/hematoxylin and Masson’s Trichrome 
stained sections. Oxidative stress was quantified by using α-nitrotyrosine (IgG2b, dilution 1:100, 
Abcam) and α-8-hydroxy-2’-deoxyguanosine (8-OHdG) (IgG2a, dilution 1:100, QED Bioscience) 
monoclonal mouse antibodies. All analyses were performed blinded.  
 
Flow cytometry 
White blood cell suspensions from whole blood were prepared by lysis of red blood cells. Cell surface 
immunolabelling of monocytes and neutrophils was performed according to the manufacturer’s 
instructions (eBioscience & BD Biosciences). Briefly, fluorochrome-conjugated monoclonal antibodies 
to CD11b (Biosciences) and to Ly6G and Ly6C (BD Biosciences) were incubated with the white blood 
cell suspensions for 30 min at 4oC in labeling buffer (1% mouse serum in PBS). Flow cytometric 
analysis was performed with FacsCalibur and then analyzed with CellQuest software (Becton 
Dickinson, San Jose), correcting for nonspecific staining with isotype antibody controls. 
 
Statistical Analysis 
Statistical analysis was performed using ANOVA and the Student-Newman-Keuls post-test (GraphPad 
InStat and Prism software). A Pearson r test was used to perform correlation analysis. A level of p<0.05 







Dietary lipid lowering led to decreased lipid levels in plasma and liver 
LDLr KO mice were fed WTD for 5 weeks to induce atherosclerotic lesion formation. 
Thereafter the diet was switched to regular chow to lower plasma cholesterol levels. As 
shown in Table 1, once the diet was switched to chow, plasma free cholesterol and total 
cholesterol levels dropped approximately 60% from 357±36 mg/dL to 156±2 mg/dL 
(p<0.001) and 70% from 1347±78 mg/dL to 438±13 mg/dL (p<0.001) at 1 week and 
decreased further to 84±3 and 222±6 mg/dL, respectively, at 6 weeks after the diet switch. 
The reduced plasma total cholesterol levels were mainly due to decreased VLDL/LDL-C 
levels (supplementary Figure S1). Moreover, an around 45% reduction in plasma 
triglycerides (p<0.001) and phospholipids (p<0.001) was observed at 1 week after the diet 
switch, which remained low during the remaining period of the experiment (Table 1). The 
reduction of plasma lipids thus mainly occurred in the first week after the dietary lipid 
withdrawal. In contrast, livers showed delayed cholesterol lowering upon switch of WTD 
to chow with the major effects seen at 3 weeks. After 3 weeks on regular chow, hepatic 
free and esterifed cholesterol levels decreased approximately 35% (p<0.001) and 75% 
(p<0.001), respectively (Table 1). Dietary lipid lowering did not affect the hepatic 
triglyceride and phospholipid content (Table 1). Of note, dietary lipid lowering did 
normalize both plasma and hepatic lipid levels at 6 weeks after the diet switch to similar 
levels as in LDLr KO mice of the same age without WTD challenge (Table 1). 
 
Table 1: Effect of dietary cholesterol lowering on plasma and hepatic lipids 




Diet  WTD Chow Chow Chow Chow 
Plasma FC (mg/dL) 357±36 156±2*** 96±4***,ǂ 84±3***,ǂ 85±3 
Plasma TC (mg/dL) 1347±78 438±13*** 232±7***,ǂǂ 222±6***,ǂǂ 237±7 
Plasma TG (mg/dL) 216±21 104±14*** 120±10*** 115±7*** 106±10 
Plasma PL (mg/dL) 748±50 489±17*** 447±23*** 405±19*** 425±15 
Hepatic FC  
(ug/mg protein) 26±1 23±1* 17±1***
,ǂǂ 17±1***,ǂǂ 16±1 
Hepatic CE  
(ug/mg protein) 41±3 31±4* 11±1***
,ǂǂ 9±1***,ǂǂ 8±1 
Hepatic TG  
(ug/mg protein) 67±2 77±7 73±3 77±4 64±9 
Hepatic PL  
(ug/mg protein) 74±4 73±4 65±3 68±2 75±5 
LDLr KO mice were fed WTD for 5 weeks. Thereafter, the animals were switched to regular chow and 
euthanized at 0 (group C), 1 (group W1), 3 (group W3) and 6 (group W6) weeks after the diet switch. LDLr 
KO control mice were kept on chow diet all the time during the experiment. Plasma and hepatic lipids were 
measured. FC, free cholesterol; TC, total cholesterol; CE, cholesteryl ester; TG, triglycerides; PL, 
phospholipids. Data represent mean ± SEM of 8 mice. Statistically significant difference ***P<0.001 and 
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Decreased circulating neutrophils and monocytes upon dietary lipid lowering 
Next, we examined the effect of dietary lipid lowering on circulating leukocytes. The 
amount of total white blood cells was 4.0±0.7 x106/mL at baseline and had a tendency to 
decrease to 3.1±0.5 x106/mL at 3 weeks and remained low (3.3±0.4 x106/mL) until 6 
weeks after the WTD withdrawal. Dietary lipid lowering did not affect the mount of 
lymphocytes in the circulation (~2.5x106/mL). As shown in Figure 1A and B, the tendency 
to a reduction in white blood cells by dietary lipid lowering can be attributed to reduced 
levels of circulating monocytes and neutrophils. Neutrophils in the circulation were 
reduced about 2-fold (p<0.05) after 1 week on chow, while monocytes did not change at 
this time point. In contrast, at 3 weeks after the dietary lipid withdrawal circulating 
monocytes were reduced ~3-fold (p<0.05). 
 
Two specific monocyte subsets that vary in their capacity to infiltrate into 
atherosclerotic lesions are characterized by different expression levels of Ly6C. Ly6Chigh 
monocytes preferentially accumulate in the growing atheroma in hyperlipidemic mice, 
while Ly6Clow monocytes do not [12]. Therefore, Ly6Chigh and Ly6Clow monocyte subsets 
were further analyzed. Both Ly6Chigh (3.1-fold, p<0.01) and Ly6Clow (3.3-fold, p<0.05) 
monocytes were reduced after 3 weeks on chow (Figure 1C and 1D). Moreover, the 
percentage of Ly6Chigh monocytes decreased from 60±2% at baseline to 47±2% (1.3-fold, 
P<0.001) at 6 weeks after the diet switch.  
 
Dynamic remodeling of established early atherosclerotic lesions upon dietary lipid 
lowering 
 
Feeding LDLr KO mice the WTD for 5 weeks induced the development of early 
atherosclerotic lesions in the aortic root, characterized by fatty streaks and accumulation of 
macrophage foam cells (Figure 2C and 3A). The dynamic remodeling of these established 
early lesions following dietary lipid lowering was investigated by analyzing the effects on 
lesion size and lesion compositions at 0 (group C), 1 (group W1), 3 (group W3) and 6 
(group W6) weeks after the diet switch to regular chow.  
Figure 1. Decreased circulating 
neutrophils and monocytes upon dietary 
lipid lowering. LDLr KO mice were fed 
Western-type diet (WTD) for 5 weeks and 
thereafter switched to regular chow for 0 
(C), 1 (W1), 3 (W3), and 6 (W6) weeks. At 
each time point, circulating neutrophils and 
monocytes were analyzed by using flow 
cytometry. Neutrophils and monocytes 
were defined as CD11b+Ly6G+ cells and 
CD11b+Ly6G- cells, respectively. 
CD11b+Ly6G- monocytes were separated 
further according to their Ly6C expression 
into Ly6Chigh and Ly6Clow monocyte 
subsets. Values represent the mean±SEM 
of 8 mice. Statistically significant 
difference *P<0.05 and **P<0.01 versus 






Figure 2. Dynamic remodeling of established early lesions upon dietary lipid lowering. Feeding LDLr 
KO mice WTD for 5 weeks induced early atherosclerotic lesion formation in the arotic root. Atherosclerotic 
lesion development was analyzed at the aortic root at 0 (C), 1 (W1), 3 (W3), and 6 (W6) weeks after the 
switch of the mice to regular chow. (A) Photomicrographs showing a scatter dot plot of atherosclerotic lesion 
quantification and representative oil-red-O stained sections (original magnification 10x2.5). Each symbol 
represents the mean lesion area in a single mouse. The horizontal bar indicates the mean value for the group. 
(B) Bar graphs showing the dynamic changes in macrophages, T cells, neutrophils, smooth muscle cells, 
collagen content and necrotic core area of early lesions after the diet switch. Statistically significant 
difference *P<0.05, **P<0.01, and ***P<0.001 versus group C; ###P<0.001 versus group W1; $P<0.05 and 
$$$P<0.001 versus group W3. (C) Pie graph showing the relative abundance of macrophage (red), smooth 
muscle cell (yellow), collagen (blue), necrotic core (black) and neutrophils (green) in the early lesions during 
the remodeling upon dietary lipid lowering. The relative percentage of each lesion component was 
normalized to sum to 100%. 
 
Stage-specific remodeling of atherosclerotic lesions 
 177
In the initial phase (the first week after the dietary lipid withdrawal), the lesions 
still progressed from 157±24 ×103 μm2 to 235±18 ×103 μm2, despite the 70% decrease in 
plasma total cholesterol levels to 438±13 mg/dL (Figure 2A). Quantification of the 
lesioncomposition indicated a 3.7-fold increase of smooth muscle cells (p<0.05) but no 
significant change in macrophages, T cells or neutrophils or collagen content of lesions 
(Figure 2B). The percentage of apoptotic cells in the lesions was only 1.3±0.3% 
(Supplementary Figure S2). Morphological analysis of the lesions also revealed the 
appearance of a necrotic core at 1 week after the diet switch. However, the mean size of 
the necrotic core area was only 2.4±0.9 ×103 μm2 (Figure 2B). As shown in Figure 2C, 
after 1 week chow diet feeding, the early lesions were still mainly composed of 
macrophage foam cells (Figure 2C). 
In the second phase (from 1 to 3 weeks on chow), the plasma total cholesterol 
levels decreased further to around 232±7 mg/dL. Interestingly, no change in the lesion size 
was detected as compared to 1 week chow feeding (W3: 248±18 ×103 μm2 vs W1: 235±18 
×103 μm2) (Figure 2A). Of note, dietary lipid lowering for 3 weeks did lead to a reduction 
in macrophages (2.1-fold, p<0.001 vs W1; 1.6-fold, p<0.05 vs C) (Figure 2B and 3B), 
while the average size of macrophage foam cells remained unchanged (data not shown). 
The smooth muscle cells (7.4-fold, p<0.05) (Figure 3C and 3D) and collagen content (7.0-
fold, p<0.05) increased further as compared to baseline (Figure 2B), which formed the 
subluminal fibrous cap (Figure 3D). Also the percentage of apoptotic cells increased ~2.3-
fold (p<0.05 vs C and W1) to 2.9±0.4% (Supplementary Figure S2). Although the buildup 
of necrotic material inside the lesions was augmented (5.0±2.8 ×103 μm2), the collagen to 
necrotic core ratio was increased 3.3-fold to 16.2±5.8, indicating that dietary lipid lowering 
induced lesion stabilization. Moreover, T cells (Figure 3E and 3F) and neutrophils of the 
lesions were not significantly changed (Figure 2B and 2C). In line, the lesion contains 
more collagen and smooth muscle cells, and fewer macrophage foam cells after dietary 
lipid lowering for 3 weeks (Figure 2C).  
In the third phase (from 3 to 6 weeks on chow), the size of the lesions reached a 
value of 323±36 ×103 μm2 (p<0.01 vs C) (Figure 2A), although the plasma total cholesterol 
levels remained low (222±6 mg/dL). The lesional macrophage area of mice kept on chow 
for 6 weeks increased 1.5-fold (p<0.05) as compared to the lesions of mice fed chow for 3 
weeks and became similar to baseline levels (Figure 2B). The amount of smooth muscle 
cells in the lesions remained relatively high, 3.9-fold (p<0.05) higher as compared to 
baseline. Moreover, the collagen content of the lesions was further increased (2.1-fold vs 
W3, 14.5-fold vs C, p<0.001) (Figure 2B and 3H), indicating that the rate of collagen 
synthesis was still higher than that of its degradation. Importantly, in the 3 additional 
weeks chow diet feeding, also a dramatic enlargement of necrotic core (4.4-fold, p<0.001 
vs W3) was observed (Figure 2B and 2C). The ratio of collagen to necrotic core was thus 
reduced 5.5-fold to 2.9±0.4 (p<0.05 vs W3). A further increase in the percentage of 
apoptotic cells was also found (4.7±0.6%, 1.6-fold vs W3, P<0.05; 3.7-fold vs C and W1, 
p<0.001) (Supplementary Figure S2). In addition, the neutrophil content of the lesions was 
increased 2.8-fold (p<0.001 vs W3) (Figure 2B and 3J). The enhanced infiltration of 
neutrophils and a decreased ratio of collagen to necrotic core suggested a proinflammatory 
phenotype of the lesions. Strikingly, the T cell content still remained the same as baseline 
(Figure 2B).  
After 6 week chow diet feeding, as shown in Figure 2C, the early lesions mainly 
consisted of macrophages, collagen and necrotic core. Interestingly, pearson correlation 




lesions was highly correlated with the macrophage (r=0.67, p=0.0048, n=16), collagen 
(r=0.85, p<0.0001, n=16), and necrotic core (r=0.66, p=0.0055, n=16) area.  
 
 
Dynamic remodeling of established advanced atherosclerotic lesions upon dietary 
lipid lowering 
 
We next examined whether the dynamic remodeling of established advanced 
atherosclerotic lesions differs from the response of early lesions upon dietary lipid 
lowering. Advanced lesions in the aortic roots were induced by feeding LDLr KO mice 
WTD for 9 weeks. The lesion size and composition were again examined at 0 (group C), 1 
(group W1), 3 (group W3) and 6 (group W6) weeks after the diet switch to regular chow. 
When the mice were fed WTD for 9 weeks prior to the switch to chow diet, dietary lipid 
lowering led to a similar reduction in plasma and hepatic lipid levels as compared to 5 
weeks WTD feeding prior to the diet switch (data not shown). As compared to early 
lesions, advanced lesions displayed a markedly lower macrophage content, increased 
smooth muscle cell content and collagen deposition (Figure 2C and 4C), while also a 
necrotic core and a fibrous cap can be distinguished. In addition, advanced lesions 
contained 2-fold more T cells (p=0.0013) and 49-fold more neutrophils (p=0.0011), 
respectively as compared to early lesions. The percentage of apoptotic cells in advanced 
lesions was also largely increased (8. 5±0.8%, 6.7-fold, p<0.001) (Supplementary Figure 
S2). Interestingly, the neutrophil content of advanced lesions was about 5-fold (p=0.0003) 
higher as compared to the level in early lesions after 6 weeks WTD withdrawal (Figure 2B 
and 4B).  
Figure 3. Photomicrographs showing 
morphometric changes of early lesions upon 
dietary lipid lowering. Sections of the aortic 
roots were stained with antibodies against Moma-
2, α-actin, CD3, and Ly6G to visualize 
macrophages (A, B, 50x), smooth muscle cells 
(SMCs) (C, D, 50x), T cells (E, F, 100x), and 
neutrophils (I, J, 100x), respectively. 
Morphological staining of atherosclerotic lesions 
in the aortic root with Masson’s Trichrome 
Accustain, which stains cytoplasma and muscle 
fiber red and collagen blue (G, H, 50x). 
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Figure 4. Dynamic remodeling of established advanced lesions upon dietary lipid lowering. Feeding 
LDLr KO mice WTD for 9 weeks induced advanced atherosclerotic lesion formation in the aortic root. 
Atherosclerotic lesion development was analyzed at the aortic root at 0 (C), 1 (W1), 3 (W3), and 6 (W6) 
weeks after the switch of the mice to regular chow. (A) Photomicrographs showing a scatter dot plot of 
atherosclerotic lesion quantification and representative oil-red-O stained sections (original magnification 
10x2.5). Each symbol represents the mean lesion area in a single mouse. The horizontal bar indicates the 
mean value for the group. (B) Bar graphs showing the dynamic changes in macrophages, T cells, neutrophils, 
smooth muscle cells, collagen content and necrotic core area of advanced lesions after the diet switch. 
Statistically significant difference *P<0.05, **P<0.01, and ***P<0.001 versus group C; #P<0.05, ##P<0.01, and 
###P<0.001 versus group W1; $P<0.05 and $$$P<0.001 versus group W3. (C) Pie graph showing the relative 
abundance of macrophage (red), smooth muscle cell (yellow), collagen (blue), necrotic core (black) and 
neutrophils (green) in the advanced lesions during the remodeling upon dietary lipid lowering. The relative 





In the initial phase upon WTD withdrawal, advanced lesions, increased 1.4-fold in 
size (778±68 ×103 μm2 vs 557±54 ×103 μm2, p<0.05) (Figure 4A). In contrast to early 
lesions, this was associated with a 1.7-fold (p<0.001) increase of macrophage content in 
advanced lesions (Figure 4B). No significant change was observed in the other lesion 
components. Notably, in the second phase from 1 to 3 weeks on chow, a significant 1.3-
fold reduction in the size of advanced lesions was observed (606±50 ×103 μm2, p<0.05 vs 
W1) (Figure 3A), which was primarily the consequence of a 2-fold reduction in the 
macrophage content of the lesions (Figure 4B and 5B). In addition, T cells (1.5-fold, 
p<0.05 vs W1) and neutrophils (1.9-fold, p<0.05 vs W1) were decreased to baseline. 
Increased fibrous cap area in the subluminal Moma-2 negative region (Figure 5B) was 
correlated with increased collagen accumulation (2.2-fold, p<0.01 as compared to 
baseline), but smooth muscle cells and the necrotic core remained the same (Figure 4B and 
4C). The collagen to necrotic core ratio was thus increased 1.8-fold to 3.7±0.6 (p<0.05, vs 
C and W1). The percentage of apoptotic cells remained unchanged (8.6±0.6%) 
(Supplementary Figure S2). All these changes indicated that advanced lesions became 
stabilized after dietary lipid lowering for 3 weeks. In line, collagen became the major 
component of advanced lesions after 3 weeks chow diet feeding (Figure 4C). 
 
In the third phase, advanced lesions, like the early lesions, progressed to 838±56 
×103 μm2 (1.4-fold, p<0.05 vs W3) (Figure 4A). This was primarily the consequence of an 
increase (2.0-fold, p<0.001) in collagen content of advanced lesions and to a lesser extent 
of an enhanced buildup of necrotic core material (1.7-fold, p<0.001) (Figure 4B and 5D). 
The macrophage area of advanced lesions did not change while smooth muscle cells 
Figure 5. Photomicrographs showing 
morphometric changes of advanced lesions 
in response to dietary lipid lowering. Sections 
of the aortic roots were stained with antibodies 
against Moma-2, α-actin, Ly6G, and CD3 to 
visualize macrophages (A, B, 50x), smooth 
muscle cells (SMCs) (E, F, 50x), neutrophils 
(G, H, 100x), and T cells (I, J, 100x), 
respectively. Morphological staining of 
atherosclerotic lesions in the aortic root with 
Masson’s Trichrome Accustain, which stains 
cytoplasma and muscle fiber red and collagen 
blue (C, D, 50x). 
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(Figure 5E and 5F) decreased 1.9-fold (p<0.05 vs W3; 2.4-fold, p<0.05 vs C) after the 3 
additional weeks chow diet feeding (Figure 4B). The ratio of collagen to necrotic core 
remained stably high (4.0±0.4, p<0.01 vs C). The percentage of apoptotic cells in the 
lesions was even slightly decreased to 7.1±0.6% (p<0.05 vs W1) (Supplementary Figure 
S2). Moreover, neutrophils of advanced lesions (Figure 5G and 5H) were dramatically 
reduced (3.7-fold, p<0.05 vs W3, 5.4-fold, p<0.05 vs C) at 6 weeks (Figure 4B). T cells of 
advanced lesions (Figure 5I and 5J) decreased further (1.9-fold, p<0.01 vs C) to the similar 
levels of early lesions (Figure 4B). In line, advanced lesions became the collagen-rich 
lesions after dietary lipid lowering for 6 weeks (Figure 4C). Interestingly, pearson 
correlation analyses demonstrated that after normalization of hypercholesterolemia, the 
size of advanced lesions was also highly correlated with collagen (r=0.91, p=0.0002, n=16) 
and necrotic core (r=0.80, p=0.0003, n=16) content, but not correlated with macrophage 
content (r=0.39, p=0.14, n=16). 
 
Effects of dietary lipid lowering on inflammatory cells in the adventitia of mice with 
early and advanced lesions 
 
Adventitial inflammatory cells also play a critical role in the progression of atherosclerotic 
lesions [13]. The response of inflammatory cells in the adventitia to dietary lipid lowering 
might thus influence the progression of established lesions. Therefore, total and 
degranulated mast cells, neutrophils, and T cells in the adventitia underlying the early and 
advanced lesions were analyzed following WTD withdrawal. Upon dietary lipid lowering, 
total and degranulated mast cells in the adventitia of early lesions increased 2.1-fold 
(p<0.05 vs C and W1) and 3.8-fold (p<0.05), respectively at 3 weeks and remained stably 
high (total: 2.8-fold, p<0.01 vs C; degranulated: 3.9-fold, p<0.05 vs C) at 6 weeks (Figure 
6B&C). Degranulated mast cells can recruit neutrophils by secretion of KC, the murine 
ortholog of IL-8 [14]. In line, also a significant increase of neutrophils (1.9-fold, p<0.01 vs 
C; 1.2-fold, p<0.05 vs W1) was observed in the adventitia of early lesions at 3 weeks after 
WTD withdrawal. Unexpectedly, at 6 weeks, neutrophils declined 2-fold to approximately 
the levels at baseline (p<0.05 vs W3) (Figure 6D). As compared to early lesions, the 
adventitia of advanced lesions contained more total (1.7-fold, p=0.0251) and degranulated 
(5.2-fold, p=0.0072) mast cells and neutrophils (3.6-fold, p=0.0008) before the diet switch. 
While total mast cells did not change in the adventitia of advanced lesion after the WTD 
withdrawal, dietary lipid lowering did lead to a reduction of degranulated mast cells (3.1-
fold, p<0.001 vs C) after 1 week on chow, which remained stably low during the remainder 
of the experiment (Figure 6B and 6C). Neutrophils in the adventitia of advanced lesions 
declined in time (6.8-fold, p<0.001, W6 vs C) to the baseline levels of early lesions at 6 
weeks on chow (Figure 6D). 
As an important component of adaptive immunity, T cells are critical for the 
progression rather than initiation of atherosclerosis [15]. In line, 16-fold more T cells 
(p=0.0004) were observed in the adventitia of advanced lesions as compared to early 
lesions. As shown in Figure 6E, T cells in the adventitia of early lesions increased 
approximately 2-fold (p<0.01 vs C) in the first week after the WTD withdrawal and did not 
significantly change afterwards, while a 1.7-fold (p<0.05 vs W1) reduction of T cells was 
detected in the adventitia of advanced lesions from 1 to 3 weeks, which remained low (1.9-
fold, p<0.01 vs W1) at 6 weeks on chow. The amount of T cells in the adventitia of 
advanced lesions, however, remained 7.9-fold (p=0.0003) higher as compared to the levels 







Figure 6. Effect of dietary lipid lowering on inflammatory cells in the adventitia of early and advanced 
lesions. (A) Representative photomicrographs of mast cells (200x), degranulated mast cells (arrow, 200x), 
neutrophils (100x) and T cells (100x) in the adventitia. Bar graphs showing the dynamic changes of total 
mast cells (B), degranulated mast cells (C), neutrophils (D) and T cells (D) in the adventitia of early (closed 
circles) and advanced (open circles) lesions after the switch of WTD to chow diet. Values are means±SEM 
(n=8). Statistically significant difference *P<0.05, **P<0.01, and ***P<0.001 versus group C; #P<0.05, 
##P<0.01, and ###P<0.01 versus group W1; $P<0.05 versus group W3. 
 
Effects of dietary lipid lowering on oxidative stress in early and advanced lesions 
To study the effect of dietary lipid lowering on oxidative stress in the established lesions, 
the mount of nitrotyrosine and 8-hydroxy-2’-deoxyguanosine (8-OHdG) in the lesions 
were quantified after the diet switch. Although the plasma cholesterol decreased after 6 
weeks on chow, the amount of nitrotyrosine and 8-OHdG in the early lesions was 
significantly increased 17-fold (p=0.009) and 3.3-fold (p=0.043), respectively in the early 
lesions (Supplementary Figure S3A). In contrast, the oxidative stress was reduced in 
advanced lesions as evidenced by the reduction of nitrotyrosine (13-fold, p=0.005) and 8-
OHdG (5.0-fold, p=0.0003) (Supplementary Figure S3B). 
 
Effects of dietary lipid lowering on the established atherosclerotic lesion development 
in the coronary artery and aortic arch 
 
The lesion development in the coronary artery and aortic arch was next analyzed. In line 
with the fact that the aortic root is the most susceptible site for atherosclerosis in murine 
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models, no lesion formation was visible in the coronary artery of LDLr KO mice after 5 
weeks WTD feeding. Even after 9 weeks on WTD, only 2 out of 8 mice displayed very 
small lesions (lesion size: 5.6 x 103 μm2 and 7.2 x 103 μm2). Moreover, LDLr KO mice did 
not develop any atherosclerotic lesions in the aortic arch after 5 weeks on WTD (data not 
shown). After 9-week WTD feeding, macrophage-rich fatty streak lesions had formed in 
the aortic arch with a mean lesion area of 86.5±16.4 x 103 μm2 (Supplementary Figure 
S4A). The ratio of collagen to macrophages in the aortic arch after 9 weeks on WTD 
(0.053±0.021) was similar to the established early lesions in the aortic root (0.051±0.015) 
after 5 weeks WTD feeding. No necrotic core was visible in these established lesions of the 
aortic arch (Supplementary Figure S4D). After the first week on the chow, no significant 
change was found in the lesion size (97.8±13.4 x 103 μm2) and composition 
(Supplementary Figure S4). Three weeks chow diet feeding led to a ~2.0-fold (p<0.05 vs C 
and W1) and ~7.5-fold (p<0.01 vs C and W1) increase in size and collagen content, 
respectively (Supplementary Figure S4A and C). In addition, a small necrotic core became 
evident. However, the mean size was only 2.5 × 103 μm2 (p<0.05 vs C and W1) 
(Supplementary Figure S4D). The lesion increased further in size (1.5-fold, p<0.05 vs W3; 
~3-fold, p<0.001 vs C and W1) and collagen content (2.4-fold, p<0.001 vs W3; ~20-fold vs 
C and W1 ) after an additional 3 weeks on chow, i.e. total 6 weeks on chow 
(Supplementary Figure S4A and C). Also, an enlargement of the necrotic core was 
observed (5.5-fold, p<0.001 vs W3). The ratio of collagen to necrotic core was thereby 
reduced 5.2-fold to 5.8±1.3 (P<0.05 vs W3) (Supplementary Figure S4D). Meanwhile, 
dietary lipid lowering did not significantly affect the macrophage content, although a 
tendency to a similar profile was observed as established early lesions in the aortic root 
(Supplementary Figure S4B). Taken together, dietary lipid lowering did lead to similar 
changes on early lesions in both arotic root and aortic arch. 
 
Discussion 
The present study for the first time investigated the dynamic remodeling of established 
early and advanced atherosclerotic lesions upon dietary lipid lowering. Strikingly, both 
established early and advanced atherosclerotic lesions continued to progress after the 
withdrawal of dietary lipids, which was strongly correlated with the induction of collagen 
and necrotic core content of the lesions. However, after normalization of 
hypercholesterolemia, early lesions exhibited a proinflammatory phenotype while 
advanced lesions became less inflammatory. The clear differences in the response of early 
and advanced lesions to dietary lipid lowering indicate that the severity of the lesions 
affected their dynamic response to lipid lowering. 
Dietary lipid lowering, as expected, induced a decrease in plasma and hepatic 
cholesterol levels. However, both established early and advanced lesions in LDLr KO mice 
could further increase in size when the plasma cholesterol levels of the animals was 
normalized to around 220 mg/dL, i.e. lower than 300 mg/dL that is prerequisite for 
initiation of lesion development [16]. This finding indicates that the plasma cholesterol 
levels required for lesion progression are lower than those for lesion initiation. This might 
also explain why progression of atherosclerotic lesions can occur in patients with normal 
LDL-C levels (< 90 mg/dL) after lipid lowering treatment with statins [3]. In line, a robust 
reduction of the plasma LDL-C levels (<70 mg/dL) is required to halt the progression of 
established atherosclerotic lesions in humans [3, 4]. However, it should be noted that some 
patients cannot reach this threshold level of LDL-C even after intensive lipid lowering 
treatment. Combined therapy that targets multiple pathogenic mechanisms involved in 




Consistent with previous findings in rabbits [17] and miniature pigs [18], dietary 
lipid lowering also led to massive collagen accumulation in the lesion of LDLr KO mice. 
Importantly, we observed that the collagen content was highly correlated with the size of 
both early and advanced lesions from 3 to 6 weeks after normalization of 
hypercholesterolemia. Despite being important for providing mechanical stability to the 
lesion, excessive collagen may also stimulate lesion development by serving as a depot for 
proatherogenic molecules (modified lipoproteins, growth factors and glycation end-
products) and by promoting foam cell formation [19]. Moreover, massive collagen 
accumulation might obstruct the access of healthy phagocytotic cells to clear apoptotic 
cells in the lesions, thereby leading to the increased necrotic core formation. Necrotic core 
areas are sites of active inflammation and oxidative stress [20, 21], which could thus 
further promote the progression of lesions. In agreement, we found that necrotic core 
formation increased in time upon dietary lipid lowering. It should thus be carefully 
investigated if inhibition of collagen synthesis in combination with lipid lowering might be 
a potential therapeutic strategy for the treatment of atherosclerosis.  
Recruitment of monocytes into atherogenic foci is central to the initiation and 
progression of atherosclerosis. Hypercholesterolemia induces Ly6Chigh monocytosis [22, 
23], subsequently contributing to atherogenesis [12]. Reduction of plasma cholesterol 
levels by statins could reduce Ly6Chigh monocytosis [22]. However, the anti-inflammatory 
effects of statins beyond cholesterol lowering could also contribute to these alterations. In 
the present study, we showed that cholesterol lowering alone by dietary lipid withdrawal 
could not only decrease circulating monocytes, but also normalize the increased levels of 
Ly6Chigh monocytes in LDLr KO mice. Of note, these effects were mainly observed at 3 
weeks after the diet switch. Therefore, both early and advanced lesions continued to 
accumulate macrophages in the first week after dietary lipid lowering, probably as a result 
of monocyte recruitment from the circulation. Swirski et al demonstrated that apart from 
the bone marrow, spleen is another reservoir for a large number of monocytes [24]. These 
splenic monocytes can be recruited to inflammatory sites. Interestingly, reduced monocytes 
in the subcapsular red pulp of spleen was also observed after 1 week on chow (unpublished 
data), indicating that splenic monocytes might account for the increased macrophage 
accumulation in lesions within the first week after the diet switch. However, more 
experiments remain to be done to test this hypothesis. From 1 to 3 weeks after the diet 
switch, dietary lipid lowering reduced the macrophage content of both early and advanced 
lesions. Meanwhile, the size of macrophage foam cells and necrotic core was not 
significantly changed. Moreover, the rate of apoptosis was either very low in the early 
lesions or remain stable in the advanced lesions, we thus speculate that the reduction of 
macrophages is mainly the consequence of their emigration. Emigration of monocyte-
derived foam cells from atherosclerotic lesions and regression of established 
atherosclerotic lesions has been elegantly shown by transplantation of a region of the aorta 
with atherosclerotic lesions from hypercholesterolemic apoE KO mice to 
normocholesterolemic wildtype mice [25]. From 1 to 3 weeks after WTD withdrawal, the 
lesion size was not increased in early lesions and even reduced in advanced lesions, 
indicating that dietary lipid lowering can inhibit the progression and/or induce the 
regression of established lesions. However, despite the reduced Ly6Chigh monocytosis upon 
dietary lipid lowering, macrophage accumulation in the early lesions was enhanced again 
from 3 to 6 weeks after the diet switch. Interestingly, the macrophage area was highly 
correlated with the lesion size of early lesions but not of advanced lesions at this time point 
after WTD withdrawal. In agreement, using bone marrow transplantation we recently 
demonstrated that the growth of established early lesions under hypercholesterolemia is 
mainly caused by the continuous recruitment of monocyte-derived cells, while this process 
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is largely impaired in established advanced lesions [26]. Thus, inhibition of monocyte 
infiltration combined with lipid lowering might be a more efficient therapeutic strategy for 
the treatment of established early lesions than advanced lesions. 
Another important finding is that early and advanced lesions showed a different 
inflammatory phenotype after normalization of hypercholesterolemia. Early lesions 
became proinflammatory, as evidenced by a decreased ratio of collagen to necrotic core, an 
elevated neutrophil content, and increased oxidative stress, while advanced lesions became 
less inflammatory. Zernecke et al demonstrated that an expansion of circulating neutrophils 
leads to more neutrophil infiltration into lesions [27]. However, dietary lipid lowering did 
reduce the levels of circulating neutrophils. This thus cannot contribute to the increased 
neutrophil infiltration in the lesions upon dietary lipid lowering. Moreover, in line with 
previous study [28], the area of necrosis did not correlate with neutrophil accumulation. 
Actually, almost no neutrophil was found in close proximity of the necrotic core in the 
atherosclerotic lesion. Interestingly, quantification of inflammatory cells in the adventitia 
of early lesions revealed increased numbers of degranulated mast cells. Activation of mast 
cells not only recruits monocytes, neutrophils and other mast cells by secreting their 
respective chemoattractant MCP-1, KC and eotaxin [14, 29], but also promotes 
macrophage apoptosis, probably thereby leading to the augmented buildup of necrotic core 
material [30]. In line, the enhanced infiltration of monocytes and neutrophils into the 
lesions, the increased recruitment of mast cells into the adventitia, and a dramatic 
enlargement of necrotic core were observed upon progression of the early lesions after 
normalization of hypercholesterolemia. Increased macrophages and neutrophils in early 
lesions could generate more reactive oxygen species through NADPH oxidase and 
myeloperoxidase [31], thereby leading to the enhanced oxidative stress. Therefore, the 
proinflammatory phenotype of early lesions might be the consequence of mast cell 
activation in the adventitia. Importantly, Sun et al recently demonstrated that mast cells 
promote atherogenesis by promoting the secretion of the proinflammatory cytokine IL-6 
and IFN-γ [32]. Also, the activation of mast cells is involved in induction of rupture of 
advanced lesions [30]. Targeting mast cell activation might thus be a promising strategy 
for combination with lipid lowering therapies for treatment of established atherosclerotic 
lesions.  
We recognize the limitations of the current study. Dietary lipid lowering might not 
be as effective as the use of statins in the treatment of atheroclerosis, due to their many 
pleiotropic effects beyond their cholesterol lowering capacity [33]. Also mice have no 
cholesterol ester transport protein (CETP) while humans do [34]. Moreover, in contrast to 
humans, LDLr KO used in our study developed atherosclerosis at the aortic root and 
descending aorta rather than coronary artery. In addition, mice seldom show signs of 
myocardial infarction or stroke [35] as murine atherosclerotic lesions are not prone to 
plaque rupture. Therefore, it is clear that findings based on mouse models must be 
carefully evaluated in larger animal models and in humans. 
In summary, our study provides important insights into the dynamic remodeling of 
established atherosclerotic lesions upon dietary lipid lowering. Progression of established 
atherosclerotic lesions after dietary lipid lowering indicates that more effective therapeutic 
strategies are needed for the treatment of atherosclerosis. The dynamics of lesion 
remodeling upon dietary lipid lowering are complex and depend on the stage of 
atherosclerotic lesion development. Establishment of stage-specific therapeutic protocols 
might thus improve the eventual outcome. However, the requirement of stage-specific 
therapy for atherosclerosis calls for the development of better molecular imaging tools to 
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Supplementary Figure S1. Effect of dietary cholesterol lowering on lipoprotein distribution of total 
cholesterol (TC). LDLr-/- mice were fed WTD for 5 weeks to induce the lesion formation. Thereafter, the 
animals were switched to regular chow and euthanized at 0 (C), 1 (W1), 3 (W3), and 6 weeks after the diet 
switch. 30 μL aliquot of serum was fractionated by a Pharmacia Smart column and TC of each fraction was 
determined. Fractions 3 to 6 represent VLDL, fractions 8 to 12 represent LDL, and fractions 16 to 20 





Supplementary Figure S2. Effect of dietary cholesterol lowering on the cell apoptosis in the established 
lesions. LDLr-/- mice were fed WTD for 5 and 9 weeks to induce the lesion formation. Thereafter, the 
animals were switched to regular chow and euthanized at 0 (C), 1 (W1), 3 (W3), and 6 weeks after the diet 
switch. Apoptosis is expressed as the percentage TUNEL-positive to total nuclei in the atherosclerotic 
lesions. Values represent the mean±SEM of 8 mice. Statistically significant difference *P<0.05 and 









Supplementary Figure S3. Effect of dietary cholesterol lowering on oxidative stress in the established 
lesions. LDLr-/- mice were fed WTD for 5 and 9 weeks to induce the lesion formation. Thereafter, the 
animals were switched to regular chow and euthanized at 0 (C), 1 (W1), 3 (W3), and 6 weeks after the diet 
switch. Oxidative stress is expressed as the mount of nitrotyrosine and 8-hydroxy-2’-deoxyguanosine 
(oh8dG) in the atherosclerotic lesions. Values represent the mean±SEM of 5 mice. Statistically significant 




Supplementary Figure S4. Effect of 
dietary cholesterol lowering on the 
development of established lesions 
in the aortic arch. LDLr-/- mice were 
fed WTD for 9 weeks to induce the 
lesion formation. Thereafter, the 
animals were switched to regular chow 
and euthanized at 0 (C), 1 (W1), 3 
(W3), and 6 weeks after the diet 
switch. Mean lesion area (A) and 
macrophage (B), collagen (C) and 
necrotic core (D) content were 
quantified as mentioned in the 
materials and methods. Values 
represent the mean±SEM of 8 mice. 
Statistically significant difference 
*P<0.05, **P<0.01, and ***P<0.001 
versus group C; #P<0.05, ##P<0.01, 
and ###P<0.001 versus group W1; 
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Atherosclerosis is a progressive disease in which macrophages play an essential role. 
Macrophage infiltration into the arterial wall induces the development of an early 
atherosclerotic lesion. However, the dynamics of macrophage infiltration into the arterial 
wall during lesion progression remains poorly understood. 
In this study, low-density lipoprotein receptor knockout (LDLr−/−) mice were fed a 
Western-type diet (WTD) for 3, 6, 9, and 12 weeks to induce the formation of 
atherosclerotic lesions with different degrees of complexity. Subsequently, these mice were 
transplanted with bone marrow overexpressing enhanced green fluorescent protein (EGFP) 
to track donor-derived cells, including macrophages. After 8 weeks WTD feeding post-
transplant, macrophage infiltration was evaluated by immunohistochemical staining of 
donor-derived macrophages (EGFP+F4/80+) in the aortic roots. We found that the growth 
of pre-existing initial lesions was mainly caused by continued recruitment of donor-derived 
macrophages into the arterial wall. Interestingly, macrophage infiltration into pre-existing 
more advanced lesions was largely impaired, likely due to the formation of fibrous caps. In 
addition, interference with the expression of macrophage ATP-binding cassette transporter 
1 (ABCA1), an ABC-transporter involved in cellular cholesterol efflux and macrophage 
recruitment into tissues, affects the infiltration of macrophages into pre-existing early 
lesions, but not into advanced lesions. 
In conclusion, our data suggest that the dynamics of macrophage infiltration into the 
arterial wall varies greatly during atherogenesis, and thus may affect the efficiency of   











Atherosclerosis is a progressive disease characterized by the accumulation of lipid-laden 
macrophages and fibrous elements within the large arteries. Recent studies have suggested 
that atherosclerosis is a dynamic vascular disease, displaying both progression and 
regression of atherosclerotic lesions, as well as marked changes in composition that affect 
plaque stability [1]. Hypercholesterolemia, especially that resulting from high levels of 
very low-density lipoprotein and low-density lipoprotein cholesterol (VLDL/LDL-C), is 
one of the key risk factors in the development of atherosclerotic lesions [2]. However, 
hypercholesterolemic mice become resistant to atherosclerosis when bred to a macrophage-
deficient background [3], illustrating the crucial role of macrophages in promoting lesion 
initiation and progression. Macrophages are transformed into foam cells upon 
accumulation of (modified) lipoproteins, resulting in the formation of fatty streaks which 
represent the earliest detectable atherosclerotic lesions. Macrophages also play important 
roles in innate and acquired immune responses [4]. They mediate inflammatory response 
by secreting various cytokines, chemokines, and growth factors, thus encouraging the 
recruitment of other cell types (e.g., monocytes, T cells, fibroblasts, and smooth muscle 
cells) which promote atherogenesis. Moreover, macrophages produce a variety of matrix-
degrading proteases that can affect plaque stability by inducing weakening of the fibrous 
cap [5,6]. Thus, macrophages play essential roles in all stages of atherosclerotic lesion 
development. Although the critical role of macrophage infiltration in the initiation of 
atherosclerosis is generally accepted, the dynamics of macrophage infiltration into the 
arterial wall during atherosclerosis progression remains an open question.  
The accumulation of macrophages in atherosclerotic lesions primarily depends on 
the infiltration of bone marrow-derived monocytes into the arterial wall. In this study, to 
clarify the dynamics of macrophage infiltration into the arterial wall during atherogenesis, 
low-density lipoprotein receptor knockout (LDLr−/−) mice with pre-existing initial or more 
advanced atherosclerotic lesions were transplanted with bone marrow overexpressing 
enhanced green fluorescent protein (EGFP) to track donor-derived cells, including 
macrophages. We show that the ability of donor-derived macrophages to infiltrate into the 
arterial wall is influenced by the severity of the pre-existing lesions. This may have 
important implications for the design of pharmaceutical interventions aimed at targeting 
macrophage infiltration into the arterial wall. ATP-binding cassette transporter 1 
(ABCA1)-dependent cholesterol efflux is a crucial factor in prevention of excessive 
cholesterol accumulation in macrophages of the arterial wall and their transformation into 
foam cells [7-10]. Therefore, the concept that promotion of macrophage cholesterol efflux 
by up-regulating ABCA1 might prevent progression or even induce regression of 
atherosclerosis is remarkably attractive. Moreover, ABCA1 has also been implicated as a 
factor which is important for the recruitment of macrophages into tissues [9]. For the 
design of new therapeutic strategies aimed at up-regulating ABCA1, it is essential to 
quantify the effect of ABCA1 on macrophage infiltration into lesions. Hence, studies were 
performed in which LDLr−/− mice with pre-existing initial or advanced lesions were 
transplanted with ABCA1 knockout (KO) or ABCA1 overexpressing bone marrow, also 
co-expressing EGFP. We find that overexpression of ABCA1 decreases macrophage 
recruitment specifically into early lesions, resulting in reduced lesion sizes. Our data 
suggest that preventing macrophage recruitment into very early lesions provides a 
therapeutic strategy to reduce atherosclerosis burden. Increasing macrophage ABCA1 may 








C57BL/6 mice that express a transgene coding for enhanced green fluorescent protein (EGFP) under 
control of the human ubiquitin C promoter were obtained from the Jackson Laboratory (Bar Harbor, 
ME, USA). These mice, called UBC-EGFP/BL6, express GFP in all tissues examined, with high levels 
of GFP expression observed in hematopoietic cells (henceforth called EGFP/WT) [11]. Mice 
homozygous for the null mutant ABCA1 gene and expressing EGFP (henceforth called EGFP/ABCA1 
KO), and mice overexpressing human ABCA1 bacterial artificial chromosome (BAC) and EGFP 
(henceforth called EGFP/hABCA1) were generated by crossbreeding. All the transgenic mice are on the 
C57BL/6J background. Homozygous LDLr−/− mice (C57BL/6 background) were purchased from the 
Jackson Laboratory (Bar Harbor, ME, USA) as mating pairs and bred at the Gorlaeus Laboratory, 
Leiden, The Netherlands. Mice were maintained on regular chow (4.3 % w/w fat and no added 
cholesterol; RM3, Special Diet Services, Witham, UK) until the beginning of the study (8 - 10 weeks of 
age), at which time LDLr−/− mice were fed a Western-type diet (WTD) (15% w/w cacao butter and 
0.25% w/w cholesterol; Diet W, Ab diets, Woerden, The Netherlands) to induce hypercholesterolemia 
and atherosclerosis. Animal experiments were performed at the Gorlaeus laboratory in accordance with 
National Laws. All experimental protocols were approved by the Ethics Committee for Animal 
Experiments of Leiden University. 
 
Generation of chimeras by bone marrow transplantation (BMT) 
To induce bone marrow aplasia, female LDLr−/−  mice without or with pre-existing atherosclerotic 
lesions were exposed to a single dose of 9 Gy (0.19 Gy/min, 200 kV, 4 mA), using an Andrex Smart 
225 Röntgen source (YXLON International, Copenhagen, Denmark) with a 6-mm aluminium filter 1 
day before BMT. Bone marrow was harvested by flushing the femurs and tibias from the donor mice 
with phosphate-buffered saline (PBS). Single-cell suspensions were prepared by passing the cells 
through a 30-μm nylon gauze. Irradiated recipients received 0.5 x 107 bone marrow cells by intravenous 
injection into the tail vein. Drinking water was supplied with antibiotics (83 mg/L ciprofloxacin and 67 
mg/L polymyxin B sulfate) and 6.5 g/L sucrose.  
 
Flow cytometry 
In order to determine the extent of repopulation of circulating blood cells with donor cells post-
transplant, whole blood was collected each week after BMT. Blood cell suspension in PBS was 
subjected to flow cytometric analysis (FACS) to detect EGFP fluorescence. 
 8 weeks after BMT, transplanted mice were euthanized and the spleen and intestinal lymph 
nodes were harvested. Single-cell suspensions were prepared by passing the spleen and lymph nodes 
through a 30-µm nylon gauze. Leukocytes from the spleen were isolated by density gradient 
centrifugation with Lympholyte (Cedarlane Laboratories, Hornby, Ontario, Canada) according to 
manufacturer’s protocol. Cell suspensions from the spleen and lymph nodes were incubated with 1% 
normal mouse serum in PBS and stained for surface markers (0.5 µg Ab/300 000 cells). All antibodies 
were purchased from eBiosciences (Belgium). Samples were analyzed by flow cytometry. All data was 
acquired on a FACSCalibur and was analyzed with CELLQuest software (BD Biosciences). 
 
Serum lipid analyses 
After an overnight fast, ≈100 µL of blood was drawn from each mouse by tail bleeding. Serum levels of 
total cholesterol (TC), free cholesterol (FC), and esterified cholesterol (CE) were determined using 
enzymatic colorimetric assays (Roche Diagnostics, Mannheim, Germany), with 0.03 U/ml cholesterol 
oxidase (Sigma Chemical Co., USA), 0.065 U/ml peroxidase, and 15 μg/ml cholesteryl esterase 
(Seikagaku, Tokyo, Japan) in reaction buffer (1.0 KPi buffer, pH=7.7 containing 0.01 M phenol, 1 mM 
4-amino-antipyrine, 1% polyoxyethylene-9-laurylether, and 7.5% methanol). The concentrations of 
phospholipids (PL) and triglycerides (TG) in serum were determined using enzymatic colorimetric 
assays (Spinreact S.A. and Roche Diagnostics, respectively). Precipath I (Roche Diagnostics) was used 
as an internal standard. Absorbance was read at 490 nm. The distribution of lipids over the different 




(3.2x300mm, Smart-system, Pharmacia, Uppsala, Sweden). TC, TG, and PL contents in the effluent 
were determined as described above. 
 
Histological and immunocytochemical analysis of the aortic root 
To analyze atherosclerosis development, transplanted mice were euthanized, hearts and aortas were 
perfused in situ with PBS for 20 to 30 minutes via a cannula in the left ventricle, and subsequently 
stored in 3.7% neutral-buffered formalin (Formal-Fixx, Shandon Scientific Ltd, UK). Cryostat sections 
of the aortic root (10 μm) were collected and stained with Oil-Red-O/hematoxylin (Sigma Diagnostics, 
St. Louis, MO). Mean lesion area (in μm2) was calculated from 10 consecutive sections, starting at the 
appearance of the tricuspid valves. Moreover, sections on separate slides were stained with a primary 
monoclonal antibody to MOMA-2 (Rat anti-mouse IgG2b, dilution 1:50; Research diagnostics), and a 
secondary antibody conjugated to alkaline phosphates (Goat anti-rat IgG-AP, dilution 1:200; Sigma). 
MOMA-2 is a useful marker for broad detection of monocytes and macrophages. BCIP/NBT (Sigma) 
was used as enzyme substrates. In addition, sections were immunolabeled with a primary monoclonal 
antibody to F4/80 (Rat anti-mouse, dilution 1:200; BMA Biomedicals) for detection of mature 
macrophages, and a peroxidase-conjugated secondary antibody (Jackson ImmunoResearch 
Laboratories, Suffolk, UK). Masson trichrome staining (Sigma Diagnostics, St Louis, Mo) was used to 
visualize collagen (blue staining). The macrophage and collagen contents of lesions were subsequently 
calculated as the percentage of mean positive area versus mean total lesion area using 5 consecutive 
sections per mouse by computer-aided morphometric analysis. A histological classification of 
atherosclerotic lesions in the aortic root was performed on Oil-Red-O/hematoxylin and Masson's 
Trichrome stained sections according to the recommendations of the American Heart Association [12]. 
Images were obtained with a Leica image analysis system, consisting of a Leica DMRE microscope 
coupled to a camera and Leica Qwin Imaging software (Leica Ltd., Cambridge, UK).  
 To track donor-derived macrophages, cryostat sections of the aortic root were double-
immunolabeled with the primary monoclonal antibodies, rat anti-mouse F4/80 for detection of 
macrophages, and goat anti-mouse JL-8 (CLONTECH Laboratories, Inc., Palo Alto, CA; dilution 
1:2000) for detection of EGFP. Secondary antibodies were conjugated to Cy3 and FITC (Jackson 
ImmunoResearch Laboratories, Suffolk, UK), respectively. Nuclei were stained with 4,6-diamidino-2-
phenylindole (DAPI) (Serva Feinbiochemica, Heidelberg, Germany). Photomicrographs were taken 
using a Bio-Rad Radiance 2100 MP confocal laser scanning system equipped with a Nikon Eclipse 
TE2000-U inverted fluorescence microscope (Melville, NY). The acquisition of images and analysis of 
lesions were performed in a blinded fashion.  
 
Hepatic lipid composition and liver histology/immunohistology 
Hepatic lipids were extracted according to Bligh and Dyer [13]. After dissolving the lipids in 2% Triton 
X-100, contents of FC, CE, PL, and TG in liver tissue were determined as described above and 
expressed as micrograms per milligram (µg/mg) of protein.  
Cryostat sections of the liver (8 μm) were collected and routinely stained with Oil-Red-
O/hematoxylin (Sigma Diagnostics, St. Louis, MO) for lipid visualization. In addition, to investigate the 
replacement of Kupffer cells post-transplant, liver sections were also double-immunolabeled to detect 
macrophages and EGFP as described above.  
 
Statistical Analyses 
Data were presented as means±SEM. Statistical analyses were performed using one- and two-way 
ANOVA using Graphpad Prism Software (Graphpad Software, Inc.; http://www.graphpad.com). The 
level of statistical significance was set at p<0.05. 
 
Results  
Generation of LDLr−/− mice with pre-existing atherosclerotic lesions by WTD feeding 
To induce the development of atherosclerotic lesions with different degrees of complexity, 
LDLr−/− mice were maintained on regular chow diet or fed a Western-type diet (WTD) for 
3, 6, 9, and 12 weeks. On chow, the majority of serum cholesterol in LDLr−/− mice is 
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transported by LDL and HDL (data not shown). Serum TC was increased by ~2-fold 
(p<0.01) and ~5-fold (p<0.001) after 3 and 6 weeks WTD feeding, respectively, and the 
increases in TC were primarily due to in the VLDL/LDL-C fractions (data not shown). As 
shown in Table 1, serum levels of FC and CE were induced by 3 and 6 weeks WTD 
feeding. No further increases in serum FC and CE were observed after 9 and 12 weeks 
WTD feeding, indicating that a steady-state serum cholesterol level was reached after 6 
weeks WTD feeding. Serum levels of PL, but not TG, were also induced by WTD feeding 
(Table 1). The elevated PL levels were primarily due to increases in the VLDL/LDL 
fractions (data not shown).  
 
Table 1: Effect of WTD feeding on serum and hepatic lipids in LDLr−/− mice  









1 0 6      78±4    338±18    497±18 143±13 
2 3 6 221±14*    732±11**    687±13* 154±19 
3 6 6   362±25*** 1712±74***  985±45** 164±38 
4 9 6 216±36* 1643±58*** 1023±64** 147±29 












1 0 6      16±1       8±2 70±4 156±6 
2 3 6 21±2*     32±5** 74±3 134±9 
3 6 6  28±2**     47±3** 77±4 130±7 
4 9 6      36±2***, #    60±7***, #  83±8* 114±5 
5 12 6      39±1***, #    68±3***, # 81±6 113±7 
Serum levels of free cholesterol (FC), cholesterol ester (CE), phospholipids (PL), and triglycerides (TG) were 
determined in LDLr−/− mice fed on regular chow diet (baseline, group 1) or a high-cholesterol Western-type 
diet (WTD) for 3, 6, 9, and 12 weeks (group 2-5). Moreover, hepatic lipids were extracted from these WTD-
fed LDLr-/- mice, and hepatic levels of FC, CE, PL, and TG were determined. Data represent mean±SEM of 6 
mice per group. Statistically significant differences *p<0.05, **p<0.01, ***p<0.001 vs. LDLr−/− mice on chow 
(group 1); #p<0.05 vs. LDLr−/− mice on WTD for 6 weeks (group 3).  
The liver of WTD-fed LDLr−/− mice displayed massive accumulation of lipids, as 
examined by Oil-red-O staining (data not shown) and hepatic lipid composition analysis 
(Table 1). Of note, LDLr−/− mice which had been challenged with WTD for a longer 
period (i.e., 9 and 12 weeks WTD fed mice) displayed higher levels of intrahepatic 
cholesterol, mainly FC and CE. 
Next, atherosclerotic lesion development was analyzed in the aortic root of LDLr−/− 
mice at different time points after initiation of the WTD challenge. No atherosclerotic 
lesions were found in LDLr−/− mice on chow. After 3 week WTD feeding, small initial 
lesions (31±7x103 µm2, n=6) were formed, primarily composed of macrophage-derived 
foam cells. The lesion size increased further after 6, 9, and 12 weeks WTD feeding 
(190±43x103 µm2, n=6, 505±51x103 µm2, n=6, and 600±11x103 µm2, n=6, respectively) 
(Fig. 1). Based on the lesion composition, plaques were classified as fatty streak lesions 
(58±4.2% for the macrophage content, and 5±1.4% for the collagen content), more 
advanced lesions (24±3.1% for the macrophage content, and 16±2.0% for the collagen 
content), and advanced fibroatheroma lesions (22±2.5% for the macrophage content, and 






Fig. 1: Western-type diet induces atherosclerosis development in LDLr−/− mice. A: Atherosclerotic 
lesion development was analyzed in the aortic root of LDLr−/− mice after 0, 3, 6, 9, and 12 weeks WTD 
feeding. Representative images for Oil-Red-O, MOMA-2 (monocytes and macrophages), F4/80 
(macrophages), and Masson trichrome (collagen) staining. Original magnification 50x. B: The mean 
lesion area was calculated from Oil-Red-O/hematoxylin-stained cross-sections of the aortic root at the 
level of the tricuspid valves. The macrophage and collagen contents of the lesions were quantified in 5 
consecutive sections. Values represent the mean of 6 mice per group. *p<0.05, **p<0.01 and 
***p<0.001 vs. on chow. 
 
Generation of LDLr−/− mice with pre-existing atherosclerotic lesions and over-
expressing EGFP in macrophages 
To assess the dynamics of macrophage infiltration into the arterial wall during 
atherosclerosis development, we performed a BMT where bone marrow from EGFP/WT 
mice was transplanted into LDLr−/− mice that had been fed WTD for 0, 3, 6, 9, and 12 
weeks prior to BMT (EGFP/WT → LDLr−/−). The transplanted animals were sacrificed 
after 8, 11, 14, 17, and 20 weeks WTD feeding in total (i.e., 8 weeks WTD feeding after 
BMT) (Fig. 2A). To exclude potential direct effects of irradiation on plaque morphology, 
we have compared initial lesions and advanced lesions in LDL receptor knockout mice 
before irradiation and 3 days after irradiation. Neither lesion size nor lesion composition 
was significantly changed as a result of the irradiation (data not shown).  
Regardless of the duration of WTD feeding prior to BMT, circulating whole blood 
cells were quantitatively replaced by donor-derived cells (EGFP-positive, EGFP+), starting 
at 6 days after BMT, and reaching a level of 99±0.2% at 8 weeks post-transplant (see 
Supplemental Fig. S1). This indicated that the bone marrow transfers were successful. 
Independently of the duration of WTD feeding prior to transplantation, BMT 
resulted in a temporary decrease in serum TC levels (22~35%), primarily due to 
significantly reduced VLDL/LDL-C levels, as well as moderately decreased HDL-C levels 
(data not shown). Of note, this effect is specific for mice on WTD, as it was not observed 
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in mice that had been transplanted while being fed regular chow diet in our previous 
studies [9,10]. Nevertheless, the new steady-state serum cholesterol levels were still 
adequately high to induce further progression of the pre-existing atherosclerotic lesions. At 
the time of sacrifice EGFP/WT → LDLr−/− mice without established lesions (i.e., 0+8 
weeks WTD fed mice) and the transplanted mice with pre-existing initial lesions (i.e., 3+8 
or 6+8 weeks WTD fed mice) had similar serum levels of FC and CE. However, the 
transplanted mice with pre-existing more advanced lesions (i.e., 9+8 or 12+8 weeks WTD 
fed mice) displayed significantly (p<0.05) higher levels of serum CE, but not FC (Table 2). 
PL and TG levels were similar in all groups, except for the transplanted group which had 
been fed WTD for 6 weeks prior to BMT (i.e., 6+8 weeks WTD fed mice), showing 
slightly lower PL and TG levels.  
Table 2: Serum lipid levels in the transplanted LDLr−/− mice with pre-existing 












1 0+8 10 653±9 870±30 702±39 326±58 
2 3+8 10 625±9 913±14 642±31 270±49 
3 6+8 10   658±14 1056±51    529±31
**  144±7** 
4 9+8 10   671±17 1264±74* 614±33 193±25 
5 12+8 10   680±18 1303±68* 620±30 193±29 
Prior to BMT, LDLr−/− mice had been fed a high-cholesterol Western-type diet (WTD) for 0, 3, 6, 9, and 12 
weeks. Serum levels of free cholesterol (FC), cholesterol ester (CE), phospholipids (PL), and triglycerides 
(TG) were determined in the transplanted LDLr-/- mice after 8, 11, 14, 17, and 20 weeks WTD feeding in 
total, that is, 8 weeks WTD feeding after BMT. Data represent mean±SEM of 10 mice per group. Statistically 
significant differences *P<0.05, **P<0.01 vs. transplanted LDLr−/− mice without pre-existing lesions (group 
1).  
 
Macrophage infiltration into pre-existing atherosclerotic lesions with different 
degrees of complexity 
Next, atherosclerotic lesion development was analyzed in the aortic root of EGFP/WT → 
LDLr−/− mice after 8, 11, 14, 17, and 20 weeks WTD feeding in total (i.e., 8 weeks WTD 
feeding after BMT) (Fig. 2B and 2C). In the transplanted mice without pre-existing lesions 
(i.e., 0+8 weeks WTD fed mice), fatty streak lesions were formed (304±20x103 µm2, n=10), 
mostly composed of macrophage-derived foam cells and no fibrous cap. In the transplanted 
mice which had been fed WTD for 3 and 6 weeks prior to BMT, pre-existing initial lesions 
had formed before transplantation (31±7x103 µm2, n=4 and 190±43x103, n=4, respectively), 
and they progressed into larger sized lesions (336±34x103 µm2, n=10 and 480±68x103 
µm2, n=10) at 8 weeks after BMT (i.e., 3+8 and 6+8 weeks WTD feeding, respectively). 
Moreover, in the transplanted mice which had been fed WTD for 9 and 12 weeks prior to 
BMT, pre-existing more advanced lesions had formed (505±51x103 µm2, n=4 and 
600±11x103 µm2, n=4, respectively), characterized by a low macrophage content, an 
increased collagen content, and fibrous cap formation. These pre-existing more advanced 
lesions increased only slightly in size (696±46x103 µm2, n=10 and 720±82x103 µm2, n=10, 
respectively) at 8 weeks after BMT (i.e., 9+8 and 12+8 weeks WTD feeding, respectively). 
Immunohistochemical staining was performed to distinguish between the pre-existing 
lesions (EGFP-negative, EGFP–) and the newly formed lesions (EGFP-positive, EGFP+). 




WTD fed mice), the aortic lesions were exclusively composed of donor-derived EGFP 
expressing cells, which were primarily F4/80+ macrophages  (Fig. 2B-1). In contrast, in 
 
Fig. 2: Generation of LDLr−/− mice with pre-existing atherosclerotic lesions and overexpressing 
EGFP in macrophages. A: The experimental setup is demonstrated. Bone marrow from EGFP/WT 
donors was transplanted into LDLr−/− mice that had been fed WTD for 0, 3, 6, 9, and 12 weeks prior to 
BMT (EGFP/WT → LDLr−/−). The transplanted animals were sacrificed after 8, 11, 14, 17, and 20 
weeks WTD feeding in total (i.e., 8 weeks WTD feeding after BMT). Subsequently, the pre-existing and 
newly formed atherosclerotic lesions were analyzed. B: Representative images for Oil-Red-O staining 
of the atherosclerotic lesions with freshly infiltrated donor-derived macrophages showing massive lipid 
accumulation (black arrows). Corresponding merged photomicrographs of EGFP (green), F4/80 (red) 
for macrophages, and DAPI for nuclei (blue) in the aortic root lesions. Co-localization of macrophages 
with EGFP fluorescence is yellow-green (white arrows). A fibrous cap (yellow arrow) was clearly 
observed in pre-existing advanced fibroatheroma lesions, and almost no donor-derived macrophages 
were detected within these lesions. Original magnification 200x. C: The mean lesion area was 
calculated from Oil-Red-O/hematoxylin-stained cross-sections of the aortic root of EGFP-WT → 
LDLr−/− mice at the level of the tricuspid valves. The influx of donor-derived cells and donor-derived 
macrophages was evaluated by quantifying the total EGFP+ and EGFP+F4/80+ areas in the aortic root of 
EGFP-WT → LDLr−/− mice, respectively. Values represent the mean of 10 mice per group. *p<0.05 and 
**p<0.01 vs. transplanted mice without pre-existing lesions (i.e., 0+8 weeks WTD fed mice). #p<0.05 
vs the indicated group. N.S. = non-significant.  
 
EGFP/WT → LDLr−/− mice with pre-existing initial lesions (i.e., 6+8 weeks WTD fed 
mice), the fatty streak lesions had grown partly by forming a new layer of EGFP+F4/80+ 
donor-derived macrophages above the pre-existing EGFP– lesions. Furthermore, a few 
donor-derived macrophages had infiltrated inside the pre-existing initial lesions (Fig. 2B-
2). Interestingly, in EGFP/WT → LDLr−/− mice with pre-existing more advanced lesions 
(i.e., 9+8 weeks WTD fed mice), influx of donor-derived cells, including F4/80+ 
macrophages, into the arterial wall was largely blocked, as only a very thin layer of newly 
infiltrated cells had accumulated on top of the fibrous cap of the established complex 
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lesions (Fig. 2B-3). Furthermore, almost no donor-derived cells were detected within the 
pre-existing advanced fibroatheroma lesions (i.e., 12+8 weeks WTD fed mice) (Fig. 2B-4). 
By quantifying the EGFP+F4/80+ areas, we did not find a significant difference in the 
influx of donor-derived macrophages into the arterial wall of the transplanted mice without 
pre-existing lesions (i.e., 0+8 weeks WTD fed mice) as compared to those with pre-
existing initial lesions (i.e., 3+8 or 6+8 weeks WTD fed mice) (Fig. 2C). In total 78±22% 
of the infiltrated EGFP+ cells were F4/80+ macrophages. The remainder percentage will 
include F4/80-negative macrophages, as well as dendritic cell, T cells, neutrophils, and 
mast cells. Interestingly, significantly (p<0.05) lower influx of donor-derived macrophages 
into the arterial wall was observed in the transplanted mice with pre-existing more 
advanced lesions (i.e., 9+8 or 12+8 weeks WTD fed mice). Under these conditions, the 
percentage of EGFP+ cells that also expressed F4/80 had decreased to 55±7% and 52±24 of 
the total amount of EGFP+ cells, respectively. These results suggest that the dynamics of 
cellular infiltration and more specific macrophage infiltration into the arterial wall is 
largely impaired in more advanced atherosclerotic lesions. 
 
Replacement of liver, spleen and lymph node resident macrophages in transplanted 
LDLr−/− mice  
The liver contains the most abundant macrophage population in the body. At 8 weeks after 
BMT, a large amount of the F4/80-positive (F4/80+) resident macrophages in the liver, 
Kupffer cells, expressed EGFP, and were thus of donor-origin (Fig. 3). Calculation of the 
 
Fig. 3: Replacement of Kupffer cells in the liver of transplanted LDLr−/− mice with pre-existing 
atherosclerotic lesions with different degrees of complexity. Representative merged 
photomicrographs of EGFP (green), F4/80 (red) for Kupffer cells (hepatic resident macrophages), and 
DAPI for nuclei (blue) in the liver of EGFP-WT → LDLr−/− mice. Co-localization of Kupffer cells with 
EGFP fluorescence (thus of donor-origin) is yellow-green (white arrows). Kupffer cells without EGFP 
fluorescence (thus of recipient-origin) are red (yellow arrows). Original magnification 400x. The 
density of F4/80+ and EGFP+F4/80+ cells was calculated as the number of stained cells per 25000 μm2 in 
the liver of EGFP-WT → LDLr−/− mice. Regions of interest were selected blindly using DAPI staining 
as a reference. Values represent the average from at least 5 adjacent sections. We further determined the 
ratio EGFP+F4/80+cells/F4/80+cells, indicative for the replacement of Kupffer cells. Values represent 
the mean of 10 mice per group. *p<0.05 vs. transplanted mice without pre-existing lesions (i.e., 0+8 




ratio EGFP+F4/80+cells/F4/80+cells, indicative for the replacement of Kupffer cells, 
showed that >50% of the Kupffer cells were replaced. Interestingly, significantly (p<0.05) 
higher replacement of Kupffer cells was observed in the liver of EGFP-WT → LDLr−/− 
mice with pre-existing more advanced lesions (i.e., 9+8 or 12+8 weeks WTD fed mice) 
than those without pre-existing lesions (i.e., 0+8 weeks WTD fed mice) or with pre-
existing initial lesions (i.e., 3+8 or 6+8 weeks WTD fed mice).  
In addition, higher replacement of resident macrophages in the spleen and lymph 
nodes was found in the transplanted mice with pre-existing more advanced lesions than 
those without pre-existing lesions or with pre-existing initial lesions, as determined by 
FACS analysis (see Supplemental Fig. S2). Thus, the observed impaired infiltration of 
macrophages into more advanced atherosclerotic lesions is not a consequence of a 
generally impaired macrophage infiltration into tissues. Actually, macrophage infiltration 
into other organs was increased, probably as a result of an enhanced inflammatory status in 
those transplanted animals with pre-existing more advanced lesions. 
 
The effect of macrophage ABCA1 expression on the development of pre-existing 
atherosclerotic lesions in LDLr−/− mice 
Previously, we demonstrated a protective role for macrophage ABCA1 in atherosclerosis 
development in LDLr−/− mice without pre-existing lesions [9,10], and disruption of 
ABCA1 in hematopoietic cells resulted in enhanced recruitment of macrophages into 
multiple tissues (e.g. the liver and spleen) [9]. To reveal the effect of ABCA1 expression 
on the infiltration of macrophages into pre-existing atherosclerotic lesions, bone marrow 
from EGFP/ABCA1 KO, EGFP/hABCA1, and EGFP/WT mice was transplanted into 
LDLr−/− mice that had been fed WTD for 6 and 9 weeks prior to BMT (EGFP/ABCA1 KO 
→ LDLr−/−, EGFP/hABCA1 → LDLr–/–, and EGFP/WT → LDLr–/–), and subsequently 
challenged for another 15 and 12 weeks with WTD, respectively (Fig. 4A).  
Successful reconstitution of recipients with donor-derived cells was established at 
12 or 15 weeks after BMT. Genomic DNA isolated from the EGFP/ABCA1 KO → 
LDLr−/−, EGFP/hABCA1 → LDLr–/–, and EGFP/WT → LDLr–/– mice contained the 
ABCA1 null mutant, the human ABCA1, and only the murine ABCA1 gene, respectively 
(see Supplemental Fig. S3). Independently of the presence of pre-existing lesions, 
macrophage ABCA1 expression did not significantly affect serum HDL-C levels (data not 
shown), which is in line with our previous findings [9,10].  
Atherosclerotic lesion development was analyzed in the aortic root of EGFP/WT → 
LDLr–/–, EGFP/hABCA1 → LDLr–/–, and EGFP/ABCA1 KO → LDLr−/− mice after 21 
weeks WTD feeding in total (i.e., 15 and 12 weeks WTD feeding after BMT). As shown in 
Fig. 4B, macrophage ABCA1 deficiency did not significantly affect the development of 
pre-existing initial lesions (mean lesion areas: 803±113x103 µm2, n=12 and 758±86x103 
µm2, n=12 for EGFP/ABCA1 KO → LDLr−/− mice and EGFP/WT → LDLr–/– controls, 
respectively, P=0.13), while macrophage ABCA1 overexpression moderately (p=0.05) 
inhibited the progression of pre-existing initial lesions (mean lesion area: 631±42x103 µm2, 
n=8 for EGFP/hABCA1 → LDLr–/– mice). On pre-existing advanced lesions, no effect of 
deletion or overexpression of macrophage ABCA1 was observed (mean lesion areas: 
783±42x103 µm2, n=12, 807±63x103 µm2, n=8, and 742±60x103 µm2, n=10 for 
EGFP/ABCA1 KO → LDLr−/− mice, EGFP/hABCA1 → LDLr–/– mice, and EGFP/WT → 
LDLr–/– controls, respectively). 
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By quantifying the EGFP+F4/80+ areas in the lesions, we observed that influx of 
ABCA1 deficient macrophages into the pre-existing initial lesions was not significantly 
 
Figure 4: The effect of macrophage ABCA1 expression on the development of pre-existing 
atherosclerotic lesions in LDLr−/− mice. A: The experimental setup is demonstrated. Bone marrow 
from EGFP/ABCA1 KO, EGFP/hABCA1, and EGFP/WT mice was transplanted into LDLr−/− mice that 
had been fed WTD for 6 and 9 weeks prior to BMT (EGFP/ABCA1 KO → LDLr−/−, EGFP/hABCA1 
→ LDLr–/–, and EGFP/WT → LDLr–/–), and subsequently challenged for another 15 and 12 weeks with 
WTD, respectively. B: The mean lesion area was calculated from Oil-Red-O/hematoxylin-stained cross-
sections of the aortic root of transplanted mice with pre-existing initial lesions or with pre-existing more 
advanced lesions. C: The influx of donor-derived cells and macrophages was evaluated by quantifying 
the total EGFP+ and EGFP+F4/80+ areas in the aortic root of transplanted animals. Values represent the 
mean of 8-12 mice per group. *p<0.05 vs. EGFP/WT transplanted mice. N.S. = non-significant. 
 
changed (mean EGFP+F4/80+ areas: 468±107x103 µm2, n=12 and 389±44x103 µm2, n=12 
for EGFP/ABCA1 KO → LDLr–/– mice and EGFP/WT → LDLr–/– controls, respectively), 
while influx of ABCA1 overexpressing macrophages into the pre-existing initial lesions 
was significantly (p<0.05) impaired (mean EGFP+F4/80+ area: 291±28x103 µm2, n=8 for 
EGFP/hABCA1 → LDLr–/– mice) (Fig. 4C). Independent of the type of donor bone 
marrow used, EGFP+F4/80+ cells comprised ~75% of the total amount of EGFP+ infiltrated 
cells. As expected, the infiltration of bone marrow-derived macrophages into the pre-
existing more advanced lesions was substantially lower than that into the pre-existing 
initial lesions. Importantly, the influx of donor-derived macrophages into the established 
more advanced lesions was not affected by macrophage ABCA1 expression (mean 
EGFP+F4/80+ areas: 161±28x103 µm2, n=12 and 165±29x103 µm2, n=8, and 137±54x103 




EGFP/WT → LDLr–/– controls, respectively). Moreover, total amount of EGFP+ cells that 
had infiltrated the lesions was not affected. 
 
Discussion 
In this study, bone marrow transplantation was utilized to investigate the dynamics of 
macrophage infiltration into the arterial wall during the pathogenesis of atherosclerosis. By 
tracking donor-derived macrophages (EGFP+F4/80+), we demonstrate that (1) the growth 
of pre-existing early lesions is mainly caused by continued infiltration of macrophages into 
the arterial wall, (2) macrophage infiltration into pre-existing more advanced lesions is 
largely impaired, most likely due to the formation of a fibrous cap, and (3) macrophage 
ABCA1 expression affects the infiltration of macrophage into pre-existing early lesions, 
but not into more advanced lesions.  
After transplantation, pre-existing fatty streak lesions largely increased in size, 
which was mainly caused by continued infiltration of donor-derived macrophages into the 
arterial wall. Moreover, we found that influx of ABCA1 overexpressing macrophages into 
the pre-existing fatty streak lesions was significantly impaired. ABCA1-mediated 
cholesterol efflux is a key factor to prevent the accumulation of macrophage foam cells in 
the arterial wall. In addition, ABCA1 modulates cholesterol content both on the cell 
surface and within intracellular compartments, and thereby impacts macrophage function 
via influencing cellular inflammatory cytokine secretion [14-18]. However, it was also 
suggested that not all of the anti-inflammatory properties of ABCA1 are a consequence of 
its lipid transport activity. ABCA1 interacts with its acceptor (i.e., apoAI its mimetic 
peptides), and activates signaling molecules (i.e., Janis kinase 2) [19-22]. Macrophage 
ABCA1 thus exerts multiple anti-atherogenic functions, which may explain the inhibitory 
effect of ABCA1 overexpression on the infiltration of macrophages into pre-existing fatty 
streak lesions, resulting in reduced lesion size. These findings suggest that preventing 
macrophage recruitment into early stages of lesion development provides a promising 
therapeutic strategy to reduce atherosclerosis burden, and increasing macrophage ABCA1 
expression may be one avenue of doing so. Surprisingly, no significant effect of ABCA1 
deficiency was observed on macrophage recruitment into pre-existing early lesions. Bone 
marrow transplantation has been shown to affect atherosclerotic lesion development [23]. 
Therefore, the lack of an effect of macrophage ABCA1 knock out on lesion progression 
and macrophage infiltration may be due to BMT-dependent effects on lesion progression. 
Pre-existing more advanced lesions increased only slightly in size after 
transplantation, and the infiltration of donor-derived macrophages into these lesions was 
largely impaired. In mice with pre-existing advanced lesions, we did observe a 
significantly higher replacement of tissue macrophages, as compared to mice without pre-
existing lesions or with pre-existing early lesions. Wouters et al. demonstrated that dietary 
cholesterol can provoke hepatic inflammation in hyperlipidemic mice, possibly due to the 
direct activation of Kupffer cells upon scavenging remnant lipoproteins [24]. Recently, the 
effect of dietary cholesterol on hepatic inflammation was further elucidated by the same 
group, and it was suggested that intrahepatic cholesterol influences progression, inhibition 
and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice [25]. In this study, we 
found that LDLr−/− mice with pre-existing more advanced lesions displayed higher levels 
of intrahepatic cholesterol, which may trigger an inflammatory response in the liver of 
these animals. Our findings also indicate that the impaired influx of macrophages into 
atherosclerotic lesions of mice with pre-existing more advanced lesions is not the 
consequence of a reduced capacity of macrophage to infiltrate into tissues under these 
conditions. Lesion progression coincides with the formation of a fibrous cap, which is 
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essential for the stability of the plaque. Currently, it is most likely that the formation of 
fibrous caps in pre-existing advanced lesions directly prevents further influx of 
macrophages into the arterial wall. Importantly, our results indicate that therapeutic 
modulation of macrophage infiltration would not be expected to have beneficial effects on 
more advanced lesions. In line, we show that neither disruption nor up-regulation of 
macrophage ABCA1 expression significantly influences the development of 
atherosclerotic lesion in mice with pre-existing more advanced lesions.  
In conclusion, we have established a new model for studying the dynamic changes 
in lesion development using the technique of bone marrow transplantation. It must be 
noted that the bone marrow transplantation procedure, and in particular the irradiation 
required to eliminate the endogenous bone marrow cells, might impact on the atherogenic 
process. However, using this model we for the first time have been able to show that the 
dynamics of macrophage infiltration into the arterial wall largely differs during 
atherosclerotic lesion development. This may affect the efficiency of pharmaceutical 
interventions aimed at targeting macrophage infiltration into the arterial wall. 
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Fig. S1: Verification of success of bone 
marrow transplantation. The appearance 
of donor-derived EGFP-expressing blood 
cells in the circulation was determined by 
FACS analysis at different time points after 
transplantation. 
 




Fig. S2: Replacement of spleen and lymph node resident macrophages in transplanted LDLr−/− 
mice. At 8 weeks post-transplant, the proportion of EGFP labeled cells that were immunoreactive for 
F4/80 (i.e., the percentage of EGFP+F4/80+cells from F4/80+cells) in the spleen and intestinal lymph 
node of EGFP-WT → LDLr−/− mice with pre-existing lesions was determined by FACS analysis. 
Values represent the mean of 10 mice per group. Data are presented as mean±SEM. *p<0.05 vs. 








Fig. S3: Verification of success of bone marrow transplantation. The hematologic chimerism of the 
transplanted LDLr−/− mice was determined using genomic DNA from bone marrow by polymerase 
chain reaction (PCR) at 12 or 15 weeks post-transplant. The forward and reverse primers 5'-
TTTCTCATAGGGTTGGTCA-3' and 5'-TGCAATCCATCTTGTTCAAT-3' for the null mutant 
ABCA1, 5'-TGGGAACTCCTGCTAAAAT-3' and 5'-CCATGTGGTGTGTAGACA-3' for the wild-
type gene, and the forward and reverse primers 5’-GGCTGGATTAGCAGTCCTCA-3’ and 5’-
ATCCCCAACTCAAAACCACA-3’ for the human ABCA1 were used. A: Amplification of the 
ABCA1 null mutant gene resulted in a 1.0kb PCR band, whereas the wild-type ABCA1 gene yielded a 
1.3kb band. B: Amplification of the human ABCA1 gene resulted in a ~304bp PCR band, whereas the 
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Objective: The beneficial effect of reconstituted HDL (rHDL), composed of human 
apolipoprotein AI (apoAI) and phosphatidylcholine (PC), on atherosclerosis might be 
attributed to both its capacities to induce cholesterol efflux from macrophage foam cells 
and suppress inflammation. The aim of the present study is to investigate whether 
promotion of macrophage cholesterol efflux alone by phosphatidylcholone (PC) infusion 
could modify established atherosclerotic lesions. 
Methods and Results: In-vitro cholesterol efflux studies demonstrated that at high 
concentrations (>84 μg/mL), PC particles induced cholesterol efflux from macrophage 
foam cells as efficiently as rHDL containing the same amount of PC. Also, a single 
intravenous injection of 1680 mg/kg PC increased plasma free and total cholesterol levels 
in female LDL receptor knockout mice on Western-type diet. Importantly, PC infusion 
rapidly decreased the macrophage content and increased the amount of collagen in both 
established early and advanced lesions. 
Conclusions: Promotion of macrophage cholesterol efflux by PC infusion does lead to the 
















Numerous studies have demonstrated that HDL is an inverse predictor of cardiovascular 
disease [1]. Elevating the plasma levels of HDL is therefore regarded as a promising 
therapeutic strategy for atherosclerosis. The atheroprotective properties of HDL might be 
attributed to its role in prevention of foam cell formation, oxidative stress, inflammation, 
and thrombosis [2]. It is hypothesized that HDL induces cholesterol efflux from 
macrophage foam cells and subsequently promote reverse cholesterol transport, thereby 
inhibiting atherogenesis [3]. Recent human studies have shown that the cholesterol efflux 
capacity of HDL in humans has a strong inverse association with both carotid intima-
media thickness and the likelihood of angiographic coronary artery disease [4]. However, it 
is still unclear whether enhancement of the efflux capacity of HDL alone could stabilize 
established atherosclerotic lesions and protect against the development of atherosclerosis. 
A promising approach to increase the circulating levels of HDL is infusion of 
reconstituted HDL (rHDL), composed of human apolipoprotein AI (apoAI) and 
phosphatidylcholine (PC). rHDL infusion increases the cholesterol efflux capacity and 
anti-inflammatory properties of plasma HDL and modifies atherosclerotic lesions in both 
mice [5,6] and humans [7, 8]. The atheroprotective effects of rHDL are mainly attributed 
to apoAI, its main protein component, as apoAI induces cellular cholesterol efflux via 
ABC-transporter A1 (ABCA1) [9] and suppresses inflammation [10, 11]. PC particles are 
also acceptors for cholesterol effluxed via ABC-transporter G1 (ABCG1), scavenger 
receptor class B type I (SR-BI), and aqueous diffusion [13]. Infusion of large amounts of 
PC is thus expected to have substantial effects. Also repeated infusion of large unilamellar 
vesicles composed of egg PC, removes cholesterol and regresses the atheroma in 
cholesterol-fed rabbit [14]. However, studies investigating rHDL do not include PC 
particles as controls [7, 8, 15]. Our present study clearly demonstrates that the PC 
component of rHDL is sufficient to induce cholesterol efflux and stabilize atherosclerotic 
lesions in mice.  
 
Methods 
Preparation of PC particles and rHDL 
3.08 g cholic acid sodium salt (Sigma) was dissolved in 25 mL of buffer containing 10 
mmol/L Tris-HCl, 10 mmol/L NaCl, 1 mmol/L EDTA, pH 8.0. In this buffer 4.2 g soybean 
phosphatidylcholine (Phospholipon 90, Nattermann Phospholipid, Germany) was dissolved 
for 6 hours at room temperature. After dialysis against 1% sucrose solution, the 
concentration of PC in the solution was determined (Spinreact, Girona, Spain) and adjusted 
to 84 mg/mL. Sucrose was added to a final concentration of 10%. PC particles were 
prepared freshly and sterile-filtered before use. The particle size was determined by 
dynamic light scattering (ZetaSizer Nano, Malvern Instruments, U. K.). The mean diameter 
of two main populations of PC particles (Peak 1 and 2) is 4.4±0.6 nm and 24.7±2.4 nm, 
respectively (Supplementary Figure 1).  
rHDL (CSL-111, Behring AG, Switzerland) consists of apoAI isolated from human 
plasma and PC from soybean (Phospholipon 90, Nattermann Phospholipid, Germany) with 
a molar ratio of 1:150. Before use, rHDL was reconstituted with 50 mL of sterile water to 
yield a clear, pale-yellow solution containing 20 mg/mL apoAI and 84 mg/mL PC in 10% 
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Mice 
LDL receptor knockout (LDLr KO) female mice, obtained from the Jackson Laboratory 
(Bar Habor, USA) were bred at the Gorlaeus Laboratories and maintained on sterilized 
regular chow, containing 4.3% (w/w) fat and no added cholesterol (RM3; Special Diet 
Service, Witham, UK). At the age of 12 weeks the LDLr KO mice were challenged with a 
Western-type diet (WTD) containing 15% (w/w) total fat and 0.25% (w/w) cholesterol 
(Diet W, Special Diet Services, Whitham, UK) for 5 weeks (n= 32) or 9 weeks (n= 32) to 
induce the development of early and advanced atherosclerotic lesions, respectively. 
Subsequently, animals received a single intravenous injection of 1680 mg/kg PC or vehicle 
(control group). After 48 hours, animals were sacrificed under full anesthesia. Animal 
experiments were performed at the Gorlaeus Laboratories of the Leiden/Amsterdam Center 
for Drug Research in accordance with the National Laws. All experimental protocols were 
approved by the Ethics Committee for Animal Experiments of Leiden University. 
 
Cholesterol efflux studies 
Thioglycollate-elicited peritoneal macrophages, harvested from LDLr KO mice, were 
loaded with 0.5 μCi/mL 3H-cholesterol and 2.5% serum from LDLr KO mice on chow diet 
in DMEM/0.2% BSA for 24 h at 37oC. Cholesterol efflux was studied by incubation of 
cells with DMEM/0.2%BSA supplemented with reconstituted HDL containg 10, 20, or 50 
μg/mL apoAI (CSL Behring AG, Switzerland) or 42, 84, or 210 μg/mL soybean 
phosphatidylcholine. After a 6- or 24-hours efflux period, radioactivity in the cells and 
medium was determined by liquid scintillation counting. Cholesterol efflux is defined as 
(dpmmedium/ dpmcell +dpmmedium) x 100%.  
 
Lipids Analysis 
The concentrations of cholesterol in serum were determined by incubation with 0.025 
U/mL cholesterol oxidase (Sigma) and 0.065 U/mL peroxidase and 15 μg/mL cholesteryl 
esterase (Roche Diagnostics, Mannheim, Germany) in reaction buffer (1.0 KPi buffer, 
pH=7.7 containing 0.01 M phenol, 1 mM 4-amino-antipyrine, 1% polyoxyethylene-9-
laurylether, and 7.5% methanol). Phospholipids (PL) in serum were determined using a 
standard enzymatic colorimetric assay (Spinreact, Girona, Spain).  
 
Histological Analysis of the Aortic Root 
On sacrifice the arterial tree was perfused in situ with phosphate buffer solution (PBS) and 
the heart was excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; Shandon 
Scientific Ltd., UK) until use. Atherosclerotic lesion development was quantified in oil red 
O/hematoxylin-stained cryostat sections of the aortic root from using the Leica image 
analysis system, consisting of a Leica DMRE microscope coupled to a video camera and 
Leica Qwin Imaging software (Leica Ltd). Mean lesion area (in μm2) was calculated from 
10 oil red O/hematoxylin-stained sections, starting at the appearance of the tricuspid 
valves. Sections were immunolabeled against MOMA-2 (monoclonal rat IgG2b, dilution 
1:50, Research diagnostics) for detection of monocytes/macrophages. Collagen content of 
the lesions was visualized with aniline blue by using Masson’s Trichrome accustain 
according to the manufacturer’s instructions (Sigma). Histochemical stainings were 
subsequently quantified in 5 consecutive sections by computer-aided morphometric 







Statistical analysis was performed using ANOVA and the Student-Newman-Keuls post-
test (GraphPad InStat and Prism software). A level of p<0.05 was considered significant. 
 
Results and Discussion 
PC particle induced cholesterol efflux from macrophage foam cells 
Reconstituted HDL (rHDL), composed of apoAI and phospholipids, is an efficient 
cholesterol acceptor in vitro and in vivo [17, 18]. ApoAI induces cholesterol efflux via 
ABCA1 while particles rich in phospholipid accept cholesterol transported by SR-BI, 
ABCG1 and aqueous diffusion [17, 19]. To test the efficiency of PC particles in induction 
of cholesterol efflux, PC and rHDL particles were incubated with [3H]-cholesterol labeled 
macrophage foam cells for 6 or 24 hours. As shown in Figure 1, after 6-hour incubation, at 
the concentration of 42 μg/mL (the concentration of PC in rHDL containing 10 μg/mL 
apoAI), rHDL induced 1.6-fold (P<0.05) more cholesterol efflux as compared to PC 
particles, which might be attributed to apoAI-mediated cholesterol efflux. Interestingly, 
with the increase of the concentration of rHDL, the difference between rHDL and a 
comparable amount of PC in particles lacking apoAI diminished and finally was 
completely absent at the concentration of 210 μg/mL PC. Similar results were also found 
after 24 hours in the presence of rHDL and PC particles (data not shown). These data 
indicate that PC could induce cholesterol efflux as efficiently as rHDL at concentrations 
above 84 μg/mL. Since small PC particles are more efficient in inducing cholesterol efflux 
from macrophages as compared to larger ones [17, 20], it is likely athat  the smallest PC 
particles in the PC solution with a mean diameter of 4.4±0.6 nm (Supplementary Figure 1) 
greatly contributed to the PC-mediated cholesterol efflux. 
 
Figure 1. PC promotes cholesterol efflux from serum-loaded macrophages. Peritoneal macrophages 
from wildtype mice were labeled for cholesterol efflux as described in the materials and methods. Basal 
efflux to media (in the absence of added acceptors) has been subtracted from the data shown. Values are 
mean±SEM (n=3 mice). Statistically significant difference *P<0.05 vs PC. 
 
PC particles mobilized FC in vivo and modified the composition of established early 
and advanced atherosclerotic lesions 
Previous studies showed that infusion of rHDL containing 400 mg/kg apoAImilano quickly 
modulates the stability of atherosclerotic lesions in apoE KO mice [6]. Thus, in the present 
study, 1680 mg/kg of PC particles, comparable to the amount of PC in rHDL at 
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concentration of 400 mg/kg apoAI, or control vehicle were intraveneously injected into 
female LDLr KO mice fed WTD for 5 weeks. This allowed us to determine whether 
augmentation of macrophage cholesterol efflux alone could modulate established early 
lesions. The plasma lipid levels were determined at 1 and 48 hours after infusion. As 
shown in Figure 2A, at 1 hour after infusion, a dramatic increase (4.3-fold, p<0.001) of 
plasma phospholipid (PL) levels was observed in PC-treated animals as compared to 
controls, indicating successful infusion. PC-treated animals also showed increased levels of 
plasma free cholesterol (FC) (1.4-fold, p<0.001) and total cholesterol (TC) (1.1-fold, 
p<0.05) levels. At 48 hours after infusion, the levels of plasma PL in PC-treated mice were 
declined to the levels of control mice. In contrast, slight increases in plasma FC (1.2-fold, 
p<0.01) and TC (1.2-fold, p<0.01) levels were still evident                        
in PC-treated mice (Figure 2B). In line with our in-vitro efflux data, PC could thus also 
mobilize FC in vivo, similar to rHDL [18].  
 
Next, the effects of PC infusion on the established early atherosclerotic lesions 
were evaluated at the aortic root. As shown in Figure 3A and 3B, infusion of a large dose 
of PC did not affect the size of established early lesions. However, PC infusion did lead to 
a 1.3-fold (p=0.053) reduction of the macrophage content and a 1.8-fold (p=0.023) 
increase in the amount of collagen in early lesions (Figure 3B and 3C).  
To further determine the effects of PC particle infusion on established advanced 
lesions, female LDLr-/- mice were fed WTD for 9 weeks prior to the treatment with PC 
particles. Infusion of PC also increased the plasma FC and TC levels in mice with 
advanced lesions at 1 and 48 hours after infusion (data not shown). As shown in Figure 4A, 
strikingly, the size of advanced lesions at the aortic root of PC-treated mice was 1.4-fold 
(p=0.0369) smaller than that of control mice at 48 hours after infusion of PC particles. 
Similar to early lesions, PC infusion also led to a reduced macrophage (1.4-fold, p=0.085) 
and an increased collagen (1.4-fold, p=0.0238) content of advanced lesions. 
Figure 2. PC infusion increased plasma 
free and total cholesterol, and 
phospholipid levels. Animals were put on 
WTD for 5 weeks and were separated into 
two groups with equal plasma cholesterol 
levels. At 1 (A) and 48 (B) hours after 
infusion with PC or control vehicle, plasma 
was collected for lipid analysis. Values are 
means±SEM. Statistically significant 








Augmentation of cholesterol efflux by PC particles infusion leads to lesion 
stabilization as evidenced by reduced macrophage content and increased collagen 
accumulation in both established early and advanced lesions. Lesion stabilization is crucial 
for prevention of acute luminal thrombosis [21]. Increased macrophage content and 
decreased collagen content are associated with the vulnerable lesion phenotype. Colesterol 
loading impairs the migration capacity of macrophages [22], which probably leads to the 
retention of foam cells in atherosclerotic lesions. Moreover, macrophage foam cells are the 
main producer of MMPs in the lesions [23]. The present study as well as pevious studies 
[14, 24] clearly show that PC particles can promote cellular cholesterol efflux in vitro and 
FC mobilization in vivo. Thus, augmentation of cholesterol efflux from cells in lesions 
might stabilize the plaque by restoring the migration capacity of macrophages and 
decreasing the production of MMPs.  
Figure 3. PC modulates the 
composition of the established early 
lesions. Animals were put on WTD for 5 
weeks to induce the established early 
lesions at the aortic root. At 48 hours 
after infusion of PC, animals were 
euthanized. (A) Photomicrographs 
showing a scatter dot plot of 
atherosclerotic lesion quantification. 
Each symbol represents the mean lesion 
area in a single mouse. The horizontal 
line represents the mean of the group. 
(B) Representative photomicrographs 
showing oil-red-O and Masson’s 
Trichrome stained sections (original 
magnification 10x4). (C) Bar graphs 
showing quantification of macrophage 
and collagen content in the lesions. 
Values represent the mean±SEM. 
 





In conclusion, we provide evidence that promoting macrophage cholesterol efflux 
by infusion of PC particles stabilizes established atherosclerotic lesions. Apart from apoAI 
mediated efflux, it is thus likely that the PC component of rHDL contributes to its 
cholesterol efflux inducing capacity and exerts beneficial effects on atherosclerosis. 
Studies on rHDL are thus recommended to include PC alone as control. 
 
Acknowledgements 
This work was supported by grants from the Netherlands Heart Foundation (#2001T4101 
to M.V.E. and Y.Z., and the Established Investigator grant 2007T056 to M.V.E.). 
 
 
Figure 4. PC modulates the 
composition of the established 
advanced lesions. Animals were put 
on WTD for 9 weeks to induce the 
established advanced lesions in the 
aortic root. At 48 hours after infusion 
of PC, animals were euthanized. (A) 
Photomicrographs showing a scatter 
dot plot of atherosclerotic lesion 
quantification. Each symbol represents 
the mean lesion area in a single 
mouse. The horizontal line represents 
the mean of the group. (B) 
Representative photomicrographs 
showing oil-red-O and Masson’s 
Trichrome stained sections (original 
magnification 10x4). (C) Bar graphs 
showing quantification of macrophage 
and collagen content in the lesions. 
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Samples  Intensity (%) Mean diameter (nm) 
PC 
Peak 1 34.5±1.0 4.4±0.6 
Peak 2 43.5±0.4 24.7±2.4 
Peak 3 16.5±1.6 627.3±81.1 
Supplementary Figure 1. Determination of the size of PC particles. The upper graph showing the 
size distribution by intensity. The lower table summarizing the quantification of mean diameter of 
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11.1 English Summary 
Atherosclerosis is the major cause of death in the Western society due to the development 
of acute clinical events such as myocardial infarction and cerebral stroke. Currently, 
lowering plasma LDL cholesterol (LDL-C) levels using statins, inhibitors of de-novo 
cholesterol synthesis, is the main therapeutic strategy to prevent the progression of 
atherosclerosis. The remaining high incidence of cardiovascular disease indicates a clear 
need for new therapies. Numerous epidemiological studies have established HDL 
cholesterol (HDL-C) levels as an inverse predictor for atherosclerosis. HDL has important 
anti-oxidative and anti-inflammatory properties. The most important atheroprotective 
function of HDL is, however, facilitation of reverse cholesterol transport (RCT), a process 
in which HDL removes excess cholesterol from peripheral tissues and subsequently 
delivers it to the liver for biliary excretion. In this thesis, the importance of RCT for 
prevention of atherosclerosis and the potential of RCT augmentation for the treatment of 
atherosclerosis were evaluated. 
 
11.1.1 The importance of reverse cholesterol transport for prevention of 
atherosclerosis 
Key regulators of HDL metabolism are ABC-transporter A1 (ABCA1) and scavenger 
receptor BI (SR-BI). ABCA1 is the rate-limiting factor for HDL biogenesis, while SR-BI 
delivers cholesteryl ester (CE) from HDL to the liver. To get insight in the putative 
synergistic role of ABCA1 and SR-BI in RCT and atherosclerosis, ABCA1/SR-BI double 
knockout (dKO) mice were generated. In Chapter 2, ABCA1/SR-BI dKO mice on chow 
diet were phenotypically characterized. On one hand, dKO mice displayed a complete 
blockade of selective cholesterol ester (CE) uptake by the liver, similar as observed 
previously for single SR-BI KO mice. On the other hand, dKO mice resembled ABCA1 
KO mice with respect to hypocholesterolemia and HDL loss. Deletion of ABCA1, SR-BI, 
or both impaired RCT from wildtype (WT) macrophages to a similar extend. However, 
dKO mice did accumulate enlarged macrophage foam cells in the lung and Peyer’s patches, 
clearly illustrating the importance of ABCA1 and SR-BI for cellular cholesterol 
homeostasis. Due to the lack of pro-atherogenic lipoproteins, no atherosclerotic lesions 
were evident in the aortic root of dKO mice. In Chapter 3, the effect of combined 
deficiency of ABCA1 and SR-BI on atherogenesis was further determined by feeding dKO 
mice an atherogenic diet (ATD), containing 15% cocoa butter, 1% cholesterol, and 0.5% 
cholate for 10 weeks. DKO mice displayed lower plasma total cholesterol levels than WT 
mice, mainly due to the absence of HDL. Plasma non-HDL-C levels in dKO mice were 
higher than ABCA1 KO mice but much lower than SR-BI KO mice. Enhanced 
macrophage foam cell accumulation was again observed in the peritoneal cavity of dKO 
mice on ATD. As compared to WT mice, HDL deficiency in ABCA1 KO mice and dKO 
mice induced leukocytosis and promoted atherosclerotic lesion development by 
recruitment of leukocytes into lesions and adventitia. Also, SR-BI KO mice displayed 
elevated levels of non-HDL and abnormally large HDL, increased leukocyte infiltration 
into lesions and surrounding adventitia, and enhanced atherosclerosis. These findings 
clearly indicate the crucial role of HDL-mediated RCT for prevention of atherosclerosis. 
Strikingly, disruption of ABCA1 in SR-BI KO mice attenuated atherosclerotic lesion 
development. This coincided with reduced plasma levels of monocyte chemoattractant 
MCP-1 and expression of the adhesion molecule ICAM-1 in the arterial wall, which 
probably led to reduced infiltration of monocytes from the circulation into the arterial wall. 
Evidence is accumulating that not only proatherogenic lipoproteins, like LDL and VLDL, 
but also dysfunctional HDL can induce secretion of MCP-1 from the arterial wall and 
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upregulates the expression of ICAM-1 on arterial endothelial cells [1]. The observed 
reduced atherosclerotic lesion development in dKO mice is thus probably the result of 
diminished dysfunctional HDL and reduced plasma levels of pro-atherogenic lipoproteins 
upon inactivation of ABCA1, leading to reduced infiltration of monocytes into the arterial 
wall.  
 
11.1.2 The importance of cellular cholesterol efflux mechanisms for prevention of 
atherosclerosis 
As a hallmark of atherosclerosis, macrophage-derived foam cells are an early and 
persistent component of atherosclerotic lesions. They play a key role in disease progression, 
as both lipid scavengers and inflammatory mediators. Cholesterol efflux mechanisms in 
macrophages, the first step of RCT, are essential for prevention of foam cell formation. The 
relative roles of various efflux pathways in net cholesterol efflux from macrophage foam 
cells in atherosclerotic lesions were reviewed in Chapter 4. In addition to their essential 
role in HDL metabolism, ABCA1 and SR-BI are important modulators of cellular 
cholesterol efflux to lipid-poor apolipoprotein AI (ApoAI) and mature HDL, respectively. 
In Chapter 5, the combined effect of macrophage ABCA1 and SR-BI deficiency on foam 
cell formation and atherosclerotic lesion development was investigated by transplantation 
of bone marrow from ABCA1/SR-BI dKO mice into LDL receptor (LDLr) KO mice. Upon 
challenge with Western-type diet (WTD), dKO transplanted mice showed lower plasma 
cholesterol levels compared to respective controls, probably due to less food intake, 
impaired intestinal absorption, and reduced VLDL production. However, massive foam cell 
formation was evident in the peritoneal cavity and spleen of dKO mice. Importantly, 
combined deletion of macrophage ABCA1 and SR-BI also increased circulating levels of 
pro-inflammatory KC (murine IL-8) and IL-12, and accelerated atherosclerosis. Under 
high-dietary lipid conditions, both ABCA1 and SR-BI in bone marrow-derived cells are 
thus essential for prevention of macrophage foam cell formation and atherosclerosis, and 
other cholesterol efflux mechanisms cannot compensate for the absence of these two 
cholesterol transporters. 
Strikingly, Brunham et al. showed that specific deletion of ABCA1 in macrophages 
did not affect atherogenesis in LDLr KO mice [2]. This was suggested to be the 
consequence of the fact that deletion of the LDLr on macrophages impairs the sterol-
induced upregulation of macrophage ABCA1 expression and macrophage cholesterol 
efflux [3]. In Chapter 6, bone marrow from LDLr/ABCA1 dKO mice and respective 
controls was transplanted into LDLr KO mice to investigate the interaction between the 
LDLr and ABCA1 on leukocytes and the consequences for atherosclerotic lesion 
development. Deletion of the macrophage LDLr did not affect cholesterol efflux from bone 
marrow-derived macrophages in vitro or macrophage foam cell formation in vivo. Of note, 
leukocyte ABCA1 deficiency resulted in increased foam cell formation and promoted 
atherosclerosis both in the presence and absence of the LDLr, clearly indicating that the 
atheroprotective effect of leukocyte ABCA1 is independent of LDLr expression. 
Interestingly, LDLr/ABCA1 dKO transplanted animals displayed less lymphocytosis, 
reduced recruitment of T cells into adventitia underlying lesions, and smaller lesions as 
compared to single ABCA1 KO transplanted animals. These findings suggest that in 
addition to the role ABCA1 in cholesterol efflux, leukocyte ABCA1 might protect against 
atherosclerosis by inhibiting the proliferation and recruitment of T cells. 
ABCA1 facilitates cholesterol efflux from macrophages to lipid-free/poor 




for macrophage ABCA1-faciliated RCT and the atheroprotective effects of leukocyte 
ABCA1 was evaluated. Lipoprotein-depleted serum (LPDS) and HDL of LDLr/ApoAI 
dKO mice showed reduced cholesterol efflux capacity from WT macrophages as compared 
to the counterparts of LDLr KO mice. However, macrophage ABCA1 deficiency did not 
lead to further reduced cholesterol efflux to LPDS and HDL of LDLr/ApoAI dKO mice or 
radio-labeled cholesterol excretion into feces in LDLr/ApoAI dKO mice. Therefore, 
ApoAI and macrophage ABCA1 are identified as functional partners in macrophage RCT. 
Next, LDLr/ApoAI dKO mice were transplanted with bone marrow from ABCA1 KO 
mice and WT controls. Upon challenge with WTD, ABCA1 deficiency accelerated 
atherosclerosis in LDLr/ApoAI dKO mice, despite reduced non-HDL cholesterol levels. 
This clearly indicates that leukocyte ABCA1 can protect against atherosclerosis even in 
absence of circulating ApoAI. Thus, in addition to macrophage RCT, other mechanisms 
are involved in the atheroprotective effects of leukocyte ABCA1, especially under 
conditions in which circulating ApoAI is absent. Interestingly, the accelerated 
atherosclerosis in LDLr/ApoAI dKO mice with ABCA1 deficiency in bone marrow-
derived cells coincided with enhanced monocytosis and neutrophilia in the circulation, 
induced plasma levels of important chemoattractants of monocytes and neutrophils MCP-1 
and KC, and augmented neutrophil accumulation in lesions. These findings suggest that, in 
addition to its essential role as a facilitator of cellular cholesterol efflux, the 
atheroprotective effects of leukocyte ABCA1 could also be attributed to its anti-
inflammatory function. 
 
11.1.3 The potential of augmentation of reverse cholesterol transport from 
macrophage for the treatment of atherosclerosis 
To evaluate the potential of augmentation of RCT from macrophages to reduce established 
atherosclerotic lesions, different strategies, including dietary lipid lowering, 
overexpression of ABCA1 on macrophages, and infusion of synthetic cholesterol-free 
phosphatidylcholine (PC) discs, were tested. In Chapter 8, LDLr KO mice were fed WTD 
for 5 and 9 weeks to induce early and advanced lesion development. Thereafter, the 
animals were switched to a chow diet to lower plasma cholesterol levels and the dynamic 
response of the lesions was investigated. Dietary lipid lowering reduced the macrophage 
content of both early and advanced established lesions. However, progression of lesion 
development continued as a result of expansion of collagen and the necrotic core. 
Importantly, early lesions became more pro-inflammatory, while inflammation was 
reduced in advanced lesions. The severity of the established lesions thus determined the 
dynamics of lesion remodeling upon lowering of plasma cholesterol, indicating the 
importance of establishing stage-specific therapeutic protocols for the treatment of 
atherosclerosis.  
In Chapter 9, BMT experiments in LDLr KO mice with established lesions were 
used to study the potential of ABCA1 overexpression in bone marrow-derived cells, 
including macrophages, for the treatment of atherosclerosis. Overexpression of ABCA1 
inhibited macrophage infiltration into early, but not into advanced lesions. The latter is 
likely the consequence of the fact that macrophage infiltration into established advanced 
lesions was largely impaired, due to the presence of fibrous caps. Therefore, the severity of 
the pre-existing lesions could influence the therapeutic potential of ABCA1 overexpression 
in bone marrow-derived cells.  
Infusion of reconstituted HDL (rHDL), composed of human ApoAI and 
phosphatidylcholine (PC), protects against atherosclerosis probably by induction of 
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cholesterol efflux from macrophage foam cells and inhibition of inflammation [5,6]. PC 
discs, like rHDL, can accept cholesterol transported via SR-BI, ABCG1, and aqueous 
diffusion. Infusion of large amounts of PC is therefore expected to positively affect cellular 
cholesterol efflux and thus atherosclerosis. In Chapter 10, the effect of PC discs on 
macrophage cholesterol efflux in vitro and the progression of established atherosclerotic 
lesions in LDLr KO mice was evaluated. First, as expected, PC particles at high 
concentrations (>84 μg/mL) induced cholesterol efflux from macrophages as efficiently as 
rHDL containing the same amount of PC. Importantly, augmentation of macrophage 
cholesterol removal by a single infusion of high-dose PC discs rapidly led to stabilization 
of established lesions in LDLr KO mice on WTD. The PC component of rHDL thus 




11.2 Concluding remarks and future perspectives 
Using our unique transgenic animals and the technique of bone marrow transplantation we 
investigated the importance of HDL-mediated RCT for prevention of atherosclerotic lesion 
development. Although many other molecules are also involved in RCT, ABCA1, ApoAI, 
and SR-BI are considered good candidates for pharmaceutical intervention to elevate 
HDL-C, facilitate cholesterol efflux from lesions, promote the delivery of cholesterol to the 
liver, and thus prevent or even regress atherosclerosis. Combined therapeutic targeting of 
these molecules in RCT is expected to greatly improve the efficacy of the treatment for 
atherosclerosis.  
The potential of overexpression of SR-BI and ABCA1 for treatment of 
atherosclerosis has been investigated in animal models. Overexpression of hepatic SR-BI 
reduces atherosclerosis in LDLr KO mice [7]. In contrast, overexpression of ABCA1 in the 
liver of LDLr KO mice [8] and apoE KO mice [9] induces not only HDL but also 
proatherogenic apoB-containing lipoproteins, thereby accelerating the development of 
atherosclerotic lesions. Lately, Brunham et al. demonstrated that moderate overexpression 
(2-fold instead of 20-fold) of hepatic ABCA1 does confer atheroprotection in LDLr KO 
mice [2]. Interestingly, the expression of hepatic SR-BI is important for preserving the 
beneficial effects of HDL on both endothelial progenitor cells (EPCs) and endothelial cells 
(EC) [10]. Hepatocyte-specific ABCA1 overexpression via adenoviral vectors increases 
HDL-C, but decreases SR-BI protein in liver and abrogates the beneficial effects of HDL 
on EC function [10]. Therefore, combined overexpression of ABCA1 and SR-BI in the 
liver may prove more successful in the prevention of atherosclerosis.  
Augmentation of cholesterol efflux from macrophage foam cells in atherosclerotic 
lesions, the first step of RCT, is considered to be an attractive approach to prevent or even 
regress established lesions. Established transporters facilitating cellular cholesterol efflux 
are ABCA1, ABCG1, and SR-BI [11]. Combined deletion of ABCA1 and ABCG1 [12] or 
ABCA1 and SR-BI [13] on bone marrow-derived cells induces extreme macrophage foam 
cell formation and accelerates atherosclerosis. These findings highlight the potential of 
these cholesterol transporters as therapeutic targets. A therapeutic strategy to up-regulate 
ABCA1 and ABCG1 in macrophages is pharmacological activation of the liver X receptors 
(LXRs) [14]. Activation of LXRs on macrophages is required for regression of 
atherosclerotic lesions [15]. Systemic application of LXR agonists, however, induces off-
target effects in liver, including increased lipogenesis and production of TG [16]. This 




macrophages inside the atherosclerotic lesion. In addition, the expression of the cholesterol 
transporters ABCA1 and SR-BI in lesions is upregulated during atherosclerosis regression 
[17]. It is thus worthwhile to investigate if therapeutic upregulation of ABCA1 and SR-BI 
in atherosclerotic lesions might be a potential new strategy for induction of atherosclerotic 
lesion regression.   
For decades, elevation of HDL-C is believed to be a promising strategy for 
treatment of atherosclerosis as levels of HDL correlate inversely with cardiovascular risk. 
Elevation of circulating ApoAI and HDL indeed induces rapid atherosclerosis regression in 
ApoE KO mice [18]. Clinical approaches to raise HDL-C include oral administration of 
cholesterol ester transfer protein (CETP) inhibitors and intravenous administration of 
rHDL (ApoAI-PC complex). CETP is an enzyme that exchanges cholesterol esters in HDL 
for triglycerides in VLDL [19]. The CETP inhibitor torcetrapib efficiently elevates HDL-C 
and enhances the cholesterol efflux capacity of HDL in treated patients [20]. It, however, 
failed in a clinic trial with 15067 patients at high cardiovascular risk, owing to off-target 
effects on blood pressure, and increased levels of aldosterone [21]. Two other CETP 
inhibitors, dalcetrapib and anacetrapib, have entered clinical evaluation. The safety of 
dalcetrapib and anacetrapib was recently affirmed in clinical trials [22, 23]. The results of 
continuing large end-point trials will prove if the inhibition of CETP is a good therapeutic 
target for reducing cardiovascular risk by elevation of HDL.       
Moreover, infusion of rHDL has been proven to be a promising therapy for 
atherosclerosis [24, 25, 26]. Although we show that PC, the phospholipid component of 
rHDL, has beneficial effects on atherosclerosis at high doses, the ApoAI in rHDL might 
augment cholesterol efflux by facilitating cholesterol efflux via ABCA1. In addition, 
ApoAI has other atheroprotective properties, such as anti-oxidation and anti-inflammation 
[11]. Interestingly, the induction of FC mobilization by rHDL infusion is dependent on the 
expression of SR-BI [27]. Thus, overexperssion of SR-BI might enhance the beneficial 
effect of rHDL infusion.  
Recent findings also indicate that anti-inflammatory strategies or inhibition of 
monocyte infiltration are crucial for inducing regression of atherosclerosis [28]. 
Atherosclerotic lesion development results from a combination of hypercholesterolemia 
and an inflammatory response. We demonstrated in this thesis, that in addition to their 
importance for macrophage RCT, the atheroprotective effects of ABCA1 and ApoAI could 
also be attributed to their anti-inflammatory function. This highlights the enormous 
therapeutic potential of targeting these factors for the treatment of atherosclerosis. 
Increasing evidence is accumulating that the steady-state levels of HDL cholesterol 
in plasma poorly reflect HDL function. HDL can be modified by atherogenic factors, like 
oxidative stress and inflammation, and turn into a dysfunctional particle with decreased 
cholesterol efflux capacity [11]. It should, however, be noted that a preserved cholesterol 
efflux capacity of HDL does not necessarily reflect the functionality of the other 
atheroprotective properties of HDL, such as its anti-inflammatory and endothelial 
preservation properties [29]. It is thus important to monitor all anti-atheroprotective 
properties of HDL during the treatment of atherosclerosis. Laboratory assessments of HDL 
function includes evaluation of cholesterol efflux capacity, its PON1 (paraoxonase) 
activity for its anti-oxidant capacity, the expression of endothelial adhesion molecules for 
its anti-inflammatory function, sphingosine-1-phosphate mass for its nitric oxide-
promoting capacity, and the coagulation system for its anti-coagulant property [30]. 
Development and validation of assays that can be easily used in a clinical setting will be of 
great importance for prediction of cardiovascular risk and assessment of the success of 
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therapeutic interventions. 
In addition to macrophages, cellular cholesterol homeostasis might also be crucial 
for the function of other cell types involved in the pathogenesis of atherosclerosis. 
Increased cholesterol content in T lymphocytes is associated with augmented activation 
and proliferation [31]. Recruitment of these activated T cells into the arterial wall could 
accelerate atherosclerosis. Also, secretion of insulin is impaired by increased accumulation 
of cholesterol in islet β-cells [20463468]. Subsequent hyperglycemia due to low levels of 
insulin in patients with type 2 diabetes could also modify HDL leading to a cholesterol 
efflux capacity and accelerated development of atherosclerosis [11]. Therefore, the role of 
cellular cholesterol homeostasis in these cell types warrants future investigation. These 
studies will highlight the importance of systemic augmentation of RCT for treatment of 
atherosclerosis at different levels.  
In conclusion, as described in this thesis, the importance of RCT in atherosclerosis 
has been established and augmentation of RCT is a promising target for the treatment of 






































11.3 Dutch Samenvatting 
Hart- en vaatziekten vormen de voornaamste doodsoorzaak in de westerse wereld. Een 
belangrijke oorzaak voor de ontwikkeling van hart- en vaatziekten is de vorming van 
vernauwingen in de bloedvaten, de zogenaamde atherosclerose ofwel aderverkalking 
genoemd. Een belangrijke risicofactor voor het ontstaan van atherosclerose is een te hoog 
cholesterolgehalte. Huidige therapieën richten zich voornamelijk op het verlagen van het 
(slechte) cholesterol in lage-dichtheids lipoproteïnen (LDL) en zeer-lage-dichtheids 
lipoproteïnen (VLDL). Hoewel de incidentie van atherosclerose sterk is verminderd blijft 
het aantal patiënten dat lijdt aan hart- en vaatziekten hoog. Veel klinische onderzoeken 
laten zien dat het cholesterol in (goede) hoge-dichtheids lipoproteïnen (HDL) een 
beschermende rol kan spelen bij de ontwikkeling van atherosclerose. De belangrijkste 
functie van HDL richt zich op de verwijdering van cholesterol uit perifere weefsels, welke 
vervolgens via de lever wordt uitgescheiden (omgekeerd cholesterol transport, ofwel 
RCT). In dit proefschrift is het belang van RCT voor de bescherming tegen atherosclerose 
onderzocht. Daarnaast zijn de effecten van RCT stimulatie als een mogelijk nieuwe 
behandeling van atherosclerose geëvalueerd.  
 
11.3.1 Het belang van RCT ter bescherming tegen atherosclerose 
ABC-transporter A1 (ABCA1) en scavenger receptor BI (SR-BI) spelen een belangrijke rol 
in het HDL metabolisme. ABCA1 is essentieel voor de productie van HDL, terwijl SR-BI 
zorgt voor het transport van cholesteryl esters (CE) van HDL naar de lever. Om inzicht te 
krijgen in de veronderstelde rol van ABCA1 en SR-BI in RCT en atherosclerose, zijn er 
muizen gecreëerd die ABCA1 en SR-BI missen (dubbele knockout muizen, ofwel dKO). In 
Hoofdstuk 2 zijn deze muizen gekarakteriseerd. Net als SR-BI deficiënte muizen, 
vertoonden dKO muizen geen opname van CE uit HDL door de lever. Aan de andere kant 
hadden ze, in overeenstemming met ABCA1 deficiëntie, hypocholesterolemie en weinig 
tot geen HDL. Deficiëntie van ABCA1, SR-BI of beide zorgde voor een identieke reductie 
in RCT vanuit wildtype (WT) macrofagen. dKO muizen vertoonden stapeling van 
macrofaag schuimcellen in de long en Peyer’s patches. Dit suggereert een functie van 
ABCA1 en SR-BI in cellulaire cholesterol homeostase. Vanwege de afwezigheid van pro-
atherogene lipoproteïnen ontwikkelden dKO muizen echter geen atherosclerotische lesies. 
In Hoofdstuk 3 is het effect van gecombineerde deficiëntie van ABCA1 en SR-BI op 
atherogenese verder onderzocht door deze muizen voor een periode van 10 weken een 
atherogeen dieet te voeren. Dit dieet bevat 15% cacaoboter, 1% cholesterol en 0.5 cholaat. 
Voornamelijk door de afwezigheid van HDL hadden dKO muizen lagere cholesterol 
waarden dan de WT muizen. VLDL en LDL concentraties in dKO muizen waren hoger dan 
in ABCA1 KO muizen, maar veel lager dan in SR-BI KO muizen. Ook na het atherogene 
dieet vertoonden dKO muizen verhoogde macrofaag schuimcel vorming in het peritoneum. 
Vergeleken met WT muizen resulteert de HDL deficiëntie in ABCA1 KO en dKO muizen 
in verhoogde leukocytose en meer atherosclerose door verhoogde rekrutering van 
leukocyten naar de atherosclerotische lesie en de adventitia. Daarnaast vertoonden SR-BI 
KO muizen verhoogd VLDL/LDL en abnormaal groot HDL, verhoogde leukocyt infiltratie 
in de lesies en omringende adventitia en toegenomen vorming van atherosclerose. Deze 
resultaten onderstrepen de cruciale beschermende rol van HDL afhankelijke RCT met 
betrekking tot atherosclerose. Het is opmerkelijk dat ABCA1 deficiëntie in SR-BI KO 
muizen atherosclerose vermindert. Verlaagde plasma concentraties van monocyt 
chemoattractant MCP-1 en verlaagde expressie van het adhesie molecuul ICAM-1 in de 
vaatwand, leidt waarschijnlijk tot verminderde infiltratie van monocyten vanuit de 
circulatie in de vaatwand. Niet alleen de proatherogene lipoproteïnen LDL en VLDL, maar 
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ook niet-functioneel HDL induceert MCP-1 secretie en verhoogt ICAM-1 expressie in 
endotheelcellen in de vaatwand [17941290]. De verminderde atherosclerose ontwikkeling 
in dKO muizen is dus waarschijnlijk veroorzaakt door de verlaging van de hoeveelheid 
niet-functioneel HDL en proatherogene lipoproteïnen in het plasma als gevolg van ABCA1 
deficiëntie. 
 
11.3.2. Het belang van cellulaire cholesterol efflux mechanismen ter preventie van 
atherosclerose 
Macrofagen spelen een belangrijke rol bij de initiatie en de progressie van atherosclerose. 
Deze cellen fungeren als de opruimcellen voor vetten en produceren grote hoeveelheden 
ontstekingsfactoren die het ziekteproces beïnvloeden. Cholesterol efflux mechanismen in 
macrofagen, de eerste stap van het RCT, zijn essentieel om stapeling van cholesterol en dus 
schuimcel vorming te voorkomen. In Hoofdstuk 4 is het relatieve belang van verschillende 
cholesterol efflux routes van macrofaag schuimcellen in atherosclerotische lesies 
samengevat. Naast hun belangrijke rol in het metabolisme van HDL zijn ABCA1 en SR-BI 
ook betrokken bij efflux van cholesterol vanuit macrofagen naar apolipoproteïne AI 
(ApoAI) en HDL. In Hoofdstuk 5 is gebruik gemaakt van de beenmergtransplantatie 
(BMT) techniek. Het effect van gecombineerde uitschakeling van ABCA1 en SR-BI in 
macrofagen op schuimcel vorming en atherosclerose werd onderzocht door middel van 
transplantatie van ABCA1/SR-BI dKO beenmerg naar LDL receptor (LDLr) KO muizen. 
Het voeren van een Western-type dieet (WTD) resulteerde in de dKO getransplanteerde 
muizen tot een verminderde verhoging van de concentraties cholesterol in het bloed. Dit 
kwam waarschijnlijk door verlaagde voedselinname, aangetaste absorptie in de darmen en 
verminderde VLDL productie. Desondanks vertoonden deze dKO getransplanteerde 
muizen extreme schuimcel vorming in het peritoneum en de milt. Gecombineerde 
deficiëntie van macrofaag ABCA1 en SR-BI resulteerde ook in verhoogde concentraties 
pro-inflammatoir KC (muizen IL-8) en IL-12 en versnelde atherosclerose. Onder condities 
van hoge, dieet-geïnduceerde, concentraties vetten zijn zowel ABCA1 als SR-BI in 
beenmerg afgeleide cellen dus essentieel voor de preventie van macrofaag schuimcel 
vorming en atherosclerose. Andere cholesterol efflux mechanismen kunnen niet 
compenseren voor de afwezigheid van deze cholesterol transporters. 
Een opvallende bevinding van Brunham et al. is dat specifieke genetische 
uitschakeling van ABCA1 op macrofagen geen effect had op atherogenese in LDLr KO 
muizen [17322896]. Dit zou veroorzaakt kunnen worden doordat macrofaag LDLr 
deficiëntie de vet geïnduceerde opregulatie van ABCA1 op macrofagen en daarmee 
macrofaag cholesterol efflux uit macrofagen verhinderd [18029360]. In Hoofdstuk 6 zijn 
LDLr KO muizen getransplanteerd met beenmerg van LDLr/ABCA1 dKO muizen en hun 
respectievelijke controles om de interactie tussen de LDLr en ABCA1 op leukocyten en de 
gevolgen voor de ontwikkeling van atherosclerotische lesies te onderzoeken. Macrofaag 
LDLr deficiëntie had geen invloed op de cholesterol efflux van beenmerg afgeleide 
macrofagen in vitro of macrofaag schuimcel vorming in vivo. Leukocyt ABCA1 deficiëntie 
resulteerde echter in een verhoogde schuimcel vorming en meer atherosclerose, zowel in 
de aanwezigheid als afwezigheid van LDLr expressie. Hieruit blijkt duidelijk dat het 
beschermende effect van leukocyt ABCA1 op atherosclerose onafhankelijk is van LDLr 
expressie. LDLr/ABCA1 dKO getransplanteerde muizen vertoonden minder lymfocytose, 
verminderde rekrutering van T-cellen naar de adventitia van het bloedvat met 
atherosclerotische lesies, en kleinere lesies in vergelijking met ABCA1 KO 
getransplanteerde dieren. Deze bevindingen suggereren dat ABCA1 in leukocyten, naast 




proliferatie en de rekrutering van T-cellen. 
ABCA1 bevordert cholesterol efflux van macrofagen naar apolipoproteïnen, 
waaronder ApoAI [11162594]. In Hoofdstuk 7 is het belang van circulerend ApoAI voor 
macrofaag ABCA1 afhankelijke RCT en het beschermende effect van leukocyt ABCA1 op 
atherosclerose onderzocht. Lipoproteïnen-deficiënt serum (LPDS) en HDL van 
LDLr/ApoAI dKO muizen vertoonden een verminderde capaciteit om cholesterol efflux te 
induceren vanuit WT macrofagen in vergelijking met die van LDLr KO muizen. Echter, 
macrofaag ABCA1 deficiëntie leidde niet tot een verder gereduceerde cholesterol efflux 
naar LPDS en HDL van LDLR/ApoAI dKO muizen noch tot verminderde uitscheiding van 
radioactief gemerkt cholesterol vanuit WT macrofagen in de ontlasting van LDLR/ApoAI 
dKO muizen. Daarom worden ApoAI en macrofaag ABCA1 gezien als functionele 
partners in macrofaag RCT. Vervolgens werden LDLr/ApoAI dKO muizen 
getransplanteerd met beenmerg van ABCA1 KO muizen of WT controles. Het voeren van 
WTD aan deze muizen resulteerde, ondanks de verlaging van cholesterol in VLDL en LDL, 
bij ABCA1 deficiëntie in versnelde ontwikkeling van atherosclerose in LDLr/ApoAI dKO 
muizen Hieruit blijkt duidelijk dat leukocyt ABCA1, zelfs in de afwezigheid van 
circulerend ApoAI, beschermt tegen atherosclerose. Naast macrofaag RCT dragen dus ook 
andere mechanismen bij aan de beschermende effecten van leukocyt ABCA1, vooral onder 
omstandigheden waarin circulerend ApoAI afwezig is. De versnelde atherosclerose in 
LDLr/ApoAI dKO muizen met macrofaag ABCA1 deficiëntie viel samen met een 
verhoogde monocytose en neutrofilie in het bloed, verhoogde plasmaspiegels van de 
belangrijke monocyt en neutrofiel chemoattractants van monocyten en neutrofielen; MCP-
1 en KC, en verhoogde neutrofiel accumulatie in de lesies. Deze bevindingen suggereren 
dat de beschermende effecten van leukocyt ABCA1, naast cholesterol efflux, ook kunnen 
worden toegeschreven aan een anti-inflammatoire werking. 
 
11.3.3 Bevordering van RCT vanuit macrofagen ter bescherming tegen atherosclerose 
Om te onderzoeken of een mogelijke toename van de macrofaag RCT capaciteit beschermt 
tegen de ontwikkeling van atherosclerose zijn verschillende strategieën getest, waaronder 
dieet afhankelijke verlaging van cholesterol in het bloed, macrofaag ABCA1 overexpressie 
en infusie van synthetische cholesterol-vrije fosfatidylcholine (PC) deeltjes. In Hoofdstuk 
8 werden LDLr KO muizen gedurende 5 of 9 weken WTD gevoerd om de vorming van 
beginnende en vergevorderde atherosclerotische lesies te stimuleren. Daarna kregen de 
dieren chow dieet om lagere plasma cholesterol spiegels te verkrijgen. De dynamische 
respons van de gevestigde lesies werd onderzocht. Dieet geïnduceerde verlaging van 
cholesterol verminderde de hoeveelheid macrofagen in de vergevorderde lesies. Echter, de 
lesie ontwikkeling werd voortgezet als gevolg van de uitbreiding van collageen en de 
necrotische gebieden. Het is opvallend dat beginnende lesies meer pro-inflammatoir 
werden, terwijl de ontsteking was verminderd in vergevorderde lesies. De ernst van de 
lesies bepaalde dus de effecten van de verlaging van het plasma cholesterol op de lesie. Dit 
onderstreept het belang van het stadium van atherosclerotische lesie ontwikkeling voor 
onderzoek naar nieuwe therapeutische strategieën gericht op vermindering van 
atherosclerose. 
In Hoofdstuk 9 werden BMT experimenten in LDLr KO muizen met 
vergevorderde lesies gebruikt om de mogelijkheden van ABCA1 overexpressie in 
beenmerg-afgeleide cellen voor de behandeling van al aanwezige atherosclerose te 
bestuderen. ABCA1 overexpressie remde macrofaag infiltratie in beginnende, maar niet in 
vergevorderde lesies. Dat laatste is waarschijnlijk het gevolg van het feit dat infiltratie van 
macrofagen in bestaande lesies in een vergevorderd stadium van ontwikkeling grotendeels 
werd verminderd als gevolg van de aanwezigheid van een fibrotische laag. De ernst van de 
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al bestaande lesies bepaalt dus de therapeutische mogelijkheden van ABCA1 overexpressie 
in beenmerg-afgeleide cellen.  
Infusie van artificieel HDL (rHDL), bestaande uit menselijk ApoAI en PC, 
beschermt tegen atherosclerose door cholesterol efflux uit macrofaag schuimcellen 
stimuleren en de ontstekingsreactie te remmen [10918070, 12937162, 20609437]. PC 
deeltjes, zoals rHDL, kunnen cholesterol opnemen dat uit cellen wordt getransporteerd via 
SR-BI, ABCG1 en diffusie. Infusie van grote hoeveelheden PC zou dan ook naar 
verwachting een positief effect kunnen hebben op efflux van cholesterol uit cellen en dus 
atherosclerose. In Hoofdstuk 10 werd het effect van PC deeltjes op macrofaag cholesterol 
efflux in vitro en de ontwikkeling van al aanwezige atherosclerotische lesies in LDLr KO 
muizen geëvalueerd. Zoals verwacht zorgden hoge concentraties PC deeltjes (>84 μg/ml) 
voor een inductie van cholesterol efflux uit macrofagen. De PC deeltjes bleken net zo 
efficiënt als rHDL met dezelfde hoeveelheid PC. De verhoging van macrofaag cholesterol 
verwijdering door een enkele infusie van een hoge dosis PC deeltjes leidde tot een snelle 
stabilisatie/regressie van de aanwezige lesies in LDLr KO muizen op WTD. De PC 
component van het rHDL draagt dus bij aan de cholesterol efflux inducerende capaciteit en 
oefent een gunstig effect uit op de ontwikkeling van atherosclerose. 
Samengevat toont dit proefschrift het belang van RCT aan voor het remmen van 
atherosclerotische lesie ontwikkeling. ABCA1 en SR-BI, zowel in de lever als de 
macrofagen kunnen worden beschouwd als kandidaten voor farmaceutische interventie om 
HDL te verhogen, macrofaag cholesterol efflux te bevorderen, cholesterol transport naar de 
lever te stimuleren, en zo te beschermen tegen atherosclerose. Verscheidene mogelijkheden 
voor het verhogen van macrofaag cholesterol efflux zijn geëvalueerd, welke hopelijk 
zullen leiden tot nieuwe behandelingen die zich richten op stimulering van RCT. De 
verworven kennis over de effecten van de ernst van de bestaande lesies op lesie 
transformatie en monocyt infiltratie na interventie helpen bij de ontwikkeling van 
stadiumspecifieke therapieën tegen atherosclerose. Daarnaast suggereren de nieuwe 
bevindingen van ABCA1 en HDL niveaus op leukocytose dat cholesterol homeostase van 
leukocyten de immuunrespons beïnvloedt, wat een verband aangeeft tussen 




























11.4.1 胆固醇的逆向转运在预防动脉粥样硬化中的重要性  
高密度脂蛋白代谢的关键调节分子是 ABC 转运体 A1（ABCA1）和清道夫受体
BI（SR-BI）。 ABCA1 是高密度脂蛋白生物合成的限速因素，而 SR-BI 介导肝脏从
高密度脂蛋白中摄入胆固醇酯（CE）。为了研究 ABCA1 和 SR–BI 在 RCT 和预防动
脉粥样硬化中的协同作用，ABCA1/SR-BI 双敲除（dKO）小鼠被制造出来。首先，
我们在第一章研究了 ABCA1/SR-BI dKO 小鼠在普通的 chow 饮食条件下的表型特
征。一方面，dKO 小鼠类似 SR-BI KO 小鼠，它们的肝脏无法从高密度脂蛋白中选
择性的摄取胆固醇酯（CE）。另一方面，dKO 小鼠又相似 ABCA1 KO 小鼠显示了
低胆固醇血症和血清中高密度脂蛋白的缺失。从野生型（WT）的巨噬细胞中流出的
胆固醇逆向转运在 dKO 小鼠体内是减少的， 其减少的程度类似 ABCA1 和 SR–BI 单
基因敲除小鼠。然而，dKO 小鼠在肺和 Peyer 氏斑积聚了增大的巨噬细胞源的泡沫
细胞，清楚地说明了 ABCA1 和 SR–BI 在细胞胆固醇平衡中的重要性。由于血液中
缺乏促动脉粥样硬化的脂蛋白，dKO 小鼠的主动脉根部并没有动脉粥样硬化病变。
为了近一步研究 ABCA1 和 SR-BI 共同缺乏对动脉粥样硬化的影响，在第二章， 
dKO 小鼠被给予含有 15％的可可脂，1％胆固醇，和 0.5％胆盐的致动脉粥样硬化的
饮食（ATD）为期 10 个星期。 DKO 小鼠的血浆总胆固醇水平依然比 WT 小鼠低
下，其主要是由于高密度脂蛋白的缺失。dKO 小鼠血浆中非高密度脂蛋白的胆固醇
的水平是高于 ABCA1 KO 小鼠，但比 SR-BI KO 小鼠低很多。增强的巨噬细胞源性
的泡沫细胞再次在 dKO 小鼠腹腔中堆积。与 WT 小鼠相比，高密度脂蛋白在





是至关重要的。引人注目的是，ABCA1 的缺失阻止了动脉粥样硬化病变在 SR-BI 
KO 小鼠中的发展。ABCA1 的缺失还降低了 SR-BI KO 小鼠的血浆中单核细胞趋化
因子 MCP-1 的水平和粘附分子 ICAM-1 在动脉壁上的表达水平，这很可能导致了单
核细胞浸润到病变中的减少。不断积累的证据显示不仅引发动脉粥样硬化的非高密
度脂蛋白，如 LDL 和极低密度脂蛋白（VLDL），而且功能失调的高密度脂蛋白也
可诱导动脉壁 MCP-1 的分泌和上调动脉内皮细胞上 ICAM-1 的表达[1]。因此，dKO
小鼠动脉粥样硬化病变的减少很可能是由于 ABCA1 的缺失降低了血浆中致动脉粥
 
























Brunham 等最近发现 ABCA1 在巨噬细胞上的特异缺失并不影响 LDLr KO 小鼠
动脉粥样硬化的发展[2]。他们认为这是由于删除巨噬细胞上 LDLr 下调甾醇诱导的巨
噬细胞 ABCA1 的表达和巨噬细胞胆固醇流出[3]的后果。为了验证这一假设，在第六
章，LDLr/ABCA1 dKO 小鼠和其对照小鼠的骨髓被移植到 LDLr KO 小鼠内。LDLr
缺失并不影响从骨髓来源的巨噬细胞在体外胆固醇流出或体内的巨噬细胞源性泡沫
细胞的形成。值得注意的是， 无论 LDLr 的存在与否, ABCA1 在骨髓细胞上的缺乏
都促进了泡沫细胞的形成和动脉粥样硬化的增加。这明确表示骨髓细胞上 ABCA1
对动脉粥样硬化的保护作用是不需要 LDLr 的存在。有趣的是，LDLr/ABCA1 dKO
移植动物与 ABCA1 KO 移植动物相比显示了减少的血液淋巴细胞，降低了 T 细胞在
动脉外膜的浸润，和较小的动脉粥样硬化病灶的形成。这些结果表明除了在胆固醇







































度是可能影响增强骨髓细胞上 ABCA1 的表达的治疗疗效。 
人载脂蛋白 AI 和卵磷脂（PC）组成的重组高密度脂蛋白（rHDL）输液可以阻
止动脉粥样硬化的发展。这很可能是通过诱导巨噬细胞源的泡沫细胞胆固醇流出和
抑制炎症来起作用的 [5,6]。 PC 颗粒与 rHDL 颗粒一样，可以接受通过 SR-BI，
ABCG1，和水扩散转运出的胆固醇。输注大量的 PC 颗粒悬液因此很可能积极影响
到细胞内胆固醇流出，从而改善动脉粥样硬化病变。因此，第十章评估了 PC 颗粒
在体外对巨噬细胞胆固醇流出和 LDLR KO 小鼠动脉粥样硬化病变的进展的影响。
首先，正如所料，在高浓度（> 84 g/mL）PC 诱导巨噬细胞胆固醇流出的能力等同
于含有相同数量的 PC 的 rHDL。重要的是，单次高剂量的 PC 颗粒的输注可以迅速
稳定在 LDLR KO 小鼠体内已成立的病变。因此，rHDL 的 PC 组分是有助于 rHDL
诱导的胆固醇流出和改善动脉粥样硬化的。 
综上所述，本论文探讨了 RCT 对抑制动脉粥样硬化病变形成中的重要性。肝脏
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